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Summary 
An  effective  immune  system  is  essential  for  constant  surveillance  of  potential 
threats to the organism, its’ primary role being to provide resistance to infection. Thus, 
the  immune  system  must  be  able  to  discriminate  between  pathogenic  and  self  or 
harmless foreign antigens in order to not only achieve a productive immune response 
but  also  to  avert  unwarranted  hyperreactivity  and  the  potential  development  of 
autoimmunity. A delicate balance between these two fundamental requirements of the 
immune system must therefore exist. 
T cells take central roles in the orchestration of the immune response. They are 
responsible for adaptive cell-mediated immunity and as such they can eliminate infected 
cells, produce cytokines that help in the resolution of the infection, stimulate other cells 
of the immune system to participate in the immune response and turn into long-lived 
memory cells. It is not surprising then that a wealth of mechanisms exist in order to 
ensure that T cells mediate immunity against pathogenic antigens but not to self or 
harmless ones. Indeed, various checkpoints in T cell development exist in the thymus to 
enable,  on  the  one  hand  a  large  pool  of  diverse  and  functional  T  cells  capable  of 
recognising virtually all antigens while, on the other hand, eliminating self-reactive T 
cells. As some self-reactive T cells manage to leave the thymus, additional mechanisms 
have  evolved  to  continually  protect  against  auto-reactive  and  allergic  inflammatory 
responses  in  the  periphery.  These  mechanisms  of  peripheral  tolerance  include  cell-
mediated suppression of T cell responses, T cell apoptosis and T cell anergy. Anergy is 
a long-lived, cell-intrinsic mechanism that is characterised by  cell cycle progression 
arrest and reduced IL-2 production. While T cell priming requires recognition of the 
cognate antigen in the context of MHC and co-stimulation via the interaction of its 
CD28 receptor with CD80/86 on an APC, recognition of the cognate antigen in the 
context of MHC without co-stimulation, such as when antigen is presented by immature 
APCs in the absence of inflammation, leads to anergy. These anergic T cells will also be 
hyporresponsive to re-challenge, even under immunogenic conditions. 
The  acquisition  of  the  anergic  phenotype  is  an  active  process,  with  negative 
regulators  of  T  cell  signalling  being  induced.  Among  these  are  some  E3  ubiquitin-
protein  ligases  which  recognize  target  proteins  for  ubiquitination  and  catalyse  the 
transfer of ubiquitin to them, directing them to the proteasome or to the endosomes. 
While a protein targeted to the proteasome is degraded by it, proteins in the endosomes 
can either be recycled for further signalling or directed to the lysosomes, where they are iii
also degraded; in any case, ubiquitination leads to downregulation of the activity of 
signalling  elements,  whether  permanently  (degradation)  or  temporarily  (recycling). 
Therefore a stable difference in the gene expression profile between anergic and primed 
T cells could be achieved through ubiquitin modification translating into an increase in 
turnover of signalling mediators involved in the T cell response, thereby establishing a 
persistent unresponsive state. In fact, some key signalling mediators involved in T cell 
activation, such as PLCγ-1 and PKCθ, have been shown to be downregulated by the 
ubiquitin pathway in the context of anergy induction. Conversely, the  E3 ubiquitin-
protein ligases Cbl-b, Itch and Grail have been shown to be upregulated during anergy. 
These and other E3-ubiquitin-protein ligases have also been shown to ubiquitinate and 
downregulate TCR signalling elements. 
However,  many  of  the  studies  leading  to  these  findings  have  relied  upon 
biochemical assessment of signalling in T cell lines or clones, at the population level 
following  pharmacological  stimulation  in  vitro.  The  data  generated  in  this  way  is 
sometimes conflicting with that of studies which focused on the knockout of a single 
gene, followed by analysis of the phenotype. Moreover, as in vitro pharmacological 
stimulation data represents the responses of all cell types in the sample population at 
any one time, it does not necessarily reflect the responses of individual antigen-specific 
T cells within their environmental niche within lymphoid tissue. Information relating to 
differential  kinetics  or  subcellular  localisation  of  signals  generated  by  functionally 
distinct subgroups within a population could help assess the full picture regarding the 
role of E3 ubiquitin-protein ligases during the induction and maintenance phases of T 
cell anergy. 
The main objectives of this thesis were therefore to determine the expression of 
Cbl-b, Itch and Grail in individual antigen-specific CD4
+ T cells in both the induction 
and  maintenance  phases  of  anergy,  in  vitro  and  in  vivo,  and  to  investigate  their 
functional signalling role(s) in the maintenance of the tolerance phenotype. In order to 
accomplish these objectives, induction of priming or tolerance in ovalbumin (OVA323-
339 peptide)-specific T cells from DO11.10 TCR transgenic mice in vitro or, following 
adoptive transfer of near physiologically relevant numbers of such cells into recipients, 
in  vivo,  was  carried  out.  Functional  outcome,  measured  in  terms  of  cell  cycle 
progression,  proliferation,  cytokine  readout  assays,  antibody  production  and  T  cell 
migration  was  correlated  with  E3  ubiquitin-protein  ligases  expression  and  the 
ubiquitination status of the TCR signalling machinery. Cbl-b, Itch and Grail protein 
expression in LN tissue, antigen-specific CD4
+ T cells and subcellular compartments iv
was assessed. Moreover, quantitative analysis at the single cell level was carried out by 
tracking the antigen-specific CD4
+ T cells in vitro and in vivo by using Laser Scanning 
Cytometry.  This  relatively  new  technology  combines  the  quantitative  capabilities  of 
flow cytometric analysis of cells with the ability to analyse them within a tissue in situ
within their microenvironmental niche, thus more within physiological parameters.  
This study shows Cbl-b expression to be upregulated in CD4
+ T cells undergoing 
induction of both anergy and priming, when compared to naïve cells. This is a departure 
from  the  view  that  states  Cbl-b  is  a  differential  factor  promoting  anergy.  In  the 
maintenance phase, Cbl-b levels also appear upregulated in both anergic and primed 
antigen-specific T cells. Interestingly, Cbl-b concentrates in the periphery of anergic 
cells immediately after re-stimulation and this concentration of Cbl-b in the periphery of 
the cells was also observed for primed T  cells  after re-stimulation but at later time 
points. These data may therefore implicate Cbl-b in the modulation of T cell activation 
in the context of CD28 co-stimulation, rather than acting solely as a selective agent in 
the promotion of anergy. 
Itch was similarly found to be upregulated in anergising and priming CD4
+ T 
cells, when compared to naïve cells. In fact, cells undergoing priming were found to 
express more Itch than those undergoing anergy. Likewise, in the maintenance phase, 
re-stimulation of primed cells resulted in higher Itch expression than re-stimulation of 
anergic antigen-specific T cells. Itch appears therefore to not play an exclusive role in 
anergy but instead acting in the general context of TCR signalling. Moreover, Grail 
expression was found to be upregulated in priming CD4
+ T cells while there is also 
evidence it was transiently expressed at high levels during the anergy induction phase. 
Intriguingly,  in  the  maintenance  phase,  Grail  is  associated  with  the  migration  of 
antigen-specific T cells into the follicles. 
In summary, the data presented here indicate that upregulation of Cbl-b, Itch and 
Grail  is  not  exclusive  to  T  cells  undergoing  or  maintaining  anergy,  as  priming  and 
primed T cells also exhibit expression and upregulation of these signals. While these 
data therefore show that these molecules cannot be used as markers for T cell anergy, 
and while the search for a bona fide T cell anergy marker continues, it also opens up 
new  possibilities  for  their  role(s)  in  modulation  of  T  cell  activation.  By  advancing 
knowledge of the key signalling events that take place during antigen recognition, more 
targeted approaches for enhancing or inhibiting immunity or tolerance can be devised. v
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1 INTRODUCTION 
1.1 The immune system 
An  effective  immune  system  is  essential  for  constant  surveillance  of  potential 
threats to the organism, its’ primary role being to provide resistance to infection. The 
immune  system  is  made  up  of  two  arms:  innate  immunity  and  adaptive  immunity, 
which together provide the immune system with the ability not only to recognize the 
difference  between  “danger”  (e.g.,  a  pathogen)  and  a  harmless  situation  but  also  to 
mount  protective  responses  that  are  increasingly  effective  on  re-encounter  with  the 
particular pathogen [1]. 
1.1.1 Innate immunity 
The innate immune system is involved in resisting infection by way of barrier 
mechanisms,  by  ingesting  and  killing  the  pathogen  and  by  mediating  inflammation. 
Anatomical barriers like the skin and the mucous membranes, physiological barriers 
such as body temperature and pH are the first defences a potential pathogen must face. 
Inflammation has three major functions: deliver additional effector molecules and cells 
to the site of infection (which contribute to the killing of pathogens), to induce local 
blood clotting (which provides another barrier to the spread of the infection) and to 
promote  the  repair  of  injured  tissue.  Innate  immunity  can  be  mediated  by  cells, 
circulating proteins such as the complement system, and anti-microbial peptides such as 
defensins and cathelicidins [2]. 
The  cells  of  the  innate  branch  of  the  immune  system  are  the  macrophages, 
dendritic cells (DCs), neutrophils, eosinophils, basophils, mast cells and natural killer 
cells (NKs). Macrophages and neutrophils are phagocytic cells that engulf pathogens 
and destroy them in intracellular vesicles. DCs are also phagocytic cells, but they are 
involved in presenting antigen to cells of the adaptive immune system, thus allowing its 
activation.  Eosinophils,  basophils  and  mast  cells  are  secretory  cells,  releasing  the 
contents of their granules after antibody activation. Unlike all the other cells of the 
innate  immune  system,  which  differentiate  from  the  common  myeloid  progenitor 
together  with  platelets  and  erythrocytes,  NK  cells  differentiate  from  the  common 
lymphoid progenitor (together with B and T cells); they are involved in recognition and 
elimination of tumour and virus-infected cells [2].3
DCs are a specialised population of professional antigen presenting cells (APCs) 
that appear to be the cells primarily responsible for initiating naïve T cells responses. 
Immature  DCs  are  highly  phagocytic  and  act  to  capture  microbial  antigens  in  the 
periphery. DCs are induced to migrate from the site of infection to the T cell-rich areas 
of the lymph nodes (LNs) after antigen uptake and, once exposed to microbial products 
or  proinflammatory  cytokines,  they  become  mature  DCs.  Mature,  LN-located  DCs 
express high levels of MHC-associated peptides derived from the pathogen and cell 
surface  molecules  such  as  B7.1/CD80,  B7.2/CD86  and  CD40  (ligands  for  CD28 
(CD80/86) and CD154 (CD40), which are expressed on most naïve T cells, especially 
those in the CD4 subset). Once activated, APCs also produce cytokines that contribute 
to the stimulation and modulation of T cells and their responses [1]. 
Recognition in the innate immune system is based on non-clonally distributed 
receptors  called  pattern  recognition  receptors  (PRRs),  which  recognize  certain 
molecular  patterns  (pathogen-associated  molecular  patterns,  PAMPs),  that  are 
conserved across a  range of pathogens [3]. Triggering of  certain  receptors by some 
pathogen products is also important in the induction of adaptive immunity, because, as 
described above, DCs and macrophages are led to display co-stimulatory molecules that 
contribute to their priming of T cells. The most characterised class of PRRs that lead to 
such a response is the Toll-like receptor family (TLRs). Each of the members of the 
TLR family recognise a different set of PAMPs; for instance, TLR-3 recognises dsRNA, 
TLR-4  dimer  (with  MD-2  and  CD14)  recognises  lipopolysaccharide  (LPS)  and 
lipoteichoic acids, and TLR-5 recognises flagellin [2]. 
1.1.2 Adaptive immunity 
Unlike  innate  immune  responses,  adaptive  immune  responses  are  reactions  to 
specific antigenic challenges. The adaptive immune system is constituted by B and T 
cells which function as the mediators of humoral (antibody-mediated) and cell-mediated 
immunity, respectively. It is essentially a self-regulated system, since both the mature, 
naïve T cell receptor repertoire and the mature, naïve B cell receptor repertoire  are 
generated by interaction with self-ligands rather than non-self ligands to ensure self-
tolerance.  Another  important  characteristic  is  the  development  of  immunological 
memory which allows the immune system to respond more rapidly and more effectively 
to a second encounter with an antigen [1]. 4
1.1.2.1 B cells 
B  cells  are  responsible  for  humoral  immunity.  They  produce  and  secrete 
antibodies upon activation and differentiation into plasma cells. In the majority of cases, 
binding of antigen to the B-cell receptor (BCR) on a naïve mature B cell will lead to its 
activation only when T cell help is provided. The BCR comprises antigen-binding and 
signal  transducing  units.  Every  B  cell  clone  produces  an  antibody  with  unique 
specificity that can carry out various functions depending on its isotype. After receiving 
T  cell  help  in  the  form  of  cytokines  and  CD40  ligation,  B  cells  proliferate  and 
differentiate into populations of antibody-secreting plasma cells or memory  B cells; 
isotype class switching also occurs during this process. Antibodies, depending on their 
isotype,  can  act  via  neutralisation,  opsonisation  or  complement  activation,  but  the 
ultimate common goal is dealing with extracellular forms of pathogens and their toxic 
products. Antibodies are immunoglobulin proteins which consist of re-arranged heavy 
(H)  and  light  (L)  chains  which  contain  variable  (V)  regions  that  bind  to  specific 
antigens [2]. 
As B cells constitutively express MHC class II molecules and are efficient at 
acquiring antigen, they can also act as APCs for T cells, although they are not the most 
efficient  ones.  Evidence  for  B  cells  having  cytokine  effector  (Be1  and  Be2)  and 
regulatory functions (Bregs) also exists [2, 4]. 
1.1.2.2 T cells 
T cells are responsible for cell-mediated immunity and can be broadly subdivided 
into  several  classes  according  to  their  expression  of  certain  cell  surface  proteins 
(“markers”). 
Two distinct lineages arise early in T cell development: the αβ and the γδ T cells, 
which  have  different  types  of  T  cell  receptor  (TCR).  The  γδ  T  cells  are  the  minor 
population of T cells; when mature, they will express CD3 but not CD4 or CD8; they 
can be found in the gut mucosa and the epidermis. γδ T cells are non-peptide-MHC-
restricted;  and  they  are  thought  to  be  involved  in  immune  regulation,  tumour 
surveillance and specific primary immune responses [5]. 
αβ T cells also express CD3 when mature and can be split into two main types, 
according to their co-receptor: CD8
+ and CD4
+ T cells. However, Natural Killer T cells 
(NKT), which are a minor population of αβ T cells, can also be CD4
+ or CD8
+, or 
neither,  but  their  expression  of  a  variety  of  molecular  markers  that  are  typically 
associated with NK cells warrants them this different designation. Another point of their 5
distinction from conventional αβ T cells is that the TCRs of NKT cells are far more
limited in diversity; also, they recognise lipids and glycolipids presented by CD1d, not 
classical peptide:MHC complexes [6]. 
CD8
+  T  cells,  also  known  as  cytotoxic  T  cells  (TC),  exhibit  MHC  class  I 
restriction and upon recognising their specific antigen in association with MHC class I 
in the presence of interleukin-2 (IL-2) proliferate and differentiate into effector cells 
known  as  cytotoxic  T  lymphocytes  (CTLs).  CTLs  are  responsible  for  eliminating 
tumour cells, grafted cells or virally infected cells from the body [2]. 
CD4
+ T cells are MHC class II restricted and are also known as T helper (TH) 
cells as they act to stimulate other cells of the immune system to participate in the 
immune response, namely TC and B cells [2]. 
MHC class I presents peptides derived from proteins synthesised in the cytosol. 
For example, in virus-infected cells, viral proteins expressed in the cytosol are subject to 
proteasomal proteolysis and the resulting peptides are translocated into the endoplasmic 
reticulum (ER) lumen for loading onto waiting MHC class I molecules. In contrast, 
extracellular antigens are presented by MHC class II molecules. Such antigens can be 
taken up by immature DCs and targeted to lysosomes, where MHC class II molecules 
are located in the MHC Class II compartment for loading with processed peptide. After 
maturation, the DCs undergo cytoplasmic reorganization and a redistribution of peptide-
MHC class II molecules occurs with their migration to the plasma membrane where 
they can present the antigen to T cells. Another mechanism, termed cross-presentation, 
allows some forms of extracellular antigen to also stimulate CD8
+ T cells via the MHC I 
pathway. This is helpful for immunity against viruses that do not infect DCs directly or 
against tumour antigens that are not endogenously expressed by DCs [7]. 
1.1.2.2.1 The TCR 
The TCR recognises peptide antigens; however this recognition only takes place if 
the peptide antigen is combined with the MHC – the TCR is specific for peptide antigen 
combined with the MHC rather than antigen alone. The process of T cell maturation 
includes random rearrangements of a series of gene segments that encode the antigen-
binding receptor chains. This random rearrangement of genes (combinatorial V-J and 
V-D-J  joining  and  alternative  joining  of  D  gene  segments),  coupled  with  other 
mechanisms for  generating diversity  (like junctional flexibility  and P-  and N-region 
nucleotide addition) is capable of generating over 10
9 unique antigenic specificities, 
though this vast potential is in practise restricted/reduced due to selection processes in 6
the thymus. These selection processes eliminate T cells with self-reactive receptors, 
allowing  only  those  which  have  receptors  capable  of  weakly  recognizing  antigen 
associated with MHC molecules to mature [8]. The end result of these processes is the 
production of a vast, diverse and functional self-tolerant repertoire of TCRs, capable of 
recognising virtually all antigens. 
The TCR has two chains (α and β or γ and δ, the αβ heterodimer being the most 
common), each comprising an amino-terminal domain which exhibits marked sequence 
variation due to the aforementioned gene rearrangement and a constant domain. Each 
TCR chain also contains a short connecting sequence (connecting to the other chain of 
the heterodimer) and a transmembrane region which anchors each chain in the plasma 
membrane and allows the TCR to interact with the chains of the CD3 complex that 
allows transport of the TCR to the cell surface and acts to transduce TCR signals [8]. 
The  CD3  complex  comprises  two  heterodimers,  made  of γε and  δε  chains,  which 
associate with the TCR (Figure 1.1), and a homodimer of ζζ chains (some T cells 
(~10%) will express a heterodimer of ηζ chains instead). The cytoplasmic tails of the 
CD3 complex and of the ζ chains contain a motif called the immunoreceptor tyrosine-
based activation motif (ITAM) which forms the basis of TCR signalling [8]. 
1.1.2.2.2 T cell development 
T  cells  develop  from  progenitors  that  are  derived  from  the  pluripotent 
haematopoietic stem cells in the bone marrow and migrate through the blood to the 
thymus,  where  T  cell  development  takes  place  (Figure  1.2).  Developing  T  cells 
(thymocytes)  are  initially  double-negative  (ie,  not  expressing  CD4  or  CD8),  turn 
double-positive and exit the thymus as single-positive. There are at least four different 
double-negative  stages,  which  are  identified  based  on  the  expression  of  CD44  and 
CD25.  Double-positive  thymocytes  are  selected  by  self-peptide:self-MHC  molecules 
and if nothing at all is recognized, the cell will most likely suffer death by neglect [8]. 
However, if the TCR weakly recognizes such antigen, T cell development continues, 
this  process  being  termed  positive  selection  [9].  However,  if  the  recognition  is  too 
strong, cell death by apoptosis usually occurs, in a process known as negative selection 
[10]. It is interesting to point out that in peripheral lymphoid organs (like the lymph 
nodes) ligation of the TCR by a peptide:MHC complex would lead to activation and 
subsequent proliferation and cytokine production; elimination of these T cells in the 
thymus thus prevents their potentially harmful activation later on. Tissue-specific and 
developmental-specific proteins would not be expected to be expressed in the thymus 7
but they are so by stromal cells, namely medullary epithelial cells, under control of the 
AIRE  gene in order to optimise the processes  of self-tolerance. Moreover, although 
negative selection may not remove all T cells reactive to self antigens, there are other 
mechanisms that prevent their activation once they leave the thymus [2]. Interestingly, 
natural  regulatory  T  cells  are  hypothesized  to  come  from  the  group  of  cells  whose 
avidities for self-antigens are between the lower end of the negative selection spectrum 
and the higher end of the remaining positively selected cells [11]. 
The  thymocyte's  fate  is  determined  during  positive  selection.  Double-positive 
cells  (CD4
+/CD8
+)  that  are  positively  selected  on  MHC  class  II  molecules  will 
eventually become CD4
+ cells, by downregulating CD8; this occurs through signalling 
via the ITAM pathway. On the other hand, cells positively selected on MHC class I 
molecules  become  CD8
+  cells  [2].  Unless  they  recognise  antigen,  such  T  cells  that 
emigrate from the thymus and join the recirculating pool in the periphery divide and die 
off slowly, maintaining T cell homeostasis [2]. Such mature recirculating T cells play a 
pivotal role in defending the organism against invading pathogens. 
1.1.2.2.3 T cell activation 
Naïve T cells are found concentrated in the lymphoid organs such as the lymph 
nodes and spleen, but they constantly re-circulate, thus providing an effective immune 
surveillance  system.  The  naïve  T  cells  enter  the  LNs  from  the  blood  via  the  high 
endothelial venules (HEVs) and pass through to the paracortex, a specialized T cell 
compartment.  The  high  surface  expression  of  CD62L  and  the  chemokine  receptor 
CCR7 on naïve T cells are associated with their migration into the LN. Once there, T 
cells scan avidly for recognisable antigen; this is presented to them by APCs [12]. 
Optimum activation of naïve CD4
+ T cells in the LNs requires signals through the 
TCR  via  peptide  bound  to  class  II  MHC  as  well  as  secondary  signals  from 
costimulatory ligands such as CD80, CD86 and CD40 provided by activated DCs [13]. 
This two signal requirement also ensures immune responses develop only when they are 
needed (Figure 1.3). Coordinated action between these signals leads to proliferation of 
naïve cells and begins the process of their differentiation to fully functional effectors 
capable  of  secreting  high  levels  of  cytokines  and  participating  in  helper  and 
inflammatory reactions. 8
1.1.2.2.4 T cell differentiation 
CD4
+ TH cells activation leads to the generation of a clone of effector TH cells. 
Effector CD4
+ TH cells are characterized phenotypically by a decrease in the expression 
of CD62L and a concomitant increase in CD44 expression. Effector cells of different 
types  can  be  generated,  depending  on  the  cytokine  milieu  in  which  the  antigenic 
stimulus  is  received  (Figure  1.4).  For  example,  TH1  cells  express  the  signature 
transcription factor T-bet and produce IL-2, IFNγ and TNF-α. IFNγ upregulates IL-12 
production by DCs and macrophages and this IL-12, in turn, causes an increase in IFNγ
production in TH cells and so promotes TH1 cell differentiation in a positive feedback 
loop. Moreover,  IFNγ downregulates  IL-4 production thus, further promoting a TH1 
phenotype.  TH1  cells  contribute  to  the  cellular  immune  response  by  improving  the 
bactericidal  activities  of  macrophages,  by  stimulating  proliferation  of  CTLs  and  by 
inducing B cells to produce opsonising antibodies [14]. 
TH2  cells  promote  humoral  immunity.  They  express  the  transcription  factor 
GATA-3 and can produce IL-4, IL-5, IL-6, IL-10 and IL-13 [15]. IL-4 stimulates TH
cells  to  differentiate  into  TH2  cells  and  induces  B  cell  production  of  neutralising 
antibodies  [14].  IL-10  inhibits  IL-2  and  IFNγ  production;  it  also  abrogates  IL-12 
production by DCs and macrophages. 
TH17  cells  are  thought  to  have  evolved  to  cope  with  a  range  of  extracellular 
bacterial  pathogens  although  they  have  been  reported  to  play  critical  roles  in  the 
induction and propagation of autoimmune and allergic inflammation [16]. TH17 cells 
can produce IL-17A, IL-17F, IL-6 and IL-21. Transforming growth factor-β (TGF-β) 
and  IL-6  act  co-operatively  and  non-redundantly  to  promote  TH17  commitment 
although it has been proposed that IL-21 can replace IL-6 and act alongside TGF-β [17, 
18].  Retinoic  acid-related  orphan  receptors  (ROR)  are  the  key  transcription  factors 
underlying  TH17  differentiation;  both  RORα  and  RORγt  are  critical  and  somewhat 
redundant in promoting its differentiation [19, 20]. 
There is yet another functional type of T cells: regulatory T cells (Treg). As well as 
acting to homeostatically  control immune responses, Treg  cells suppress pathological 
immune  responses  to  self  antigens  in  autoimmune  disorders  or  foreign  antigens  in 
transplantation  and  graft  versus  host  disease  [11].  Naturally  occurring  Treg  cells 
(CD4
+CD25
+Foxp3
+ Treg cells) arise in the thymus whereas the adaptive Treg cells may 
originate during an immune response; it is thought these differentiate from naïve T cells 
in the presence of TGF-β, following TCR stimulation. Adaptive Treg cells can be further 9
subdivided in Tr1 and TH3 cells. The general mechanism by which they act involves the 
inhibition of the proliferation of other T cell populations [20]. 
Once effector cells are generated, their functional role requires that they relocate 
so they can interact with responding B cells and provide help and/or to migrate to the 
sites  of  infection.  Evidence  indicates  that  these  relocations  are  regulated  by  the 
acquisition  or  increase  in  expression  of  multiple  adhesion  molecules  (such  as  the 
integrin VLA-4 for TH1 cells migrating into the periphery) and a switch in the pattern of 
chemokine receptor expression [2]. 
Following pathogen clearance, contraction of the population(s) of effector T cells 
takes place, as well as the development of long-lived memory cells. Both CD4
+ and 
CD8
+  T  cells  can  differentiate  into  two  different  types  of  memory  cells:  effector 
memory cells and central memory cells. Effector memory T cells can rapidly mature 
into  effector  T  cells  and  secrete  large  amounts  of  IFN-γ,  IL-4  and  IL-5  after  re-
stimulation;  their  integrin  profile  also  suggests  that  they  are  specialized  for  rapidly 
entering inflamed tissues. On the other hand, central memory T cells take longer to 
mature into effector T cells after re-stimulation and they seem more programmed to 
help B cells in the LNs than migrating to inflamed tissues [2]. 
1.2 The lymphoid organs 
Lymphocytes circulate in the blood and lymph but can also be found concentrated 
in some specific locations, called lymphoid organs. These are actually more than just a 
concentration  of  lymphocytes:  they  are  organized  aggregates  of  lymphocytes  in  a 
framework of non-lymphoid cells [2]. 
Lymphoid organs can be divided into three groups: central or primary lymphoid 
organs, peripheral or secondary lymphoid organs, and tertiary lymphoid organs. Primary 
lymphoid organs are the ones in which production of lymphocytes occurs: the bone 
marrow (B cells) and the thymus (T cells). The secondary lymphoid organs are those in 
which adaptive immune responses are initiated, where mature naïve lymphocytes are 
maintained and where effector cells of the B and T cell lineages are differentiated. The 
peripheral  lymphoid  organs  comprise  the  lymph  nodes,  the  spleen  and  the  mucosal 
lymphoid tissues of the gut, the nasal and respiratory tract, the urogenital tract and other 
mucosa.  They  are  widely  distributed  in  order  to  detect  and  respond  to  offending 
antigens  wherever  they  enter  the  body  [21].  Tertiary  lymphoid  organs  are  ectopic 10
accumulations of lymphoid cells that arise in chronic inflammation through a process 
called lymphoid neogenesis. They arise in non-lymphoid locations [22]. 
1.2.1 The lymph nodes 
Lymph nodes are situated at the interface of the blood and lymphatic systems, 
where they contribute to efficient initiation of adaptive immune responses by bringing 
cell-associated  and  soluble  antigens  draining  from  peripheral  tissues  together  with 
circulating  lymphocytes  entering  from  the  blood.  LNs  have  a  highly  organized  and 
complex architecture composed of distinct cellular compartments and structures, at the 
heart of which is a non-haematopoietic cell backbone (Figure 1.5). Among the cells that 
are critical for generating this backbone are the fibroblastic reticular cells (FRCs) and 
the follicular dendritic cells (FDCs) [23]. 
Lymph nodes are interconnected by a system of lymphatic vessels which drain 
extracellular fluid from tissues, from the lymph nodes, and back into the blood. They 
are enveloped by a fibrous capsule and an underlying subcapsular sinus. The lymph 
node  has  three  distinct  regions:  cortex,  paracortex  and  medulla.  The  cortex,  located 
closer to the periphery of the LNs, contains B cells and FDCs. In the centre of the LN 
lies the paracortex, which is composed of T cells and DCs. The medulla consists of 
lymphatic tissue. T and B cells circulate constantly through the LN by entering via the 
HEVs and exiting via efferent lymphatic vessels. Antigen and DCs enter via afferent 
lymphatic vessels at multiple sites along the capsule [22]. 
These structural features of the LNs promote interactions between the APCs and 
the few lymphocytes specific for any given antigen.
1.3 Immune tolerance 
Tolerance in the immune system is required in order to prevent immune responses 
to self components, harmless environmental antigens and necessary foreign materials, 
like  food.  T-cell  tolerance  to  self-antigens  is  generated  through  both  central  and 
peripheral mechanisms. Central tolerance takes place during T cell development in the 
thymus and includes both negative selection and the generation of natural regulatory T 
cells as outlined above (section 1.1.2.2.2). By contrast, peripheral tolerance refers to the 
processes that lead to tolerance if a T cell recognizes self-antigen or harmless foreign 
antigens outside of the thymus [24, 25]. 11
1.3.1 Peripheral tolerance 
Since  central  tolerance  is  not  sufficient  to  prevent  autoimmunity  or  allergy, 
additional mechanisms have evolved to continually protect against auto-reactive and 
allergic  inflammatory  responses  in  the  periphery.  These  processes  include  antigen 
ignorance, cytokine deviation, active suppression, clonal deletion and anergy induction 
[26]. 
1.3.1.1 Antigen ignorance 
Antigen ignorance is elicited when the antigen is not presented to the T cells or 
when their TCR has low avidity to it. In the first case, a physical barrier is involved in 
preventing the antigen’s access to the lymphoid system or, alternatively, in excluding T 
cells from the site of antigen expression [27]. 
1.3.1.2 Cytokine deviation 
Cytokine deviation consists of a shift in the differentiation process of naïve T cells 
to  TH2  cells,  which  translates  into  limiting  inflammatory  cytokine  secretion,  thus 
hampering potential autoimmune responses; it is thought to occur after partial signalling 
via the TCR [28]. 
1.3.1.3 Active suppression 
Active suppression or dominant tolerance is carried out by  regulatory  T cells. 
These may act on effector T cells, suppressing their production of IL-2 and inhibiting 
their proliferation by means of cell-cell contact but they may also mediate bystander 
suppression by exerting non-specific suppressive effects on other antigen-reactive cells 
in the vicinity [26, 29]. 
Most regulatory T cells express CD25; these CD4
+CD25
+ Tregs have the capacity 
to suppress bystander populations of naïve T cells specific for an unrelated antigen [30, 
31]. Moreover, CD4
+CD25
+ Tregs can suppress the cytokine production and proliferation 
of both CD4
+ and CD8
+ T cells in vitro [32, 33]. It is thought the immunosuppressive 
cytokine transforming growth factor-β (TGF-β) can lead to the generation of Tregs in the 
periphery as mice with a disruption in the TGF-β signalling have decreased numbers of 
CD4
+CD25
+ Tregs [34]. At the same time, T cells which are unable to respond to TGF-β
are not suppressed by Treg cells [35]. 
Natural regulatory T cells (CD4
+CD25
+Foxp3
+ Tregs, section 1.1.2.2.2) arise in the 
thymus and are considered part of the central tolerance mechanisms, though they too 12
will emigrate from the thymus and exert their functions elsewhere. The transcription 
factor  Foxp3  drives  their  differentiation  but  TCR/MHC  class  II  interactions,  IL-2 
signalling, B7:CD28 signalling are also required [26]. 
Also, as discussed above, adaptive regulatory cells can arise after contact with 
antigen. These cells have been grouped in a number of classes that will be described in 
the following sections. 
1.3.1.3.1 Tr1 
CD4
+  T  regulatory  1  (Tr1)  cells  were  first  identified,  following  multiple 
stimulations of naïve T cells with antigen, in the presence of high concentrations of IL-
10 in vitro [36]. Such Tr1 cells produce TGF-β but not IL-4, being able to suppress TH2 
responses in an antigen-specific manner [36] and OVA-specific Tr1 cells have been 
shown to prevent inflammatory bowel disease when they are adoptively transferred into 
recipient mice subsequently fed OVA [37]. 
1.3.1.3.2 TH3 
Another subset of CD4
+ Tregs has been described, which produce varying amounts 
of the TH2 cytokines IL-4 and IL-10, but have been shown to be a population distinct 
from TH2 cells since they also produce TGF-β [37]. The produced IL-10 suppresses TH1 
activity  via  downregulation  of  the  expression  of  costimulatory  molecules  and  IL-12 
production by APCs [38]. 
1.3.1.3.3 CD8
+ suppressor T cells 
Early  studies  pointed  towards  the  involvement  of  CD8
+  T  cells  in  active 
suppression although their mechanisms of action were not fully elucidated [39, 40]. 
While  systemic  tolerance  was  unaffected,  CD8
-/-  mice  exhibited  deficient  local 
suppression of IgA responses in the gut after feeding antigen, indicating that CD8
+ Tregs
may be important for the regulation of mucosal immune responses [41]. Subsequently, a 
population of CD8
+ Tregs which expresses Foxp3 was found in human; these CD8
+ Tregs
act  by  secretion  of  the  CC  chemokine  ligand  4  (CCL4)  which  can  inhibit  T  cell 
activation by interfering with TCR signalling [42].
1.3.1.4 Clonal deletion 
Clonal  deletion  or  activation-induced  cell  death  (AICD)  in  T  lymphocytes 
provides a mechanism of tolerance in both a central (when it is happening in the context 13
of negative selection) and a peripheral context. Clonal deletion leads to the elimination 
of  reactive  T  cell  clones  upon  encountering  antigen  [43]  via  a  process  in  which 
activation through the TCR results in apoptosis. AICD can occur in a cell-autonomous 
manner (for example, during negative selection) and is influenced by the nature of the 
initial T-cell activation events [44]. In peripheral T cells it is often caused by interaction 
of the death ligand, Fas ligand (CD95 ligand, FasL) with Fas (which is expressed in T 
cells); FasL expression can be induced in T cells – leading to T cell suicide – or in 
nonlymphoid  tissues  in  response  to  activated  T  lymphocytes  –  leading  to  T  cell 
fratricide - [44]. 
1.3.1.5 Anergy induction 
Anergy is the functional inactivation of T cells. Anergy induction occurs upon 
encountering  antigen  presented  by  immature  DCs,  after  which  naïve  T  cells  fail  to 
mount  a  productive  immune  response  and  most  importantly,  will  also  be 
hyporresponsive  to  re-challenge.  Anergy  is  therefore  a  long-lived,  cell-intrinsic 
mechanism that contributes to the prevention of autoimmune and allergic diseases [43]. 
Hyporresponsiveness,  or  unresponsiveness,  translates  as  a  lack  of  interleukin-2 
production by these T cells, as well as non-proliferation in response to antigen [45]. 
Anergy  induction  occurs  when  T  cells  are  stimulated  through  the  TCR  in  the 
absence of co-stimulation [46, 47]. Several methods have been used to mimic induction 
of such anergy in vitro [48-50], including exposure to immobilised anti-CD3 antibodies 
in the absence of co-stimulatory signals [49, 51]. Under such conditions, relative to 
priming conditions (TCR ligation + co-stimulation, mimicked by anti-CD3+anti-CD28), 
re-stimulation  with  antigen  leads  to  downregulated  IL-2  production  and  decreased 
proliferation  of  the  T  cells.  This  state  of  anergy  can  be  (partially)  reversed  by  the 
addition of exogenous IL-2 to the T cells [52]. 
While  some  experimental  protocols  of  tolerance  induce  both  anergic  and 
regulatory T cells, the primary factors that differentially promote the appearance of one 
group of these cells over the other have not been identified [26]. Moreover, to date, the 
identification of a marker specific for anergic T cells has remained elusive. 14
1.4 T cell signalling 
1.4.1 TCR-mediated signalling 
TCR binding by the MHC-peptide complex results in the activation of the Src 
kinases, Fyn and Lck, the latter being associated with the co-receptors CD4 and CD8 
(Figure 1.6). Activated Lck and/or Fyn then phosphorylate the ITAMs in the ζ chains 
associated  with  the  TCR-CD3  complex [53]  with  the  result  that  the  phosphorylated 
ITAMs recruit the tyrosine kinase ζ-associated protein of 70 kDa (ZAP-70) [14]. ZAP-
70 is then phosphorylated and activated by Lck/Fyn leading to the phosphorylation of 
the  transmembrane  adapter  protein,  linker  for  activation  of  T  cells  (LAT)  [54]. 
Phosphorylated LAT delivers the activation signals through recruitment and assembly 
of a signalosome containing Grb2, Grb2-related adapter downstream of Shc (GADS), 
SH2 domain-containing leukocyte protein of 76 kDa (SLP-76), and phospholipase Cγ1 
(PLCγ-1) [55]. 
To counter-regulate these tyrosine kinase and lipid signals, TCR signalling can 
be negatively regulated by several kinases and phosphatases, including C-terminal Src 
kinase (Csk), SH2 domain-containing phosphatases 1 and 2 (SHP-1/2), SH2 domain-
containing inositol phosphatase (SHIP) and Phosphatase and Tensin homolog deleted 
on chromosome 10 (PTEN) [56]. These actions occur in a highly organized membrane 
structure, the immunological synapse (IS). 
PLCγ-1, after activation by phosphorylation, hydrolyses phosphatidylinositol 4, 
5-bisphosphate (PIP2) to  yield inositol 1, 4, 5-trisphosphate (IP3) and diacylglycerol 
(DAG) [14]. IP3 binds to its receptor on the membrane of the ER triggering Ca
2+ release 
and subsequent Ca
2+ influx through plasma membrane channels [26]. This leads to an 
increased  intracellular  Ca
2+  concentration  which  is  required  for  the  activation  of 
calmodulin,  which  in  turn  activates  calcineurin  (Cn).  Cn  is  a  calcium-dependent 
phosphatase consisting of a catalytic and calmodulin-binding subunit A (CnA) and a 
Ca
2+-binding regulatory subunit B (CnB); in resting T cells, enzymatic activity of CnA 
is kept inactive by binding to CnB. Calmodulin binding to CnA after the binding of Ca
2+
to CnB results in the activation of enzymatic activity of CnA [57]. Activated Cn de-
phosphorylates  the  transcription  factor  nuclear  factor  of  activated  T  cells  (NFAT), 
revealing  its  nuclear  localisation  sequence,  allowing  its  translocation  to  the  nucleus 
where it associates with activator protein-1 (AP-1) to direct the synthesis of genes like 
IL-2 [58]. AP-1 activation is discussed below. 15
DAG promotes membrane association and activation of signalling proteins with 
C1 domains like Ras guanyl-releasing protein 1 (RasGRP1) and various members of the 
protein  kinase  C  (PKC)  family  [45,  59]  to  propagate  intermediate  downstream 
signalling  events  including  serine/threonine  phosphorylation,  Ca
2+  mobilisation,  G-
protein activation and membrane lipid phosphorylation [14]. For example, the GADS-
mediated  recruitment  of  the  guanine  nucleotide  exchange  factor  (GEF)  RasGRP1 
promotes the conversion of Ras-GDP (inactive form) to Ras-GTP (active form) in a 
DAG-dependent  manner  [60-62].  In  addition,  Grb2  forms  a  complex  with  Son  of 
Sevenless (SOS), a GEF also capable of promoting exchange of guanosine triphosphate 
(GTP)  for  guanosine  diphosphate  (GDP)  on  Ras  [63].  Thus  GADS-mediated 
recruitment of the Ras GEFs, SOS and RasGRP1 to the signalosome couples the TCR to 
Ras activation. Consequently, active Ras-GTP recruits the serine/threonine kinase Raf1 
to the plasma membrane [64], where it is fully activated by phosphorylation involving 
p21-activated kinase-1 (Pak1) and Pak3 [65]. Pak1 and Pak3 are activated by Cdc42 
and Rac, and this will be discussed further below. Activated Raf1 then phosphorylates 
the  mitogen-activated  protein  kinase  kinase  (MAPKK),  MEK  (MAPK  extracellular 
signal-regulated kinase (Erk) kinase) which, in turn, phosphorylates Erk [67, 68]. Erk 
activates Elk-1 [66], a transcription factor required for transactivation of c-Fos [67]. 
A major role of the PKC family of serine/threonine kinases in T cell activation 
lies  in  the  activation  of  the  transcription  factor  nuclear  factor  κB  (NF-κB).  Of  the 
isoforms present in T cells, PKCθ is probably  the only one that localizes to the IS 
during  antigen-specific  interactions  [68].  Here,  it  mediates  the  phosphorylation  of 
caspase-recruitment domain (CARD)-containing membrane associated guanylate kinase 
protein 1 (Carma1) (also known as CARD11), an event that induces binding of Carma1 
to  B  cell  lymphoma  10  (Bcl10)  and  mucosa-associated-lymphoid-tissue  lymphoma 
translocation gene 1 (Malt1), thus forming the Carma1-Bcl10-Malt1 (CBM) complex 
[69].  Malt1,  acting  from  the  CBM  complex,  recruits  the  E3  ubiquitin-protein  ligase 
tumour-necrosis-factor-receptor-associated  factor  6  (Traf6)  which  promotes  the 
activation of the inhibitor of NF-κB (IκB) kinase (IKK) complex [70, 71]. The IKK 
complex  is  formed  by  IKKα,  IKKβ  and  IKKγ  (also  known  as  NEMO);  the 
ubiquitination of the catalytically inactive subunit IKKγ allows the phosphorylation of 
IKKα and IKKβ subunits, fully activating IKK; it is thought Traf6 is also involved in 
the recruitment of Tak1, the serine/threonine thought to phosphorylate IKKα and IKKβ
[72]. 16
Once activated, the IKK complex phosphorylates IκB, which in resting T cells 
associates with NF-κB, retaining it in the cytoplasm. However, following IKK-mediated 
phosphorylation and consequent degradation of IκB, NF-κB translocates to the nucleus 
[73]. The NF-κB transcription factor family comprises the Rel proteins p65 (RelA), 
RelB,  c-Rel,  NF-κB1  (p105/p50)  and  NF-κB2  (p100/p52),  which  can  form  various 
combinations of homo- and heterodimers [73]. NF-κB has many and diverse roles in 
adaptive as well as innate immunity; in T cell activation it is involved in mediating 
antiapoptotic effects as well as promoting cytokine production like IL-2, IL-12, IFNγ
[74]. 
1.4.2 CD28-mediated signalling 
The signalling events described so far report only to those emanating from the 
TCR alone. However, as stated before, these signals are not sufficient for effective T 
cell priming; for this to occur, co-stimulation is required (Figure 1.7) [8]. Indeed, in the 
absence  of  co-stimulation,  TCR-signalling  results  in  a  state  of  hypo-responsiveness 
characterised by a lack of IL-2 production, which is required for autocrine and paracrine 
stimulation of T cell proliferation associated with priming [45]. 
T  cell  co-stimulation  via  CD28  engagement  enhances  TCR  proximal  signals 
through  Lck  and  phosphatidylinositol  3-kinase  (PI3K)  activation.  PI3K  activation  is 
necessary for optimal lymphocyte proliferation; it consists of a p85 regulatory subunit, 
which is recruited to CD28 and a p110 catalytic subunit, which is activated by the 
regulatory subunit when recruited by CD28 [75]. PI3K is then in position to convert 
PIP2 into the second messenger phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) which 
recruits  cytoplasmic  proteins  containing  pleckstrin  homology  (PH)  domains  to  the 
plasma  membrane  [75].  Phosphoinositide-dependent  kinase  1  (PDK1)  and  Akt  (also 
known as PKB) are two of these proteins and their presence at the same site leads to Akt 
phosphorylation and subsequent activation by PDK1 [76]. Activated Akt will contribute 
to the activation of NF-κB by what is thought  to be indirect activation of the  IKK 
complex  [80].  By  contrast,  PTEN  negatively  regulates  Akt  activation  by 
dephosphorylating PIP3, resulting in PIP2 production [77]. 
PDK1 may also phosphorylate PKC (although its membrane localisation is not 
PH domain-mediated), thus contributing to its full activation and hence, leading to more 
NF-κB nuclear translocation [78]. 17
Co-stimulation via CD28 also allows for the activation of two more classes of 
MAPKs:  Jnk  (c-Jun  N-terminal  kinase)  and  p38  MAPK.  To  understand  how  this 
happens it is important to describe the mechanism of action of Vav1, a GEF with a PH 
domain.  Vav1  activation  occurs  in  two  waves,  the  first  being  mediated  by  Fyn 
immediately after TCR ligation and the second by ZAP-70 after its recruitment to the 
IS. Binding to PIP3 (mediated by the PH domain) enhances its GEF activity and such 
Vav activation leads to further cytoskeletal rearrangements, IS stabilisation and signal 
transduction  [79].  Thus,  Vav1  associates  with  phosphorylated  SLP-76  via  its  SH2 
domain and also binds the Tec family protein tyrosine kinase (PTK) and IL-2 tyrosine 
kinase (Itk), which are required for optimal PLCγ-1 activation [80]. Vav1 then activates 
the  plasma  membrane-localised  Cdc42  and  Rac,  members  of  the  Rho  family  of 
GTPases,  which  in  turn  activate  Pak1  and  Pak3  [65,  81].  Cdc42  can  also  activate 
Wiskott-Aldrich syndrome protein (WASP) which leads to actin polymerisation and 
cytoskeletal rearrangement [82]. The Paks will activate MKK4 (also known as SEK1) 
which in turn phosphorylates Jnk, thus activating it [83, 84] resulting in phosphorylation 
of  c-Jun  [85].  These  Paks  are  also  thought  to  activate  MKK3/6  which  in  turn 
phosphorylates  p38  MAPK  [86].  Similarly  to  Erk,  p38  MAPK  contributes  to  the 
activation of c-Fos [87], and the activation of c-Fos and Jun resulting from Erk, p38 and 
Jnk MAPkinase recruitment allows formation of the heterodimeric transcription factor 
AP-1, which is necessary but not sufficient for IL-2 transcription and production [58]. 
Thus integration of the signalling events emanating from TCR and CD28 results 
in  the  activation  of  the  full  complement  of  transcription  factors  required  for  cell 
survival,  proliferation  and  cytokine  production,  all  necessary  components  of  any 
effective immune response. These transcription factors are most prominently NFAT and 
NF-κB, and similarly IL-2 is the most important immediate product of these signalling 
transduction pathways leading to T cell priming. 
1.4.3 The role of inhibitory co-stimulatory molecules 
The CD28 family of receptors (CD28, cytotoxic T-lymphocyte-associated antigen 
4 [CTLA-4, also known as CD152], inducible co-stimulator [ICOS], program death-1 
[PD-1, also known as CD279], and B- and T-lymphocyte attenuator [BTLA, also known 
as CD272]) plays a critical role in controlling the adaptive arm of the immune response 
[88]. CD28 is constitutively expressed on T cells but in contrast CTLA-4, ICOS, PD-1 
and  BTLA  are  sequentially  induced  following  T-cell  activation  [89].  T  cell  co-
stimulators and co-inhibitors belong to two structural families of surface proteins, either 18
the immunoglobulin superfamily (to which the B7 family of ligands belongs) or the 
tumour necrosis factor receptor  (TNFR) superfamily. Costimulatory members of the 
TNFR superfamily include OX40, CD40, HVEM and others [90]. 
CTLA-4 shows high homology with CD28 and is capable of binding CD80 and 
CD86 at an even higher affinity [91, 92]. However, unlike CD28, it is responsible for 
inhibiting the activation of T cells [93]. This effect is illustrated by the phenotype of 
CTLA-4 deficient mice, which develop a fatal lymphoproliferative disease with massive 
organ infiltration by immune cells [94]. This disease is mainly mediated by CD4
+ T 
cells;  these  were  characterized  as  being  highly  activated,  showing  enhanced 
proliferation and increased production of TH2 associated cytokines [95]. Normally, upon 
T  cell  activation  CTLA-4  surface  expression  increases  and  out-competes  CD28  for 
ligand (CD80/86) binding [96]. Such crosslinking of CTLA-4 leads to cell cycle arrest 
at the G1 phase and reduced production of  IL-2, which is accompanied by reduced 
activation of the transcription factors NF-κB, NFAT and AP-1 [97-99]. Precisely how 
CTLA-4  is  able  to  mediate  consequent  inhibitory  signals  remains  elusive,  although 
upregulation of Cbl-b levels appears to be involved [100]. 
By contrast, ICOS has a unique ligand, ICOS-L (also known as CD275, B7RP-1 
and B7-H2) and induction of ICOS expression is influenced by both TCR and CD28 
signalling. To date, the p85α subunit of PI3K is the only signalling molecule shown to 
interact with ICOS and ICOS stimulation results in greater recruitment, phosphorylation 
and activation of Akt. Like CD28, ICOS delivers positive signals and has been shown to 
play roles in T-cell differentiation, cytokine secretion (increased production of IL-4, IL-
6 and IL-10), and survival (namely by inhibiting AICD) [89]. 
PD-1 is an inhibitory receptor which binds to PD-ligand1 (PD-L1, also known as 
B7-H1 and CD273) and PD-L2 (also known as B7-DC and CD274) [14]. PD-L1 is 
constitutively  expressed  by  lymphoid  cells  (T  and  B  cells),  myeloid  cells  (DCs, 
macrophages and mast cells) and non-haematopoietic cells (β cells of the pancreas and 
endothelial cells of the heart) [101, 102] whereas PD-L2 is inducibly expressed on DCs, 
macrophages  and  mast  cells  [103].  Before  their  exit  to  the  periphery,  T  cells  in 
lymphoid  organs  rapidly  up-regulate  PD-1  upon  tolerogen  recognition  [104];  this 
upregulation is thought to be mediated by the common gamma-chain cytokines IL-2, 
IL-7,  IL-15,  and  IL-21  [105].  The  role  of  PD-1  in  peripheral  tolerance  was  first 
indicated by PD-1 knockout mice, which spontaneously develop autoimmune diseases 
[106]. Moreover, both PD-1 and its ligands are required for the inhibitory signal to 
occur as the loss of the PD-1:PD-L1 interaction (by antibody blockade) was shown to 19
break  CD8
+  T  cell  tolerance  to  intestinal  self-antigen,  leading  to  severe  enteric 
autoimmunity [107]. Further work revealed PD-L1 expression in non-haematopoietic 
tissue  (pancreatic  islets)  protected  against  immunopathology  after  transplantation  of 
syngeneic islets into diabetic recipients as such PD-L1 signalling inhibited pathogenic 
self-reactive CD4
+ T cell–mediated tissue destruction and effector cytokine production 
[108]. Indeed, when T cells are still in the lymphoid organs, ablation of the PD-1:PD-L1 
interaction prevents anergy and, most interestingly, blockade of this interaction can in 
fact render anergic T cells responsive to antigen [104].
Finally,  BTLA  is  an  inhibitory  receptor  preferentially  expressed  in  TH1  cells. 
BTLA engagement of HVEM (its only ligand) produces pro-inflammatory signals via 
activation of NF-κB whereas HVEM engagement of BTLA produces inhibitory signals 
through  SHP-1/2.  HVEM  is  highly  expressed  in  naïve  T  cells  but  its  expression 
decreases  during  T  cell  activation  and  is  restored  to  high  levels  as  cells  become 
quiescent [90]. 
1.4.4 Signalling in anergy 
It  is  curious  to  note  that  the  induction  of  anergy  leads  initially  to  the  clonal 
expansion of T cells. In fact, anergy induction requires T cell activation and new protein 
synthesis [109]. Nevertheless, relating to proximal TCR signalling, while still capable 
of being recruited to the TCR-CD3 complex under conditions of anergy, the levels of 
tyrosine phosphorylation of  ZAP-70 were significantly  reduced  compared to primed 
cells [110]. Moreover, the recruitment and localisation of LAT to the IS also appears to 
be defective in anergic T cells as a result of impaired palmitoylation of LAT [111]. The 
mechanisms  thought  to  be  involved  in  anergy  induction  and  maintenance  include 
transcriptional regulation of cytokines, inhibition of cell cycle progression and blockade 
of  intracellular  signalling  [112,  113].  An  overview  of  the  modulation  of  signalling 
pathways involved in the induction and the maintenance of anergy  can be found in 
Figure 1.8 and Figure 1.9, respectively. 
In anergy induction, Ca
2+ flux and the subsequent mobilisation of NFAT occurs as 
in priming [114]. However, in the absence of co-stimulatory signalling, IL-2 production 
does not occur; this is due to a block at the transcriptional level caused by reduced 
binding of the AP-1 heterodimer complex to the IL-2 promoter. The AP-1 complex is 
no longer being formed in the nucleus due to incomplete activation of the Jnk and p38 
MAPK  pathways  as  CD28  signalling  is  required  for  their  full  activation  [45]. 
Incomplete activation of Jnk and p38 MAPK also reflects in reduced NF-κB activity 20
[112].  In  anergic  T  cells  Ca
2+-mediated  translocation  of  NFAT  to  the  nucleus  is 
unaffected  but  induction  of  c-Fos  and  Jun  is  severely  impaired  as  a  result  of 
downregulated activity of Erk and Jnk [115]. 
Although  at  first  sight  perhaps  rather  surprising,  NFAT  is  in  fact  critical  for 
anergy induction, as inhibiting Cn with cyclosporin A to prevent NFAT translocation 
into the nucleus also blocks anergy induction [49]. Clearly, the acquisition of an anergic 
phenotype is not simply a passive default process due to lack of costimulatory signalling 
but rather a very active process as seen by the induction of negative regulators of T cell 
signalling [116]. Induction of these negative regulators at the transcriptional level is in 
part mediated by NFAT. 
An immediate target of NFAT-mediated transcription following Ca
2+ mobilisation 
in T cells is the early growth response (Egr) family of transcription factors. Microarray 
analysis of CD4
+ TH1, clone A.E7 cells either anergised with anti-CD3 antibody alone 
or fully stimulated with both anti-CD3 and anti-CD28 antibodies indicated that high 
levels of expression of Egr2 (but not Egr1), persisted for 2 or 5 days in anergised T cells 
[117].  Moreover,  treatment  of  T  cells  with  Egr2-targeted  small  interfering  RNA 
(siRNA) before antibody stimulation prevented the induction of anergy. Egr2 and Egr3 
were  both  found  upregulated  in  anergised  CD4
+  TH1,  clone  A.E7  cells  and  their 
transduction  with  Egr2  or  Egr3  decreased  Il2  transcription  while  increasing  Cbl-b 
expression [118]. By contrast, in vivo peptide administration revealed Egr3-deficient T 
cells to be resistant to anergy induction [118]. Egr2 and Egr3 expression is dependent 
on the activity of calcineurin and PKC [118]. Together these results indicate Egr2 and 
Egr3 have a role in conferring the anergic state; although their mechanism of action is 
yet to be fully determined; it is possible that in the absence of CD28 co-stimulatory 
signals, transcriptional complexes of NFAT and Egr proteins (or Egr proteins alone) 
drive the induction of the anergic programme. 
Another target of NFAT-mediated transcription is the transcriptional repressor of 
the Il2 gene Ikaros. Ikaros is required for the induction of anergy but is also expressed 
in naïve cells, where it blocks Il2 transcription in the absence of co-stimulatory signals 
[119]. During anergy induction its mRNA expression is upregulated [116] and it binds 
to  the  Il2  promoter  where  it  induces  histone  deacetylation,  an  epigenetic  change 
enabling stable repression of Il2 transcription [120]. In antigen-experienced TH1 cells 
activation through the TCR and CD28 downregulates Ikaros activity while treatment 
with ionomycin upregulates it [112, 120]. Curiously, therefore, Ikaros has also been 21
identified as a positive regulator for TH2 cell differentiation by promoting chromatin 
accessibility for TH2-related transcription factors [121]. 
NFAT is also responsible for proximal TCR signalling defects in anergic cells. 
For instance, it induces diacylglycerol kinase (DGK) which inhibits RasGRP activation 
by  converting  the  secondary  messenger  DAG  into  phosphatidic  acid  (PA),  thus 
depleting DAG levels [116]. Both DGKα and DGKζ contribute to such blockage of the 
Erk MAPK pathway and as such, they are both required for the induction of anergy 
[122, 123]. There are also a number of additional signals that have been reported to 
block the Erk MAPK pathway, without affecting DGK expression and leading to the 
establishment  of  anergy  [124].  For  example,  Fyn-mediated  activation  (by  means  of 
phosphorylation)  of  phosphoprotein  associated with  glycosphingolipid-enriched 
microdomains (PAG) leads to the recruitment of Csk to the membrane, where Csk will 
phosphorylate  and  inhibit  Lck  [125].  In  fact,  a  decrease  in  the  level  of  Lck  with  a 
concomitant  increase  in  the  level  of  Fyn  in  anergic  TH1  cell  clones  had  long  been 
observed [126-128].  
Indeed, lack of full Erk MAPK pathway activation has long been associated with 
anergy [129]. For example, another way that this pathway can be inhibited in anergy is 
via the GTPase, Rap1 as Rap1 accumulation has been shown to suppress Erk activation 
in  anergic  T  cells  [48].  Moreover,  while  anergic  antigen-specific  T  cells  have  less 
phospho-Erk than primed cells following re-stimulation with antigen [130], Rap1 was 
shown to be expressed by more anergic than primed T cells. Also, whereas phospho-Erk 
localises to the TCR and lipid rafts in such primed cells, it exhibits a diffuse cellular 
distribution in anergic cells. By contrast, Rap1 localises with the TCR and lipid raft 
structures  in  anergic  cells,  but  not  in  primed  cells  [131].  The  precise  mechanisms 
involved  are  not  clear  but  the  Fyn-Cbl-CrkL-C3G-Rap1  signalling  complex,  which 
cannot be found in primed T cells, allows inhibition of the Erk MAPK pathway to occur 
by Rap1 competing with, and sequestering Raf1 from Ras [48]. C3G is a GEF which 
activates Rap1 [132] whilst CrkL, a SH2-containing adaptor protein is involved in the 
recruitment  of  C3G  [133].  It  is  hypothesised  Cbl  could  enable  CrkL’s  recruitment, 
though the exact mechanism is still open to debate [134]. The Cbl proteins, as well as 
Itch and Grail are E3 ubiquitin protein ligases; these have been reported to have diverse 
roles in anergy, which will be addressed further below. 
IL-2R-mediated signalling is required for T cells to escape anergy induction. The 
Il2 gene is transcribed via CD28 co-stimulation, thus contributing to anergy avoidance. 
IL-2 binding to the IL-2R induces activation of the MAPK and Jak3-Stat5 pathways 22
although avoidance of anergy appears to be as a result of the PI3K-Akt pathway [112] 
possibly because Akt targets p27
kip1, a cyclin-dependent kinase (CDK) inhibitor (CKI) 
for  proteolytic  degradation,  leading  to  de-repression  of  CDK1/2  and  cell  cycle 
progression [112]. p27
kip1 can also bind RhoA, inhibiting actin polymerisation and co-
operation with Rap1 [135]; it can also bind Jab1, which is a co-activator of Jun, thus 
inhibiting gene transactivation by AP-1 [136]. 
1.4.5 The immunological synapse 
In lymphocytes, many of the molecules involved in cell signalling are associated 
with detergent-insoluble, sphingolipid and cholesterol-rich domains in the plasma cell 
membrane, known as lipid rafts [14]. These structures play a role in T cell signalling as 
they  function as specialised signalling compartments in the cell membrane, wherein 
molecules are recruited, phosphorylated and activated [137]. For example, in resting T 
cells the TCR-CD3 complex is thought to reside outside lipid rafts translocating to it 
after  ζ  chain  phosphorylation  by  Lck  [138].  It  is  believed  lipid  raft  macrodomains 
assemble to form the IS as the composition of lipid rafts is indistinguishable from that 
of the IS [14]. 
The IS is composed of several molecules which are found together and spatially 
segregated from others at the contact interface between a T cell and an APC [14]. The 
IS is thought to be the fundamental level of cellular organization that must be achieved 
to  obtain  full  T-cell  activation  [139,  140].  It  works  by  allowing  relatively  small 
molecules to come into contact with their ligands on the APC, which would be difficult 
to occur as they would be blocked by large, abundant glycoproteins on an unpolarised T 
cell. High-resolution immunofluorescence imaging of T cell–APC conjugates reveals 
that a mature IS has a specific doughnut shaped arrangement in which molecules are 
arranged  in  distinct  spatial  domains:  smaller  molecules  such  as  the  TCR,  CD4  and 
CD28, which originate from small clusters of lipid rafts, coalesce to form a single, large 
molecular platform called the central supramolecular activation complex (cSMAC) at 
the  T  cell-APC  contact  site;  larger  molecules  such  as  leukocyte  function-associated 
antigen-1 (LFA-1) and talin form the peripheral SMAC (pSMAC) (Figure 1.10) [140]. 
As mentioned earlier, the localisation of LAT to the IS is defective in anergic T cells 
and moreover, upon re-stimulation with antigen, anergic T cells fail to translocate CD3 
into the cSMAC and hence, assembly of the IS in human anergic T cells is arrested 
[141]. 23
1.5 Apoptosis and cell cycle 
The numbers of a population of cells can be controlled via programmed cell death, 
proliferation  and  differentiation.  Programmed  cell  death,  also  called  apoptosis,  is  a 
tightly  regulated  and  multi-step  process  which  requires  the  cleavage  of  intracellular 
proteins,  DNA  degradation  and  loss  of  cell  shape  and  volume.  Proliferation  is 
dependent  on  cell  cycle  progression,  which  usually  also  involves  cell  growth. 
Differentiation implies functional differences between cells which usually reflect on the 
expression of different surface proteins and other immune mediators, in the case of T 
cells. 
1.5.1 Apoptosis 
Apoptosis  provides  a  mechanism  for  the  disposal  of  unwanted  cells  in  a 
coordinated manner and without the generation of inflammation (unlike necrosis, which 
also leads to cell death, but arising from injury, the organelles swell and the cell bursts, 
releasing  its  intracellular  contents  which  can  trigger  an  inflammatory  response  and 
potentially, autoimmunity). This mechanism also protects the organism by enabling the 
destruction of damaged or potentially harmful cells [142]. 
Most  of  the  observed  changes  associated  with  apoptosis  (such  as  DNA 
degradation, protein cleavage, etc) are implemented by a set of cysteine proteases called 
caspases. Caspases are localised in the cytosol in an inactive pro-caspase form and upon 
apoptotic stimuli are converted into active caspases. Caspases can be divided into two 
main groups: the initiator caspases which are processed first, and the effector caspases 
which can be activated by initiator caspases to drive the ordered disassembly of the 
apoptotic cell [143]. 
There are two major pathways known to activate caspase-dependent apoptosis: the 
classical  caspase  pathway  and  the  mitochondrial  pathway.  The  classical  caspase,  or 
extrinsic, pathway is initiated upon ligation of death receptors such as Fas/CD95 which 
in turn recruit Fas associated protein with a death domain (FADD). FADD can convert 
pro-caspase 8 into caspase 8 (active form), which can then activate the effector caspase, 
caspase 3 [144]. 
On the other hand, the mitochondrial, or intrinsic, pathway involves the loss of 
mitochondrial membrane potential. The B cell lymphoma-2 (Bcl-2) family proteins are 
important regulators of  the mitochondrial pathway [145]. Bcl-2 family  members are 
regulated predominantly at the level of transcription and the balance of expression of 24
pro-survival  and  pro-apoptotic  Bcl-2  family  proteins  determines  the  fate  of  the  cell 
[146].  In  activated  T  cells,  PKCθ-mediated  NF-κB  transcriptional  activity  leads  to 
upregulation of Bcl-2 and Bcl-xL, two pro-survival members of the Bcl-2 family [147]. 
1.5.2 Cell cycle 
Proliferation requires cell cycle progression while cell cycle arrest prevents the 
expansion of a population of cells. The eukaryotic cell cycle comprises four distinct 
phases. G1 is characterised by the cell undergoing induction of gene expression and 
protein synthesis, resulting in an increase in cell size and production of all the proteins 
required for DNA synthesis. DNA duplication occurs in S phase (synthesis) and after 
chromosome replication, a second growth period, G2, allows the cell to monitor DNA 
integrity and cell growth prior to M phase (mitosis) when the cell finally divides. The 
resulting daughter cells either immediately enter G1, potentially to go through the full 
cycle again or alternatively, enter the G0 phase (quiescence) [148]. 
To  make  sure  cell  division  yields  functional  and  DNA-healthy  daughter  cells, 
checkpoints exist throughout the cell cycle, namely in G1, G2 and M phases [149]. Cell 
cycle checkpoints and cell cycle progression are mediated by a variety of signalling 
molecules. Progression through the cell cycle, which is crucial for optimal activation of 
T cells, is driven by complexes formed by cyclins and CDKs. CDK activation requires 
cyclins; depending of the phase of cell cycle, different cyclins associate with the CDKs 
[150]. Activity of the cyclin/CDK complexes is inhibited by direct binding of CKIs, 
such  as  p27
kip1,  whose  expression  is  downregulated  by  transcriptional  and  post-
transcriptional mechanisms [151]. 
The commitment of cells to DNA synthesis occurs at the G1 checkpoint; upon 
receiving  an  activation  signal,  Ras-mediated  Erk  activation  and  subsequent  AP-1 
transcription are induced, with the latter causing the upregulation of cyclin D [152]. 
Cyclin D can then bind to CDKs 4 or 6 and the resulting complexes promote G1/S 
transition  by  initiating  the  sequential  phosphorylation  of  the  retinoblastoma  protein 
(Rb). Hypophosphorylated Rb binds the transcription factor E2F, which is required for 
transcription of S phase genes such as cyclins E and A. Cyclin E-CDK2 and cyclin A-
CDK1/2 complexes will further phosphorylate and inactivate Rb, leading to cell cycle 
progression [153]. 
p27
kip1, which can inhibit CDK4/6 as well as CDK1/2 is most highly expressed in 
quiescent cells [151]. It exerts its inhibitory effects on CDK activity when it is localised 
in the nucleus [154] and consistent with this, Erk activation has been associated with the 25
nuclear  export  of  p27
kip1  [155].  Once  in  the  cytoplasm  p27
kip1  binds  to  SCF
Skp2,  a 
protein complex that targets it for ubiquitination and degradation [156]. 
1.6 Ubiquitination 
Ubiquitination, also sometimes referred to as ubiquitylation or ubiquitinylation, is 
a posttranslational modification of proteins that involves the conjugation of ubiquitin to 
a target protein. It has a broad impact on many cellular processes, including transport, 
DNA replication, modification of protein function, facilitation of cell-surface-receptor 
turnover and control of gene transcription. 
The steps involved in ubiquitination are as follows (Figure 1.11): an ubiquitin-
activating enzyme, enzyme 1 (E1) binds ubiquitin, a 76-amino-acid peptide, by forming 
a thioester bond via its active site cysteine with the carboxyl group of glycine 76 of 
ubiquitin. The activated ubiquitin molecule is then transferred to the cysteine residue of 
the active site of an ubiquitin-conjugating enzyme, enzyme 2 (E2). The ubiquitin-E2 
complex is then recruited by a third enzyme, a ubiquitin-protein ligase, enzyme 3 (E3), 
which specifically binds a protein substrate and facilitates the transfer of ubiquitin from 
the E2 to the target protein by promoting the formation of an isopeptide bond between a 
lysine residue in the substrate and the active carboxy terminus of ubiquitin [157]. 
Upon the addition of the first ubiquitin to the substrate, several other ubiquitins 
may be added (polyubiquitination) essentially by repetition of the same biochemical 
reaction, but with the modification that the isopeptide bond is formed between glycine 
76 of the activated ubiquitin and the ε group of one of seven lysines (K6, K11, K27, 
K29, K33, K48 and K63) of the ubiquitin moiety already attached to the substrate to 
form an elongated ubiquitin chain [158]. Alternatively, a substrate can be tagged with a 
single ubiquitin molecule (monoubiquitination) and such monoubiquitination can occur 
on a single lysine residue or on several lysine residues, leading to multiubiquitinated 
substrates. The same E2-E3 complex can have the dual role of adding either a monomer 
of ubiquitin or elongating the chain. Thus, the decision to add one or more ubiquitin 
moieties does not appear to be regulated by fundamental differences between E3s [159]. 
Whilst  monoubiquitination,  multiubiquitination  and  polyubiquitination  via  K63 
are  usually  associated  with  non-degradative  processes,  including  cellular  trafficking, 
subcellular  location,  function,  stability,  protein-protein  recognition,  and  activity,  in 
general, substrates with a polyubiquitin chain of four or more ubiquitins linked through 
K48 are destined to be degraded by the 26S proteasome [160-163]. The 26S proteasome 26
catalyses  the  unfolding  and  proteolysis  of  its  substrates  and  is  formed  by  two 
complexes: the 20S core complex and the 19S regulatory complex. The 19S complex, 
located at either end of the 20S complex, recognizes polyubiquitinated substrates and 
unfolds  them  for  degradation  by  proteases  to  simple  aminoacids  by  the  proteolytic 
active sites within the interior chamber of the proteasome formed by the cylindrical 
stack of four heptameric rings of the 20S complex [157]. Polyubiquitination via K11, 
K29  and  K33  is  also  associated  with  non-degradative  processes,  but  there  are  less 
examples of this type of cellular regulation [164]. Polyubiquitination via K6 and K27 is 
not  yet  very  well  understood  [165].  Despite  not  promoting  proteasomal-mediated 
degradation of proteins, K63-linked ubiquitination appears to have an important role in 
targeting proteins to the lysosome, where they are processed [160]. 
It is important to appreciate that ubiquitination is a reversible process, an essential 
feature  for  regulating  subcellular  location,  protein-protein  interaction  and,  generally 
speaking, protein function [166]. Regulatory roles of ubiquitin arise partially due to the 
fact that ubiquitin and polyubiquitin chains serve as three-dimensional signals that are 
recognised  by  many  different  types  of  ubiquitin-binding  domain-containing  proteins 
[167].  The  removal  of  ubiquitin  from  proteins  is  carried  out  by  deubiquitylation 
enzymes  (DUBs),  which  are  proteases  that  cleave  ubiquitin  chains  from  protein 
substrates or their degraded fragments [166]. 
Target substrates, despite being quite diverse, are recognized with high selectivity 
due to the existence of many E3s (there are more E3s than E2s and more E2s than E1s) 
with  different  substrate  specificities  recognizing  only  a  few  proteins  that  share  a 
particular  ubiquitination  signal,  usually  a  small  primary  sequence  motif  [164].  The 
recognition of this primary signal allows the substrate to be marked with the secondary 
signal,  ubiquitin,  which  can  be  extended;  all  the  proteasome  needs  for  substrate 
recognition is a K48-linked polyubiquitin chain of four or more ubiquitins, allowing it 
to successfully interact with and degrade many unrelated proteins [158]. 
The  concept  that  cellular  proteins  can  be  targeted  for  modification  by  small 
proteins is now expanding beyond ubiquitin. A growing list of ubiquitin-like (UBL) 
proteins, which also bind substrate proteins, thus altering their fate or function is being 
identified and characterized [168]. UBLs include at least five distinct proteins that are 
related in sequence to ubiquitin - such as SUMO-1 and ISG15, which has been reported 
as involved in immune system regulation - as well as two that are not [157, 164].27
1.6.1 Ubiquitination in T cell tolerance 
Ubiquitination of selected target proteins has been shown to contribute to both 
central  tolerance  and  peripheral  tolerance  mechanisms  [157].  As  ubiquitination  can 
affect  signalling  pathways  in  multiple  ways,  from  reversible  protein  inactivation  to 
protein  degradation,  it  is  a  plastic  and,  as  such,  useful  process  to  rapidly  modulate 
signals [169]. In T cell tolerance both E3 ubiquitin-protein ligases and DUBs have been 
reported to be specifically induced and/or exert specific activity towards or against the 
acquisition of a certain functional outcome [157, 166]. 
1.6.1.1 E3 ubiquitin-protein ligases 
E3 ligases play a pivotal role in ubiquitination, because they recognize the target 
acceptor protein and so dictate the specificity of the reaction. Interestingly, they often 
catalyse  the  transfer  of  ubiquitin  from  E2  not  only  to  target  proteins  but  also  to 
themselves  (self-ubiquitination)  [170].  They  exist  both  as  multisubunit  enzyme 
complexes  and  as  single  chain  polypeptides  and  can  be  classified  into  three  major 
families:  RING-  (Really  interesting  new  gene),  HECT-  (homologous  to  the  E6-
associated protein C terminus) and U-box-type E3 proteins [171]. No information exists 
so far regarding involvement of U-box E3s in vertebrate immunity. However, the single 
polypeptide  RING-  and  HECT-type  E3  ligases  have  been  implicated  in  regulating 
immunity, as they have been found to antagonise immune function through the counter-
regulation of the TCR signalling machinery [170] and the RING E3 proteins have also 
been found to regulate cell cycle and apoptotic mechanisms [172]. The mechanisms 
they employ are distinct: thus, the zinc RING finger domain recruits the ubiquitinated 
E2  and  facilitates  the  transfer  of  the  ubiquitin  monomer  to  the  target  protein  [164] 
whilst the HECT domain of the HECT E3 ligases itself binds ubiquitin from the E2-
ubiquitin complex and transfers it to the target protein [164]. The HECT E3 proteins 
may  also  contain  a  WW  domain,  which  is  involved  in  targeting  the  substrates  for 
ubiquitination by mediating interactions with proline-rich regions in other proteins, and 
a C2 domain that mediates translocation to the plasma membrane/endosome in response 
to increase in intracellular Ca
2+ [164]. 
1.6.1.1.1 Cbl-b 
The Casitas B lineage lymphoma (Cbl) family has three mammalian homologues: 
c-Cbl, Cbl-b and Cbl3 (also known as Cbl-c) [173]. Cbl-b is expressed throughout a 
great number of different cell types and tissues; on a cell-to-cell basis, the protein levels 28
of Cbl-b are highest in bone marrow-derived mast cells and lowest in the thymus, while 
spleen  and  LN  cells  express  equivalent  levels  [174].  In  macrophages,  Cbl-b  is  a 
negative  regulator  of  TLR-mediated  inflammatory  responses  by  binding  to,  and 
promoting the degradation of, MyD88 and TRIF [175]. Also in macrophages, Cbl-b-
deficiency  leads  to  LFA-1  activation  and  increased  endothelial  adhesion  [176]. 
Similarly, in neutrophils, Cbl-b promotes the downregulation of TLR4 expression from 
the cell surface. It also prevents unchecked inflammatory responses [177]: for example, 
in human neutrophils, Cbl is a negative regulator of IL-8-mediated chemotaxis by a 
mechanism potentially involving p85 regulatory subunit of PI3K [178]. Likewise, in 
mast  cells,  Cbl-b  works  as  a  negative  regulator  of  IgE-mediated  production  of 
inflammatory cytokines such as TNF-α, IL-6 and MCP-1 via a mechanism which might 
include modulation of Syk and IκB activity [174]. In B cells, Cbl-b is a regulator of 
BCR-mediated signalling via PLCγ-2 and Syk [179, 180] and Cbl and Cbl-b both take 
part in mediating B cell anergy to protein antigen [181]. 
Cbl-b, a 120 kDa RING-type single polypeptide E3 ligase, is the main Cbl family 
member  found  in  mature  T  cells  [173,  182].  Initial  experiments  with  a  T  cell  line 
revealed Cbl-b mRNA and protein levels to be upregulated during ionomycin-induced 
anergy; this upregulation required calcineurin [183]. Other studies have reported Cbl-b 
downregulation as an early event that seems to be required for optimal T cell activation 
and which is potentiated by CD28 co-stimulation; Cbl-b levels recover at later time 
points, however, and appear to contribute to the triggering of TCR trafficking to the 
lysosome  associated  with  homeostatic  control  of  T  cell  activation  [182,  184-187]. 
Further support for a role for Cbl family members in preventing T cell activation was 
provided by a study in which a TH1 cell line, adenovirally transduced with dominant-
negative Cbl (inhibits both c-Cbl and Cbl-b) and stimulated by TCR ligation and CD28 
co-stimulation, revealed increased production of IL-2 and increased phosphorylation of 
Vav, Akt, Erk and p38 when compared to cells transduced with an empty vector [188]. 
Vav,  which  can  be  synergistically  activated  by  CD28  co-stimulation,  appears  to  be 
required for the infiltration and retention of primed T cells in antigenic tissue [80], and 
has been further confirmed to be regulated by Cbl-b [189]. 
Globally, therefore, it is thought Cbl-b activity contributes to the downregulation 
of TCR signalling, allowing the onset and maintenance of anergy. Consistent with this 
idea, Cbl-b deficiency allows activation of NF-κB immediately upon TCR ligation in 
the absence of CD28 co-stimulation of primary CD3
+ splenic T cells, in vitro [190]. 
This effect is thought to be achieved by the loss of Cbl-b releasing the need for CD28-29
mediated  activation  of  PI3K-Akt,  which  is  required  for  the  formation  of  the  CBM 
complex, and PKCθ, which is responsible for coupling the IKKs to the CBM complex, 
thus enabling NF-κB activation [190]. This is because Cbl-b-mediated ubiquitination of 
the p85α regulatory subunit of PI3K reduces its binding to CD28 and TCRζ, resulting 
in reduced downstream Akt activation [191]. Loss of Cbl-b however was not shown to 
affect the activation of Erk, Jnk, p38, AP-1, PLCγ-1, calcium flux and NFAT [190]. By 
contrast, a study involving the generation of a double knockout mouse reported that 
Cbl-b
-/-c-Cbl
-/- CD4
+ T cells showed reduced downmodulation of the TCR upon TCR 
engagement which did translate into prolonged activation of Erk [182] suggesting that 
c-Cbl  may  play  a  differential  role  such  as  in  the  regulation  of  Erk  activation. 
Nevertheless,  to  some  extent,  closely  related  members  of  the  Cbl  family  appear  to 
display functional redundancy. 
Cbl-b is a promoter of peripheral tolerance as seen in vivo by its prevention of 
clinical onset of autoimmunity resulting from AIRE deficiency [192]; also, Cbl-b
-/- mice 
develop  spontaneous  autoimmunity  evidenced  by  lymphoid  infiltration  in  various 
organs and the formation anti-dsDNA antibodies [193-195]. In vitro, Cbl-b
-/- T cells 
show  enhanced  proliferation  and  IL-2  production  in  response  to  TCR  stimulation, 
displaying CD28-independent cell activation [194, 195]. These are characteristics of 
deficient anergy induction; defects in the development of anergy in vitro and in vivo
have been described in some, but not all, studies relating to autoimmunity resulting 
from Cbl-b deficiency [183, 193, 196]. However, an alternative mechanism potentially 
involved in the autoimmunity of Cbl-b
-/- mice has been proposed, involving resistance 
to Treg suppression; Cbl-b
-/- effectorT cells were shown to be resistant to suppression by 
wild-type and Cbl-b
-/- Treg cells, in vitro [197, 198]. In vivo, such Cbl-b
-/- effectorT cells 
are  resistant  to  suppression  by  Cbl-b
-/-  natural  Treg  cells,  which  are  fully  functional 
[199]. However, generation of adaptive Treg cells seems affected by Cbl-b deficiency as 
CD4
+ T cells from Cbl-b RING finger mutant knockin or Cbl-b deficient mice showed 
impaired  TGF-β-induced  Foxp3  expression  [200].  Cbl-b
-/-  CD8
+  T  cells  were  also 
shown to be resistant to Treg-mediated suppression, and to exhibit enhanced activation 
and  rapid  tumour  infiltration  and  rejection  [201].  Consistent  with  this,  in  wild-type 
CD8
+ T cells, Cbl-b was shown to regulate antigen-induced TCR downregulation and 
IFN-γ production [186]. However, in anergic NKT cells, Cbl-b primarily induces the 
ubiquitination  of  Carma1,  while  also  affecting  NF-κB–mediated  IFN-γ  production, 
which can lead to failed tumour rejection [202]. 30
Cbl-b and c-Cbl are recruited to the IS of both naïve and anergic T cells, but at the 
naïve synapse, after TCR ligation and CD28 co-stimulation, CD28 signalling leads to 
the ubiquitination and degradation of Cbl and this does not occur in anergic cells [100]. 
Interestingly, in unstimulated naïve cells, polyubiquitination of Cbl-b also takes place 
but does not lead to its degradation [203] and with the lack of a CD28 signal during 
anergy  induction,  Cbl  molecules  are  not  degraded,  leading  to  significantly  higher 
expression of Cbl-b and c-Cbl in the anergic relative to naïve cells [100]. CD28 co-
stimulation induces greater ubiquitination and proteasomal degradation of Cbl-b than 
CD3 stimulation alone although in both cases ubiquitination starts as soon as 1 h after 
stimulation [185]. CD28 co-stimulation has been shown to downregulate Cbl-b at both 
posttranslational and transcriptional levels whilst CTLA-4-B7 interaction prevents Cbl-
b  downregulation  primarily  at  the  transcriptional  level  [100].  The  p85β  regulatory 
subunit of PI3K - which, like p85α that Cbl-b downregulates, also binds to CD28 and 
also  promotes  Akt  activation  -  is  associated  with  and  promotes  CD28-mediated 
downregulation  of  Cbl-b  [184].  PKCθ  has  also  been  found  to  be  required  for  the 
downregulation of Cbl-b in pre-activated CD3
+ T cells responding to TCR ligation and 
CD28  co-stimulation  [204];  PKCθ  associates  with  Cbl-b  and  phosphorylates  it  on 
Ser282, allowing it to be ubiquitinated [204]. The E3 ligases, Nedd4 and Itch then bind 
Cbl  proteins  and  target  them  for  proteasomal  degradation  [205];  at  least  Nedd4  is 
required for the polyubiquitination of Cbl-b induced by CD28 co-stimulation [203]. 
Cbl-b protein expression was also found up-regulated in antigen-induced anergic 
transgenic T cells (by means of OVA peptide presentation by irradiated splenic cells) 
after  ionomycin  re-stimulation  [193].  Consistent  with  this,  Cbl-b
-/-  CD4
+  T  cells 
displayed higher proliferation and IL-2 production when compared to wild type (wt) 
cells after both populations were anergised with ionomycin and re-stimulated; similarly, 
Cbl-b
-/- cells from OVA-tolerised mice proliferated after antigen re-stimulation while wt 
cells did not [193]. Reflecting these functional responses, following ionomycin-induced 
anergy, Cbl-b
-/- CD4
+ T cells showed increased expression of total and phosphorylated 
PLCγ-1 after anti-CD3 re-stimulation when compared to wt cells and consistent with 
this,  PLCγ-1  ubiquitination  is  reduced  in  Cbl-b
-/-  cells  compared  to  wt  cells  [193].  
However, the finding that re-stimulation of primed (anti-CD3+anti-CD28-stimulated) 
Cbl-b
-/-  cells  with  anti-CD3+anti-CD28  also  resulted  in  increased  p-PLCγ-1  when 
compared to wt cells [193], suggests that Cbl-b also plays a dynamic role in regulating 
priming responses, perhaps in a homeostatic manner.31
Decreased PKCθ protein expression in T cells subjected to ionomycin-mediated 
anergy has been reported after anti-CD3-re-stimulation of the cells, while Cbl
-/- T cells 
did not show this effect [183]. It is therefore thought that Cbl-b downregulates PKCθ by 
promoting its ubiquitination; as Cbl-b also promotes the ubiquitination of PLCγ-1 in 
anergic T cells, both these mechanisms are thought to contribute to the block in T cell 
activation in response to priming T cell stimulation subsequent to induction to anergy 
[183, 193]. 
Cbl  family  members  have  also  been  proposed  to  be  involved  in  regulating  IS 
activity. For example, the microclusters of MHC:peptide-engaged TCRs at the IS are 
the site of TCR signalling [206], and their persistence is controlled, in part, by c-Cbl–
mediated  ubiquitination  [207].  Anergic  cells,  which  form  a  mature  IS  albeit  with 
reduced p-Erk levels, display enhanced accumulation of c-Cbl and Cbl-b in the pSMAC 
and  Cbl-b  in  the  cSMAC,  compared  to  naïve  cells,  after  (re-)stimulation  [208]. 
Nevertheless, in this model of in vitro peptide-mediated anergy induction, anergic CD4
+
T cells formed stable T cell-APC conjugates but with less frequency than naïve cells, 
after (re-)stimulation [208]. These results would therefore appear to be inconsistent with 
the findings of a previous study which showed, in a planar lipid bilayer system, that 
mature  IS  formed  by  ionomycin-anergised  CD4
+  T  cells  were  not  stable  and  were 
disintegrating at 1 h [183]. However, at earlier time points, such anergic T cells did 
form mature synapses with an ICAM-1 ring surrounding the accumulated MHC:peptide 
molecules  [183].  Cbl-b-deficient  T  cells  also  display  increased  Rap1  activity  and 
enhanced LFA-1 mediated adhesion of T cells to ICAM-1, in vitro [209]. 
However the role of Cbl-b in T cell anergy is still under scrutiny. For instance, 
although Cbl
-/- T cells are resistant to anergy induction at low doses of ionomycin, this 
effect can be partially overcome at higher doses [183]. Moreover, one study has shown 
that Cbl-b is not necessary for the maintenance phase of anergy, as T cells anergised 
with anti-CD3 antibody, adenovirally transduced with dominant-negative Cbl (inhibits 
both c-Cbl and Cbl-b) and later re-stimulated revealed no production of IL-2 [123]. 
Consistent with this, in an in vivo system in which anergy is induced by constitutively 
expressed peripheral self-antigen, Cbl-b expression was found to be increased in anergic 
wt CD4
+ T cells and Cbl-b
-/- CD4
+ T cells proliferated more upon encountering the 
cognate self-antigen, compared to wt counterparts [196]; however, both wt and Cbl-b-
deficient  T  cells  developed  the  same  impaired  ability  to  respond  to  antigenic  re-
stimulation, as measured by IL-2, TNF-α and IFN-γ production [196]. 32
1.6.1.1.2 Itch 
Itch is a HECT-type single polypeptide E3 ligase [157] for which a role in the 
immune system was first brought to light when nonagouti-lethal or itchy mice were 
analysed;  these  mice,  which  have  a  disruption  of  Itch,  develop  severe  immune  and 
inflammatory disorders, leading to a fatal autoimmune disease characterised by itching 
of the skin, hyperplasia of the LNs, splenomegaly and lymphocytic infiltration of lungs, 
liver,  kidneys  and  heart  [210-212].  The  severe  chronic  inflammation  and  associated 
premature death that characterizes the Itchy phenotype is dependent on lymphocytes as 
Itch-deficient mice lacking mature T and B lymphocytes (Itch
-/-Rag1
-/- mice) did not 
have  the  severely  deleterious  immune  phenotype,  whilst  still  showing  mild 
inflammation [213]. The fact that the inflammatory phenotype partially persists in Itch
-/-
Rag1
-/- mice [213] suggests Itch is also playing a role in regulating the innate immune 
response, perhaps by controlling signalling downstream of the NOD2:RIP2 complex, 
preventing  NF-κB  activation  [214].  Moreover,  in  human  leukocyte  cell  lines, 
phosphorylation  of  the  G  protein  coupled  chemokine  receptor  CXCR4,  involved  in 
leukocyte chemotaxis and other biological processes [215], allows the recruitment of 
Itch to the plasma membrane, where it ubiquitinates CXCR4 [216]. Activated CXCR4 
also promotes the formation of a complex between arrestin-2 and Itch; while Itch is 
involved  in  targeting  CXCR4  to  the  endocytic  pathway,  the  arrestin-2-Itch  complex 
mediates CXCR4 sorting into the lysosome [217]. Itch
-/- cells were also shown to be 
resistant to Treg cell-mediated inhibition and to TGF-β treatment [218] reflecting the 
finding that Itch ubiquitinates the transcription factor TIEG1, which is induced after 
TGF-β stimulation, promoting its activation and leading to Foxp3 expression [218], an 
interesting role for Itch and ubiquitination as positive regulators of the activity of a 
transcription  factor.  In  mouse  embryonic  fibroblasts,  Itch  binds  and  ubiquitinates 
MKK4,  promoting  its  proteasomal  degradation  [219].  MKK4  degradation  is  stress-
induced and dependent on activation of the MKK4 substrate Jnk, which phosphorylates 
and activates Itch; MKK4 is therefore regulated by a negative feedback loop [219]. Also 
in mouse embryonic fibroblasts, Nedd4-binding partner-1 (N4BP1) has been shown to 
behave as a negative regulator of Itch by binding to it and inhibiting its ubiquitination 
activity, resulting in increased transcriptional activity of c-Jun [220]. 
Itch’s role in anergy induction was first described following ionomycin-mediated 
anergy of a T cell line, in which Itch protein and mRNA levels were upregulated in a 
calcineurin-dependent  way,  when  compared  to  unstimulated  cells  [183].  Moreover, 
under  these  conditions,  Itch  was  shown  to  ubiquitinate  PLCγ-1,  in  this  case 33
downregulating it mostly by a non-proteasomal pathway [183]. Generally, Itch’s role in 
peripheral tolerance is thought to be helping in implementing the anergic status of T 
cells  by  downregulating  TCR  signal  in  the  absence  of  CD28  co-stimulation,  and 
modulating transcription factors. 
It  is  thought  both  Cbl-b  and  Itch  cooperate  to  regulate  T  cell  activation  and 
autoimmunity  by  polyubiquitinating  TCRζ  via  a  K33  linkage,  which  reduces  its 
association with Zap-70 [221]. As already mentioned, Itch can also ubiquitinate PLCγ-1 
in ionomycin-induced anergic cells [183] but it does not seem to regulate Erk, Jnk or 
p38  signalling  in  either  anergic  (anti-CD3-)  or  primed  (anti-CD3+anti-CD28-
stimulated)  cells  [222].  Regulation  of  NF-κB  activation  has  been  reported  to  occur 
through Itch-mediated ubiquitination and lysosomal degradation of Bcl-10 [223]; TCR 
ligation in the context of CD28 co-stimulation was found to activate Bcl-10 but later 
promote its Itch-mediated degradation [223]. However, another study reported that T 
cells from Itch
-/- mice stimulated with anti-CD3+anti-CD28 antibodies have normal NF-
κB activation [222], whilst TNF-mediated NF-κB activation is down-regulated [213]. 
Itch has also been reported to play a role in T cell differentiation. Upon activation, 
Itch
-/- αβ T cells showed preferential differentiation towards the TH2 lineage, as seen by 
increased production of IL-4 and IL-5 by T cells, although IL-2 production (but not 
IFN-γ) was also increased compared to wt cells [222]. Itch
-/- αβ T cells were also shown 
to drive the expansion of B1b cells and elevated IgM levels; elevated IgE levels were 
also observed in Itchy mice and these were induced by IL-4 production by Itch
-/- γδ T 
cells [224]. Unlike conventional B cells (B2 cells), B1 cells undergo self renewal in the 
periphery and have no memory; B1b cells, unlike B1a cells do not express CD5 [225].  
Itch’s effects on T cell differentiation appear to be mediated by JunB [226], a 
transcription factor whose degradation diminishes the transcription of Il4, a critical gene 
for TH2 differentiation [227]. Itch can polyubiquitinate JunB via K48 linkage, targeting 
it  to  the  proteasome,  after  being  activated  by  Jnk  [222,  226,  228].  Itch  can  also 
ubiquitinate c-Jun, but in this case, this action is antagonised by c-Abl, which following 
localisation to the nucleus after T cell activation phosphorylates c-Jun, preventing its 
ubiquitination and targeting for degradation by Itch [229]. 
Itch can itself be phosphorylated in its proline-rich region (Ser199, Ser232 and 
Thr222) by activated Jnk following TCR stimulation [222] and this phosphorylation is 
necessary to disrupt an inhibitory interaction between the WW domain of Itch and its 
catalytic HECT domain, inducing the catalytic activity of Itch [226, 228]. By contrast, 
Fyn-mediated phosphorylation of Tyr371 leads to reduced activity of Itch [230] while 34
CTLA-4-mediated signal transduction leads to de-phosphorylation of Itch, activating it 
and  leading  to  increased  overall  ubiquitination  of  proteins;  knocking  down  Itch 
prevented  CTLA-4-mediated  inhibition  of  IFN-γ  and  IL-4  but  not  IL-2  mRNA 
upregulation [231]. Nedd4 family interacting protein 1 (Ndfip1), which is upregulated 
after T cell activation, binds to and can also lead to Itch activation, contributing to the 
degradation of JunB [232]. 
Studies of the maintenance phase of anergy revealed PKCθ as another potential 
target of Itch as, while ionomycin-induced anergic wt T cells showed a decrease in 
PKCθ  protein  expression  after  anti-CD3-stimulation  of  T  cells,  Itch
-/-  ionomycin-
anergised T cells did not show this effect [183]. Also, Itch was shown to be relocated 
from  the  cytoplasm  to  the  detergent-insoluble  fraction  of  the  cell,  probably  the 
endosomes  or  endocytic  vesicles,  when  anergic  cells  are  re-stimulated  with  antigen 
[183]. 
1.6.1.1.3 Grail 
Grail is a transmembrane RING-type single polypeptide E3 ligase of 62-66 kDa 
that has been reported to localise to endosomal compartments [233]; an intact RING 
finger domain is required for its function as an E3 ligase [233]. Grail mRNA was found 
in the brain, kidney, heart, liver, ovary, testes and thymus [233] and has been reported 
to be upregulated in a T cell line, after re-stimulation of such anergised T cells with 
peptide antigen [233]. In addition, following ionomycin-mediated anergy of a clonal T 
cell line, Grail protein expression was also found to be upregulated when compared to 
the  naïve  T  cells  and  this  upregulation  depended  on  calcineurin  signalling  [233]. 
Consistent with this, expression of Grail in retrovirally-transduced T cell hybridomas 
limited anti-CD3+anti-CD28-induced IL-2 and IL-4 production [233]; this was found to 
be  dependent  on  the  ubiquitination  activity  of  Grail  and  its  actin-driven  endocytic 
trafficking [233]. 
Further work explored the correlation between expression of Grail and functional 
outcome. For instance, in CD4
+KJ1-26
+ T cells, Grail mRNA levels were found to be 
upregulated 3 d after immunisation with peptide in a tolerising regime when compared 
to  those  from  untreated  mice  or  mice  immunised  with  peptide  plus  LPS  (priming 
protocol) [234]. Also, constitutive expression of Grail in naïve CD4
+ T cells was found 
to result in reduced proliferation and IL-2 production levels, while a dominant-negative 
form of Grail prevented the reduced proliferation and IL-2 production levels associated 
with tolerising stimuli [234]. Another study showed that Grail mRNA expression was 35
found to be high in resting and stimulated TH1 cells; however, while TH1 Grail
-/- T cells 
produced more IFN-γ than Grail
+/+ cells, neither TH2 nor TH17 Grail
-/- T cells produced 
more IL-4 or IL-17, respectively, than their wt counterparts [235]. 
Regarding the maintenance phase of anergy, initial experiments in a T cell line 
showed Grail mRNA expression to be upregulated after re-stimulation of anergised cells 
with peptide-antigen, when compared to unstimulated cells [233]. Moreover, Grail
-/-
mice stimulated under tolerising conditions show no reduction of proliferation and IL-2, 
IL-4 and IFN-γ production after re-stimulation when compared to unstimulated mice 
and  wt  mice  stimulated  under  tolerising  conditions  [236].  Consistent  with  Grail-
deficiency  preventing  the  onset  of  tolerance,  aged  Grail
-/-  mice  also  showed 
splenomegaly, increased size of mesenteric lymph nodes, lymphocyte infiltration of the 
lungs and high titers of anti-dsDNA antibodies [236]. Moreover, a putative role in the 
development of autoimmune diseases was implicated by the findings that Grail
-/- mice 
displayed exacerbated experimental autoimmune encephalomyelitis [236]. Suppression 
of Grail expression was also found to prevent the immune hyporresponsiveness that 
develops as a result of chronic schistosomiasis [237]. 
There is a strong association between Grail expression and some of the functional 
hallmarks of anergy, such as reduced cytokine production. However, Grail function in 
peripheral tolerance is certainly not restricted to T cell anergy.  For instance, forced 
expression  of  Grail  in  a  T  cell  line  was  sufficient  for  conversion  to  a  suppressor 
phenotype in a contact-dependent manner [238]. In fact, it was found Grail mRNA and 
protein are more highly expressed in naturally occurring Treg cells than in effector T 
cells  [238].  Also,  in  a  systemic  model  of  peptide-specific  tolerance  induction  via 
intravenous peptide administration, adaptive Treg cells were induced which expressed 
higher  levels  of  Grail  mRNA  than  either  tolerised  or  primed  effector  cells  [238]. 
Moreover, in Treg cells from Grail
-/- mice, expression of TH17 cell-specific genes IL-17, 
IL-21, RORα and RORγ were found to be upregulated when compared to wt Treg cells 
[236]. Unlike the previous forced expression studies, here Grail was not found to be 
required for the generation of naturally occurring or adaptive Treg cells but was instead 
found to be required for their suppressive functions [236]. Another group showed Grail-
deficient  T  cells  had  increased  proliferation  and  IL-2  production  in  vitro  when  re-
stimulated after ionomycin- or TGF-β-induced anergy, or when stimulated while co-
cultured with Treg cells from either Grail
-/- or Grail
+/+ mice. In addition, Grail
-/- Treg cells 
were less effective in suppressing Grail
+/+ effector T cells further implicating Grail in 
the suppressive functions of Treg cells [235]. Grail is thought to be required for these by 36
means of mediating the suppression of the TH17 cell-specific genes [236]. For instance, 
IL-21  production  is  promoted  by  NFATc1;  in  Grail-deficient,  anti-CD3  stimulated, 
naïve T and Treg cells, NFATc1 mRNA expression is upregulated [236] whereas, in wt 
cells, it is proposed that NFATc1 mRNA expression decreases due to Grail-mediated 
proteasomal degradation of the TCR-CD3 complex [236]. However, unlike the situation 
in murine cells, Grail expression in human CD4
+CD25
+ T cells is no higher than in 
CD4
+CD25
- T cells [239]. Nevertheless, in humans, it was found that the level of Grail 
mRNA expression in CD4
+ T cells is higher in ulcerative colitis patients in remission 
than  in  those  from  healthy  humans  or  active  ulcerative  colitis  patients  [239].  By 
contrast, in vitro ionomycin-induced anergic CD4
+ T cells from human peripheral blood 
express more Grail, Itch and c-Cbl mRNA than unstimulated cells [239]. Moreover, 
another  study  in  human  CD4
+  T  cells  in  which  Jagged-1-induced  Notch  signalling
during stimulation inhibits T cell proliferation and TH1- and TH2-associated cytokine 
production,  whilst  re-stimulation  induces  normal  proliferation  but  inhibits  cytokine 
production  [240],  revealed  that  this  T  cell  hyporresponsiveness  was  found  to  be 
associated with up-regulation of Grail, while c-Cbl and Itch did not vary much [240]. 
The mechanisms associated with the above Grail-mediated mechanisms of anergy 
are not clear but it was found that anergic DO11.10 T cells (induced by ionomycin), re-
stimulated  with  peptide  pulsed  A20  B  cells,  exhibited  severe  disruption  of  actin 
polarisation, unlike (re-)stimulated naïve DO11.10 T cells [241], suggesting that Grail 
may be involved in the formation of unstable IS in anergic T cells. This impaired actin 
polarisation in re-stimulated anergic T cells was indeed found to require Grail, as shown 
by  siRNA  knockdown  experiments  [241]  and,  corroborating  this,  increased  Grail 
expression results in reduced T cell:APC conjugation efficiency [241]. 
Therefore, Grail may promote decreased proliferation and cytokine production via 
regulation of mediators of actin reorganization that is triggered by CD28 co-stimulation 
and  is  required  for  productive  IS  formation  and  endocytic  traffic.  As  to  which 
intermediaries might be affected, in Grail-overexpressing cells Vav1 phosphorylation 
levels were no different than those of control cells in the initial minutes after TCR 
ligation, just as there were no differences in calcium flux and LFA-1 function [241]. 
Also, consistent with this model, no differences in the activation status of p38 or Erk in 
Grail-overexpressing cells was observed [233, 241]; however the effect of Grail on Jnk 
activation is disputed as Grail-overexpressing cells were reported to exhibit reduced Jnk 
phosphorylation  in  the  initial  minutes  after  TCR  ligation  [241]  while  other  work 
reported the Jnk pathway as not being affected [233, 242]; these latter two studies both 37
involved ionomycin+PMA activation, in which Jnk phosphorylation proceeds as usual 
[115] and this may explain why the other group did find modulation of Jnk activation by 
Grail, using a non-ionomycin+PMA approach. 
Grail  has  also  been  found  to  bind  and  ubiquitinate  Rho  guanine  dissociation 
inhibitor  (RhoGDI),  favouring  its  binding  to  and  sequestration  of  RhoA  from  the 
membrane (where RhoA needs to be for activation [243]) [242]. Consistent with this, 
Grail expression in the Jurkat T cell line inhibited RhoA activation but not Rac1, cdc42 
or  Ras  while  expression  of  constitutively  active  RhoA  overcame  Grail-mediated 
inhibition of IL-2 production [242]. 
Another potential direct target of Grail is CD154, also known as CD40L. CD154 
expression  is  low  and  intracellular  on  naïve  CD4
+  T  cells,  but  following  TCR 
stimulation  cell  surface  CD154  increases  rapidly  within  6–8  h  [244].  Consequent 
CD154-mediated trimerisation of CD40 on mature APCs results in elevation of cell 
surface expression of CD80 and CD86, which in turn bind CD28 on T cells and provide 
reciprocal  bidirectional  costimulatory  signals  for  full  T  cell  activation  [244].  Grail 
upregulation  in  ionomycin-anergised  CD4
+  T  cells,  compared  to  unstimulated  and 
ionomycin+PMA-stimulated cells, was correlated with CD154 downregulation [245]. 
Indeed, Grail was found to bind to the extracellular portion of CD154 and facilitate 
transfer  of  ubiquitin  molecules  from  the  intracellular  RING  domain  to  the  small 
cytosolic portion of CD154, leading to its proteasomal degradation [246]. Grail also 
targets  CD154  trafficking  to  the  cell  surface  through  the  Grail-positive  endosomal 
compartments [245]. However, a recent study did not find CD154 expression changed 
in  Grail-deficient  mice  [235],  perhaps  hinting  at  another,  redundant  regulatory 
mechanism to keep CD154 expression in check. 
Interestingly, Grail has also been implicated in the direct downregulation of the 
TCR:CD3 complex as Grail
-/- CD4
+ T cells anergised via stimulation with anti-CD3 
antibody were showed to express more TCRβ and CD3ζ than wt cells [236]. In fact, 
Grail was demonstrated to downmodulate the TCR-CD3 complex through ubiquitin-
dependent proteasomal degradation [236]. 
Grail is associated with and regulated by two isoforms of the ubiquitin-specific 
protease otubain 1 [247]. Retrovirally transduced otubain 1-expressing T cells contained 
negligible amounts of endogenous Grail, proliferated well and produced large amounts 
of  IL-2  after  ionomycin+PMA  stimulation  [247].  Otubain  1,  whose  expression  is 
positively regulated by the Akt-mTOR pathway [248], thus controls Grail instability by 
promoting its autoubiquitination and degradation [247]. In contrast, cells expressing the 38
alternatively  spliced  isoform,  otubain  1  alternative  reading  frame  1,  contained  large 
amounts of endogenous Grail and were functionally anergic, proliferating poorly and 
producing little or no IL-2 after ionomycin+PMA stimulation [247]. Stabilisation of 
Grail is thus controlled by otubain 1 alternative reading frame 1, which in association 
with  USP8  (a  DUB),  promotes  deubiquitination  and  hence,  prevents  degradation  of 
Grail [247]. 
1.6.1.1.4 Smurfs 
It  has  recently  been  shown  that  Rap1  is  ubiquitinated  by  Smad  ubiquitination 
regulatory factor-2 (Smurf2), in developing neurons [249]. The ubiquitination of Rap1 
by this HECT domain E3 ubiquitin-protein ligase targets it for proteasomal degradation 
and,  by  doing  so,  restricts  its  expression  to  a  single  neurite  in  developing  neurons, 
which  is  necessary  to  ensure  neurons  extend  only  one  axon  [249].  Although  only 
inactive  Rap1  is  a  substrate  for  Smurf2,  increased  Smurf2  expression  allows  the 
complete degradation of Rap1 [249]. Similarly, the closely related Smurf1 has been 
shown to regulate cell polarity and motility in tumour cells by the ubiquitination of 
another GTPase, RhoA [250]. Smurf1 is recruited to the leading edge of the cell by 
PKCζ where it regulates the local level of active RhoA [250]. 
Both Smurf1 and Smurf2 form complexes with Smad proteins, which allows both 
proteins to be exported from the nucleus to the cytoplasm [251, 252]. For example, the 
active Smurf2-Smad7 complex will promote the ubiquitination of TGF-β receptors, thus 
terminating TGF-β signalling [252]; in the end Smurf2 ubiquitinates itself and Smad7, 
promoting the degradation of the complex [253]. In human breast cancer MDA-MB-231 
cells, Smurf2 also interacts with Smurf1, ubiquitinating it and promoting its degradation 
and inhibiting the migration of the cancer cells. By contrast, Smurf1 failed to induce 
degradation of Smurf2 [254]. 
These  data  illustrate  the  direct  role  of  the  Smurf  proteins  in  regulating  some 
signalling proteins also involved in T cell activation. As this regulatory role involves the 
selected,  localised  targeting  of  signalling  intermediaries  for  ubiquitination  and 
proteasomal degradation it is possible Smurf1 and/or Smurf2 are active and playing a 
similar role in events that lead to T cell anergy. 39
1.7 Aims 
The  core  aim  of  this  work  is  to  identify  key  differential  signalling  events  in 
antigen-specific T cells that direct priming or tolerance, at the single cell level both in 
vitro and in vivo. In particular, the investigation of the role of the E3 ubiquitin-protein 
ligases, such as Cbl-b, Itch and Grail in the induction and maintenance phases of anergy 
will  take  centre  stage.  The  working  hypothesis  is  that  Cbl-b,  Itch  and  Grail  are 
differentially upregulated during the induction of anergy and contribute to its onset by 
promoting ubiquitin-mediated downregulation of specific key signalling elements that 
transduce  TCR-mediated  priming,  thus  preventing  T  cell  proliferation  and  cytokine 
production; it is also hypothesised that after re-stimulation of anergic T cells these E3 
ligases would remain highly expressed and further contribute to the maintenance phase 
of the anergic state. In order to address the role of Cbl-b, Itch and Grail in the induction 
and maintenance phases of anergy, their expression and localisation in tolerised and 
primed  antigen-specific  CD4
+  T  cells  in  vitro  and  in  vivo  will  be  determined  and 
following assessment of the expression and ubiquitination levels of the TCR signalling 
machinery these parameters will be correlated with the functional responses of priming 
or  tolerance.  Functional  parameters  for  priming  or  tolerance  such  as  cytokine 
production, proliferation and migration into B cell follicles (priming) versus cell cycle 
arrest and apoptosis (tolerance) will be analysed. 40 
Figure 1.1: The TCR:CD3 complex structure. 
The TCR consists of two chains, each comprising an amino-terminal domain which 
exhibits marked sequence variation and a constant domain; the most common form of 
association of the two chains in T cells is the αβ heterodimer. Each TCR chain also 
contains  a  short  connecting  sequence  which  connects  to  the  other  chain  of  the 
heterodimer - not depicted - and a transmembrane region which anchors each chain in 
the  plasma  membrane,  allowing  the  TCR  to  interact  with  the  chains  of  the  CD3 
complex. While the TCR recognises and binds its peptide, the CD3 complex signals to 
the cell that antigen has bound. The CD3 complex comprises two heterodimers, made of 
γε and δε chains, and a homodimer of ζζ; the cytoplasmic tails of the γ, δ , ε, and ζ
chains contain the ITAM signalling motif which forms the basis of TCR signalling. ε ε ε ε δ δ δ δ γ γ γ γ ε ε ε ε
ζ ζ ζ ζ ζ ζ ζ ζ
α α α α β β β β
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Figure 1.2 T cell development takes place in the thymus. 
The earliest precursor T cells, the haematopoietic stem cells (HSC) enter the thymus via 
venules near the cortico-medullary junction. The developing T cells (thymocytes) are 
initially  double-negative  (DN;  ie,  not  expressing  CD4  or  CD8)  and  CD44
+CD25
-
(DN1), and go through a controlled program of gene expression that leads them to DN2 
(CD44
+CD25
+), DN3 (CD44
lowCD25
+, with expression of pre-TCR) and DN4 (CD44
-
CD25
-,  still  expressing  pre-TCR).  As  thymocytes  turn  double-positive  (DP; 
CD4
+CD8
+), they re-arrange the α-chain locus and form the TCR αβ heterodimer in 
association with CD3, being ready to recognise peptide:self-MHC molecules; however, 
most  double-positive  thymocytes  die  by  failing  to  be  positively  selected  or  as  a 
consequence of negative selection. Eventually, some DPs cease to express one of the 
two co-receptor molecules, becoming either CD4 or CD8 single-positive cells (SPs), 
which will exit the thymus to form the peripheral T cell repertoire. The cortical stroma 
is composed of epithelial cells which contribute to thymocyte’s proliferation and cell 
survival; they also express both MHC class I and MHC class II, which determine the 
thymocyte's fate during positive selection. After positive selection thymocytes migrate 
from the cortex to the medulla, which plays a role in negative selection. DCs, which 
express co-stimulatory molecules absent from the cortex, and medullary epithelial cells, 
which express tissue-specific and developmental-specific peptides, can be found in this 
environment. DN1
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DN4
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CD4+ SP CD8+ SP
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Figure 1.3: Optimum activation of naïve T cells requires two signals. 
Engagement of the TCR by peptide:MHC complex (signal 1) in the absence of co-
stimulation can lead to T cell anergy and/or apoptosis. In order for T cells to proliferate 
and  begin  the  process  of  differentiation  and  production  of  effector  cytokines, 
CD80/CD86  engagement  of  CD28  (signal  2)  must  take  place  alongside  TCR 
engagement  by  peptide:MHC  complex.  APCs, namely  DCs,  upregulate  CD80/CD86 
expression after maturation, which occurs after activation by the pathogen’s products, 
ensuring immune responses develop only when needed.DC DC
T cell T cell
TCR TCR
Proliferation
Differentiation
Effector function
Anergy
Apoptosis
CD28 CD28
MHC
Ag
MHC
Ag
CD80/8643 
Figure 1.4: T cell differentiation. 
Activation of naïve CD4
+ TH cells leads to the generation of a clone of effector TH cells. 
Effector cells of different types can be generated, depending on the cytokine milieu in 
which the antigenic stimulus is received. This milieu is strongly influenced by mature 
DCs,  which  produce  different  cytokines  depending  on  the  environmental  conditions 
along  with upregulation of CD80/CD86. These cytokines are the basis for the third 
signal, which is required for T cell differentiation. Differentiation of TH1 cells requires 
IFNγ  and  IL-12;  this  clone  expresses  the  signature  transcription  factor  T-bet  and 
produces IL-2, IFNγ and TNF-α. Differentiation of TH2 cells requires IL-4 and they can 
produce IL-4, IL-5, IL-6, IL-10 and IL-13; the transcription factor GATA-3 is required 
for their differentiation. Differentiation of TH17 cells requires TGF-β and  IL-6; this 
clone expresses the signature transcription factor RORγt and produces IL-17A, IL-17F, 
IL-6 and IL-21. I
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Figure 1.5: Lymph node structure. 
Lymph nodes are enveloped by a fibrous capsule and have three distinct regions: cortex, 
paracortex and medulla. The cortex, located closer to the periphery of the LNs, contains 
B cells and FDCs. In the centre of the LN lies the paracortex, which is composed of T 
cells  and  DCs.  The  medulla  consists  of  lymphatic  tissue.  T  and  B  cells  circulate 
constantly through the LN by entering via the high endothelial venules (HEVs) and 
exiting via efferent lymphatic vessels, together with lymph. Lymph draining from the 
extracellular spaces of the body carries antigens and DCs from the tissues to the LNs via 
the afferent lymphatics vessels. T cells migrate to the paracortex where they encounter 
DCs; T cells that do not encounter their specific antigen leave the LN to return to the 
circulation while T cells that encounter their specific antigen on the surface of mature 
DCs proliferate, differentiate and migrate to the follicular areas where they provide B 
cell  help.  Some  follicles  may  contain  areas  of  intense  B  cell  proliferation  called 
germinal centers; FDCs attract naïve and activated B cells to the follicles. Primed T 
cells will themselves exit the LN after a few rounds of proliferation. C
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Figure 1.6: TCR-mediated signalling. 
TCR binding by the MHC-peptide complex results in the activation of Fyn, associated 
with CD3, and Lck, associated with CD4. Activated Lck and Fyn then phosphorylate 
the  ITAMs  of  CD3,  allowing  the  recruitment  and  activation  of  ZAP-70.  ZAP-70 
phosphorylates  LAT,  which  delivers  the  activation  signals  through  recruitment  and 
assembly  of  a  signalosome  containing  Grb2,  GADS,  SLP-76  and  PLCγ-1.  PLCγ-1, 
hydrolyses PIP2 to yield IP3 and DAG. IP3 binds to its receptor on the membrane of the 
ER  triggering  Ca
2+  release  and  subsequent  Ca
2+  influx  through  plasma  membrane 
channels; this leads to an increased intracellular Ca
2+ concentration which will lead to 
the activation of calcineurin. Activated calcineurin de-phosphorylates NFAT, allowing 
its  translocation  to  the  nucleus  where  it  associates  with  other  transcription  factors, 
promoting  transcription  of  many  genes.  DAG  promotes  membrane  association  and 
activation of PKCθ and RasGRP1. PKCθ mediates the phosphorylation of Carma1, an 
event that induces binding of Carma1 to Bcl10 and Malt1, thus forming the Carma1-
Bcl10-Malt1  (CBM)  complex.  Malt1,  acting  from  the  CBM  complex  promotes  the 
activation of the IKK complex (by recruiting Traf6). Once activated, the IKK complex 
phosphorylates IκB, releasing it from NF-κB, and thus allowing NF-κB to translocate to 
the  nucleus,  where  it  will  promote  gene  transcription.  RasGRP1  promotes  the 
conversion  of  Ras  to  its  activated  form  and  active  Ras  recruits  Raf  to  the  plasma 
membrane,  allowing  its  activation.  Raf  phosphorylates  MEK,  which,  in  turn, 
phosphorylates  Erk.  Erk  activation  leads  to  the  activation  of  c-Fos,  allowing  the 
formation of the heterodimeric transcription factor AP-1. Lck
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Figure 1.7: CD28-mediated signalling. 
TCR binding by the MHC-peptide complex in the presence of CD28 co-stimulation 
allows the full activation of the signalling events which lead to T cell priming. In this 
figure, signalling events induced by the TCR-mediated signalling are also depicted, but 
not  described;  see  text  and  Figure  1.6  for  explanation  on  them.  CD28  engagement 
enhances TCR proximal signals through Lck and PI3K. Activated PI3K converts PIP2
into PIP3 which allows the recruitment of cytoplasmic proteins containing pleckstrin 
homology domains to the plasma membrane, such as PDK1,  Akt and  Vav1. Akt is 
activated by PDK1 and will contribute to the activation of NF-κB by what is thought to 
be indirect activation of the IKK complex. PDK1 may also phosphorylate PKCθ thus 
contributing  to  its  full  activation  and  hence,  leading  to  more  NF-κB  nuclear 
translocation. Vav1 requires Fyn, ZAP-70 and PIP3 to become fully activated. Activated 
Vav1 associates with phosphorylated SLP-76 and then activates the plasma membrane-
localised Cdc42 and Rac, which in turn activate Pak1 and Pak3. The Paks will activate 
MKK4, which in turn phosphorylates Jnk, thus activating it resulting in phosphorylation 
of  Jun.  The  Paks  also  activate  MKK3/6,  which  in  turn  phosphorylates  p38  MAPK. 
Similarly to Erk, p38 MAPK contributes to the activation of c-Fos, and the activation of 
c-Fos and Jun resulting from Erk, p38 and Jnk MAPkinase recruitment allows formation 
of the heterodimeric transcription factor AP-1, which is necessary for IL-2 transcription. Lck
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Figure 1.8: Signalling in anergy induction. 
In this figure, some of the signalling events induced by TCR ligation are also depicted, 
but not described in full; see text and Figure 1.6 for explanation on them. In anergy 
induction, Ca
2+ flux and the subsequent mobilisation of NFAT occurs as in priming. 
However,  in  the  absence  of  co-stimulatory  signalling,  AP-1  and  NF-κB  are  not 
activated,  and  hence  the  priming  program  can  not  be  completed;  without  these  two 
transcriptional factors, NFAT promotes the transcription of anergy-inducing genes, such 
as Egr2, Egr3, Ikaros, DGK, Cbl-b, Itch and Grail. The Egr proteins will further drive 
the induction of the anergic transcriptional programme, while Ikaros acts as a repressor 
of Il2 transcription by binding to the Il2 promoter. DGK converts DAG into PA, thus 
depleting  its  levels  and  preventing  full  activation  of  PKCθ  and  RasGRP1.  Fyn 
activation  leads  to  a  decrease  in  the  levels  of  Lck,  in  the  absence  of  CD28-co-
stimulation. Fyn is also involved in the Fyn-Cbl-CrkL-C3G-Rap1 signalling complex 
which allows Rap1 to sequester Raf1 from Ras, thus preventing Erk phosphorylation. In 
the  absence  of  CD28  co-stimulation,  p27
kip1  is  found  inhibiting  CDK1/2,  thus 
preventing cell cycle progression. Also in the absence of CD28 co-stimulation, Cbl-b 
ubiquitinates the p85α  regulatory subunit of PI3K, inhibiting PI3K signalling. Grail 
ubiquitinates RhoGDI, allowing its sequestration of RhoA, and preventing cytoskeletal 
polarisation. Itch and Cbl-b can also promote the downregulation of PLCγ-1. Lck
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Figure 1.9: Signalling in the maintenance phase of anergy. 
When anergic T cells re-encounter antigen in the context of CD28 co-stimulation, the 
genes that were induced or upregulated during the induction phase will come into play 
to maintain the hyporresponsive state of the cell. Some of the mechanisms are the same 
as those in effect during anergy induction. For instance, Ikaros acts as a repressor of Il2
transcription by binding to the Il2 promoter, possibly with the help of the Egr proteins. 
DGK converts DAG into PA, thus depleting its levels and preventing full activation of 
PKCθ and RasGRP1. The Fyn-Cbl-CrkL-C3G-Rap1 signalling complex allows Rap1 to 
sequester Raf1 from Ras, thus preventing Erk phosphorylation. In the absence of CD28-
dependent  Akt  signalling,  p27
kip1  inhibits  CDK1/2,  thus  preventing  cell  cycle 
progression. Itch and Cbl-b promote the downmodulation of PLCγ-1 and PKCθ. Itch 
can also ubiquitinate Jun, targeting it to degradation in the proteasome; the activity of 
Jun can also be prevented by p27
kip1, which also inhibits cytoskeletal polarisation via
inhibition of RhoA, which is also inhibited by Grail.  Fyn
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Figure 1.10: The immunological synapse. 
A mature IS has a specific arrangement in which molecules are arranged in distinct 
spatial  domains:  smaller  molecules  such  as  the  TCR,  CD4  and  CD28  form  a  large 
molecular platform called the central supramolecular activation complex (cSMAC) at 
the  T  cell-APC  contact  site;  larger  molecules  such  as  LFA-1  and  talin  form  the 
peripheral SMAC (pSMAC). C
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Figure 1.11: Ubiquitination. 
The  steps  involved  in  ubiquitination  are  as  follows:  an  ubiquitin-activating 
enzyme (E1) binds ubiquitin. The activated ubiquitin molecule is then transferred to an 
ubiquitin-conjugating enzyme (E2). The ubiquitin-E2 complex is then recruited by a 
third  enzyme,  an  ubiquitin-protein  ligase  (E3),  which  specifically  binds  a  protein 
substrate and facilitates the transfer of ubiquitin from the E2 to the target protein. Upon 
the addition of the first ubiquitin to the substrate, several other ubiquitins may be added 
(polyubiquitination)  essentially  by  repetition  of  the  same  biochemical  reaction. 
Polyubiquitination  can  develop  through  isopeptide  bonds  between  glycine  76  of  the 
activated ubiquitin and  the ε  group of one of seven lysines of the ubiquitin moiety 
already attached to the substrate; the most commonly found polyubiquitin chains are 
those  composed  of  ubiquitins  linked  through  lysine  48  (K48)  and  lysine  63  (K63). 
Alternatively,  a  substrate  can  be  tagged  with  a  single  ubiquitin  molecule 
(monoubiquitination) and such monoubiquitination can occur on a single lysine residue 
or on several lysine residues, leading to multiubiquitinated substrates. It is important to 
appreciate  that  ubiquitination  is  a  reversible  process,  the  removal  of  ubiquitin  from 
proteins  being  carried  out  by  deubiquitylation  enzymes  (DUBs).  Substrates  with  a 
polyubiquitin chain of four or more ubiquitins linked through K48 are targeted to the 
26S proteasome, where they are degraded. Monoubiquitination, multiubiquitination and 
polyubiquitination via K63 of a substrate protein usually result in different regulatory 
outcomes other than proteasomal degradation of the protein. A
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CHAPTER 2 
MATERIALS AND METHODS 52
2 MATERIALS AND METHODS 
2.1 Animals 
DO11.10 TCR transgenic mice on a BALB/c background were used as donors of 
defined antigen-specific T cells [255]. These transgenic T cells recognize OVA323-339/I-
A
d  and  are  detectable  using  the  KJ1-26  clonotypic  antibody,  allowing  studies  in  a 
defined, clonal T cell population [256]. 
BALB/c  (H-2
d,  IgM
a)  mice,  as  well  as  DO11.10  TCR  transgenic  mice  on  a
BALB/c background, were used as donors of DCs. The BALB/c is an inbred mouse 
strain originated in 1923 by McDowell. All animals were maintained under standard 
animal house conditions and in accordance with Home Office regulations. 
2.2 Reagents and cell culture 
All  cell  culture  reagents  were  purchased  from  Invitrogen  (UK)  whilst  other 
experimental  reagents  were  from  Sigma-Aldrich  (UK)  unless  otherwise  stated.  Cell 
culture was carried out under aseptic conditions in an incubation chamber at 37ºC with 
5% CO2. 
2.3 Preparation of primary murine T cells for in vitro analysis 
2.3.1 Extraction of lymph node cells 
Peripheral  (axillary,  brachial,  inguinal,  cervical  and  popliteal)  (PLNs)  and 
mesenteric lymph nodes (MLNs) were removed from DO11.10 TCR transgenic mice, 
pooled and forced through Nitex (Cadisch Precision Meshes, UK) to generate single cell 
suspensions. The cells were washed in sterile RPMI-1640 medium, counted by trypan 
blue exclusion and the percentage of CD4
+KJ1-26
+ T cells was determined by flow 
cytometry (as described in section 2.5.1.1 and Figure 2.1). 
2.3.2 Isolation of CD4
+ T cells 
Where indicated, CD4
+ T cells were isolated by negative selection via indirect 
magnetic labelling of non-CD4
+ T cells. The  method, as supplied and described by 
Miltenyi Biotec (UK), consists of labelling non-CD4
+ T cells (cytotoxic T cells, B cells, 53
NK cells, DCs, macrophages, granulocytes and erythroid cells) with a cocktail of biotin-
conjugated monoclonal antibodies (against CD8a (Ly-2), CD45R (B220), DX5, CD11b 
(Mac-1) and Ter-119) and, later, binding these with anti-biotin monoclonal antibodies 
coupled to MicroBeads. The magnetically labelled non-CD4
+ T cells are depleted by 
retaining them on a MACS column in the magnetic field of a MACS separator, while 
the unlabelled CD4
+ T cells pass through the column. 
The steps involved in the process were as follows: cells were centrifuged (300 g, 
10 min) and the pellet re-suspended in 40 µl of MACS buffer (PBS, 0.5% bovine serum 
albumin  (BSA),  2  mM  EDTA)  per  10
7  total  cells,  and  incubated  with  the  biotin-
conjugated antibodies (10 µl per 10
7 total cells, for 10 min). Anti-biotin MicroBeads (20 
µl per 10
7 total cells) in 30 µl of MACS buffer (per 10
7 total cells) were added and 
incubated for 15 min. Cells were washed in MACS buffer and centrifuged (300 g, 10 
min). After assembling the LS column in the SuperMACS separator and washing it, the 
cell pellet was re-suspended in 500 µl of MACS buffer (per 10
8 total cells) and added to 
the column. The effluent (unlabelled cells) was collected. All procedures were carried 
out at 4ºC. 
2.3.3 Stimulation of murine T cells 
DO11.10 TCR transgenic T cells were cultured at a concentration of 10
6 cells/ ml/ 
well  in  complete  medium  (RPMI-1640,  10%  FCS,  2  mM  L-glutamine,  100  U/ml 
penicillin,  100  U/ml  streptomycin,  0.05  mM  β–mercaptoethanol)  with  1  µg/ml 
immobilised  anti-CD3  antibody  (clone  145-2C11,  BD  Pharmingen)  for  the  time 
indicated in the absence or in the presence of 1 µg/ml anti-CD28 antibody (clone 37.51, 
BD Pharmingen) to induce anergy or priming, respectively [49, 51, 130, 257, 258]. 
Anti-CD3 antibody was immobilised by incubation for 3 h at 37
oC in the plastic plate; 
immobilised anti-CD3 antibody will be referred throughout the thesis as anti-CD3 or α-
CD3. Alternatively, T cells were cultured in complete medium and stimulated with 200 
ng/ml  ionomycin  or  200  ng/ml  ionomycin  plus  20  ng/ml  phorbol  12-myristate  13-
acetate (PMA) in order to induce anergy or priming, respectively [222, 235, 259-261]. 
There was also a population of T cells cultured in vitro that received no stimulus; this 
control group was termed naïve T cells. 
Where  indicated,  the  proteasome  inhibitor  lactacystin  (Biomol/Enzo  Life 
Sciences, UK) was added to the T cell culture at a concentration of 25 µM [262, 263]. 54
2.3.4 Analysis  of the maintenance phase of anergy and  priming  of T 
cells 
2.3.4.1 Production of GM-CSF-conditioned media 
The supernatant from GM-CSF-secreting X63 myeloma cell line was used as the 
source of GM-CSF for the generation of DCs. X63 cells were quickly thawed at 37ºC 
from liquid nitrogen, washed and plated in 5 ml complete medium supplemented with 
0.5  mg/ml  G418.  After  one  week  cells  were  re-suspended  in  fresh  complete  media 
without G418 and split. A week later cells were centrifuged, the supernatant stored at -
20ºC and the cells re-plated. Further rounds of cell culture and supernatant recovery 
ensued. The supernatant contains highly concentrated granulocyte-macrophage colony-
stimulating factor (GM-CSF) secreted by the X63 cells and was filter-sterilised before 
freezing. 
2.3.4.2 Generation of DCs 
Single  cell  suspensions  were  generated  from  harvested  bone  marrow  from 
BALB/c mice. Cells were counted by trypan blue exclusion and DC progenitors were 
plated at 2 x 10
5 cells/ml in DC media (RPMI-1640, 10% GM-CSF-conditioned media, 
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 0.05 mM 
β–mercaptoethanol). DC cultures were subsequently fed at day three after plating with 
further 10 ml of DC media per plate. At day 6 after plating, 10 ml of media from each 
plate was removed and the DCs were fed with 10 ml of DC “reduced” media (RPMI-
1640,  5%  GM-CSF-conditioned  media,  10%  FBS,  2  mM  L-glutamine,  100  U/ml 
penicillin, 100 U/ml streptomycin, 0.05 mM β–mercaptoethanol). 
2.3.4.3 Maturation and stimulation of DCs 
Day  8  DCs  were  matured  with  1  µg/ml  of  LPS  (Salmonella  abortus,  Sigma-
Aldrich) for 24 h before being loaded with 1 µg/ml of OVA323-339 peptide for 2-3 h and 
then washed. 
2.3.4.4 Re-stimulation of DO11-10 TCR transgenic T cells 
DO11.10 TCR transgenic T cells were extracted from mice and incubated with 
anti-CD3 or anti-CD3 plus anti-CD28 for 48 h, as described before. After that time, 
cells were washed twice with RPMI-1640, re-plated and rested in complete in complete 
medium for an additional 48 h. Following the induction of anergy or priming, the viable 55
transgenic  T  cells  were  counted  by  trypan  blue  exclusion  and  re-stimulated  by  co-
culture with LPS-matured, OVA323-339-loaded DCs at a ratio of 1:1 (5 x 10
5 DO11.10 
TCR transgenic T cells + 5 x 10
5 DCs in 2 ml medium/ well) for 1 and 20 h in 6-well
plates (Corning, Netherlands). Freshly extracted (naïve)  DO11.10 TCR transgenic  T 
cells were also co-cultured with LPS-matured, antigen-pulsed DCs for the same periods 
of  time.  After  that,  all  cells  were  scraped  off  the  bottom  of  the  plates  and,  where 
indicated, DO11.10 TCR transgenic T cells and non-DO11.10 cells were separated and 
isolated. 
2.3.4.5 Isolation of DO11.10 TCR transgenic T cells 
DO11-10 TCR transgenic T cells were isolated by MACS. For this, a positive 
selection protocol was used. Here, magnetically-labelled cells are first retained in the 
column and, after the unlabelled cells run through and after the column is removed 
away from the magnetic field, later recovered. Cells extracted from lymph nodes were 
incubated with biotin-conjugated KJ1-26 antibody and later anti-biotin MicroBeads, in 
an  analogous  manner  to  that  for  CD4
+  T  cells  isolation  by  negative  selection.  The 
unlabelled cells (non-DO11.10 cells) were collected, after which the LS column was 
removed from the separator and placed on a new collection tube. MACS buffer was 
added to the column and the magnetically labelled cells (DO11.10 TCR transgenic T 
cells) were flushed out and collected. 
2.4 In vivo tolerance assay 
2.4.1 Preparation and purification of T cell suspensions 
Lymph  nodes  and  spleen  were  removed  from  DO11.10  TCR  transgenic  mice, 
pooled and forced through Nitex to generate single cell suspensions. CD4
+ T cells were 
purified from freshly harvested tissue using T cell enrichment immunocolumns (VH Bio 
Ltd, UK) according to the manufacturer’s instructions. Briefly, single cell suspensions 
were layered over Lympholyte-M media and centrifuged at 1000 g for 20 min at room 
temperature (RT). The lymphocyte layer was then carefully removed from the interface, 
diluted to a final volume of 10 ml in PBS, centrifuged at 1000 g for 5 min and re-
suspended in 2 ml PBS. Cell Reagent (1.5 ml, supplied with kit) was added and the total 
volume was made up to 5 ml with PBS before incubation for 20 min at 4ºC. PBS (4 ml) 
was then added and the cells were centrifuged at 1000 g for 5 min and re-suspended in 1 56
ml PBS. Next, the solution was transferred to CD4 negative selection immunocolumns 
(supplied with kit) and PBS was added until 10 ml of eluate was collected. The eluate 
was centrifuged at 1000 g for 5 min and re-suspended in RPMI 1640 medium. The cells 
were washed, counted and the percentage of purified T cells was calculated using flow 
cytometry (by staining an aliquot for CD4
+KJ1-26
+ T cells) [264]. 
2.4.2 Adoptive transfer of antigen-specific T cells 
Enriched (75-85% CD4
+KJ1-26
+ T cells) T cell suspensions were generated from 
lymph nodes and spleens from DO11.10 mice as described above. After calculating the 
number of KJ1-26
+ T cells in the suspension, 3 x 10
6 DO11.10 TCR transgenic T cells 
in  200  µl  sterile  RPMI  1640  medium  were  injected  intravenously  (i.v.)  into  age-
matched, female BALB/c recipients [264, 265].
2.4.3 Administration of antigen 
Recipient  mice  were  injected  with  OVA323-339  (100  µg  i.v.)  in  the  absence  or 
presence  of  1  µg  LPS  in  200  µl  PBS,  to  induce  systemic  tolerance  or  priming, 
respectively, 24 h after adoptive transfer. Naïve mice received the same amounts of PBS 
i.v.. To elicit a secondary response, mice were challenged with OVA323-339 (100 µg i.v. 
in 200 µl PBS) and LPS (1 µg), 7 days later [266-268]. 
2.5 Flow cytometry 
2.5.1 Staining for surface markers 
Aliquots  of  cells  (10
5-10
6  per  sample)  in  5  ml  polystyrene  tubes  (Falcon,  BD 
Pharmingen) were washed with 200 µl cold FACS buffer (0.05% sodium azide, 2% 
FCS in PBS) at 450 g for 5 min at 4°C. Cells were re-suspended in 200 µl Fc receptor 
(FcR) blocking buffer (anti-CD16/32, clone 2.4G2, hybridoma supernatant, 10% mouse 
serum,  0.1%  sodium  azide)  containing  the  appropriate  fluorochrome-conjugated  or 
biotinylated primary antibodies, or the respective isotype controls for 15-30 min in the 
dark, at 4ºC. The FcR blocking buffer blocks non-specific binding of antibody to such 
FcR-bearing cells because anti-CD16/32 binds to FcγRII/III and the immunoglobulin in 
mouse  serum  binds  to  FcγRI.  Details  of  the  antibody  clones,  their  specificities  and 
isotype controls used are provided in Table 2.1. Table 2.2 contains details regarding the 57
different fluorochromes used. Cells were then washed with 1 ml FACS buffer as before 
and, where appropriate, biotinylated antibodies were detected following incubation with 
fluorochrome-conjugated streptavidin for 15-30 min in the dark, at 4ºC. Finally, cells 
were washed again in FACS buffer and re-suspended in 100-300 µl FACSFlow (BD 
Pharmingen)  immediately  before  analysis  using  a  FACSCalibur  (BD  Pharmingen) 
fluorescence-associated cell sorter (FACS) and CellQuest software (BD Pharmingen). 
When  immediate  acquisition  of  events  was  not  possible,  cells  were  fixed  while  in 
suspension  in  FACSFlow  by  adding  1%  formaldehyde.  Two,  three  or  four-colour 
analysis was performed on a minimum of 10,000 events. 
2.5.1.1 Identification of DO11.10 TCR transgenic T cells 
Cells  were  incubated  with  PE-conjugated  anti-CD4  antibody  and  biotinylated 
anti-DO11.10 TCR antibody, or their respective isotype controls, for 20 min at 4ºC. 
Cells  were  then  washed  in  FACS  buffer  and  incubated  with  FITC-conjugated 
Streptavidin  for  10  min  at  4ºC.  Two-colour  flow  cytometry  acquisition  with  a 
FACSCalibur  machine  was  performed  on  20,000  events  and  these  analysed  with 
CellQuest software (Figure 2.1). 
2.5.2 Detection of intracellular signalling molecules 
Cells  were  firstly  stained  for  surface  markers,  prior  to  permeabilisation  as 
described above. For staining intracellular proteins, cells were washed with 1 ml PBS 
before addition of 200 µl Cytofix/Cytoperm solution (BD Pharmingen) for 20 min at 
4ºC and further washing twice with 500 µl Perm/Wash solution (BD Pharmingen) (450 
g, 5 min). The relevant anti-intracellular protein antibodies or their respective isotype 
controls were added in 50 µl Perm/Wash solution/tube and incubated with the cells in 
the dark at RT for 30 min. After washing, cells were incubated with fluorochrome-
conjugated secondary antibody, in the dark at RT for 30 min. Finally, cells were washed 
again,  re-suspended  in  250  µl  FACS  flow  and  analysed  using  FACSCalibur  and 
CellQuest software. 
2.5.3 Biotinylation of KJ1-26 antibody 
The  clonotypic  monoclonal  antibody  KJ1-26  detects  the  transgenic  α/β  TCR 
expressed by DO11.10 mice and was purified from the original hybridoma as described 
previously  [256].  Solutions  containing  1  mg/ml  purified  antibody  were  dialysed 58
overnight  in  Slide-A-Lyzer  dialysis  cassettes  (Pierce)  against  50  mM  Sodium 
Bicarbonate buffer (pH 8.5) at 4ºC and 1 ml aliquots were then mixed with 75 ng Sulfo-
NHS-Biotin  (Pierce)  for  30  min  at  RT.  Free  biotin  was  then  removed  by  dialysing 
overnight with PBS/0.05% NaN3 at 4ºC and the biotinylated antibody stored at 4ºC
[269]. 
2.6 Western Blotting 
2.6.1 Preparation of whole cell lysates 
After stimulation, the reactions were terminated by washing the cells in ice-cold 
PBS. The cell pellets were then re-suspended in 100 µl of ice-cold modified RIPA lysis 
buffer (50 mM Tris buffer, pH 7.4 containing 150 mM sodium chloride, 2% (v/v) NP 
40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA, 10 mM sodium orthovanadate, 0.5 
mM phenylmethylsulfonylfluoride, 10 µg/ml chymostatin, 10 µg/ml leupeptin, 10 µg/ml 
antipain, 10 µg/ml pepstatin A and 10 µg/ml aprotinin). After re-suspending the pellet, 
the cells were solubilised for 30 min on ice before centrifugation of lysates at 16,000 g
for 15 min. The resulting supernatants (whole cell lysates) were stored at -20ºC. 
2.6.2 Protein quantification 
The  protein  concentration  of  the  whole  cell  lysates  was  assessed  by  the  BCA 
protein assay. This method, supplied and described by Pierce, utilizes bicinchonic acid 
(BCA) as the detection reagent for Cu
1+, which is formed when Cu
2+ is reduced by 
protein under alkaline conditions; when two molecules of BCA chelate one Cu
1+ ion, a 
purple-coloured product is formed; this exhibits a strong absorbance at 562 nm, which 
is  linear  with  increasing  protein  concentrations.  Briefly,  5  µl  of  sample,  or  5  µl  of 
differently diluted albumin standards, or 5 µl of water were added to 95 µl of the Micro 
BCA working solution in triplicate in a 96-well plate, incubated for 30 min at RT and 
absorbance values determined by spectrometry (Dynex Technologies, UK). Absorbance 
data was converted into protein concentration with Revelation (Dynex Technologies) 
software. 
2.6.3 SDS Page 
Equal  protein  amounts  of  whole  cell  lysates  were  resolved  using  the  XCell 
SureLock Mini-Cell kit with NuPAGE Novex high-performance pre-cast Bis-Tris gels 59
and NuPAGE buffers and reagents (all supplied by Invitrogen). The appropriate volume 
of 4 x NuPAGE  LDS (Lithium Dodecyl Sulfate) sample buffer and 10 x NuPAGE 
reducing agent were added to the whole cell lysates (sample) prior to heating (70ºC for 
10 min). Sample solutions (40 µl) containing 30 µg of protein was added to each well 
(Seeblue Plus2 marker in buffer was added to one well) and samples were resolved 
using NuPAGE Bis-Tris gels (10%, 12% or 4-12%) with NuPAGE MOPS or MES 
running buffer (supplemented with NuPAGE antioxidant) at 180 V for 1 h following the 
manufacturers instructions. Gels were then transferred onto nitrocellulose membranes 
(Amersham, UK) using NuPAGE transfer buffer with 20% (v/v) methanol at 30 V for 1 
h. 
2.6.4 Western blotting 
Following transfer, nitrocellulose membranes were washed once in TBS/Tween 
(0.5 M NaCl and 20 mM Tris pH 7.5 with 0.1% (v/v) Tween-20) and blocked for 1 h in 
TBS/Tween  containing  5%  non-fat  milk  protein.  Membranes  were  washed  with 
TBS/Tween (3 x 5 min) and incubated with the appropriate primary detection antibody 
(Tables 2.3 and 2.4) overnight at 4ºC. All antibodies were diluted in TBS/Tween with 
5% BSA. Following incubation with primary antibody, nitrocellulose membranes were 
washed with TBS/Tween (3 x 5 min) and incubated in the appropriate HRP-conjugated 
secondary  antibody  (Table  2.4)  containing  5%  non-fat  milk  protein  for  1  h. 
Nitrocellulose membranes were then washed with TBS/Tween (3 x 5 min) and protein 
bands were visualised using the enhanced chemiluminescence (ECL) detection system. 
Nitrocellulose  membranes  were  incubated  in  a  mixture  of  equal  volumes  of  ECL 
solution A (2.5 mM luminol, 0.4 mM p-coumaric acid and 100 mM Tris pH 8.5) and 
ECL solution B (0.002% hydrogen peroxide and 100 mM Tris pH8.5) for 1 min before 
exposing  membranes  to  Kodak  X-Ray  film  in  a  dark  chamber.  Nitrocellulose 
membranes  were  sometimes  stripped  and  re-probed  with  an  alternative  primary 
antibody.  Membranes  were  stripped  for  1  h  at  RT  in  stripping  buffer  (100  mM  2-
mercaptoethanol, 2% SDS and 62.5 mM Tris pH 7) after which they were washed in 
TBS/Tween (4 x 10 min) and blocked, washed and re-probed again. 
All the antibodies showed themselves specific (Figure 2.2) and thus of use in 
immunocytochemistry. The anti-Itch and anti-Grail antibodies detect not only the full 
length Itch and Grail proteins but also their degradation products, which appear as a 
band of lower molecular weight. 60
2.6.5 Immunoprecipitation 
Samples (50 µg of protein from each condition) were normalized to 1 µg/µl with 
modified RIPA lysis buffer, incubated with 10 µl protein G bead slurry (Pierce) for 1 h 
at 4ºC on orbital rotator and centrifuged (16,100 g, 2 min, 4ºC) to clear non-specific 
binding of proteins to the subsequently discarded protein G-containing pellet. Antibody 
was pre-loaded with protein G beads (5 µg antibody per 50 µg protein, 25 µl protein G 
slurry per sample) for 1 h at 4ºC, centrifuged (16,100 g, 2 min, 4ºC) and the pellet re-
suspended in lysis buffer (25 µl per sample). The samples were incubated with the pre-
loaded protein G beads (overnight, 4ºC, on orbital rotator) and washed 3 times with ice-
cold lysis buffer (16,100 g, 2 min, 4ºC). Sample buffer and reducing agent were added 
to the pellet which was boiled (5 min, 100ºC) and then centrifuged (16,100 g, 2 min, 
4ºC).  The  supernatant  was  resolved  using  NuPAGE  Bis-Tris  gels  and  analysed  via 
Western blotting as described above. 
2.7 Immunofluorescence of cells 
2.7.1 Preparation of cells 
In  vitro  cultured  T  cells  or  T  cells  co-cultured  in  vitro  with  DCs  were 
cytocentrifuged  (75  µL  of  cells  for  4  min  at  40  g)  onto  a  slide  using  a  Cytospin3 
centrifuge (Thermo Shandon, UK). The area to be stained was marked with wax pen 
and the cells were fixed in 4% formaldehyde in PBS for 15 min. The cells were washed 
with PBS for 5 min and incubated in 1% blocking reagent (Perkin Elmer, UK) in PBS 
for 10 min. 
2.7.2 Immunocytochemistry 
Staining  for  a  plasma  membrane  protein  was  carried  out  in  most  of  the 
experiments. The DO11.10 transgenic TCR or the CD4 co-receptor were the membrane 
proteins chosen for staining. To identify DO11.10 TCR T cells, biotinylated KJ1-26 
antibody was added for 30 min at RT (100 µL of a 1:250 dilution in 1% blocking 
reagent  in  PBS  from  a  1.6  mg/ml  stock  was  used).  To  identify  CD4
+  T  cells, 
biotinylated anti-CD4 antibody was added for 30 min at RT (in 100 µL of a 1:250 
dilution in 1% blocking reagent in PBS). At the same time, isotype controls were added 
to another set of cytospins (Table 2.5). In either case, the cells were then washed in 61
PBS for 3 min for three times and incubated with 50 µL of a 1:100 dilution from stock 
in 1% blocking reagent in PBS of SA-HRP for 25 min at RT. After three more 3 min 
PBS washes, 50 µL of a 1:50 dilution from stock of biotinylated tyramide was added 
and incubated for 10 min at RT, the tissue washed again three times in PBS and 50 µL 
of a 1:500 dilution from 1 mg/ml stock in 1% blocking reagent in PBS of SA-Alexa 
Fluor 647 added to the samples; incubation lasted 30 min at RT (Figure 2.3). The cells 
were  incubated  three  times  in  PBS  containing  0.1%  azide/  3%  H2O2  for  5  min  for 
quenching excess SA-HRP. 
After  three  washes  in  PBS  for  3  min,  the  cells  were  permeabilised  in  50  µL 
permeabilisation buffer (2% FCS, 2 mM EDTA, pH 8.0, 0.1% w/v saponin in PBS) for 
5 min. After three 10 s washes in PBS, the cells were incubated in 50 µL 1% blocking 
reagent, 0.1% w/ v saponin in PBS for 15 min. The cells were then incubated with 50 
µL of an appropriate dilution from stock of the antibody of choice or relevant isotype 
control.  Cells  were  washed  again  (3  x  3  min)  in  PBS  before  incubation  with  the 
corresponding  HRP-linked  secondary  antibody  (in  1%  blocking  reagent,  0.1%  w/  v 
saponin in PBS, for 25 min). After three more 3 min PBS washes, 50 µL of a 1:150 
dilution  from  stock  in  0.0015%  H2O2  in  amplification  buffer  of  Alexa  Fluor  488-
labelled tyramide was added for 10 min at RT (Figure 2.4), the cells were washed in 
PBS  a  further  3  min  for  three  times,  allowed  to  dry  and  mounted  in  one  drop  of 
Vectashield with DAPI (Vector Laboratories). A coverglass was mounted and sealed 
onto  the  slide  with  nail  varnish  and  the  slide  stored  in  aluminium  foil  at  4ºC.  The 
resulting  cytospins  were  analysed  in  the  Laser  Scanning  Cytometer  (LSC) 
(CompuCyte). LSC data analysis was performed using WinCyte software (CompuCyte). 
Fluorescence images were also taken using the attached fluorescence microscope, as 
described further below. 
2.8 Immunofluorescence of tissue sections 
2.8.1 Preparation of tissue sections 
Inguinal lymph nodes were removed from DO11.10 TCR transgenic mice and 
fixed in 1% paraformaldehyde in PBS at 4ºC for 24 h. They were then transferred into 
30% sucrose in PBS for a further 48 h before being frozen in liquid nitrogen in optimal 
cutting temperature (OCT) embedding medium (Sakura) and stored at -70ºC. Sections 62
(6  µm)  were  cut  and  subsequently  stored  at  -20ºC  for  up  to  72  h  before  staining. 
Sections were stained as described below. 
2.8.2 Immunohistochemistry 
Slides were fixed in acetone, areas to be stained were marked with wax pen and 
allowed to dry; samples were re-hydrated with PBS for 5 min and incubated with 100 
µL PBS containing 0.1% azide/ 3% H2O2 for 15 min, three times. Tissue was then 
washed with PBS for 3 min, two times, incubated with 100 µL of a solution of four 
drops  of  stock  avidin  (Vector  Laboratories)  in  1  ml  3%  BSA  for  12  min  to  block 
endogenous biotin-binding proteins, and washed again with PBS for 5 min. Next, tissue 
was  incubated  with  100  µL  of  a  solution  of  four  drops  of  stock  biotin  (Vector 
Laboratories) in 1 ml 3% BSA for 12 min to block the remaining biotin binding sites on 
the avidin, and washed again with PBS for 5 min. 
The  sections  were  incubated  with  biotinylated  KJ1-26  antibody  (100  µL  of  a 
1:250 dilution in 3% BSA from a 1.6 mg/ml stock was used), or matching isotype, for 
30 min at RT. The tissue was then washed in PBS for 3 min three times and incubated 
with 100 µL of a 1:100 dilution from stock in 3% BSA of Streptavidin-HRP (Perkin 
Elmer) for 25 min at RT. After three more 3 min PBS washes, 100 µL of a 1:50 dilution 
from  stock  in  amplification  buffer  (Perkin  Elmer)  of  biotinylated-tyramide  (Perkin 
Elmer) was added and incubated for 10 min at RT. The tissue was washed again three 
times  in  PBS  and  50  µL  of  a  1:500  dilution  from  1  mg/ml  stock  in  3%  BSA  of 
Streptavidin-Alexa Fluor 647 (Perkin Elmer) was added for 30 min at RT (Figure 2.3). 
The tissue was washed in PBS for 3 min (for three times), followed by incubation in 
PBS containing 0.1% azide/ 3% H2O2 for 10 min. After one 10 s wash in PBS, the 
tissue was permeabilised in PBS containing 3% BSA, 0.1% Triton X-100 for 1 h. 
The tissue was then washed with PBS for (3 x 10 s) and incubated with PBS 
containing 0.1% azide/ 3% H2O2 (2 x 10 min). After another step of washing (3 x 3
min) with PBS, the tissue was incubated with 100 µL of an appropriate dilution of 
antibody raised against the target signal transducer of choice, or the matching isotype, in 
3% BSA, 0.1% Triton X-100 (Table 2.6) for 16 h at 37ºC. The tissue was then washed 
in PBS (3 x 3 min) before addition of 50 µL of a 1:100 dilution of stock of the desired 
anti-IgG-HRP  conjugate  antibody,  with  or  without  anti-B220-FITC  antibody,  or 
matching isotype, in 3% BSA, 0.1% Triton X-100 (30 min, at RT). After three more 3 
min  PBS  washes,  50  µL  of  a  1:100  dilution  from  stock  in  0.0015%  H2O2  in 63
amplification buffer (Molecular Probes) of Pacific Blue-labelled tyramide (Molecular 
Probes) was added for 10 min, at RT (Figure 2.4), the tissue was washed in PBS a 
further 3 min for three times, allowed to dry and mounted in one drop of Vectashield 
(Vector Laboratories) mounting media. A coverglass was mounted and sealed onto the 
slide with nail varnish and the slide stored in aluminium foil at 4ºC. The resulting tissue 
sections  were  analysed  in  the  LSC.  Fluorescence  levels  were  quantified  and 
photographs taken, as described in the next section. 
2.9 Laser scanning cytometry 
Laser scanning cytometry is a very useful tool for analysing signal transduction 
events at the single-cell level [270]. It allows the quantification of fluorescent signals 
while also allowing imaging of each and every cell in the slide. It possesses a xy re-
location feature that allows locating in the slide a cell that has been acquired previously 
and  is  represented  in  a  scattergram  plot.  It  combines  both  scanning,  automated 
quantification with more fine-tuned, manually-taken photography. Unlike the FACS, in 
which  cells  have  to  be  in  suspension  and  dissociated  from  their  native  surrounding 
tissue, the LSC can be used to analyse scattered cells and cells within a tissue - in situ - 
in the midst of their niche, thus more within physiological parameters. Also unlike the 
FACS, which only allows detection of positive cells and their fluorescence intensity, the 
LSC  enables  analysis  of  subcellular  localisation  of  the  molecules,  which  is  very 
important since the activity of many molecules is determined by their localisation. The 
use of the LSC for assessment of signalling pathways in immune cells and tissue has 
been established in this laboratory [271]. 
Alexa Fluor 488 and FITC (green) were excited using the argon ion laser and 
measured using filter cube D 530/ 30 nm. Alexa Fluor 647 (long red) was excited using 
the Helium-Neon laser and measured using filter cube H1 650/ LP. Alexa Fluor 350, 
DAPI and Pacific Blue (blue) were excited using the UV laser [272, 273]. 
2.9.1 LSC data collection on individual cells 
Analysis  of  any  sample  by  LSC  involves  setting  up  adequate  data  collection 
display (.DPR) and protocol (.PRO) files and parameters in WinCyte. In the Parameters
sub-menu of the Instrument settings menu, the blue, green and long red sensor boxes 
were checked to ensure fluorescence detected by these sensors was included in the data 
file. To detect cytocentrifuged cells (cytospins) it is necessary to establish “contours” 64
first (Figure 2.5A). The primary contour, or threshold contour, is usually set on the 
cell’s nucleus [130, 271]. This is identified by staining with dyes that bind to the DNA, 
like DAPI [274]. In the Computation sub-menu, the threshold contour was set on blue, 
as this is the colour of the DAPI stain. The minimum area was then set to 5 µm
2, 
enabling detection of DAPI stained nuclei that are sized 5 µm
2 and above. This is the 
optimal minimum area for the T lymphocytes described hereafter. Using the LSC scan 
data display, the integration contour was then situated 11 pixels (1 pixel = 0.5 µm (x-
axis) and 0.5 µm (y-axis) for 40x objective) outside the threshold contour, so as to 
define the outer edge of the cells already identified on the basis of their nuclear staining. 
The integration contour allowed calculation of the total fluorescence within each cell 
(fluorescence  integral  value)  and  this  integration  contour  setting  was  optimal  for 
collecting  data  on  T  lymphocytes.  Peripheral  contouring  was  enabled  to  define  the 
peripheral area of the cell. Peripheral contours were set between the threshold contour 
(defined by the nucleus when contouring on DAPI) and the integration contour (defined 
by the edge of the cell) and so the fluorescence emitted peripheral to the nucleus could 
be measured (fluorescence peripheral integral value). Finally, two background contours 
measure the background fluorescence outside the cells and this value is automatically 
subtracted from the measured fluorescence values. 
The area of the slide to be scanned (the area of the slide where the cells were) was 
delimited  in  the  Scan  Area  section.  Next  the  photomultiplier  tube  (PMT)-Voltage, 
Offset, and Gain settings were set to 15-35%, 1800-2200, and 255, respectively, for 
blue,  green,  and  long  red.  The  optimal  settings  for  these  parameters  would  change 
slightly  depending  on  different  reagents  and  other  cell  types  used.  A  setting  is 
considered optimal when there is little or no saturation. Saturation occurs when the 
detector  no  longer  responds  to  increased  levels  of  signal  and  is  indicated  by  the 
presence of dark blue lines in the upper third of the PMT scale. Settings would be 
changed to achieve no more than 75 saturated pixels. The power of the Argon laser was 
set to 5 mW. 
Next, the threshold value was set to 3000 thus, ensuring all cells emitting blue 
fluorescence at a level ≥3000 fluorescence units were detected as events. This setting 
was verified for each batch of staining and varied from 2000 to 4000 depending on the 
intensity of the nuclear staining. Setting the optimal threshold value for detection of 
cells is crucial so as to allow maximal cellular resolution and collection. For example, if 
the threshold value is set too low then multiple cells may be detected as one cell and 
conversely, if a high threshold value is set, cells with low or medium intensity staining 65
will not be detected at all (Figure 2.5B). Therefore, a compromise must be made when 
setting the threshold value so as to detect the maximum number of true single cells in a 
sample. The area was then scanned and the data file saved. 
2.9.1.1 Identification of antigen-specific T cells 
When  analysing  cytospins,  the  primary  contouring  parameter  was  set  on  the 
nuclear  localization  of  the  DNA  dye,  DAPI,  to  detect  all  of  the  cellular  events  as 
described above. Antigen-specific T cells were identified via their DO11.10 transgenic 
TCR receptor after staining with the KJ1-26 antibody. As the TCR is expressed on the 
plasma membrane of the cell, the data derived from the integration contour was used to 
distinguish the antigen-specific T cells. In addition, the expression level of intracellular 
molecules in antigen-specific T cells was quantified by gating on the KJ1-26
+ cells and 
measuring the integral fluorescence value for the intracellular molecule in question. The 
expression level of intracellular molecules was also measured in the peripheral-to-the-
nucleus area of the cell, using the peripheral contours. For analysis purposes the positive 
gate was positioned according to the fluorescence obtained using the appropriate isotype 
controls. CD4
+ T cells can also be identified in the same way as KJ1-26
+ cells, also 
allowing for further analysis of the intracellular molecule of choice in CD4
+ T cells 
(Figure 2.6). 
2.9.1.2 Cell cycle analysis 
The LSC can be used for determining the stage of the cell cycle a cell is in since it 
allows the measurement of content and concentration of DNA at the same time via 
DAPI nuclear staining [273]. The content of DNA can be assessed via DAPI Integral 
(sum of all fluorescence in the cell) while the concentration of DNA (condensation) can 
be assessed via DAPI Max Pixel (the most highly fluorescent pixel value in the cell). 
Therefore, by plotting Max Pixel against Integral values of DAPI nuclear staining the 
different cell cycle stages can easily be identified (Figure 2.7). For example, cells in S 
phase can be identified by their increased DNA content. However, cells in the other 
mitotic  stages  (G2/M  phase)  which  also  contain  high  amounts  of  DNA  can  be 
differentiated  due  to  the  higher  level  of  chromatin  condensation.  By  contrast,  cells 
arrested at the G1/G0 stage (red gate) of the cell cycle contain half the amount of DNA 
(2n DNA) compared to cells in G2/M (4n DNA) and can therefore be identified by the 
lower  DNA  content,  as  detected  by  lower  DAPI  Integral  values.  Cells  undergoing 
apoptosis contain subdiploid DNA content due to their fragmented DNA placing them 66
below  cells  in  G1/G0  on  the  scattergram.  Newly-formed  daughter  cells  (NFDCs) 
represent cells which have recently undergone mitosis and can be identified due to their 
small nuclei which still conserve highly condensed DNA. 
2.9.2 LSC data collection on lymph node tissue 
The LSC can also be used to assess fluorescence signals in sections of tissue. As 
with analysis of single cells, adequate data collection display and protocol files and 
parameters must be set up in WinCyte. The blue, green and long red sensor boxes were 
checked. Contours must also be created; here, the primary contouring parameter was set 
using the long red sensor which detects the Alexa Fluor 647-stained transgenic TCR on 
the  cell  surface,  thus  identifying  all  the  antigen-specific  T  cells  in  the  section  and 
allowing measurement of any signal expressed by these T cells in situ. An advantage of 
using the adoptive transfer system for this analysis is that it generates a relatively low, 
near  physiological,  frequency  of  antigen-specific  transgenic  T  cells.  This  approach 
overcomes the usual problem encountered with cells in tissue, where they can be so 
densely packed to prevent setting an accurate threshold based on a cell surface marker. 
The optimal settings for such sporadically distributed T cells are as follows: threshold 
value: 3500; minimum area: 5 µm
2; power of Argon laser: 5 mW; PMT, offset, and gain
settings: 22-32%, 2048, and 255, respectively, for blue; 30-40%, 2048, and 255, for 
green; and 22-32%, 2048, and 255, for long red. PMT settings varied depending on the 
intensity of staining in different batches of tissue. 
By  contrast,  in  order  to  detect  the  densely  packed  B  cell  follicles,  phantom 
contours are required (Figure 2.8). Phantom contours differ from the contours described 
thus far in that they comprise a lattice of contours, which is placed over the tissue 
section, consequently generating fluorescence values which represent the relevant area 
of the tissue section as a whole, rather than individual cells [271]. For example, when 
phantom contours are set to detect fluorescence emitted from the B cell stain, B220-
FITC, this allows the identification of B cell rich areas, not individual B cells, and 
permits the generation of tissue maps on which the x- and y-position of the B cell rich 
areas can be plotted. Phantom contours were generated as follows. On the Phantoms
tab, phantom contouring was enabled, and the lattice pattern and allow overlap of events 
options were selected; the radius was set to 6 µm and the minimal distance between 
phantoms centres was set to 20 µm. 
It is possible to combine the tissue maps showing B cell distribution with the ones 
showing DO11.10 TCR transgenic T cells, thus allowing assessment of the position of 67
the antigen-specific T cells regarding the different areas of the lymph node (follicular 
versus paracortical areas). 
As before, the expression level of intracellular molecules in antigen-specific T 
cells  was  quantified  by  gating  on  the  KJ1-26
+  cells  and  measuring  the  integral 
fluorescence value for the intracellular molecule in question. For analysis purposes the 
positive gate was positioned according to the fluorescence obtained using appropriate 
negative/isotype controls 
2.9.3 Immunofluorescence microscopy 
Fluorescence images were taken using a connected 3CCD colour vision camera 
(regulated by a Hamamatsu and Orbit controller) and the OpenLab version 3.0.9 digital 
imaging program (Improvision, Warwick, UK). 
2.10 Other functional assays 
2.10.1[
3H]thymidine uptake DNA synthesis/ proliferation assay 
Cells were cultured at a concentration of 4 x 10
5 cells per well (2 x 10
5 T cells + 2 
x 10
5 DCs per well, for re-stimulation), in complete RPMI 1640 medium, in triplicate, 
for 48 or 72 h, in 96-well flat-bottomed plates (Corning) at 37ºC in a 5% CO2 incubator. 
DNA  synthesis  was  assessed  in  all  samples  by  addition  of  1  µCi  per  well  of  [
3H] 
thymidine (Western Infirmary, Glasgow). Cells were then harvested onto glass fibre 
filter mats (Wallac, Warrington, UK) using a Betaplate 96-well harvester (Amersham) 
after  an  additional  16  h.  [
3H]thymidine  incorporation  was  assessed  using  a  1205
Betaplate liquid scintillation counter (Amersham). Where indicated, 10 ng/ml rIL-2 (gift 
from Dr D. Xu, University of Glasgow, Glasgow, UK) was added at the beginning of 
the proliferation assay. 
2.10.2Assessment of antigen-specific cytokine production 
Production  of  relevant  cytokines  by  T  cells  was  quantified  by  enzyme-linked 
immunosorbent  assay  (ELISA).  To  detect  IL-2  and  IFNγ  in  culture  supernatants, 
Immulon-4  plates  (Costar)  were  coated  with  rat  anti-mouse  IL-2  or  IFNγ  capture 
antibodies (1 or 1.5 µg/ml, respectively; 50 µl/well; BD Pharmingen) for 16 h at 4ºC 
before being blocked with 10% FCS in PBS for 1 h at 37ºC. Sample supernatants were 
added  for  3  h  at  37ºC  and  following  washing  with  0.05%  Tween20  in  PBS,  were 68
subsequently  incubated  with  biotinylated  rat  anti-mouse  IL-2  or  IFNγ  detection 
antibodies (0.5 or 1 µg/ml, respectively; 50 µl/well; BD Pharmingen) for 1 h at 37ºC. 
Plates were then incubated with 50 µl extravidin peroxidase per well (diluted 1:1000 in
PBS/0.2%  FCS/0.05%  Tween20)  for  1  h  at  37ºC  before  being  treated  with  TMB 
Microwell Peroxidase Substrate. Recombinant murine IL-2 or IFNγ preparations (BD 
Pharmingen)  were  used  to  produce  standard  curves  from  which  cytokine  levels  in 
samples were calculated. 
2.11 Statistical analysis 
Results  are  expressed  as  mean  ±  SEM,  unless  otherwise  stated.  To  test 
significance, different types of statistical tests were performed, the type of test varying 
according to the experimental setup; it was considered p≤0.05 to be significant and there 
is further discrimination of p values of *≤0.05, **<0.01, ***<0.001. All statistical tests 
were performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, 
USA, www.graphpad.com. 69 
Figure 2.1: Identification of DO11.10 TCR transgenic T cells by flow cytometry. 
Lymphocytes are first distinguished via their forward scatter (FSC), which correlates 
with their size, and side scatter (SSC), which correlates with their granularity; events 
gated within region 1 (R1) are lymphocytes. These events are then analysed for the 
expression of CD4 co-receptor (CD4
+ T cells) and DO11.10 TCR (B). Usually, 30-40% 
of lymphocytes were found to be CD4
+DO11.10
+ T cells (gated within R2). Isotype 
controls for the CD4 and KJ1-26 antibodies are also shown (A). 100 101 102 103 104
061106 0h LN.001
R2
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Table 2.1: List of antibodies used in flow cytometry. 5
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Table 2.2: List of fluorochromes used in flow cytometry (A) and laser scanning 
cytometry (B). 6
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Table 2.3: List of primary antibodies used in Western blotting. a
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Table 2.4: List of primary anti-ubiquitin moieties antibodies (A) and secondary 
antibodies (B) used in Western blotting. 3
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Figure 2.2: Assessment of antibody specificity by Western blotting. 
Lymph nodes were extracted from BALB/c mice and mashed up. Viable T cells were 
cultured in vitro without stimuli (1) or in the presence of anti-CD3 antibody (2); cells 
were cultured for a total of 20 h, after which they were harvested and lysed (A). Total 
protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a  nitrocellulose 
membrane. The membrane was analysed by Western blotting for proteins of interest: it 
was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 10 min with TBS-T, probed with 
primary antibody overnight in the cold room, washed 3 x 5 min with TBS-T, incubated 
with HRP-linked secondary antibody for 1 h, washed 3 x 5 min with TBS-T, incubated 
with  ECL  solution  for  1  m,  and  developed.  The  membrane  was  then  stripped  and 
subsequently re-probed again; antibodies for Itch, Cbl-b and Grail were used (B). Anti-Grail
191 KDa
97 KDa
64 KDa
51 KDa
39 KDa
28 KDa
Anti-Cbl-b
191 KDa
97 KDa
64 KDa
51 KDa
39 KDa
28 KDa
Anti-Itch
191 KDa
97 KDa
64 KDa
51 KDa
39 KDa
28 KDa
1 2 1 2 1 2
Balb/c lymph 
node cells’
extraction
- (1) or
α-CD3 (2)
Lyse cells
Load total cell protein
Western blot
Plate
20 h
A)
B)75 
Table 2.5: List of antibodies used in immunocytochemistry. I
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Figure 2.3: Tyramide indirect signal amplification.
Tyramide signal amplification is an enzyme-based system for high density labelling of 
target  proteins.  HRP-coupled  primary  antibody  was  first  used  to  detect  the  protein. 
Next,  biotin-labelled  tyramide  was  added  and  the  HRP  catalysed  the  deposition  of 
multiple  biotin  moieties  close  to  the  target  protein.  Finally,  streptavidin-coupled 
fluorochrome was added, binding to the biotin, allowing the fluorochrome to localise 
nearby  the  target  protein,  thus  generating  a  stronger  signal,  and  allowing  the  target 
protein’s detection. Tyr Biotin
HRP
H2O2
O2
Ag
A)
Tyr Biotin
HRP
Ag
Label
B)
Tyr Biotin Tyr Tyr Biotin Biotin
Label
SA
Label
SA
Label
SA
Label
SA
HRP
Ag
C)
Tyr Biotin Tyr Tyr Biotin Biotin
Label
SA
Label
SA
Label
SA77 
Figure 2.4: Tyramide direct signal amplification. 
Tyramide signal amplification is an enzyme-based system for high density labelling of 
target  proteins.  HRP-coupled  primary  antibody  was  first  used  to  detect  the  protein. 
Next, fluorochrome-labelled tyramide was added and the HRP catalysed the deposition 
of multiple fluorochromes close to the target protein, thus generating a stronger signal, 
and allowing its detection. Tyr Label
HRP
H2O2
O2
Ag
A)
Tyr Label
HRP
Ag
B)
Tyr Label Tyr Tyr Label Label
Label
Label
SA78 
Table 2.6: List of antibodies used in immunohistochemistry. 5
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Figure 2.5: Cell detection by the LSC. 
Cells are identified in the LSC by means of contours (A). Here, the threshold contour 
was set on the nucleus (which is identified by means of DAPI DNA staining). The 
integration contour is set on an optimal number of pixels out from the threshold contour, 
a value which is based on the average size of the cell type, to allow definition of the 
edge of the cell. The inner peripheral contour is set one pixel out from the threshold 
contour and the outer peripheral contour is set one pixel in from the integration contour, 
allowing definition of the periphery of the cell. Two background contours (not shown 
here, but always used in LSC analysis) measured the background fluorescence outside 
the cells and allowed for the automatic subtraction of this value from the measured 
fluorescence values within the other contours. A cell is discriminated if it emits nuclear 
fluorescence  above  a  threshold  value  set  by  the  user  (B).  A  high  threshold  detects 
mainly individual events, whilst an intermediate threshold may detect two or more cells 
as one event and a low threshold will detect multiple cells as one event. Threshold contour
Peripheral contours
Integration contour
DAPI nuclear staining
A)
B)80 
Figure 2.6: Identification of CD4
+ T cells with the LSC. 
Firstly (leftmost panels) cells are identified by means of contouring on their nucleus, as 
described in Figure 2.4 (here, the contours’ colour scheme is different). The threshold 
contour was therefore used to select all nucleated cells by their staining with DAPI 
(showing in light grey). Next, using the integration contour, fluorescence coming from 
CD4 co-receptor-bound fluorochrome was measured (fluorescence coming from within 
the  integration  contour),  thus  allowing  the  identification  of  CD4
+  T  cells.  Positive 
staining  for  CD4  (cells  within  area  “1”  in  middle  panels)  was  gated  relative  to  the 
isotype control (A). Finally, gating on those nucleated and CD4
+ events (also using the 
integration contour), the fluorescence from the fluorochrome bound to the intracellular 
protein of choice was measured (C). Positive staining (cells within area “1” in rightmost 
panels) for the intracellular protein of choice (here, Cbl-b) was gated relative to the 
isotype control (B). A)
B)
C)
Rat IgG2a, κ (Alexa Fluor 647)
CD4 (Alexa Fluor 647)
CD4 (Alexa Fluor 647)
Rabbit IgG (Alexa Fluor 488)
Cbl-b (Alexa Fluor 488)81 
Figure 2.7: Analysis of cell cycle progression with the LSC. 
Nuclei of cytocentrifuged cells were stained with DAPI and analysis carried out by LSC 
by plotting the Max Pixel value (depicting chromatin condensation) along the x-axis 
and the Integral value (representing DNA content) along the y-axis of the scattergram. 
The plotted cells were then gated according to their xy-position on the scattergram. 
Apoptotic cells (light green gate) have the least DNA content: they contain subdiploid 
DNA due to its fragmentation, placing them leftmost and bottommost of all the cells on 
the scattergram. Cells arrested at the G1/G0 phase (red gate) of the cell cycle are diploid 
(2n DNA) and can therefore be identified on the scattergram above the apoptotic cells. 
Cells in the S phase (blue gate) can be identified by their increased DNA content above 
the G1/G0 phase cells. Moreover, cells in the other mitotic stages (G2/M phase) which 
also contain high amounts of DNA (4n DNA) can be differentiated due to a higher level 
of chromatin condensation (dark green gate), being placed rightmost and topmost of all 
the cells in the scattergram. Newly-formed daughter cells (NFDCs; yellow gate), while 
still exhibiting a high level of chromatin condensation do not have 4n DNA and as such 
can be spotted below the G2/M phase cells on the scattergram. Representative images of 
cells validating for each stage of the cell cycle are shown. To cover
Apoptotic cell G0/G1 cell S phase cell G2/M cell NFDC82 
Figure 2.8: Analysis of lymph node tissue sections with the LSC. 
Tissue  sections  were  stained  for  B220  (B  cells,  in  green),  DO11.10  TCR  (antigen-
specific transgenic T cells, in red) and Cbl-b (in blue) as shown in the leftmost panels. 
LSC detected  antigen-specific T cells using standard contours (yellow  contours; top 
leftmost panel) and measured the levels of Cbl-b inside these cells (cells gated in region 
“1” in the top middle panel). B cell rich areas were identified (similarly to antigen-
specific T cells, these were considered to be the ones in region “1” in the bottom middle 
panel) using phantom contours (these look like a lattice that overlaps the section, as 
exemplified in bottom leftmost panel). A tissue map depicting the location of Cbl-b-
expressing  antigen-specific  T  cells  within  the  lymph  node  was  generated  (bottom, 
rightmost panel). This also incorporated the  B  cell areas (follicles)  and allowed the 
identification  of  the  paracortex  (B  cell-free  area,  in  the  centre  of  the  lymph  node). 
Adequate isotype controls were used to set the gates of positive staining for B cells, 
antigen-specific transgenic T cells and Cbl-b. Numbers and statistics on these cells in 
both types of area within the lymph node can be quantified. la
b
el
DO11.10 TCR (Alexa Fluor 647) Cbl-b (Alexa Fluor 350)
B220 (FITC)
Tissue map
Paracortex
Follicles
Standard contour
Lattice of phantom contours83
CHAPTER 3 
RESULTS 84
3 RESULTS 
3.1 The induction  phase of anergy and priming in CD4
+ T 
cells 
3.1.1 Functional assessment of the induction of anergy and priming in 
CD4
+ T cells, in vitro 
CD4
+ T cells were extracted and purified from mice as described in the Materials 
and Methods chapter. These cells were then stimulated in vitro in order to render them 
anergic or primed. CD4
+ T cells were cultured with immobilised anti-CD3 antibody to 
induce  anergy  while  culture  with  immobilised  anti-CD3  antibody  and  anti-CD28 
antibody  induced  priming  [130].  This  is  because  the  CD28  receptor  acts  as  the  co-
stimulator necessary to fully activate the pathways that lead to T cell activation and 
proliferation,  while  CD3  stimulation  is  the  necessary  first  step  that  if  not  followed, 
however, leads to quiescence [275]. Addition of anti-CD3 and anti-CD28 antibodies to 
the cell culture allows for the stimulation of these receptors in the T cells. An alternative 
method to induce anergy or priming was also used: this involves the in vitro stimulation 
of the CD4
+ T cells with ionomycin for the induction of anergy and ionomycin and 
PMA for the induction of priming [276]. A schematic of the stimulation procedure can 
be found in Figure 3.1A. 
Ionomycin is a calcium ionophore which permits the increase of the intracellular 
Ca
2+  levels.  Increased  intracellular  Ca
2+  concentration  (which  occurs  under  normal 
situations following TCR stimulation) together with calmodulin leads to activation of 
Cn, a calcium-dependent phosphatase, which de-phosphorylates the transcription factor 
NFAT [57, 116]. The phorbol ester PMA activates PKC directly [277]. 
While ionomycin is sufficient to induce anergy in T cells, IL-2 production, CD69 
expression, growth and proliferation can be induced by the addition of ionomycin and 
PMA to in vitro cultured T cells; however, both pharmacological agents bypass TCR 
ligation and, hence, the initial steps in TCR signalling [122]. 
To confirm induction of priming and tolerance, CD4
+ T cells were analysed for 
their functional responses. The functional outcome of the different conditions was first 
assessed  via  an  early  activation  assay  measuring  CD69  upregulation  (Figure  3.1B). 
Here,  expression  of  the  early  activation  marker  CD69  was  determined  by  flow 85
cytometric  analysis,  with  values  represented  as  mean  fluorescence  intensity  (MFI) 
plotted as fold increase of the MFI of naïve (unstimulated) CD4
+ T cells where the MFI 
value  of  these  cells  was  taken  as  basal  and  assigned  the  “1”  value.  Anergising 
conditions (anti-CD3 antibody or ionomycin) were found to yield a slight increase in 
CD69 expression (roughly 2-fold) indicating that there is some degree of activation in 
CD4
+  T  cells  under  these  conditions.  However,  priming  conditions  (anti-CD3+anti-
CD28  antibodies  and  ionomycin+PMA)  yield  a  much  higher  increase  in  CD69 
expression (4- and 8-fold, respectively) indicating not only that CD4
+ T cells are being 
activated but showing that their activation is considerably higher than that exhibited 
under anergy-inducing conditions. This is what would be expected of priming stimuli. 
The percentage of CD4
+ T cells positive for CD69 was also analysed, showing similar 
results to the MFI (not shown). 
The  functional  outcome  of  the  different  conditions  was  also  assessed  via  a 
proliferation assay (Figure 3.1C). Here, [
3H]thymidine was added to the in vitro CD4
+
T cell culture and its incorporation in the cells’ DNA was measured to demonstrate how 
much newly-synthesised DNA was produced and hence provide an indication of cell 
cycle progression resulting in proliferation. As expected, unstimulated CD4
+ T cells 
exhibit near-zero proliferation and the anergising stimuli induced above no-stimulus-
level proliferation. However, priming stimuli induced strong proliferation of the CD4
+ T 
cells  with  well  over  10-times  the  [
3H]thymidine  levels  than  their  anergising 
counterparts. 
Collectively therefore, it is possible to say that  the stimuli intended to  induce 
priming (anti-CD3+anti-CD28 antibodies and ionomycin+PMA) are doing so, and that 
the functional outcome they are inducing in CD4
+ T cells is qualitatively different than 
the outcome generated by the intended anergising stimuli. Also, it is important to stress 
that this is happening in the intended time-frame scheduled for the induction phase 
experiments. 
3.1.2 Analysis of the expression of E3 ubiquitin-protein ligases in the 
induction phase of anergy and priming 
A number of E3 ubiquitin-protein ligases have been reported to be involved in 
signalling processes in T cells with some of these being described as playing key roles 
in the anergy versus priming decision these cells undergo [183, 193, 233]. The role(s) of 
Itch,  Cbl-b  and  Grail  warranted  further  clarification  in  regard  to  these  processes. 
Initially,  antibodies  were  acquired  and  tested  for  the  detection  of  these  proteins  via 86
Western blotting. Cells were extracted and stimulated in vitro as described before in the 
Materials and Methods chapter and following termination of reactions, total cell protein 
was extracted and analysed for the expression of relevant proteins (Figure 3.2A). For 
example, the intensity of expression of PLCγ-1 is highest in the anti-CD3+anti-CD28-
stimulated  cells  and  lowest  in  the  ionomycin-stimulated  cells  (Figure  3.2B).  This 
correlates nicely with the need for PLCγ-1 involvement in the signalling transduction 
pathways leading to priming in T cells, while during induction of anergy PLCγ-1 is 
downregulated [111, 183]. 
With respect to the E3 ubiquitin-protein ligases, Itch is induced in all stimulated 
cells  (comparing  to  unstimulated,  naïve  ones,  which  nonetheless  do  express  some 
degree of Itch) and as expected, it is highly expressed in ionomycin-stimulated cells 
(Figure 3.2B). Rather unexpectedly, it is also highly expressed in anti-CD3+anti-CD28-
treated cells whilst the anti-CD3-stimulated population expresses Itch with less intensity 
than the other two stimulated populations. Cbl-b is expressed most intensely in both the 
anti-CD3- and anti-CD3+anti-CD28-stimulated cells. However, ionomycin-stimulated 
cells also express it, indicating that it is upregulated in all stimulated cells relative to the 
unstimulated ones. The blot shows a ladder of Cbl-b bands around the 109 KDa mark, 
though  there  is  one  band  more  intense  than  all  the  others.  This  ladder  of  bands  is 
possibly  the  result  of  differential  ubiquitination  of  Cbl-b  as  mono-  or  poly-
ubiquitination  of  a  protein  (progressive  addition  of  the  8-KDa  ubiquitin  monomer) 
yields it an increasingly higher molecular weight [278] with the corresponding slower 
migration in a bis-tris gel, just as observed here. Smurf1 also exhibits a similar ladder 
pattern.  This  E3  ubiquitin-protein  ligase  is  expressed  in  the  cells  under  all  tested 
conditions although it seems to be upregulated when cells are stimulated with any of the 
stimuli.  Unstimulated  cells  not  only  have  less  Smurf1  but  they  also  exhibit  less 
ubiquitinated Smurf1 as indicated by a reduced ladder effect. By contrast, Smurf2 did 
not  exhibit  this  ladder  effect  nor  upregulation  as  its  expression  does  not  appear  to 
change with the different stimuli. As with Itch, Grail is expressed more intensely in both 
the ionomycin- and anti-CD3+anti-CD28-stimulated cells, while in anti-CD3-stimulated 
and naïve cells there is roughly the same amount of protein. 
The expression of the adaptor protein Traf6, which can act as an E3 ubiquitin-
protein ligase as well, was also assessed (Figure 3.2B). Traf6 promotes the activation of 
NF-κB [70, 71], a transcription factor required for full T cell activation [74]. As such, 
Traf6 is potentially a positive mediator of T cell priming whilst its contribution to the 
regulation of the priming Vs anergy decision is yet to be ascertained. Its expression 87
levels in unstimulated, anergising and priming T cells were firstly analysed, looking for 
differential  expression.  Traf6  is  expressed  in  all  unstimulated  and  stimulated 
populations.  There  is  clearly  more  Traf6  protein  in  anti-CD3+anti-CD28-stimulated 
cells than in anti-CD3- stimulated ones, which in turn express more than unstimulated 
ones.  However,  it  is  the  ionomycin-stimulated  cells  that  express  the  least  Traf6.  It 
would  appear  Traf6  is  being  differentially  expressed  and  that  its  highest  expression 
correlates to its requirement for T cell activation. 
As this analysis did not give any indication of the activity of E3 ubiquitin-protein 
ligases,  the  total  protein  lysates  were  also  tested  for  the  presence  of  ubiquitinated 
proteins (Figure 3.3). Globally, the ubiquitination of proteins (Figure 3.3A) is most 
intense in the anti-CD3+anti-CD28-stimulated cells, with the anti-CD3-stimulated cells 
almost  comparable.  Ionomycin-stimulated  cells  also  express  ubiquitinated  proteins 
intensely while naïve cells exhibit only basal levels of ubiquitination indicating that 
these processes are stimulated under all conditions. Next, to address the mechanisms 
involved more closely, assessment of the prevalence of mono- and poly-ubiquitinated 
proteins under the different conditions was carried out (Figure 3.3B). It was expected 
that  this  should  yield  a  pattern  of  ubiquitinated  proteins  very  similar  to  the  one 
previously  described,  however  this  does  not  happen  and  the  band  pattern  is  very 
distinct. Nevertheless, anti-CD3+anti-CD28-stimulated cells do seem to express mono- 
and  poly-ubiquitinated  proteins  most  intensely,  with  the  anti-CD3-stimulated  cells 
coming in a close second and the naïve cells expressing least. Blotting the membrane 
for the presence of only polyubiquitinated proteins (Figure 3.3C) reveals some of the 
“missing” bands encountered in Figure 3.3A, with again the highest expression being in 
anti-CD3+anti-CD28-  and  anti-CD3-stimulated  cells  although  there  were  not  many 
differences  between  any  of  the  stimuli.  In  Figure  3.3D  only  K63-linked 
polyubiquitinated proteins are shown and here, this blot most closely mirrors the global 
ubiquitination profile as many of the bands encountered in Figures 3.3A and B, come 
up again. There are some proteins more intensely K63-linked polyubiquitinated in some 
of the stimuli than others, predominantly in the anti-CD3+anti-CD28- and anti-CD3-
stimulated cells. 
The  fact  cells  undergoing  both  priming  and  anergy  exhibit  such  increased 
ubiquitination is an indication this process might be involved in the general regulation 
of  T  cell  signalling.  Possibly  this  might  occur  by  the  targeting  of  TCR  signal 
transducers  by  E3  ubiquitin-protein  ligases,  and  to  address  this,  protein  from  naïve, 
anergising and priming T cells was immunoprecipitated with an antibody against all 88
ubiquitinated  conjugates  and  then  blotted  for  proteins  of  interest  (Figure  3.4A). 
Moreover, pull-down of E3-ligases in ubiquitin-containing complexes could begin to 
identify those selectively recruited and activated under differential functional outcomes. 
Indeed, PLCγ-1, Itch, Cbl-b, Smurf1, Smurf2 and Grail were all found to co-precipitate 
with ubiquitin as early as following 1 h of stimulation with anti-CD3 antibody but not in 
unstimulated or anti-CD3+anti-CD28-stimulated cells (Figure 3.4B). However, at 20 h, 
PLCγ-1  and  Itch  co-precipitate  with  ubiquitin  in  unstimulated,  anti-CD3-  and  anti-
CD3+anti-CD28-stimulated  T  cells  whilst  Smurf1  and  Smurf2  co-precipitate  with 
ubiquitin in the unstimulated and anti-CD3-stimulated T cells; on the contrary, Cbl-b 
appears  to  co-precipitate  with  ubiquitin  only  in  the  anti-CD3+anti-CD28-stimulated 
population of T cells. 
That PLCγ-1 is found in ubiquitin-containing complexes suggests ubiquitination 
as a possible modulation factor for its expression levels. The complexing of Itch, Cbl-b, 
Smurf1,  Smurf2  and  Grail  suggests  something  else,  though;  since  these  are  E3 
ubiquitin-protein ligases, their recruitment and/or ubiquitination points for them playing 
an  active  role  in  the  modulation  of  proteins  involved  in  signal  transduction  in  the 
anergising and priming T cells. 
The Western blotting data so far relates to cells extracted from lymph nodes and 
hence may be complicated by bidirectional signalling in accessory cells, particularly as 
the  strong  preferential  induction  of  E3  ligases  under  conditions  of  anergy  (but  not 
priming) predicted by the ionomycin system [183, 233] were not replicated when cells 
were stimulated with anti-CD3±anti-CD28 antibodies. In order to have a clear picture of 
what happens in a homogenous T cell population, CD4
+ T cells were purified from the 
whole  lymph  node  cell  population  before  in  vitro  cell  culture  and  stimulation,  and 
subsequently analysed by Western blotting (Figure 3.5). Nevertheless, PLCγ-1 is again 
most intensely expressed in the anti-CD3+anti-CD28-stimulated T cells and least in the 
anti-CD3-stimulated T cells (Figure 3.6A and B), as expected and a good indication 
that both these stimuli are inducing the predicted differential functional outcome for the 
populations. However, as with the LN populations, all E3 ligases were more highly 
expressed  in  anti-CD3+anti-CD28  than  in  anti-CD3-stimulated  cells  (Figure  3.6A). 
Indeed,  Grail  was  barely  upregulated  in  anti-CD3-treated  cells  showing  comparable 
levels to those of unstimulated CD4
+ T cells. 
Although  anti-CD3+anti-CD28  antibodies  induce  the  highest  expression  of 
Smurf1 in CD4
+ T cells, its expression does not change much with the different stimuli 
(Figure 3.6B). There is a ladder of Smurf1 bands around the 86 KDa mark, just as 89
observed for the unpurified T cells (Figure 3.2B). This might be an indication that 
Smurf1 is active in CD4
+ T cells. Lck was also blotted for; this protein is involved in 
TCR signalling and it has been reported that, like PLCγ-1, anergised T cells (stimulated 
with anti-CD3 in the absence of co-stimulation) express less of it than primed T cells 
(stimulated  with  anti-CD3+anti-CD28)  [183];  here,  anti-CD3-stimulated  T  cells  are 
expressing Lck the least, as expected (Figure 3.6B). 
Smurf2 expression was also analysed in CD4
+ T cells (Figure 3.6B and C) and, 
unlike the LN cells, it seems to be upregulated in the anti-CD3+anti-CD28-stimulated 
population. Also unlike the LN cells, here (Figure 3.6C), there is not much difference 
in expression of Traf6 between the two conditions; however, anti-CD3-stimulated CD4
+
T cells seem to express a little bit more than anti-CD3+anti-CD28-stimulated CD4
+ T 
cells.  Ikaros, the transcriptional repressor involved in Il2 transcription repression by 
promoting histone deacetylation [120], also seems to be a little bit more expressed in 
anti-CD3-stimulated CD4
+ T cells than anti-CD3+anti-CD28-stimulated CD4
+ T cells, 
agreeing with previous reports of mRNA upregulation during anergy induction [116]. 
Proteins involved in the signalling transduction pathways conveying the signal 
from the TCR leading to differential outcomes (ie, anergy Vs priming) are under tight 
regulation by a number of mechanisms [111, 126, 128]. Proteins can be downmodulated 
upon receiving a specific signal and this can be a functional downmodulation by means 
of inactivation, re-location or downmodulation by degradation of the protein [111, 130, 
183]. Ubiquitination is involved in all of these processes as it can lead to conformational 
changes  resulting  in  inactivation,  re-location  and  signalling  for  degradation  via  the 
proteasome or lysosomes [183, 242, 279, 280]. At the same time, E3 ubiquitin-protein 
ligases can auto-inhibit themselves [253] and be modulated by means of ubiquitination, 
including self-ubiquitination [247]. The data above show that anergising and priming T 
cells  exhibit  many  ubiquitinated  proteins.  Some  of  these  are  K63-linked 
polyubiquitinated  proteins,  which  should  be  targeted  for  downmodulation  by 
proteasome-independent processes [159, 164]. It is important to assess if ubiquitination 
is  taking  an  active  role  in  the  downmodulation  of  proteins  in  the  TCR  signalling 
transduction pathway. And, at the same time assess if the E3 ubiquitin-protein ligases 
involved in the modulation of these signal transductors are themselves being modulated 
by ubiquitination. The most common form of regulation by ubiquitination is thought to 
be protein degradation in the proteasome. By using proteasome inhibitors it is possible 
to block proteasome function, preventing protein degradation from occurring and as a 
consequence,  resulting  in  an  accumulation  of  the  ubiquitinated  proteins  in  the  cell. 90
Lactacystin  is  one  such  potent,  cell  permeable  and  selective  proteasome  inhibitor 
affecting all three ATP-independent activities of the 20S complex of the proteasome 
[281] and as such was used to block proteasome-mediated degradation of ubiquitinated 
proteins. Cells treated with lactacystin showed generally less protein than un-treated 
cells (Figure 3.6E). 
PLCγ-1  has  been  reported  to  be  degraded  following  ubiquitination  during 
ionomycin-induced anergy [183]. This degradation however requires a second signal 
(high cell density re-plating) and the use of another proteasome inhibitor (MG132) did 
not block its degradation [183]. Here, in anti-CD3-stimulated CD4
+ T cells grown with 
lactacystin  we  observe  higher  expression  of  PLCγ-1  than  in  unstimulated  cells  also 
treated  with  lactacystin  (Figure  3.7A).  This  would  suggest  PLCγ-1  is  being 
downmodulated  in  the  anti-CD3-stimulated  CD4
+  T  cells  by  means  of  proteasome-
mediated degradation since in lactacystin-free grown cells (Figure 3.6A and B) PLCγ-1 
was  more  expressed  in  unstimulated  than  anti-CD3-stimulated  CD4
+  T  cells.  Also, 
using  another  anergy-inducing  stimulus  (ionomycin)  and  comparing  cells  thus 
stimulated  with  anti-CD3+anti-CD28-stimulated  CD4
+  T  cells  (Figure  3.7D)  shows 
once again higher expression of PLCγ-1 in the anergising cells. Since in lactacystin-free 
grown  cells  the  priming  population  expressed  the  highest  levels  of  PLCγ-1  (Figure 
3.6A and B), this would suggest lactacystin promotes the accumulation of PLCγ-1 in 
anergising cells and this is being accomplished via inhibition of proteasome-mediated 
degradation of PLCγ-1. These data suggest PLCγ-1 can be degraded, at least in part, via 
the ubiquitin-proteasome pathway, although its degradation via the lysosomal pathway 
has been previously reported [183]. 
In  a  non-anergy  model,  TCR  plus  CD4  co-ligation  induces  Cbl-mediated  Lck 
ubiquitination in the human CD4
+ T cell line SPF1, and that ubiquitination targets Lck 
to the proteasome [282] whilst in CTLs TCR triggering results in rapid degradation of 
Lck through a mechanism that is proteasome- and lysosome-independent, but sensitive 
to cysteine protease inhibitors [283]. Here (Figure 3.7A), there is not much difference 
between the two conditions, which points to Lck downregulation, as observed in anti-
CD3-stimulated CD4
+ T cells in the absence of lactacystin (Figure 3.6B), not involving 
proteasomal degradation. By contrast, expression of Itch, Cbl-b, Smurf1 and Smurf2 is 
slightly enhanced in anti-CD3 stimulated, proteasome-inhibited CD4
+ T cells (Figure 
3.7A and B). For Itch and Cbl-b this merely reflects the trend observed in lactacystin-
free  grown  cells  and  might  indicate  proteasomal  degradation  is  not  involved  in 
regulating  the  expression  of  these  proteins  or,  if  it  is  involved  it  does not  play  the 91
decisive role under these stimuli. The intensity of Smurf1 and Smurf2 expression did 
not  change  from  unstimulated  to  anti-CD3-stimulated,  lactacystin-free  grown  cells 
(Figure 3.6B) but here, when the proteasome was inhibited, both Smurf1 and Smurf2 
are slightly more expressed in anti-CD3-stimulated CD4
+ T cells than in unstimulated 
ones indicating a dynamic turnover of these E3 ligases during induction of anergy. This, 
as also happens for PLCγ-1, is an indication that both Smurfs are being downmodulated 
in anti-CD3-stimulated CD4
+ T cells by means of proteasome-mediated degradation. 
Comparing anti-CD3- with anti-CD3+anti-CD28-stimulated CD4
+ T cells grown with 
lactacystin (Figure 3.7C) suggests Smurf2 is in fact being regulated in anergising T 
cells by means of proteasomal degradation as it is more intensely expressed in these 
cells rather than the T cells undergoing priming, while in lactacystin-free grown cells 
the opposite was observed (Figure 3.6B). 
Like Smurf2, Itch, Cbl-b and Grail are also more intensely expressed in anti-CD3 
-stimulated  CD4
+  T  cells  than  anti-CD3+anti-CD28-stimulated  CD4
+  T  cells,  when 
grown with lactacystin (Figure 3.7C). Because the opposite was true in lactacystin-free 
conditions  (Figure  3.6A),  addition  of  anti-CD3  antibody  seems  likely  to  induce 
proteasomal  degradation  of  these  proteins  more  extensively  than  addition  of  anti-
CD3+anti-CD28  antibodies.  This  effect  is  specific  of  the  anti-CD3  antibody-way  of 
inducing anergy as stimulating the cells with ionomycin in the presence of lactacystin 
does not lead to accumulation of Itch, Cbl-b or Grail in greater extent than that observed 
in anti-CD3+anti-CD28-stimulated CD4
+ T cells (Figure 3.7D). 
Considering  induction  of  anergy  and  priming  involves  dynamic  processes  that 
most likely involve upregulation and downregulation of multiple signal transductors in 
different time-frames, time-course experiments were run for 3, 6, 20 and 48 h, covering 
the  induction  period  (Figure  3.8).  Reflecting  this,  whilst  at  3  h  there  are  roughly
comparable  levels  of  Itch,  Cbl-b  and  Grail  in  anti-CD3+anti-CD28-  and  anti-CD3-
stimulated CD4
+ T cells, at 48 h Itch and Cbl-b are expressed more highly in anti-
CD3+anti-CD28- relative to anti-CD3-stimulated CD4
+ T cells (Figure 3.9). Also at 48 
h, Grail is more highly expressed in anti-CD3- than anti-CD3+anti-CD28-stimulated 
CD4
+  T  cells.  By  contrast,  ionomycin+PMA-stimulated  cells  express  Grail  more 
intensely than cells stimulated with ionomycin alone, at 3 and 6 h of in vitro culture, but 
at  20  h  the  opposite  happens.  Cbl-b  is  also  more  intensely  expressed  at  6  h  in 
ionomycin+PMA-stimulated cells than cells stimulated with ionomycin alone whilst the 
opposite happens at 20 h. 92
These  total  protein  lysates  were  also  tested  for  the  presence  of  ubiquitinated 
proteins (Figures 3.10). Globally, the ubiquitination of proteins is more intense in the 
ionomycin+PMA-stimulated  cells  than  ionomycin-stimulated  cells  at  3  and  6  h  and 
perhaps consistent with this, ubiquitination of proteins also looks more intense in anti-
CD3+anti-CD28-stimulated CD4
+ T cells than in anti-CD3-stimulated CD4
+ T cells but 
predominantly at later time-points such as 48 h. Next, assessment of the prevalence of 
mono- and poly-ubiquitinated proteins in the different conditions was carried out and 
this  showed  a  similar  but  less  pronounced  pattern.  Analysis  of  only  K63-linked 
polyubiquitinated proteins showed that, at 3 h, anti-CD3-stimulated cells are expressing 
K63-linked  polyubiquitinated  proteins  more  intensely  than  anti-CD3+anti-CD28-
stimulated CD4
+ T cells but at later time-points this difference is lost and reversed at 48 
h  mirroring  the  global  ubiquitination  pattern.  Likewise,  reflecting  the  global 
ubiquitination  profile,  ionomycin+PMA-stimulated  cells  are  expressing  K63-linked 
polyubiquitinated proteins more intensely than ionomycin-stimulated CD4
+ T cells. 
Taken  together,  unlike  previous  reports  [183,  233],  these  results  indicate  that 
upregulation of E3 ligase expression and ubiquitin-mediated proteasomal degradation is 
not necessarily a key signal regulating commitment to anergy versus priming. As there 
is increasing evidence [242, 279, 280] for a role(s) for E3 ligases in regulation of signal 
transduction by proteasome-independent ways, namely by modulating the activity (via 
stability  and  protein-protein  recognition  interference),  by  promoting  changes  in 
subcellular localisation and by targeting proteins to the endocytic pathway (which can 
lead either to recycling or to degradation in the lysosome) [159], it was decided to 
analyse the role of E3 ligases in the induction of anergy and priming of T cells at the 
single cell level. 
3.1.3 Analysis of the expression of E3 ubiquitin-protein ligases in the 
induction phase of anergy and priming at the single-cell level 
3.1.3.1 Cbl-b 
After  having  demonstrated  that  the  different  stimuli  are  inducing  different 
functional outcomes (anergy and priming), the expression of some of the E3 ubiquitin-
protein ligases described above and postulated to be involved in enforcing induction of 
anergy  was  assessed  by  analysis  of  immunofluorescence  staining  of  cytospin 
preparations of primed and tolerised CD4
+ T cells. First, Cbl-b expression in CD4
+ T 
cells undergoing induction of anergy or priming in vitro was imaged and quantified 93
(Figure 3.11). This was done by staining the cells for the CD4 co-receptor and Cbl-b 
after 20 h of in vitro culture stimulation and then quantifying the resultant fluorescence 
by LSC. Surprisingly, Cbl-b was found to be expressed in a higher percentage of CD4
+
T  cells  undergoing  induction  of  priming  (anti-CD3+anti-CD28  antibodies  and 
ionomycin+PMA stimuli) than that of CD4
+ T cells undergoing anergy induction (anti-
CD3  antibody  and  ionomycin).  In  fact,  all  populations  express  Cbl-b  but  those 
undergoing anergy induction showed the lowest proportion that expressed it, with even 
a lower percentage positive population than that of the naïve CD4
+ T cell group (Figure 
3.11A). Moreover, analysis of the mean fluorescence intensity of Cbl-b expression of 
CD4
+Cbl-b
+ cells showed little or no difference between the different stimuli (Figure 
3.11B),  meaning  cells  which  are  expressing  Cbl-b  express  it  at  the  same  intensity 
regardless of whether they are undergoing anergy or priming. 
LSC also allows for the determination of the location of Cbl-b expression within a 
cell and therefore it was investigated whether Cbl-b showed a differential subcellular 
location in cells undergoing induction of priming and tolerance. For example, in Figure 
3.11C the proportion of CD4
+ cells expressing Cbl-b at the cell periphery is shown. 
Interestingly, the CD4
+ T cells treated with anti-CD3+anti-CD28 antibodies exhibited 
by far the highest percentage of cells expressing Cbl-b at the cell periphery, suggesting 
that there may be differential location of Cbl-b in this CD4
+ T cell population versus 
any of the other populations of cells as, whilst the other CD4
+ T cell populations also 
express Cbl-b at the periphery, they do not do it to the extent of the primed CD4
+ T cell 
population (taking in account Figure 3.11A). With respect to the levels of expression of 
Cbl-b in CD4
+Cbl-b
+ T cells at the periphery, Cbl-b is expressed most highly at the 
periphery of naïve T cells and at lower, but comparable levels in the primed and anergic 
populations (Figure 3.11D). 
In order to visualise the expression of Cbl-b during the induction and priming of 
CD4
+ T cells, images of the different populations were captured using a fluorescent 
microscope (Figure 3.12). As microscopy can often be subjective, the LSC was used 
blind  to  quantitate  and  then  corroborated  by  relocating  to  selected  cells,  of  which 
photographs  were  taken.  All  nucleated  cells  were  imaged  initially  based  on  DAPI 
staining (blue) and T cells were identified by their expression of CD4 (red), while the 
expression of Cbl-b was also detected (green). In the end the three images were merged, 
allowing visual assessment of Cbl-b expression in CD4
+ T cells. In these images we can 
gather  a  better  understanding  of  Cbl-b  expression  and  location:  for  example,  rather 
unexpectedly given the current proposals regarding the role of E3-ligases in tolerance 94
induction,  anti-CD3-  and  anti-CD3+anti-CD28-stimulated  cells  appear  to  exhibit  a 
similar intensity of expression of Cbl-b, as seen in Figure 3.11B). More interestingly 
perhaps, anti-CD3+anti-CD28-stimulated cells appear to exhibit a more peripheral Cbl-
b  expression,  suggesting  co-localisation  with  the  TCR.  Although  the  anti-CD3-
stimulated cells express Cbl-b more diffusely, they also have it at the periphery, and 
here it seems to concentrate in one of the poles. 
In another experiment, the expression of Cbl-b in CD4
+ T cells was also analysed 
at 40 h post-commencement of the stimuli (Figure 3.13). Again at this time-point there 
is a higher percentage of cells expressing Cbl-b in the primed relative to the anergic 
populations (Figure 3.13A) though this effect is no longer as marked as at 20 h post- 
stimulation (Figure 3.11A). Cbl-b seems to be more expressed in cells cultured with 
ionomycin+PMA than any other stimulus (Figure 3.13B) and, similarly, it seems it is 
more intensely expressed within the periphery of these cells than within the periphery of 
cells stimulated with any of the other stimuli (Figure 3.13D). These results should take 
in  account  that  only  3%  of  CD4
+  T  cells  stimulated  with  ionomycin+PMA  are 
expressing Cbl-b at the cell periphery (Figure 3.13C) and that even lower proportions 
of  cells  cultured  in  vitro  under  the  other  conditions  expressed  Cbl-b  at  the  cell 
periphery.  For  instance,  ionomycin-stimulated  cells  showed  no  Cbl-b  within  its 
periphery; this may be more of a secondary effect of culturing T cells with such a high 
concentration of ionomycin for so long than a reliable trend; visual inspection of the 
field of large portions of the slide revealed few normal-topology cells at this time-point 
(not shown). 
In order to visualise these data, colour images of the different populations were 
captured  using  a  fluorescent  microscope  (Figure  3.14).  In  the  cells  chosen  for 
photography,  anti-CD3-  and  anti-CD3+anti-CD28-stimulated  cells  appear  to  have  a 
higher intensity of expression of Cbl-b, with peripheral focal points of distribution. 
3.1.3.2 Itch 
Itch is another E3 ubiquitin-protein ligase reported to be involved in the induction 
of anergy and thus its expression in CD4
+ T cells was quantified in the same fashion as 
for Cbl-b: cells were stained for the CD4 and Itch after 20 h of in vitro induction of 
anergy and priming and then analysed by LSC (Figure 3.15). Itch was found to be 
expressed in 34% of naïve CD4
+ T cells (Figure 3.15A) and following stimulation with 
anti-CD3  and  anti-CD3+anti-CD28  stimuli this  was  found  to  be increased,  with  the 
percentage of CD4
+ T cells expressing it being 70% and 65%, respectively. By contrast, 95
under  conditions  of  stimulation  via  direct  calcium  release  (ionomycin  and 
ionomycin+PMA) a lower percentage of CD4
+ T cells were found to express Itch (19% 
and 15%, respectively). These results suggest that Itch expression during induction of 
anergy  or  priming  is  not  so  much  related  to  the  final  outcome  of  the  stimulus 
(quiescence versus activation/proliferation) but more to how the stimulus acts upon the 
cell. Interestingly though, in CD4
+Itch
+ T cells, Itch is more highly expressed in cells 
stimulated via the calcium pathway alone than by any other means (Figure 3.15B). As 
for  the  peripheral  expression  of  Itch  (Figure  3.15C),  anti-CD3-  and  anti-CD3+anti-
CD28-stimulated populations are again the ones with the highest percentage of Itch-
positive  CD4
+  T  cells  but  it  is  noteworthy  to  stress  that  ionomycin  and 
ionomycin+PMA-stimulated populations, considering their relatively low percentage of 
CD4
+ T cells expressing Itch, appear to predominantly express Itch at their periphery, 
while  this  is  not  the  case  for  naïve,  anti-CD3  and  anti-CD3+anti-CD28-stimulated 
populations of CD4
+ T cells. Again at the periphery, Itch is more intensely expressed in 
cells stimulated via the calcium pathway alone than via any of the other stimuli (Figure 
3.15D), though here the trend is not so pronounced as for total cell expression (Figure 
3.15B). 
Representative  images  of  these  populations  (Figure  3.16)  suggested  that  cells 
from all groups appeared to predominantly express Itch at the periphery relative to the 
rest of the cell. Furthermore, apart from anti-CD3-stimulated cells, all of the groups 
appear to exhibit to some extent foci of Itch expression. For example, ionomycin+PMA-
stimulated  cells  exhibit a  polarised  pattern  of  Itch  expression,  with  little  expression 
around the cell, rather the majority focused in one major locus. 
Itch expression was also analysed in CD4
+ T cells after 40 h of in vitro culture 
stimulation (Figure 3.17). At this time-point, populations of CD4
+ T cells stimulated 
with anergising stimuli have slightly higher percentage of cells expressing Itch than 
populations of CD4
+ T cells stimulated with priming stimuli, although this effect is not 
very pronounced (Figure 3.17A). However, cells stimulated under all conditions exhibit 
roughly the same expression levels of Itch, whether in the whole of the cell (Figure 
3.17B), or its periphery (Figure 3.17D). The percentage of CD4
+ T cells expressing Itch 
within their periphery also appears not to change according to the different conditions of 
in vitro culture (Figure 3.17C). Consistent with this, visualisation of these 40 h cells 
reveals  a  more  peripheral  distribution  of  Itch  with  focal  points  present  in  the 
ionomycin+PMA-representative cell. Cells representative from the other populations do 96
not  display  these  intense  foci  but  rather  display  a  more  uniform  peripheral  staining 
(Figure 3.18). 
3.1.3.3 Grail 
It is hypothesised Grail is also involved in anergy as its expression was reported to 
be upregulated during T cell anergy induction. Thus, expression of Grail at the single 
cell level during the induction of anergy and priming was quantified via LSC. This 
analysis showed Grail to be expressed in CD4
+ T cells under all conditions tested but 
the ionomycin+PMA-stimulated population contained the lowest proportion of Grail
+
cells (Figure 3.19A). In fact, not only is this the population least expressing Grail but 
there  is  also  a  striking  difference  when  compared  with  the  ionomycin-stimulated 
population, suggesting a relationship between anergy and Grail expression. On the other 
hand,  however,  the  anti-CD3+anti-CD28-stimulated  population  has  an  even  higher 
percentage of CD4
+ T cells expressing Grail than the ionomycin-stimulated population 
and also a considerably higher percentage of CD4
+ T cells expressing Grail than either 
the  naïve  or  anti-CD3-stimulated  populations,  which  have  essentially  equivalent 
percentages of CD4
+ T cells expressing Grail. Moreover, in CD4
+Grail
+ T cells, Grail is 
expressed  most  highly  in  such  cells  from  the  anti-CD3+anti-CD28  and 
ionomycin+PMA-stimulated populations (Figure 3.19B). Thus, there does not appear to 
be a correlation between either the percentage of cells expressing Grail or alternatively, 
the total expression levels of Grail in such cells and their functional outcome. These 
total expression results translate into peripheral expression (Figure 3.19C), with the 
ionomycin- and the anti-CD3+anti-CD28-stimulated populations containing the highest 
proportion of cells expressing Grail at their periphery than ionomycin+PMA- and anti-
CD3-stimulated  populations,  respectively.  As  for  intensity  of  expression  within  the 
cells,  again  it  is  the  cells  cultured  with  priming  stimuli  (anti-CD3+anti-CD28  and 
ionomycin+PMA) that express Grail the most, while anti-CD3 and ionomycin alone 
render  only  a  slightly  higher  Grail  expression  than  that  of  the  naïve  CD4
+  T  cells 
(Figure 3.19B). The intensity of Grail expression within the cells’ periphery (Figure 
3.19D) is a reflection of this trend as once again the cells grown with priming stimuli 
are the ones that express Grail the most in the periphery. These data were corroborated 
by representative images of Grail positive cells (Figure 3.20) as whilst unstimulated 
CD4
+ T cells exhibited diffuse Grail expression, stimulated cells showed a more intense 
and  peripheral  Grail  location  with  highest  expression  shown  under  conditions  of 
priming  (anti-CD3+anti-CD28  and  ionomycin+PMA);  results  from  the 97
ionomycin+PMA population should be interpreted with some caution as the cells appear 
to be undergoing apoptosis. 
By the 40 h time point, however, Grail expression is reduced under all conditions 
tested. Nevertheless, at 40 h post stimulation (Figure 3.21) anti-CD3-stimulated CD4
+
T cells were found to have the highest proportion of cells expressing Grail, higher than 
anti-CD3+anti-CD28-stimulated  CD4
+  T  cells  (18%  versus  11%,  respectively),  an 
inverse  situation  to  that  observed  at  20  h  suggesting  that  conflicting  data  with  the 
literature  may  reflect  the  differential  kinetics  observed.  Likewise,  for  the  stimuli 
affecting the calcium pathway directly, again an inverse pattern to that observed at 20 h 
is seen, with the population undergoing priming having a higher proportion of CD4
+ T 
cells positive for Grail than the population undergoing anergy (Figure 3.21A). This 
trend is reflected in the proportion of CD4
+ T cells expressing Grail within the periphery 
(Figure 3.21C) with anti-CD3-stimulated CD4
+ T cells also expressing more Grail than 
anti-CD3+anti-CD28-stimulated CD4
+ T cells while ionomycin+PMA-stimulated CD4
+
T cells express more Grail than ionomycin-stimulated CD4
+ T cells (Figure 3.21B). 
Within the periphery, however there is not much difference in terms of Grail intensity 
expression between different conditions (Figure 3.21D). Nevertheless, although there is 
no clear correlation between Grail expression and priming or tolerance, there appears to 
be inverse patterns not only of expression but also subcellular location elicited by the 
differential stimuli. 
3.1.4 Distribution  of  the  E3  ubiquitin-protein  ligase-expressing  cells 
according to the cell cycle stage 
As the above studies suggested that the expression profile of E3 ligases differed 
throughout the kinetics of the induction and priming, it was decided to correlate E3 
ligase expression with cell cycle progression in the two populations in an attempt to 
determine if there were distinct expression patterns in G0/G1 arrest (associated with 
anergy)  Vs  S  and  G2/M  phases  (associated  with  priming).  Indeed,  as  described  in 
section 2.9.1.2, LSC can be used to assess the cell cycle stage of individual T cells and 
correlate this with signalling and/or phenotypic markers. Thus, cells were stained with 
DAPI to detect nuclear DNA and anti-CD4 and anti-E3 ligase to locate T cells and the 
intracellular  protein  of  interest.  By  measuring  the  max  pixel  (which  correlates  with 
DNA concentration) and integral (which correlates to total quantity of DNA) values of 
DAPI it is possible to obtain a dot plot distribution of the population of cells which 
allows determination of their cell cycle status. 98
Firstly,  analysis  of  cell  cycle  status  of  CD4
+  T  cells  under  the  differential 
conditions of induction of priming and tolerance were examined at 20 and 40 h. CD4
+ T 
cells were gated and their DAPI max pixel VS integral values plotted, analysed and 
graphed (Figure 3.22). For this set of experiments cells in S and G2/M phases and 
newly-formed daughter cells were grouped together in one group called “Mitotic” cells. 
After 20 h of in vitro culture most (over 50%) of the CD4
+ T cells were in the G0/G1 
stage of the cell cycle, regardless of the stimulus (Figure 3.22A). Only around 10% of 
the various populations exhibited apoptosis at this time-point, although the naïve CD4
+
T  cells  (“no  stimulus”)  tended  towards  a  higher,  but  not  statistically  significant, 
proportion of apoptotic cells (above 20%). Moreover, consistent with the idea that cells 
need  to  be  activated  in  the  induction  phase  of  both  priming  and  tolerance,  similar 
proportions of the cells from each group were mitotic at this time-point. 
However, and perhaps consistent with DNA synthesis data (Figure 3.1), at the 40 
h time point (Figure 3.22B) some differences do appear. Cells stimulated with anti-
CD3 are predominantly apoptotic with the majority of the remainder arrested in G0/G1 
and only a small proportion advancing through the cell cycle. By contrast, the majority 
of population stimulated with anti-CD3+ anti-CD28 were advancing through the cell 
cycle and tended to show protection from apoptosis and growth arrest. The ionomycin-
stimulated  population  appears  to  be  overwhelmingly  arrested  in  G0/G1  but  perhaps 
surprisingly,  the  proportion  of  cells  in  apoptosis  is  just  10%  and  a  considerable 
proportion  (35%)  are  still  mitotic.  Rather  unexpectedly,  the  ionomycin+PMA-
stimulated population had a very high proportion of cells in apoptosis (44%) and equal 
percentages  of  cells  arrested  in  G0/G1  and  progressing  through  the  cell  cycle;  one 
would expect more cells in the mitotic stages of the cell cycle but it may be possible the 
intensity of the stimulus might have been too much for the cells for such a prolonged 
period. 
3.1.4.1 Cbl-b 
Consistent with the findings that, at least in the early stages (20 h) of induction of 
priming and tolerance, all the cells showed a similar profile of cell cycle progression, it 
appeared that in general CD4
+Cbl-b
+ T cells from all conditions exhibited similar cell
cycle status (Figure 3.23A). Interestingly, however, Cbl-b
+ cells from the population of 
cells stimulated with anti-CD3+ anti-CD28 do show a considerable higher proportion of 
their cells in G0/G1 (42%) than any of the other populations, perhaps suggesting that 
expression of Cbl-b antagonises progression of primed cells. Nevertheless, these results 99
seem to suggest that, regardless of the stimulus, most of the Cbl-b
+ cells are mitotic at 
this time-point. 
It is also noteworthy to stress that the level of expression of Cbl-b in a cell does 
not change according to the stage of the cell cycle as much as the proportion of cells 
expressing it within a population (Figure 3.23B). However, mitotic cells do seem to 
express more Cbl-b than G0/G1 cells (there were too few CD4
+Cbl-b
+ cells undergoing 
apoptosis  to  make  conclusions  about  Cbl-b  expression  intensity  in  apoptotic  cells). 
Perhaps rather surprisingly, anti-CD3+anti-CD28-stimulated cells seem to express most 
Cbl-b in the mitotic stages. Thus, high levels of Cbl-b expression per se do not appear to 
dictate cell cycle arrest and indeed, when total CD4
+ T cells in each cell cycle stage are 
screened for Cbl-b expression, mitotic cells show, by far, the highest proportion of Cbl-
b-expressing cells (Figure 3.23C). Thus, very few (less than 10%, regardless of the
stimulus) CD4
+ apoptotic cells are Cbl-b
+. The same holds true for cells in G0/G1 with 
the  following  exceptions:  naïve  (no  stimulus)  and  anti-CD3+anti-CD28-stimulated 
populations have 17% and 34%, respectively, of their CD4
+ T cells expressing Cbl-b. 
As for mitotic cells, as stated above, there is a high percentage of CD4
+ T cells positive 
for Cbl-b (above 35%, regardless of the nature of stimulation) but the naïve population 
(81%) and the anti-CD3+anti-CD28 population (74%) have the highest proportion of 
Cbl-b
+ cells within the CD4 positives. 
Analysis of the expression of Cbl-b according to cell cycle stage at 40 h of in vitro
culture revealed similar profiles (Figure 3.24)  as again the majority of CD4
+Cbl-b
+
cells are found in the  mitotic stages (Figure  3.24A) regardless of the nature of the 
stimulus.  Perhaps,  consistent  with  the  cell  cycle  analysis  data  (Figure  3.22B),  the 
ionomycin+PMA-stimulated  population  has  a  high  proportion  of  cells  in  apoptosis 
(25%) whilst all populations have only about 10% of Cbl-b
+ cells in G0/G1 phase with 
the exception of anti-CD3+anti-CD28-stimulated cells with just 1%. Again, the level of 
expression of Cbl-b in a cell does not appear to change much according to the stage of 
the  cell  cycle  or  the  stimuli  (Figure  3.24B);  nonetheless,  mitotic  anti-CD3-  and 
ionomycin+PMA-stimulated cells seem to express it more. Finally, analysis of the CD4
+
cells in each stage of the cell cycle again reveals that few of these are Cbl-b
+ with most 
of the Cbl-b
+ cells being mitotic(Figure 3.24C). 
3.1.4.2 Itch 
The expression of Itch was correlated with the cell cycle status of CD4
+ T cells 
during induction of priming and tolerance (Figure 3.25). Analysis of the CD4
+Itch
+100
cells revealed that for the naïve (unstimulated) population, the highest percentage of 
these CD4
+Itch
+ cells were in G0/G1 (51%) while the rest were, rather surprisingly, 
mitotic  (33%)  or  consistent  with  their  lack  of  signalling,  apoptotic  (16%)  (Figure 
3.25A).  Similarly,  CD4
+Itch
+  cells  from  the  anergic  (anti-CD3)  and  primed  (anti-
CD3+anti-CD28)  populations  were  predominantly  found  in  G0/G1  (64%  and  77%, 
respectively) while the rest of the CD4
+Itch
+ cells were mainly mitotic (35% and 20%) 
and  very  few  were  apoptotic  (1%  and  3%).  Rather  surprisingly  therefore,  for  the 
populations  of  cells  stimulated  via  the  calcium  pathway  (ionomycin  and 
ionomycin+PMA), CD4
+Itch
+ T cells were mainly mitotic (67% and 65%, respectively) 
with some also arrested in G0/G1 (30% and 32%) but only a few were found to be 
apoptotic  (3%  and  3%).  Moreover,  analysis  of  the  level  of  expression  of  Itch  in 
CD4
+Itch
+  cells  revealed  that  generally,  for  each  condition  tested,  Itch  expression 
increased  with  cell  cycle  progression  rather  than  peaking  in  G0/G1,  the  stage  most 
associated with anergy. Nevertheless, expression was highest in the ionomycin-treated 
cells and this stimulus has classically been associated with the role of E3 ligases in 
anergy (Figure 3.25B). 
When the proportion of all CD4
+ T cells in each cell cycle stage was examined for 
Itch expression, while for anergy and priming induction via the TCR there was a peak 
of Itch-positive T cells in the G0/G1 phase, for the calcium-based stimuli Itch-positive 
T  cells  were  more  associated  with  mitosis  than  growth  arrest.  Thus,  whilst  64%  of 
unstimulated CD4
+ T cells in G0/G1 phase are Itch
+ those from the anti-CD3 and anti-
CD3+anti-CD28 populations are even more so (94% and 92%, respectively), while the 
G0/G1 populations of CD4
+ T cells stimulated with ionomycin and ionomycin+PMA 
only have 13% and 8%, respectively, of Itch
+ cells (Figure 3.25C). As for mitotic cells, 
naïve, anti-CD3- and anti-CD3+anti-CD28-stimulated CD4
+ T cell populations also all 
exhibit a high proportion of Itch
+ cells (over 70%) while ionomycin- and ionomycin-
stimulated populations have 35% and 42%, respectively, of Itch-positive CD4
+ T cells. 
As for apoptotic cells, naïve, anti-CD3- and anti-CD3+anti-CD28-stimulated CD4
+ T 
cell  populations  have  once  again  a  high  proportion  of  Itch
+  cells  (over  30%)  while 
ionomycin- and ionomycin-stimulated populations have less than 7% of Itch-positive 
CD4
+ T cells. Collectively therefore, at this time point, Itch expression did not appear to 
correlate with functional outcome, but rather with the nature of the stimuli used.  
Furthermore, analysis at the 40 h time point, revealed that for all conditions tested, 
most of the CD4
+Itch
+ cells were found in the mitotic stages (Figure 3.26A). Indeed, of 
the  CD4
+Itch
+  cells  from  the  population  stimulated  with  ionomycin,  the  highest 101
proportion of these cells is in mitosis (69%) and the smallest proportion in apoptosis 
(3%). Similarly, apart from high levels of Itch in ionomycin-induced apoptotic cells, 
again  Itch  expression  tends  to  increase  with  cell  cycle  progression  (Figure  3.26B). 
Moreover, analysis of the total CD4
+ populations in each cell cycle stage revealed that
mitotic cells showed the highest proportion of Itch
+ regardless of the stimulus (Figure 
3.26C). Unlike at 20 h, unstimulated, anti-CD3- and anti-CD3+anti-CD28-stimulated 
CD4
+  cells  arrested  in  G0/G1  are  not  predominantly  Itch
+,  and  neither  are  the 
ionomycin- and ionomycin+PMA-stimulated ones, perhaps suggesting that these cells 
were transiting rather than being arrested in G0/G1. Thus, taken together, if anything 
such single cell analysis would suggest that Itch expression is more associated with 
mitosis than cell cycle arrest, at least during this induction phase where both anergic and 
priming cells need to go through an activation stage. 
3.1.4.3 Grail 
The expression of Grail according to cell cycle stage of CD4
+ T cells at 20 h was 
also  quantified  (Figure  3.27).  In  this  case,  the  CD4
+Grail
+  cells  of  the  ionomycin-
stimulated population were found to be spread roughly evenly between all the cell cycle 
stages (Figure 3.27A). By contrast, all the other populations had less than 2% of the 
CD4
+Grail
+ T cells undergoing apoptosis and all of them had more CD4
+Grail
+ cells in 
the G0/G1 than in the mitotic phases. Generally, however, mitotic cells were found to 
express more Grail than cells in other stages (Figure 3.27B), although those from the 
ionomycin+PMA group were the only ones not to show an increase in Grail expression 
from  G0/G1  to  mitotic  phases.  CD4
+  T  cells  stimulated  with  anti-CD3+anti-CD28 
appeared to express more Grail at all cell cycle stages than CD4
+ T cells from any of the 
other functional conditions. Perhaps of interest, the vast majority of CD4
+ T cells in 
G0/G1  were  positive  for  Grail,  regardless  of  the  stimuli  (Figure  3.27C).  The  vast 
majority of CD4
+ T cells in the mitotic phases were also positive for Grail, with there 
being one exception in the form of the T cells stimulated with anti-CD3+anti-CD28, of 
which less than half were positive for Grail. As for  apoptotic cells, there is a high 
percentage  of  Grail-positive  CD4
+  cells  in  the  populations  stimulated  with  anti-
CD3+anti-CD28 and ionomycin (87% and 86%, respectively), a reasonable percentage 
in the unstimulated population (40%), and a very small percentage in the populations 
stimulated with anti-CD3 and ionomycin+PMA (8% and 7%, respectively). 
Again however, any association of this E3 ligase with G0/G1 observed at 20 h 
presumably reflected cells transiting this stage as, at 40 h, apart from the anti-CD3+anti-102
CD28-stimulated population, in all other populations the majority of CD4
+Grail
+ cells 
are in the mitotic stages (Figure 3.28A). Indeed, in both anti-CD3- and ionomycin-
stimulated populations there is a higher proportion of CD4
+Grail
+ cells in the mitotic 
stages than in the corresponding priming stimulus populations (anti-CD3+anti-CD28 
and ionomycin+PMA) whilst for the anti-CD3+anti-CD28-stimulated population, most 
of the CD4
+Grail
+ cells are apoptotic (62%). The low proportion of CD4
+Grail
+ cells in 
G0/G1 is also something to take in consideration (26%, 15%, 3% and 21% for the anti-
CD3-, anti-CD3+anti-CD28-, ionomycin- and ionomycin+PMA-stimulated populations, 
respectively) and again expression levels of Grail generally appear to increase with cell 
cycle progression (Figure 3.28B). Finally, analysis of the total CD4
+ T cells in each cell 
cycle phase revealed that at 40 h, almost all of the anti-CD3-, anti-CD3+anti-CD28- and 
ionomycin+PMA-stimulated mitotic CD4
+ T cells are positive for Grail (Figure 3.28C) 
whereas only 19% of the ionomycin-stimulated mitotic CD4
+ T cells are positive for 
Grail.  Moreover,  an  even  lower  proportion  of  ionomycin-stimulated  cells  in  G0/G1 
were  Grail  positive.  Collectively,  therefore,  these  data  do  not  support  a  correlation 
expression of Grail and cell cycle arrest contributing to the induction of anergy. 
3.1.5 Analysis of the expression of E3 ubiquitin-protein ligases in the 
induction phase of anergy and priming, in vivo 
To investigate whether similar patterns of E3 ubiquitin-protein ligases expression 
are found during induction of tolerance and priming in response to antigen in vivo, Cbl-
b, Itch, Smurf1 and Smurf2 expression was examined in antigen-specific CD4
+ T cells 
in lymph node tissue, in the context of a systemic model of antigen-specific priming and 
tolerance [30, 265-267]. Thus, 24 h after adoptive transfer of antigen-specific DO11.10 
TCR T cells, recipient mice received OVA323-339 peptide i.v., either alone or together 
with LPS to induce systemic tolerance or priming, respectively (Figure 3.29A). The 
efficacy of these regimes was  confirmed by assessing the clonal expansion (Figure 
3.29B) of DO11.10 TCR T cells in the mesenteric lymph nodes, 0, 3, 5 and 10 days 
after primary exposure to the antigen. In addition, the proliferative (Figure 3.29C) and 
cytokine production (Figure 3.29D) recall responses of such antigen-specific CD4
+ T 
cells from peripheral lymph nodes were assessed at D10 ex vivo. 
The peak of antigen-specific clonal expansion of the CD4
+ T cells was observed, 
at D3 after immunisation in both the tolerised and primed groups (Figure 3.29B), as 
previously reported [265, 266]. As expected, there was no major clonal expansion in the 
naïve group during the time-course and, at all times after primary immunisation, there 103
was  significantly  higher  clonal  expansion  in  the  tissues  harvested  from  primed 
compared  to  tolerised  mice,  as  also  shown  previously  [265,  284].  By  D10,  clonal 
expansion in the immunised groups had dropped to below that of the naïve group. 
After  re-stimulation  with  OVA323-339  in  vitro,  T  cells  from  tolerised  mice  also 
showed  reduced  proliferation  (Figure  3.29C)  and  IFNγ  production  (Figure  3.29D) 
relative to T cells from primed mice. T cells from naïve mice proliferated significantly 
more  than  the  tolerised  group  but  less  than  the  primed  group.  The  same  trend  is 
observable for IFNγ production, although no longer on a significant scale. Collectively, 
these  data  show  that  i.v.  administration  of  OVA323-339  with  or  without  LPS  as  an 
adjuvant, induced priming and tolerance, respectively, in vivo. 
3.1.5.1 Cbl-b 
The in vitro studies in the previous sections pointed towards an upregulation of 
Cbl-b in priming CD4
+ T cells rather than anergising CD4
+ T cells; but the question 
remained how this would translate into an in vivo antigen-specific situation. 
As described before, in this study, 24 h after adoptive transfer of antigen-specific 
DO11.10 TCR T cells, recipient mice received OVA323-339 peptide i.v., either alone or 
together with LPS to induce systemic tolerance or priming, respectively. At D5 after 
immunisation, PLNs were harvested and prepared for immunohistochemistry. D5 was 
chosen as by then enough time had passed to allow induction of tolerance and priming 
and  at  the  same  time  there  was  still  a  significant  difference  in  clonal  expansion  of 
DO11.10 T cells between tolerised and primed groups (Figure 3.29B). 
The tissue sections were stained for DO11.10 TCR T cells (red; KJ1-26
+ T cells) 
and Cbl-b (blue) expression. The LSC was used to quantify Cbl-b expression in such 
antigen-specific T cells within the lymph node tissue. Representative images of these 
tissue  sections  (Figure  3.30A  and  B)  showed  that,  consistent  with  its  ubiquitous 
expression  in  haematopoietic  cells  [177,  180,  202,  285,  286],  Cbl-b  expression  was 
detected throughout the lymph node section and not only KJ1-26
+ T cells. In contrast to 
the in vitro data using anti-CD3±anti-CD28 to induce anergy and priming, analysis of 
the  proportion  of  DO11.10  T  cells  expressing  Cbl-b  (Figure  3.30C)  showed  that  a 
similar proportion of these cells in vivo were Cbl-b positive but that a higher percentage 
of  DO11.10  T  cells  from  tolerised  mice  were  found  to  be  expressing  Cbl-b  than 
DO11.10 T cells from primed mice (8.9% and 3.8%, respectively) however, this is not 
statistically significant. Also on the same trend, it is noteworthy to mention that the 
tolerised mice also exhibit higher levels of Cbl-b expression in the KJ1-26
+Cbl-b
+ cells 104
than  the  primed  mice  (Figure  3.30B)  though,  once  again,  this  is  not  statistically 
significant. 
3.1.5.2 Itch 
The in vitro studies (sections 3.1.2 and 3.1.3.2) pointed towards an upregulation 
of Itch protein expression in anergising and priming CD4
+ T cells when compared to 
unstimulated  CD4
+  T  cells;  differences  between  anergising  and  priming  cells  were 
minimal, but could this situation be somewhat different in the in vivo induction phase? 
As described before, for the in vivo induction phase of tolerance and priming, at 
D5 after immunisation, PLNs were harvested and prepared for immunohistochemistry. 
The tissue sections were stained for DO11.10 TCR T cells (KJ1-26
+ T cells) and Itch, 
and the LSC was used to quantify Itch expression in T cells within the lymph node 
tissue.  Again,  imaging  revealed  that  Itch  expression  (blue)  was  not  restricted  to 
DO11.10 TCR T cells (red) but rather is expressed by cells throughout the LN section 
(Figure  3.31A  and  B),  although  Itch  expression  seems  more  concentrated  in  some 
cells/patches of cells of the section. In this case, in keeping with the in vitro data, both 
tolerised and primed mice were found to be expressing Itch in a high percentage of 
DO11.10  T  cells  (34.4%  and  35.8%,  respectively),  but  there  was  no  significant 
difference between the two groups of mice (Figure 3.31C). Also, the intensity of Itch 
expression in KJ1-26
+Itch
+ cells appears to be similar for both tolerised and primed 
groups (Figure 3.31D). 
3.1.5.3 Smurf1 
The  Western  blotting  data  revealed  Smurf1  could  potentially  be  involved  in 
anergy  and  priming  induction  so  some  of  the  D5  PLN  tissue  was  also  stained  for 
DO11.10 TCR T cells (KJ1-26
+ T cells) and Smurf1, and LSC used to quantify Smurf1 
expression  in  T  cells  within  the  lymph  node  tissue.  Representative  images  of  the 
tolerised and primed tissue sections show Smurf1 expression in many cells of the lymph 
node  and  not  only  in  KJ1-16
+  cells  (Figure  3.32A  and  B).  Indeed,  only  a  small 
percentage of KJ1-26
+ T cells express Smurf1 (Figure 3.32C), and this number does 
not vary much between the tolerised and primed groups (9.2% and 8.2%, respectively) 
and although Smurf1 appears to be expressed more highly in primed KJ1-26
+Smurf1
+
cells than tolerised KJ1-26
+Smurf1
+, this is not statistically significant (Figure 3.32D). 105
3.1.5.4 Smurf2 
The Western blotting data also suggested a potential upregulation during priming 
induction, in vitro, of Smurf2. Thus, using D5 PLN tissue obtained from the systemic 
model  of  antigen-specific  priming  and  tolerance  described  before,  DO11.10  TCR  T 
cells (KJ1-26
+ T cells) and Smurf2 were stained for, and LSC used to quantify Smurf2 
expression in these antigen-specific T cells. Again, imaging revealed that Smurf2 is 
expressed throughout the lymph node, in KJ1-26
+ and non-KJ1-26
+ cells alike, in both 
tolerised  (Figure  3.33A)  and  primed  (Figure  3.33B)  mice.  However,  Smurf2  is 
expressed in a higher percentage of tolerised KJ1-26
+ T cells than primed KJ1-26
+ T 
cells  (10.7%  and  6.5%,  respectively;  Figure  3.33C)  and  at  higher  levels  (Figure 
3.33D). Despite neither of these data are statistically significant, they are different from 
the  data  observed  in  the  Western  blotting  analysis  of  in  vitro  anergy  and  priming 
induction. It remains a possibility Smurf2 might be involved in the tolerance or priming 
decision albeit its kinetics might change considerably. 
3.2 The maintenance phase of anergy and priming in CD4
+ T 
cells 
To characterise differential signalling events in the maintenance phase of anergy 
and priming an in vitro system of antigen-specific T cell re-stimulation was developed. 
T cell anergy or priming was induced in primary antigen-specific DO11.10 T cells by 
TCR engagement or by TCR engagement with appropriate co-stimulation as described 
previously [49, 130, 257]. Briefly, to do this, lymph node single cell suspensions, in 
which  typically  30-40  %  of  the  lymphocytes  were  CD4
+DO11.10
+  T  cells,  were 
cultured  for  2  d  with  plate-bound  anti-CD3  antibody  or  with  plate-bound  anti-CD3 
antibody and anti-CD28 antibody. These cells were then washed, re-plated and rested 
for an additional 2 d in fresh medium, before being re-stimulated with LPS-matured 
DCs which had been pulsed with or without OVA323-339 (referred to from now on as 
LPS-matured, OVA-loaded DCs and LPS-matured DCs, respectively) (Figure 3.34). 
The  DO11.10  T  cells  are  transgenic  for  the  TCR,  which  recognises  the  OVA323-339
peptide. 106
3.2.1 Functional analysis of DO11.10 T cells in the maintenance phase 
of anergy and priming 
To  confirm  maintenance  of  anergic  or  primed  responses  by  CD4  positive, 
DO11.10  T  cells  even  after  re-stimulation,  the  functional  hallmarks  associated  with 
these two behaviours were probed. Thus, naïve, anergised and primed DO11.10 T cells 
were first assessed for their ability to produce IL-2 in response to re-stimulation by 
FACS analysis of intracellular cytokine staining (Figure 3.35A). This revealed that less 
anergic CD4
+KJ1-26
+ T cells expressed intracellular IL-2 after re-stimulation with LPS-
matured DCs than naïve CD4
+KJ1-26
+ T cells after stimulation with the same LPS-
matured  DCs.  Most  revealing  is  the  fact  there  is  no  difference  in  IL-2-expression 
between the anergic CD4
+KJ1-26
+ cells re-stimulated with LPS-matured DCs or LPS-
matured, OVA-loaded DCs. As for the primed T cells, after re-stimulation with LPS-
matured, OVA-loaded DCs, there is an increase in the percentage of CD4
+KJ1-26
+ cells 
expressing IL-2 intracellularly, consistent with primed T cell behaviour. 
The quantity of IL-2 secreted to the medium was also measured (Figure 3.35B). 
Re-stimulating any of the three populations of T cells (naïve, anergised and primed) 
with  LPS-matured  DCs  without  antigen  does  not  elicit  strong  IL-2  production.  The 
culture  media  supernatants  from  anergised  T  cells  re-stimulated  with  LPS-matured, 
OVA-loaded DCs also failed to show any measurable levels of IL-2. However, naïve T 
cells did produce and secrete IL-2 into the culture medium and primed T cells did so to 
an even higher degree, after re-stimulation with LPS-matured, OVA-loaded DCs. Thus, 
compared to the naïve and primed T cells, the anergised T cells revealed a defect in IL-2 
production in response to antigen. Taking this in consideration with the intracellular IL-
2 levels (Figure 3.35A) there is a strong indication the population of “anergised” T cells 
had indeed become anergic and, when re-stimulated they not only failed to produce IL-2 
in response to antigen but actually blocked its production and secretion. 
Once  IL-2  is  produced,  it  binds  to  its  specific  receptor  complex  (IL-2R)  thus 
triggering T  cell proliferation [287]. Consistent with the  IL-2 data, out of the three 
populations of T cell re-stimulated with LPS-matured, OVA-loaded DCs, the primed 
population  proliferated  the  most,  the  naïve  population  proliferated  well  and  the 
anergised population exhibited vestigial proliferation (Figure 3.35C). This proliferative 
unresponsiveness can be overcome by supplementing the T cells with exogenous IL-2, 
as this bypasses the need for co-stimulation [52, 130]. In Figure 3.35D, the defective 
proliferation  was  found  to  be  partly  rescued  by  the  addition  of  exogenous  IL-2 107
(recombinant IL-2 [rIL-2]), as rIL-2 coupled with LPS-matured, OVA-loaded DCs co-
culture increased the proliferation of the anergic T cells to the same order of magnitude 
of proliferation exhibited by primed T cells in the absence of  IL-2 (Figure 3.35C). 
However, this joint stimulation of the anergic T cells still yields less proliferation of 
similarly  stimulated  naïve  T  cells  and  even  less  proliferation  than  the  similarly 
stimulated primed T cells (Figure 3.35D). In the absence of (re-)stimulation with LPS-
matured, OVA-loaded DCs, of the three T cell populations cultured with rIL-2 alone, 
major proliferation was only detected in the primed but not naïve or anergic groups 
(Figure 3.35D). Indeed, the proliferation level of these primed T cells is in the same 
order of magnitude as the one observed for naïve T cells stimulated with rIL-2 coupled 
with LPS-matured, OVA-loaded DCs co-culture. 
3.2.2 Analysis of the expression of E3 ubiquitin-protein ligases in the 
maintenance phase of anergy and priming 
To start the analysis of E3 ubiquitin-proteins expression levels in T cells in the 
maintenance phase of anergy and priming, Western blotting assays were first conducted. 
Cells  were  extracted,  stimulated  in  vitro  to  induce  anergy  or  priming  and  then  re-
stimulated to mimic the maintenance phase of anergy or priming, as described before in 
the Materials and Methods chapter. As a first step, total cell protein of the co-cultures 
was extracted and analysed for the expression of relevant proteins (Figure 3.36). 
The membrane was first blotted for PLCγ-1, as this would give an indication of 
the activation status of the cells. Of the T cell populations which were not re-stimulated 
with  antigen,  the  expression  of  PLCγ-1  is  highest  in  the  anti-CD3+anti-CD28-
stimulated cells (Figure 3.37) confirming our previous findings (section 3.1.2) that anti-
CD3+anti-CD28-stimulated  cells  became  activated  and,  hence  primed  whilst  the 
relatively reduced levels found in anti-CD3-treated cells reflected their anergic status. 
Following re-stimulation with LPS-matured, OVA-loaded DCs, PLCγ-1 is also most 
highly  expressed  in  the  anti-CD3+anti-CD28-stimulated  cells  (primed  T  cells). 
However anti-CD3-stimulated cells (anergic) appear to have upregulated their PLCγ-1 
expression compared to unstimulated cells (naïve), denoting there was some activation 
of these anergic T cells after re-stimulation. 
In the absence of re-stimulation with antigen, Cbl-b and Smurf2 were found to be 
most highly expressed in the primed T cells and least in the naïve cells. Both exhibit a 
ladder effect possibly due to ubiquitination: Smurf2, unlike Smurf1, did not exhibit this 108
ladder pattern in the earlier experiments focusing on the first 48 h of the induction 
phase, and hence perhaps this potential regulation is the result of prolonged in vitro
culture (± 120 h). As for Itch, Smurf1 and Grail, these are all expressed most highly in 
the naïve cells; Smurf1 and Grail exhibit the same expression levels in anergic and 
primed T cells while Itch is expressed at a higher level in the primed relative to the 
anergic  populations  of  cells  as  seen  in  the  induction  phase  experiments  previously 
(section 3.1.2). Smurf1 once again exhibits a ladder pattern; however, the big difference 
is the high expression levels of these proteins in naïve cells relative to the primed and 
anergic populations at this 20 h time point of the maintenance phase; perhaps prolonged 
in vitro culture induces their downregulation in anergic and primed T cells. By contrast, 
all of T cell populations express very high levels of Ikaros, without much difference of 
expression between them. 
Following re-stimulation with LPS-matured, OVA-loaded DCs, the protein levels 
of Itch, Cbl-b, Smurf1, Smurf2 and  Ikaros appear to be similar in both primed and 
anergic populations and there appears to be slightly less Grail expression in the primed 
relative to the anergic populations. Again, Cbl-b and Smurf2 exhibit an extended ladder 
pattern. Ikaros, is expressed more strongly in primed and anergic T cells than naïve T 
cells, though it may be the case (comparing with the non-re-stimulated T cells) that after 
re-stimulation all T cell populations downregulate Ikaros, being the naïve T cells the 
ones which downregulate it the most. 
The total protein lysates were also tested for the presence of ubiquitinated proteins 
(Figure 3.38). Globally, the ubiquitination of proteins (Figure 3.38A) appears to be 
most strong in the re-stimulated anergic T cells, with the primed T cells showing higher 
level  than  either  primary  antigen  responses  (naïve)  or  any  of  the  non-antigen-re-
stimulated populations. Assessment of the prevalence of mono- and poly-ubiquitinated 
proteins (Figure 3.38B) also showed that re-stimulated anergic and primed T cells do 
seem to express mono- and poly-ubiquitinated proteins more intensely than naïve T 
cells  although  the  levels  of  K63-linked  polyubiquitinated  proteins  are  roughly 
comparable in the three re-stimulated populations, albeit perhaps to a slightly lower 
extent in the primed population (Figure 3.38C). 
The analysis of E3 ubiquitin-proteins expression levels in the maintenance phase 
of anergy and priming was extended to Western blotting analysis of the antigen-specific 
KJ1-26
+ T cells co-cultured with OVA-loaded, LPS-matured DCs. Briefly, cells were 
extracted from LNs, stimulated in vitro to induce anergy or priming before being re-
stimulated to mimic the maintenance phase of anergy or priming, as described above. 109
Here  two  methods  to  induce  anergy  were  used:  by  means  of  TCR  ligation  (via 
immobilised anti-CD3 antibody) and by means of a direct increase of intracellular Ca
2+
levels  (via  ionomycin).  PLCγ-1  protein  levels  were  confirmed  to  be  reduced  in  the 
ionomycin-induced anergic T cells (not shown). After 20 h of re-stimulation with OVA-
loaded, LPS-matured DCs, KJ1-26
+ T cells were harvested and MACS-purified. Both 
the positive fraction of antigen-specific KJ1-26
+ T cells and the negative fraction of 
non-KJ1-26
+  T  cells  were  collected.  The  total  cell  protein  was  extracted  from  both 
fractions and analysed for the expression of relevant proteins (Figure 3.39). 
The membrane was blotted for DO11.10 TCR in order to check the efficacy of the 
MACS isolation (Figure 3.40). As expected, all lanes loaded with protein extracts from 
the KJ1-26
+ T cell fractions blotted positive for this transgenic TCR while none of the 
lanes  loaded  with  protein  extracts  from  the  residual  cell  fractions  did.  The  MACS 
isolation  was  thus  effective  in  enriching  antigen-specific  T  cells  and  served  as  an 
additional loading control for these populations. The two populations of anergic KJ1-
26
+ T cells expressed roughly the same amount of Erk with the primed KJ1-26
+ T cells 
exhibiting slightly less. Taking this in consideration, Itch, Cbl-b and Grail expression 
appears to be quite comparable in anergic and primed KJ1-26
+ T cells, although it may 
be slightly less in the primed population relative to the two populations of anergic cells. 
Rather  surprisingly,  Traf6  doesn’t  seem  to  be  expressed  by  these  cells  in  the 
maintenance phase. On the other hand, Ikaros is expressed most by primed KJ1-26
+ T 
cells, at slightly lower levels in TCR ligation-induced anergic T cells, whilst ionomycin-
induced  anergic  T  cells  have  substantially  less  Ikaros  expression.  Another  point 
regarding  Ikaros  is  that  it  is  expressed  more  highly  in  the  KJ1-26
+  T  cells  fraction 
relative to the non-KJ1-26
+ cells fraction, unlike all other proteins tested on this panel, 
suggesting that it may be preferentially expressed by CD4
+ T cells. 
APCs, namely DCs, but also some non-transgenic CD4
+ T cells, should make up 
most  of  the  non-KJ1-26
+  cells  fraction.  From  the  point  of  view  of  bi-directional 
signalling between antigen-specific T cells and their APCs, it is interesting to point out 
that Itch and Traf6 are expressed most highly in the non-KJ1-26
+ population co-cultured 
with the primed cells while Grail is expressed the least in these cells (Figure 3.40). 
Interestingly,  the  Itch,  Cbl-b  and  Grail  bands  reveals  different  profiles  between  the 
ionomycin-  and  anti-CD3-induced  anergic  populations  suggesting  they  may  elicit 
similar functional responses by different routes. 110
3.2.3 Analysis of the expression of E3 ubiquitin-protein ligases in the 
maintenance phase of anergy and priming at the single-cell level 
The  above  Western  blotting  analysis  of  antigen-specific  CD4
+  T  cells  in  the 
maintenance phase of priming and tolerance not only required extremely large numbers 
of cells, and hence mice, to generate the minimum protein levels, but also introduced 
potential  confounding  artefacts  by  the  requirement  to  purify  the  cells  subsequent  to 
stimulation.  Also,  although  it  provided  information  of  the  populations  of  cells  as  a 
whole, it did not allow analysis of the behaviour and protein expression patterns of 
individual cells. LSC analysis allows this, so, in the next set of experiments, naïve, 
anergic and primed T cells were re-stimulated to promote the maintenance phase and 
analysed via LSC. 
3.2.3.1 Arf6 
LSC provides analysis of the “primed” and “anergic” populations at the single cell 
level: however, not all cells in the anti-CD3-stimulated population will be anergic nor 
will  all  cells  in  the  anti-CD3+anti-CD28-stimulated  group  be  primed.  Despite 
exhaustive characterisation of phenotype over the years, there are no clear markers of 
primed versus tolerised cells and, thus, the lack of definitive markers for the functional 
states of priming and anergy may obscure some differential E3 ubiquitin-protein ligase 
expression patterns between these cohorts of cells. However, in human anergic T cells, 
ADP-ribosylation  factor-6  (Arf6)  is  reported  to  be  predominantly  localised  at  the 
plasma membrane while in primed T cells it is scattered throughout internal structures 
such as endosomes and the cytoplasm [288]. Arf6 is a member of the Arf family of 
GTPases involved in membrane traffic and regulation of the cortical actin cytoskeleton 
[289-291];  this  regulation  is  mediated  in  coordination  with  Rac1  and  RhoA,  more 
specifically, activation of Arf6 downregulates Rho signalling [292].  
During antigen recognition, the filaments of cytoskeletal actin form a scaffold for 
signalling complexes, allowing the activation of signalling cascades; they also initiate 
molecular movement on the surface of the T cells, allowing the organisation of SMACs 
[293]. The GTP-bound form of Arf6 localises predominantly at the plasma membrane 
and  is  associated  with  inhibition  of  Erk  1/2  activation,  of  IL-2  transcription  and  of 
proliferation; it is thought GTP-Arf6 accomplishes these effects by inhibition of TCR-
mediated reorganisation of polymerised actin whereas the GDP-bound form of Arf6 is 
scattered throughout the cytoplasm [291, 294]. Arf6 is therefore a potential marker for 111
assessing the current activation state of T cells, at the single cell level and hence it was 
explored whether membrane localisation of Arf6 could be used to identify anergic cells 
in our antigen-specific model of the maintenance of priming and tolerance. 
Thus, as before, DO11.10 T cells were extracted, stimulated in vitro to induce 
anergy or priming before being re-stimulated with antigen to mimic the maintenance 
phase of anergy or priming. Cells were then stained for nuclear DNA, DO11.10 TCR 
and  Arf6  and  initial  visual  inspection  of  the  slides  did  not  reveal  any  differential 
location between anergic and primed T cells; indeed many DO11.10 T cells did not 
appear to be expressing Arf6 but in those expressing it, regardless of being anergic or 
primed  cells,  Arf6  was  localised  in  the  plasma  cell  membrane  (not  shown).  LSC 
quantification confirmed that not all DO11.10 T cells express Arf6 (Figure 3.41A) but, 
interestingly, the percentage of cells expressing it increases after re-stimulation with 
peptide-pulsed DCs (compared to LPS-matured DCs only). Similarly, the percentage of 
DO11.10 T cells positive for Arf6 in the periphery also increases after re-stimulation 
with peptide-pulsed DCs (compared to LPS-matured DCs only), but this is regardless of 
whether the cells are naïve, anergic or primed (Figure 3.41C). Moreover, in terms of 
the  levels  of  Arf6  expression  per  cell  there  is  not  much  difference  between  naïve, 
anergic  and  primed  cells,  but  in  all  of  these  populations  Arf6  is  more  intensely 
expressed  after  re-stimulation  with  LPS-matured,  OVA-loaded  DCs  than  with  LPS-
matured DCs (Figure 3.41B). Paradoxically, in the periphery, Arf6 appears to be more 
intensely expressed in anergic and primed cells after re-stimulation with LPS-matured 
DCs, not LPS-matured, OVA-loaded DCs (Figure 3.41D) whereas for the naïve cells 
there are no differences of Arf6 expression between either ways of re-stimulation. From 
the previous work on human T cells [288] one was expecting anergic T cells to express 
more Arf6 in the periphery (plasma cell membrane location) than primed T cells; this is 
not the case in the event of LPS-matured, OVA-loaded DCs re-stimulation and, as such, 
Arf6 location can not be used as a marker for anergy in DO11.10 TCR T cells. 
3.2.3.2 Ubiquitination 
Firstly, total cell ubiquitination levels of the three populations were assessed after 
re-stimulation (Figure 3.42). Briefly, DO11.10 T cells were extracted, stimulated in 
vitro to induce anergy or priming before being re-stimulated with antigen to mimic the 
maintenance phase of anergy or priming. Cells were then stained for nuclear DNA, 
DO11.10 TCR and ubiquitin and the levels of protein ubiquitination in KJ1-26
+ T cells 
quantified by LSC as described in the Materials and Methods chapter. This showed that 112
the  total  levels  of  ubiquitination  of  proteins  does  not  vary  much  after  1  h  of  re-
stimulation with antigen between the conditions tested (Figure 3.42A), either in terms 
of global expression or reflecting expression at the cell periphery (Figure 3.42C), albeit 
there appears to be a slight reduction in all cases in response to antigen. There is a 
similar  pattern  after  20  h  of  re-stimulation  with  respect  to  total  expression  (Figure 
3.42B). At the cell periphery however, anergic cells re-stimulated with LPS-matured, 
OVA-loaded DCs have their proteins more intensely ubiquitinated than either naïve or 
primed T cells and, perhaps more importantly, one can see re-stimulation with LPS-
matured,  OVA-loaded  DCs  induced  protein  ubiquitination  to  higher  levels  than  re-
stimulation  with  only  LPS-matured  DCs  (Figure  3.42D).  Representative  images 
(Figure 3.43) of naïve DO11.10 TCR T cells after 20 h of re-stimulation are shown 
which indicate that protein ubiquitination can be found all over the cell, though most 
cells exhibit it most intensely at the periphery of the cells. In some cells ubiquitinated 
proteins appear to be concentrated in one or two poles, where co-localisation with the 
TCR is apparent. 
3.2.3.3 Cbl-b 
Modulation of expression of Cbl-b in DO11.10 TCR T cells was also analysed 
during the maintenance phases of anergy and priming. After 1 h of co-culture with LPS-
matured, OVA-loaded DCs (Figure 3.44), the primed population of KJ1-26
+ T cells has 
the highest proportion of cells expressing Cbl-b, although this is low and only slightly 
higher than that of the naïve and anergic populations which are comparable (Figure 
3.44A).  Moreover,  analysis  of  the  MFI  of  Cbl-b  expression  of  KJ1-26
+Cbl-b
+  cells 
showed no difference amongst the different T cell populations (Figure 3.44B), meaning 
that  the  cells  which  are  expressing  Cbl-b  express  it  at  the  same  level regardless  of 
whether they are naïve, anergic or primed. The proportion of KJ1-26
+ T cells expressing 
Cbl-b at the periphery is very low for all populations, though again primed T cells have 
the highest proportion (Figure 3.44C). Interestingly, however, with respect to the levels 
of expression of Cbl-b in KJ1-26
+Cbl-b
+ T cells at the periphery, Cbl-b is expressed 
most highly at the periphery of anergic T cells and at lower, but comparable levels in 
the naïve and primed populations (Figure 3.44D). 
After 20 h of co-culture with LPS-matured, OVA-loaded DCs (Figure 3.45), it is 
the primed population of KJ1-26
+ T cells that once again has the highest proportion of 
cells expressing Cbl-b (Figure 3.45A). Both  anergic and primed  cells  have a much 
higher proportion of cells expressing Cbl-b than naïve cells, indicating that Cbl-b has 113
been induced in these two T cell populations. This is also true for Cbl-b expression at 
the periphery (Figure 3.45C). Although the mean total levels of Cbl-b expression do 
not change as much, primed cells express more Cbl-b than naïve and anergic cells that 
have roughly the same amount (Figure 3.45B) and this difference is exacerbated at the 
cell periphery (Figure 3.45D). 
3.2.3.4 Itch 
Analysis  of  Itch  expression  during  the  maintenance  phases  of  priming  and 
tolerance revealed that at 1 h following re-stimulation by antigen of naïve, anergic and 
primed  populations,  primed  KJ1-26
+  T  cells  have  upregulated  Itch  expression  and 
exhibit the highest proportion of cells positive for Itch (Figure 3.46A). By contrast, the 
naïve and the anergic populations exhibit comparable lower proportions of Itch-positive 
cells irrespective of whether they have been exposed to antigen or not. The level of 
expression of Itch in KJ1-26
+Itch
+ T cells is also highest in primed T cells re-stimulated 
with LPS-matured, OVA-loaded DCs (Figure 3.46B). Indeed, even primed T cells re-
stimulated with LPS-matured DCs in the absence of antigen express more Itch than 
naïve and anergic populations, which have comparable levels of Itch regardless of the 
re-stimulation.  Moreover,  this  general  pattern  is  also  observed  when  examining  the 
levels  of  expression  of  Itch  at  the  periphery  of  the  cells  (Figure  3.46D).  Thus,  re-
stimulation  (Figure  3.46C)  with  LPS-matured,  OVA-loaded  DCs  increases  the 
proportion  of  KJ1-26
+  T  cells  positive  for  Itch  at  the  periphery  of  primed  T  cells 
compared to that observed with the naïve and anergic populations, and which exhibit 
comparable percentages of KJ1-26
+ T cells expressing Itch at the cell surface. However, 
the anergic population is the only one which has the same proportion of KJ1-26
+ T cells 
expressing Itch at the periphery in the presence and absence of antigen since both naïve 
and primed populations have a higher proportion of KJ1-26
+ T cells expressing Itch at 
the cell surface following challenge with LPS-matured, OVA-loaded DCs. Imaging of 
the cells confirmed that following challenge with antigen, primed cells exhibited the 
highest  levels  of  Itch  expression  and  this  was  predominantly  restricted  to  the  cell 
periphery  (Figure  3.47).  Interestingly,  in  some  naïve  cells,  Itch  could  be  found 
concentrated in one or two focal points at the periphery of the cell. 
By contrast, after 20 h of in vitro re-stimulation with LPS-matured, OVA-loaded 
DCs the proportion of KJ1-26
+Itch
+ T cells has increased in all populations but, this
increase  is  particularly  dramatic  in  the  case  of  the  primed  and  anergic  populations. 
Nevertheless, as seen at the earlier time point, the primed T cells are the ones with the 114
highest proportion while naïve cells are the ones with the lowest percentage of KJ1-26
+
cells  positive  for  Itch  (Figure  3.48A).  This  pattern  translates  well  into  peripheral 
expression (Figure 3.48C) and also with respect to the levels of expression of Itch in 
KJ1-26
+Itch
+ T cells, both in terms of throughout the whole cell (Figure 3.48B) as well 
as at the periphery (Figure 3.48D). To corroborate these data, Itch expression was also 
quantified via flow cytometry (Figure 3.48E) and in general terms, the flow cytometry 
results match those from the LSC, albeit the proportions of T cells positive for Itch are 
slightly different. Imaging of Itch expression in the three groups of cells (Figure 3.49) 
revealed that Itch is expressed throughout the entire cell but is mostly concentrated in 
the periphery, probably in the plasma cell membrane with naïve T cells expressing the 
lowest levels of Itch. Interestingly, it appears that there may be some Itch expression in 
the nucleus, particularly in anergic cells, at this time point. Also, many primed cells 
showed a more diffuse, albeit intense, localisation of Itch in the periphery, perhaps in 
vesicles. 
3.2.4 Distribution  of  the  E3  ubiquitin-protein  ligase-expressing  cells 
according to the cell cycle stage 
It has been hypothesised that unresponsiveness of anergic T cells (as measured by 
IL-2 production and proliferation) could involve cell death and/or cell growth arrest 
[295]. To assess the relative roles of these mechanisms in the maintenance phase of 
anergy, cell cycle progression in the different T cell populations was investigated using 
LSC, as described in the Materials and Methods chapter. Briefly, naïve, anergic and 
primed DO11.10 TCR antigen-specific T cells were re-stimulated with LPS-matured 
DCs loaded with OVA323-339, before being stained with DAPI and the KJ1-26 antibody. 
After  1  h  of  re-stimulation  (Figure  3.50A)  the  majority  (>50%)  of  naïve  and 
primed cells are found in the G0/G1 cell cycle phase. Although cells of the anergic 
population are also mostly found in the G0/G1 phase (41%), a considerable number of 
them are undergoing  apoptosis (25%). Moreover, by 20 h of re-stimulation (Figure 
3.50B) the anergic T cells are mostly either undergoing apoptosis (35%) or are arrested 
in G0/G1 (42%). On the other hand, the primed T cells are predominantly undergoing 
mitosis  (26%)  or  indeed  already  generated  newly-formed  daughter  cells  (NFDCs) 
(47%). As for the naïve population, these cells are mostly in G0/G1 (48%) and S (26%) 
phases. These findings confirm that the different in vitro culture regimes induce T cell 
priming  or  anergy  that  is  long-lasting  and  maintained  following  rechallenge  with 115
antigen.  They  also  suggest  that,  at  the  population  level,  anergy  involves  both  the 
induction of cell cycle arrest and apoptosis. 
As with the induction phase of anergy and priming, it was decided to correlate E3 
ubiquitin-protein  ligase  expression  with  cell  cycle  progression  in  naïve,  anergic  and 
primed populations of antigen-specific T cells in an attempt to find distinct expression 
patterns in G0/G1 arrest (associated with anergy) Vs S and G2/M phases (associated 
with priming). 
3.2.4.1 Cbl-b 
After 1 h of re-stimulation with LPS-matured, OVA-loaded DCs, most of KJ1-26
+ 
that were Cbl-b
+ from naïve, anergic and primed populations were found in the NFDCs 
stage (57, 55 and 41%, respectively) (Figure 3.51A). However, KJ1-26
+Cbl-b
+ cells 
from the primed population could also be found with high prevalence in the S phase 
(45%) while KJ1-26
+Cbl-b
+ cells from naïve and anergic populations are found at lower 
prevalences  throughout  the  G0/G1,  S  and  G2/M  phases.  Interestingly,  the  level  of 
expression  of  Cbl-b  also  changes  according  to  the  stage  of  the  cell  cycle  (Figure 
3.51B), as there is higher expression of Cbl-b at the stages of cell cycle associated with 
division (S and G2/M phases) and perhaps consistent with their increased proliferative 
capacity relative to anergic cells, naïve and primed cells seem to express the most Cbl-b 
in  the  G2/M  phase.  Moreover,  when  KJ1-26
+  T  cells  in  each  cell  cycle  stage  are 
screened for Cbl-b expression, mitotic cells (cells in S, G2/M and NFDCs) show, by far, 
the highest proportion of Cbl-b-expressing cells (Figure 3.51C). In the mitotic stages 
naïve, anergic and primed populations all have above 70% of their cells positive for 
Cbl-b. Only cells from the naïve population undergoing apoptotis were found to express 
Cbl-b, and these only constituted a low percentage of such apoptotic cells. 
Analysis of the expression of Cbl-b according to cell cycle stage after 20 h of re-
stimulation revealed that about 40% of KJ1-26
+ cells in all populations are in S phase  
although a considerable proportion of such cells from the naïve and primed populations 
are also found in G0/G1(Figure 3.52A). On the other hand, the anergic KJ1-26
+ T cells 
positive for Cbl-b are mostly to be found in the NFDC (35%) or S phases (45%), with 
the occasional apoptotic, G0/G1 and G2/M phase cells. Again, generally, the level of 
expression of Cbl-b is lowest in apoptotic and G0/G1-arrested cells (Figure 3.52B). 
Naïve cells have Cbl-b most strongly expressed in S and G2/M phases while primed 
cells exhibit strong expression of Cbl-b in S, G2/M and NFDC phases. 116
Finally, analysis of all the KJ1-26
+ cells in each stage of the cell cycle reveals that
the majority of these cells in mitotic stages are Cbl-b-positive whilst, apart from the 
primed cells which are likely to be transiting rather than arrested in G0/G1, a lower 
proportion of those in the G0/G1 phases are Cbl-b
+ (Figure 3.52C). Rather surprisingly 
therefore, the primed population has a higher percentage of Cbl-b
+ cells in apoptosis 
than either the naïve or anergic populations. 
Thus, and as previously observed in the induction phase, high levels of Cbl-b 
expression  per  se  do  not  appear  to  dictate  cell  cycle  arrest  but  rather  appear  to  be 
associated with proliferation. 
3.2.4.2 Itch 
Similarly, the expression of Itch was correlated with the cell cycle status of KJ1-
26
+ T cells after 1 h of re-stimulation with LPS-matured, OVA-loaded DCs (Figure 
3.53) revealing that about 30-40% of KJ1-26
+ cells expressing Itch, in all populations, 
are  in  S  phase  although  a  considerable  proportion  of  such  cells  from  the  naïve 
population are apoptotic (44%) with only a few cells in G0/G1, G2/M or NFDC stages 
(Figure 3.53A). By contrast, the primed KJ1-26
+ T cells positive for Cbl-b are mostly 
found in the NFDC (43%) and S phases (37%), whilst the anergic KJ1-26
+Itch
+ cells 
can be found as apoptotic (11%), G0/G1 (39%), S (44%) and as newly-formed daughter 
cells (6%). Moreover, such analysis revealed that there is a lower expression of Itch in 
apoptotic and G0/G1-arrested cells compared to the mitotic stages, regardless of the 
stimulus (Figure 3.53B). The naïve population had the most Itch intensity of expression 
in NFDCs, closely followed by the anergic population of cells (cells in S, G2/M and 
NFDCs). Consistent with this indication that Itch expression is also correlating with cell 
cycle progression, when the proportion of KJ1-26
+ T cells in each cell cycle stage was 
examined  for  Itch  expression  (Figure  3.53C),  it  was  revealed  all  NFDCs  (100%), 
regardless of the stimulus, were positive for Itch. However, it should be noted that apart 
from apoptotic cells and those of the primed  G2/M population all other stages also 
showed high proportions of the cells to be Itch
+, irregardless of their functional status. 
Further analysis of the cell cycle distribution of Itch, this time after 20 h of re-
stimulation with LPS-matured, OVA-loaded DCs revealed that the majority of primed 
KJ1-26
+Itch
+  cells  are  in  S  phase  (55%)  (Figure  3.54A).  Naïve  and  anergic  KJ1-
26
+Itch
+ cells are mainly found in G0/G1 (45 and 40%, respectively) and while, perhaps 
consistent with their relative proliferative capacities, naïve KJ1-26
+Itch
+ cells can also 
be found in considerable amounts in the S phase (32%), the remainder of anergic KJ1-117
26
+Itch
+ cells are most commonly found as apoptotic cells (37%). As seen in the 1 h 
time-point and in the induction phase, KJ1-26
+Itch
+ cells have a lower expression of 
Itch in apoptotic and G0/G1-arrested cells, which tends to increase with progression in 
the cell cycle, regardless of the origin of the population (naïve or anergic or primed) 
(Figure 3.54B). Moreover, analysis of the KJ1-26
+ populations in each cell cycle stage 
revealed that NFDCs showed the highest proportion of Itch
+ regardless of the stimulus 
(Figure 3.54C). With progression in the cell cycle, the primed population displays an 
increase  in  the  proportion  of  KJ1-26
+  cells  positive  for  Itch,  whereas  the  anergic 
population is the one which has the highest proportion of G0/G1 phase KJ1-26
+ cells 
positive for Itch. 
Thus,  taken  together,  this  single-cell  analysis  suggests  that,  although  Itch  is 
expressed more intensely in the advanced stages of the cell cycle, in the population of 
anergic cells Itch expression could be related to apoptotic and G0/G1 KJ1-26
+ T cells. 
3.2.5 Analysis of the expression of E3 ubiquitin-protein ligases in the 
maintenance phase of anergy and priming, in vivo 
The  experiments  investigating  the  roles  of  E3  ubiquitin-protein  ligases  in  the 
maintenance phases of anergy and priming in vitro suggested similarities between the 
two states, namely upregulation of Cbl-b and Itch when compared to a naïve population 
of T cells. To determine whether this was also the case in vivo, 24 h after adoptive 
transfer of DO11.10 TCR transgenic T cells, mice were immunised with OVA323-339
peptide i.v., either alone or together with LPS to induce systemic tolerance or priming, 
respectively  (Figure  3.55A).  Seven  days  after  this  primary  immunisation,  recipient 
mice were challenged with OVA323-339 + LPS i.v. and their LNs harvested 24 h later in 
order to examine the expression of E3 ligases in the maintenance phase of tolerance and 
priming. 
The LNs were sectioned and stained for DO11.10 TCR T cells and B cells. The 
number of DO11.10 TCR T cells per LN section was quantified by the LSC in naïve, 
tolerised and primed tissue. Primed tissue has more transgenic T cells than naïve and 
tolerised tissue sections, as one would expect since the primed transgenic cells should 
proliferate more than naïve and tolerised cells after re-stimulation with OVA323-339 + 
LPS  (Figure  3.55B).  In  addition,  generation  of  tissue  maps  by  LSC  allowed 
identification of the B cell-rich (follicles) and T cell (paracortex) areas, as described in 
section 2.9.2 (Figure 2.8)  and this approach was used to identify the localisation of the 
transgenic T cells in the LN, establishing whether they could be found on the follicles or 118
the paracortex. The number of KJ1-26
+ T cells in either location was divided by the 
total number of KJ1-26
+ T cells in the LN section and the data plotted in Figure 3.55C. 
As  expected,  the  proportion  of  DO11.10  TCR  T  cells  present  in  the  follicles  is 
significantly lower than the proportion of those present in the paracortex, for naïve, 
tolerised and primed transgenic T cells, as expected. Interestingly, it has been shown 
that in the primary response to antigen, more primed than tolerised T cells migrate into 
the follicles as apparently tolerised T cells are defective in their ability to migrate to the 
B cell rich areas and hence, provide B cell help [265, 284]. However, in an in vivo
model of oral tolerance [267, 296], tolerised antigen-specific T cells re-challenged with 
a  priming  stimulus  in  vivo  were  shown  to  be  able  to  enter  B  cell  follicles  while 
remaining unable to provide B cell help. In fact, this is also what appears to happen here 
in  this  systemic  model  of  tolerance  maintenance,  as  there  were  no  significant 
differences in the proportion of antigen-specific T cells present in the follicular areas 
between the tolerised and the primed groups, following secondary antigenic challenge 
(Figure 3.55C). 
3.2.5.1 Cbl-b 
Following the secondary antigenic challenge, LNs were harvested, sectioned and 
stained for DO11.10 TCR transgenic T cells (red), B cells (green) and Cbl-b (blue). The 
expression of Cbl-b in the antigen-specific T cells in LNs of naïve, tolerised and primed 
mice was then examined in situ by LSC (Figure 3.56), as described in section 2.9.2. 
Consistent with the in vitro data, although not significant, there appears to be higher 
expression of Cbl-b, both in terms of the proportion of antigen-specific T cells and 
levels  of  expression  in  such  Cbl-b
+  cells,  in  the  primed  relative  to  tolerised  mice. 
Perhaps surprisingly, however, there is a higher percentage of naïve KJ1-26
+ T cells 
expressing  Cbl-b  than  either  tolerised  or  primed  KJ1-26
+  T  cells  (Figure  3.56A). 
Moreover, these naïve KJ1-26
+Cbl-b
+ cells express Cbl-b significantly more highly than
the tolerised cells, which have comparable levels of Cbl-b expression with primed cells 
(Figure  3.56B).  Images  of  these  LNs  sections  indicate  that,  consistent  with  its 
ubiquitous  expression  in  haematopoietic  cells  [177,  180,  202,  285,  286],  Cbl-b 
expression occurs in cells throughout the LN, spanning paracortical and follicular areas, 
DO11.10 T  cells and non-DO11.10 T cells  alike in naïve (Figure 3.56C), tolerised 
(Figure 3.56D) and primed (Figure 3.56E) LN sections alike. 
Consistent with the finding that re-challenge with a priming stimulus abrogates 
the block in follicular migration of tolerised T cells, there was no difference in the 119
proportional distribution of KJ1-26
+Cbl-b
+ cells per follicles and paracortex, comparing 
the different groups, while obviously in all groups more KJ1-26
+Cbl-b
+ cells could be 
found in the paracortex than the follicles (Figure 3.57A). In other words, localisation of 
KJ1-26
+Cbl-b
+ cells mirrors the distribution of  all KJ1-26
+ T cells. Moreover, KJ1-
26
+Cbl-b
+ cells from all groups expressed comparable levels of Cbl-b (although the 
naïve cells appeared to exhibit a slightly higher expression of Cbl-b than tolerised or 
primed cells) regardless of follicular or paracortical location (although, paracortical-
localised  antigen-specific  T  cells  exhibit  a  slightly  higher  expression  of  Cbl-b  than 
follicular-localised  ones)  (Figure  3.57B).  Nonetheless,  differences  were  observed  in 
terms of percentage of KJ1-26
+ T cells expressing Cbl-b (Figure 3.57C). Thus, the 
naïve  population  of  KJ1-26
+  T  cells  in  the  paracortex  have  a  significantly  higher 
percentage of cells positive for Cbl-b than the tolerised population of KJ1-26
+ T cells in 
the paracortex. The general trend is that the naïve population of KJ1-26
+ T cells, either 
in the paracortex or the follicles, has a higher percentage of cells positive for Cbl-b than 
either the tolerised or primed populations. 
3.2.5.2 Itch 
Following  the  same  procedure  as  for  the  detection  of  Cbl-b  expression  in  the 
maintenance phase of tolerance and priming in vivo, LNs were sectioned, stained for 
DO11.10 TCR transgenic T cells (red), B cells (green) and Itch (blue), and analysed for 
Itch expression with the LSC and fluorescent microscopy (Figure 3.58). Here, unlike 
what  was  observed  in  the  in  vitro  maintenance  phase  experiments,  the  primed 
population of KJ1-26
+ T cells appeared to exhibit a lower percentage of cells positive 
for Itch than either the naïve or tolerised populations, although these differences did not 
prove significant (Figure 3.58A). Moreover, in terms of levels of expression of Itch in 
KJ1-26
+Itch
+  cells,  there  are  no  apparent  differences  between  the  three  populations 
(Figure 3.58B). Imaging of the LN sections again reveals Itch expression throughout all 
cells in the LN, in the follicles and in the paracortex, independently of the naïve (Figure 
3.58C), tolerised (Figure 3.58D) or primed (Figure 3.58E) status of the tissue. 
Analysis of the percentage of KJ1-26
+ T cells expressing Itch according to LN 
localisation was also carried out (Figure 3.59A). The proportion of KJ1-26
+ T cells 
expressing Itch in the follicles is the same for the naïve, tolerised and primed groups. 
However, not only is the proportion of naïve KJ1-26
+ T cells expressing Itch higher in 
the paracortical-located than the follicular-located transgenic T cells, but this percentage 
of naïve KJ1-26
+ T cells expressing Itch in the paracortex is higher than the percentage 120
of tolerised KJ1-26
+ T cells expressing Itch in the paracortex and significantly higher 
than  the  percentage  of  primed  KJ1-26
+  T  cells  expressing  Itch  in  the  paracortex. 
Nevertheless, in terms of levels of expression of Itch, all KJ1-26
+Itch
+ cells, regardless 
of the functional group or LN localisation, are expressing Itch at comparable levels 
(Figure 3.59B). 
3.2.5.3 Grail 
Grail  expression  was  also  assessed  in  situ,  in  the  maintenance  phase.  Thus, 
following the secondary antigenic challenge, LNs were harvested, sectioned and stained 
for DO11.10 TCR transgenic T cells, B cells and Grail. The expression of Grail in 
antigen-specific T cells in LNs of naïve, tolerised and primed mice was then examined 
by LSC, as described in section 2.9.2. This revealed that Grail is also expressed in a 
higher percentage of naïve KJ1-26
+ T cells than tolerised or primed KJ1-26
+ T cells 
(Figure 3.60A). Moreover, Grail is also expressed at lower levels in KJ1-26
+ T cells 
from tolerised relative to both naïve and primed mice (Figure 3.60B). 
Analysis of the proportion of KJ1-26
+ T cells expressing Grail according to their 
follicular/paracortical localisation (Figure 3.61A) revealed that globally, there are no 
significant differences amongst the different populations, although  the general trend is 
that, regardless of the population, a higher percentage of the antigen-specific T cells 
located  in  the  follicles  express  Grail  than  those  in  the  paracortex.  Interestingly, 
however,  the  naïve  and  the  primed  DO11.10  TCR  T  cells  localised  in  the  follicles 
express significantly more Grail than their tolerised counterparts (Figure 3.61B) whilst 
there is no such difference between naïve, primed and tolerised DO11.10 TCR T cells 
located on the paracortex. 121 
Figure 3.1: Induction of anergy and priming in T cells. 
CD4
+ T cells were extracted from lymph nodes (LNs) and purified, after which they 
were cultured in vitro in the absence or presence of the indicated stimuli in order to 
induce  anergy  or  priming  (A).  Cells  were  tested  for  functional  hallmarks  such  as 
activation (B) and proliferation (C). Activation of CD4
+ T cells was measured after 20 h 
of in vitro culture: cells were washed and stained for CD4 and CD69 (early activation 
marker). The mean fluorescence intensity (MFI) of the cells was measured via flow 
cytometry and the MFI plotted as fold increase of the MFI of naïve CD4
+ T cells (the 
MFI  value  of  naïve  CD4
+  T  cells  was  taken  as  basal  and  assigned  the  “1”  value). 
Proliferation of CD4
+ T cells was measured by means of counts per minute (cpm) of 
[
3H]thymidine incorporation in newly-synthesised DNA after 48 h of in vitro culture. 
The results shown are representative of at least two independent experiments. No stimulus
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Figure 3.2: Expression of E3 ubiquitin-protein ligases in T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. Viable T cells were 
cultured in vitro without stimuli (1) or in the presence of anti-CD3 antibody (2), or anti-
CD3 and anti-CD28 antibodies (3), or ionomycin (4); cells were cultured for a total of 
20  h,  after  which  they  were  harvested  and  lysed  (A).  Total  protein  extracts  were 
separated  by  SDS-PAGE  and  transferred  onto  a  nitrocellulose  membrane.  The 
membrane was analysed by Western blotting for proteins of interest: it was blocked in 
5% milk/ TBS-T for 1 h, washed 3 x 10 min with TBS-T, probed with primary antibody 
overnight in the cold room, washed 3 x 5 min with TBS-T, incubated with HRP-linked 
secondary antibody for 1 h, washed 3 x 5 min with TBS-T, incubated with ECL solution 
for 1 m, and developed. The membrane was then stripped and subsequently re-probed 
again,  originating  the  profile  observed  in  B.  Total  Erk  1/  2  (44  and  42  KDa, 
respectively) was used as loading control (LC). Data are representative of at least two 
independent experiments. LC: Erk 1/ 2
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Figure 3.3: Ubiquitination of proteins in T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. Viable T cells were 
cultured in vitro without stimuli (1) or in the presence of anti-CD3 antibody (2), or anti-
CD3 and anti-CD28 antibodies (3), or ionomycin (4); cells were cultured for a total of 
20 h, after which they were harvested and lysed, as described in Figure 3.2A. Total 
protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a  nitrocellulose 
membrane.  The  membrane  was  analysed  by  Western  blotting  for  all  ubiquitinated 
conjugates and free ubiquitin (A): it was blocked in 5% milk/ TBS-T for 1 h, washed 3 
x  10  min  with  TBS-T,  probed  with  primary  antibody  overnight  in  the  cold  room, 
washed 3 x 5 min with TBS-T, incubated with HRP-linked secondary antibody for 1 h, 
washed 3 x 5 min with TBS-T, incubated with ECL solution for 1 m, and developed. 
The membrane was then stripped and subsequently re-probed again for mono- and poly-
ubiquitinated conjugates (B), poly-ubiquitinated conjugates (C) and K63-linked poly-
ubiquitinated conjugates (D). The loading control can be observed in Figure 3.2B. Data 
are representative of at least two independent experiments. Mono- and 
polyubiquitinylated 
conjugates
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Figure 3.4: Immunoprecipitation of ubiquitin in T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. Viable T cells were 
cultured in vitro without stimuli (1) or in the presence of anti-CD3 antibody (2), or anti-
CD3 and anti-CD28 antibodies (3); cells were cultured for 1 and 20 h, after which they 
were  harvested  and  lysed;  total  protein  extracts  were  extracted  with  anti-ubiquitin 
antibody; the immunoprecipitates were separated by SDS-PAGE and transferred onto a 
nitrocellulose  membrane  (A).  The  membrane  was  analysed  by  Western  blotting  for 
proteins of interest: it was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 10 min with 
TBS-T, probed with primary antibody overnight in the cold room, washed 3 x 5 min 
with TBS-T, incubated with HRP-linked secondary antibody for 1 h, washed 3 x 5 min 
with TBS-T, incubated with ECL solution for 1 m, and developed. The membrane was 
then stripped and subsequently re-probed again, originating the profile observed in B. In 
the end, the membrane was probed with anti-ubiquitin antibody. U
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Figure 3.5: Induction of anergy and priming in CD4
+ T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+ T cells were cultured in vitro without stimuli (1) or in the presence of anti-CD3
antibody (2), or anti-CD3 and anti-CD28 antibodies (3), or ionomycin (4); lactacystin 
was added to a set of these T cell populations in order to inhibit proteasome function; 
cells were cultured for a total of 20 h, after which they were harvested and lysed. Total 
protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a  nitrocellulose 
membrane. The membrane was analysed by Western blotting for proteins of interest. B
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Figure 3.6: Expression of E3 ubiquitin-protein ligases in CD4
+ T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+ T cells were cultured in vitro without stimuli (1) or in the presence of anti-CD3
antibody (2), or anti-CD3 and anti-CD28 antibodies (3); where indicated lactacystin was 
added to the T cell culture; cells were cultured for a total of 20 h, after which they were 
harvested  and  lysed.  Total  protein  extracts  were  separated  by  SDS-PAGE  and 
transferred onto a nitrocellulose membrane. The membranes were analysed by Western 
blotting for proteins of interest: they were blocked in 5% milk/ TBS-T for 1 h, washed 3 
x  10  min  with  TBS-T,  probed  with  primary  antibody  overnight  in  the  cold  room, 
washed 3 x 5 min with TBS-T, incubated with HRP-linked secondary antibody for 1 h, 
washed 3 x 5 min with TBS-T, incubated with ECL solution for 1 m, and developed. 
The membranes were then stripped and subsequently re-probed again, originating the 
profile observed in A, B, C and E. Total Erk was used as loading control (LC). Data are 
representative of at least two independent experiments. A)
B)
LC: Erk 1
PLCγ-1: 135 KDa
1 2 3
Lck: 56 KDa
Smurf1: 86 KDa
Smurf2: 86 KDa
LC: Erk 1/ 2
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Traf6: 58 KDa
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Figure  3.7:  Expression  of  E3  ubiquitin-protein  ligases  in  CD4
+  T  cells  after 
proteasome inhibition. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+  T  cells  were  cultured  in  vitro  with  the  proteasome  inhibitor  lactacystin  and 
without further stimuli (1) or in the presence of anti-CD3 antibody (2), or anti-CD3 and 
anti-CD28 antibodies (3), or ionomycin (4); cells were cultured for a total of 20 h, after 
which they were harvested and lysed. Total protein extracts were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membranes were analysed 
by Western blotting for proteins of interest: they were blocked in 5% milk/ TBS-T for 1 
h, washed 3 x 10 min with TBS-T, probed with primary antibody overnight in the cold 
room, washed 3 x 5 min with TBS-T, incubated with HRP-linked secondary antibody 
for 1 h, washed 3 x 5 min with TBS-T, incubated with ECL solution for 1 m, and 
developed.  The  membranes  were  then  stripped  and  subsequently  re-probed  again, 
originating the profile observed in A, B and C. Total Erk was used as loading control 
(LC). Data are representative of at least two independent experiments. Cbl-b: 109 KDa
LC: Erk 1
A)
LC: Erk 1
PLCγ-1: 135 KDa
B)
1 2
+ Lactacystin
Lck: 56 KDa
Itch: 113 KDa 
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Figure 3.8: Inducing anergy and priming in CD4
+ T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+ T cells were cultured in vitro without stimuli (1) or in the presence of anti-CD3
antibody (2), or anti-CD3 and anti-CD28 antibodies (3), or ionomycin (4), or ionomycin 
and PMA (5); cells were cultured for 3, 6, 20 and 48 h, after which they were harvested 
and lysed. Total protein extracts were separated by SDS-PAGE and transferred onto a 
nitrocellulose membrane. The membrane was analysed by Western blotting for proteins 
of interest. B
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Figure 3.9: Expression of E3 ubiquitin-protein ligases in anergising and priming 
CD4
+ T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+ T cells were cultured in vitro without stimuli (1) or in the presence of anti-CD3
antibody (2), or anti-CD3 and anti-CD28 antibodies (3), or ionomycin (4), or ionomycin 
and PMA (5); cells were cultured for 3, 6, 20 and 48 h, after which they were harvested 
and lysed. This figure was generated from two separate experiments, one comprising the 
3 and 20 h time points, and the other comprising the 6 and the 48 h time points. Total 
protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a  nitrocellulose 
membrane. The membrane was analysed by Western blotting for proteins of interest: it 
was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 10 min with TBS-T, probed with 
primary antibody overnight in the cold room, washed 3 x 5 min with TBS-T, incubated 
with HRP-linked secondary antibody for 1 h, washed 3 x 5 min with TBS-T, incubated 
with  ECL  solution  for  1  m,  and  developed.  The  membrane  was  then  stripped  and 
subsequently re-probed again. Total Erk was used as loading control (LC). L
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Figure 3.10: Expression of ubiquitinated proteins in anergising and priming CD4
+
T cells. 
Lymph nodes were extracted from BALB/c mice and mashed up. The resulting cells 
were indirectly magnetically labelled and CD4
+ T cells were negatively selected. Viable 
CD4
+ T cells were cultured in vitro without stimuli (1) or in the presence of anti-CD3
antibody (2), or anti-CD3 and anti-CD28 antibodies (3), or ionomycin (4), or ionomycin 
and PMA (5); cells were cultured for 3, 6, 20 and 48 h, after which they were harvested 
and lysed. Total protein extracts were separated by SDS-PAGE and transferred onto a 
nitrocellulose membrane. The membrane was analysed by Western blotting for proteins 
of interest: it was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 10 min with TBS-T, 
probed with primary antibody overnight in the cold room, washed 3 x 5 min with TBS-
T, incubated with HRP-linked secondary antibody for 1 h, washed 3 x 5 min with TBS-
T,  incubated  with  ECL  solution  for  1  m,  and  developed.  The  membrane  was  then 
stripped and subsequently re-probed again. Total Erk was used as loading control (LC). 1 2 3 4 5 2 3 4 5
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Figure 3.11: Quantification of Cbl-b expression in CD4
+ T cells after 20 h of in 
vitro stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or  presence  of  the  indicated  stimuli  for  20  h,  washed,  cytocentrifuged,  stained  for 
nuclear DNA (DAPI; blue), CD4 (red) and Cbl-b (green) and Cbl-b expression in CD4
+
T cells quantified with the LSC as described in the Materials and Methods chapter. 
Firstly, all events were sorted on their nuclear staining (“cells”) and from these CD4
+ T 
cells were gated. A) shows the percentage of CD4
+ T cells that are positive for Cbl-b 
out of the whole population of CD4
+ T cells, in terms of total cell expression. B) shows 
the mean fluorescence intensity (MFI) of Cbl-b expression in those CD4
+ T cells that 
are also positive for Cbl-b in terms of total cell expression. C) shows the proportion of 
CD4
+ T cells that are positive for Cbl-b out of the whole population of CD4
+ T cells, in 
terms of peripheral cell expression. D) shows MFI of Cbl-b expression in those CD4
+ T 
cells that are also positive for Cbl-b in terms of peripheral cell expression. No stimulus
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Figure 3.12: Visualisation of Cbl-b expression in CD4
+ T cells after 20 h of in vitro
stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 20 h, washed, cytocentrifuged and stained for 
nuclear DNA (DAPI; blue), CD4 (red) and Cbl-b (green). Fluorescence was visualised 
using an Olympus BX50 fluorescent microscope and images captured and merged (x40 
objectives). Cells were identified by nuclear staining with the DNA dye DAPI (blue). 
The expression of Cbl-b was determined with an α-Cbl-b-specific antibody coupled to 
tyramide amplification and the fluorochrome Alexa Fluor 488 (AF488 - green). Staining 
of CD4 co-receptor (also by means of an α-CD4-specific antibody coupled to tyramide 
amplification and the fluorochrome Alexa Fluor 647 [AF647 – red]) allowed locating 
the cell plasma membrane. Merging these three images results in the far right image – 
“Merge”. N
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u
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Figure 3.13: Quantification of Cbl-b expression in CD4
+ T cells after 40 h of in 
vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI; blue), CD4 (red) and Cbl-b (green) and Cbl-b expression in CD4
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these CD4
+ T cells were 
gated. A) shows the percentage of CD4
+ T cells that are positive for Cbl-b out of the 
whole population of CD4
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence intensity (MFI) of Cbl-b expression in those CD4
+ T cells that are also 
positive for Cbl-b in terms of total cell expression. C) shows the proportion of CD4
+ T 
cells that are positive for Cbl-b out of the whole population of CD4
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Cbl-b expression in those CD4
+ T cells that 
are also positive for Cbl-b in terms of peripheral cell expression. -CD3
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Figure 3.14: Visualisation of Cbl-b expression in CD4
+ T cells after 40 h of in vitro
stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 40 h, washed, cytocentrifuged and stained for 
nuclear DNA (DAPI; blue), CD4 (red) and Cbl-b (green). Fluorescence was visualised 
using an Olympus BX50 fluorescent microscope and images captured and merged (x40 
objectives). Cells were identified by nuclear staining with the DNA dye DAPI (blue). 
The expression of Cbl-b was determined with an α-Cbl-b-specific antibody coupled to 
tyramide amplification and the fluorochrome Alexa Fluor 488 (AF488 - green). Staining 
of CD4 co-receptor (also by means of an α-CD4-specific antibody coupled to tyramide 
amplification and the fluorochrome Alexa Fluor 647 [AF647 – red]) allowed locating 
the cell plasma membrane. Merging these three images results in the far right image – 
“Merge”. +
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Figure 3.15: Quantification of Itch expression in CD4
+ T cells after 20 h of in vitro
stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 20 h, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI; blue), CD4 (red) and Itch (green) and Itch expression in CD4
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these CD4
+ T cells were 
gated. A) shows the percentage of CD4
+ T cells that are positive for Itch out of the 
whole population of CD4
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence  intensity  (MFI)  of  Itch  expression  in  those  CD4
+  T  cells  that  are  also 
positive for Itch in terms of total cell expression. C) shows the proportion of CD4
+ T 
cells that are positive for Itch out of the whole population of CD4
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Itch expression in those CD4
+ T cells that 
are also positive for Itch in terms of peripheral cell expression. No stimulus
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Figure 3.16: Visualisation of Itch expression in CD4
+ T cells after 20 h of in vitro
stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 20 h, washed, cytocentrifuged and stained for 
nuclear  DNA  (DAPI;  blue)  and  Itch  (green).  Fluorescence  was  visualised  using  an 
Olympus  BX50  fluorescent  microscope  and  images  captured  and  merged  (x40 
objectives). Cells were identified by nuclear staining with the DNA dye DAPI (blue). 
The  expression  of  Itch  was  determined  with  an  α-Itch-specific  antibody  coupled  to 
tyramide  amplification  and  the  fluorochrome  Alexa  Fluor  488  (AF488  -  green). 
Merging these two images results in the far right image - “Merge”. N
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Figure 3.17: Quantification of Itch expression in CD4
+ T cells after 40 h of in vitro
stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI; blue), CD4 (red) and Itch (green) and Itch expression in CD4
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these CD4
+ T cells were 
gated. A) shows the percentage of CD4
+ T cells that are positive for Itch out of the 
whole population of CD4
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence  intensity  (MFI)  of  Itch  expression  in  those  CD4
+  T  cells  that  are  also 
positive for Itch in terms of total cell expression. C) shows the proportion of CD4
+ T 
cells that are positive for Itch out of the whole population of CD4
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Itch expression in those CD4
+ T cells that 
are also positive for Itch in terms of peripheral cell expression. -CD3
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Figure 3.18: Visualisation of Itch expression in CD4
+ T cells after 40 h of in vitro
stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 40 h, washed, cytocentrifuged and stained for 
nuclear  DNA  (DAPI;  blue)  and  Itch  (green).  Fluorescence  was  visualised  using  an 
Olympus  BX50  fluorescent  microscope  and  images  captured  and  merged  (x40 
objectives). Cells were identified by nuclear staining with the DNA dye DAPI (blue). 
The  expression  of  Itch  was  determined  with  an  α-Itch-specific  antibody  coupled  to 
tyramide  amplification  and  the  fluorochrome  Alexa  Fluor  488  (AF488  -  green). 
Merging these two images results in the far right image - “Merge”. +
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Figure 3.19: Quantification of Grail expression in CD4
+ T cells after 20 h of in vitro
stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 20 h, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI; blue), CD4 (red) and Grail (green) and Itch expression in CD4
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these CD4
+ T cells were 
gated. A) shows the percentage of CD4
+ T cells that are positive for Grail out of the 
whole population of CD4
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence intensity (MFI) of Grail expression in those CD4
+ T cells that are also 
positive for Grail in terms of total cell expression. C) shows the proportion of CD4
+ T 
cells that are positive for Grail out of the whole population of CD4
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Grail expression in those CD4
+ T cells that 
are also positive for Grail in terms of peripheral cell expression. No stimulus
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Figure 3.20: Visualisation of Grail expression in CD4
+ T cells after 20 h of in vitro
stimulation. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 20 h, washed, cytocentrifuged and stained for 
nuclear DNA (DAPI; blue), CD4 (red) and Grail (green). Fluorescence was visualised 
using an Olympus BX50 fluorescent microscope and images captured and merged (x40 
objectives). Cells were identified by nuclear staining with the DNA dye DAPI (blue). 
The expression of Grail was determined with an α-Grail-specific antibody coupled to 
tyramide amplification and the fluorochrome Alexa Fluor 488 (AF488 - green). Staining 
of CD4 co-receptor (also by means of an α-CD4-specific antibody coupled to tyramide 
amplification and the fluorochrome Alexa Fluor 647 [AF647 - red]) allowed locating 
the cell plasma membrane. Images of representative cells were chosen on the basis of 
their Grail staining. Merging these three images results in the far right image - “Merge”. N
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Figure 3.21: Quantification of Grail expression in CD4
+ T cells after 40 h of in vitro
stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI; blue), CD4 (red) and Grail (green) and Itch expression in CD4
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these CD4
+ T cells were 
gated. A) shows the percentage of CD4
+ T cells that are positive for Grail out of the 
whole population of CD4
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence intensity (MFI) of Grail expression in those CD4
+ T cells that are also 
positive for Grail in terms of total cell expression. C) shows the proportion of CD4
+ T 
cells that are positive for Grail out of the whole population of CD4
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Grail expression in those CD4
+ T cells that 
are also positive for Grail in terms of peripheral cell expression. -CD3
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Figure 3.22: Analysis of cell cycle stage distribution in CD4
+ T cells. 
CD4
+ T cells were extracted from lymph nodes, purified, cultured in vitro in the absence 
or presence of the indicated stimuli for 20 h (A) or 40 h (B), washed, cytocentrifuged, 
stained for the nucleus and CD4 (plus further label with adequate fluorochrome). The 
slides were analysed in the LSC: CD4
+ T cells were gated, their DAPI max pixel Vs 
integral values plotted and adequate regions drawn matching the different cell cycle 
stages. Values are presented as percentage of CD4
+ T cells in a particular cell cycle 
stage out of the whole population of CD4
+ T cells, for that particular stimulus. Some 
stimulated populations were normalised to 100%. Cells in S phase, G2/M phase and 
newly-formed daughter cells were grouped together in one group called “Mitotic” cells. 
The results shown are the mean ± SEM of triplicate slide staining and are representative 
of three independent experiments. Apoptotic G0/ G1 Mitotic
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Figure 3.23: Analysis of Cbl-b expression according to cell cycle stage in CD4
+ T 
cells after 20 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 20 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Cbl-b (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Cbl-b
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Cbl-b
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Cbl-b
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Cbl-b 
expression.  Values  are  presented  as  MFI  of  Cbl-b  of  the  CD4
+Cbl-b
+  cells  in  a 
particular  cell  cycle  stage.  C)  CD4
+  T  cells  were  gated,  their  DAPI  max  pixel  Vs 
integral values plotted after this and cells within the different cell cycle stages checked 
for Cbl-b expression. Values are presented as percentage of Cbl-b
+ cells out of the CD4
+
cells in a particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.24: Analysis of Cbl-b expression according to cell cycle stage in CD4
+ T 
cells after 40 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Cbl-b (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Cbl-b
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Cbl-b
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Cbl-b
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Cbl-b 
expression.  Values  are  presented  as  MFI  of  Cbl-b  of  the  CD4
+Cbl-b
+  cells  in  a 
particular  cell  cycle  stage.  C)  CD4
+  T  cells  were  gated,  their  DAPI  max  pixel  Vs 
integral values plotted after this and cells within the different cell cycle stages checked 
for Cbl-b expression. Values are presented as percentage of Cbl-b
+ cells out of the CD4
+
cells in a particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.25: Analysis of Itch expression according to cell cycle stage in CD4
+ T 
cells after 20 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 20 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Itch (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Itch
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Itch
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Itch
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Itch 
expression. Values are presented as MFI of Itch of the CD4
+Itch
+ cells in a particular 
cell cycle stage. C) CD4
+ T cells were gated, their DAPI max pixel Vs integral values 
plotted  after  this  and  cells  within  the  different  cell  cycle  stages  checked  for  Itch 
expression. Values are presented as percentage of Itch
+ cells out of the CD4
+ cells in a 
particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.26: Analysis of Itch expression according to cell cycle stage in CD4
+ T 
cells after 40 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Itch (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Itch
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Itch
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Itch
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Itch 
expression. Values are presented as MFI of Itch of the CD4
+Itch
+ cells in a particular 
cell cycle stage. C) CD4
+ T cells were gated, their DAPI max pixel Vs integral values 
plotted  after  this  and  cells  within  the  different  cell  cycle  stages  checked  for  Itch 
expression. Values are presented as percentage of Itch
+ cells out of the CD4
+ cells in a 
particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.27: Analysis of Grail expression according to cell cycle stage in CD4
+ T 
cells after 20 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 20 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Grail (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Grail
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Grail
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Grail
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Grail 
expression. Values are presented as MFI of Itch of the CD4
+Grail
+ cells in a particular 
cell cycle stage. C) CD4
+ T cells were gated, their DAPI max pixel Vs integral values 
plotted  after  this  and  cells  within  the  different  cell  cycle  stages  checked  for  Grail 
expression. Values are presented as percentage of Grail
+ cells out of the CD4
+ cells in a 
particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.28: Analysis of Grail expression according to cell cycle stage in CD4
+ T 
cells after 40 h of in vitro stimulation. 
CD4
+  T  cells  were  extracted  from  lymph  nodes,  purified,  cultured  in  vitro  in  the 
presence of the indicated stimuli for 40 h, washed, cytocentrifuged, stained for nucleus, 
CD4 and Grail (these were further labelled with adequate fluorochromes). The slides 
were analysed in the LSC. A) CD4
+ T cells were gated, Grail
+ cells gated after this and 
their DAPI max pixel Vs integral values plotted. Values are presented as percentage of 
CD4
+Grail
+  T  cells  in  a  particular  cell  cycle  stage  out  of  the  whole  population  of 
CD4
+Grail
+  T  cells,  for  that  particular  stimulus.  Some  stimulated  populations  were 
normalised to 100%. B) CD4
+ T cells were gated, their DAPI max pixel Vs integral 
values plotted after this and cells within the different cell cycle stages checked for Grail 
expression. Values are presented as MFI of Itch of the CD4
+Grail
+ cells in a particular 
cell cycle stage. C) CD4
+ T cells were gated, their DAPI max pixel Vs integral values 
plotted  after  this  and  cells  within  the  different  cell  cycle  stages  checked  for  Grail 
expression. Values are presented as percentage of Grail
+ cells out of the CD4
+ cells in a 
particular cell cycle stage. + α-CD3
+ α-CD3+ α-CD28
+ Ionomycin
+ Ionomycin+ PMA
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Figure 3.29: Functional analysis of T cells from naïve, tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed) (A). At D0, 3, 5 and 10 after immunisation MLNs were harvested and 
single cell suspensions were prepared and stained for CD4 and KJ1-26; the percentage 
of CD4
+KJ1-26
+ T cells in the tissue was analysed by flow cytometry (B). At D10 after 
immunisation, PLNs were harvested and single cell suspensions were re-stimulated in 
vitro  with  or  without  antigen  to  assess  proliferation  (C)  and  IFNγ  production  (D). 
Proliferation of CD4
+ T cells was measured by means of counts per minute (cpm) of 
[
3H] thymidine incorporation in newly-synthesised DNA after 72 h of in vitro culture. 
The level of  IFNγ in culture supernatants was  detected by  ELISA  at 48 h after re-
stimulation in vitro. Both proliferation and IFNγ production data are expressed as fold 
increase in signal from samples re-stimulated in the presence of antigen compared with 
the signal from those re-stimulated with media alone. Data represent mean ± SD for 
three mice per group and each animal sample was performed in triplicate. Statistical 
significance  was  determined  by  one-way  ANOVA  (one  way  analysis  of  variance) 
followed by the Bonferroni post-test. Statistical significance was assumed when p≤0.05; 
*≤0.05, **<0.01. 0
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Figure 3.30: Cbl-b expression in DO11.10 TCR transgenic T cells within the lymph 
node of tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with OVA323-339 (tolerised) or OVA323-339 + LPS (primed). At D5 
after  immunisation,  PLNs  were  harvested  and  prepared  for  immunohistochemistry. 
Tissue  sections  were  stained  for  DO11.10  TCR  transgenic  T  cells  (red)  and  Cbl-b 
(blue).  Photographs  were  taken  of  the  tolerised  (A)  and  primed  (B)  tissue.  Cbl-b 
expression in T cells was quantified with the LSC: KJ1-26
+ T cells were gated and the 
percentage of these cells expressing Cbl-b plotted (C); the MFI of Cbl-b in KJ1-26
+Cbl-
b
+ T cells was plotted in D. Data represent mean ± SEM for three mice per group. 
Student’s unpaired t test analysis for two-tail p value was used. Tolerised Primed
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Figure 3.31: Itch expression in DO11.10 TCR transgenic T cells within the lymph 
node of tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with OVA323-339 (tolerised) or OVA323-339 + LPS (primed). At D5 
after  immunisation,  PLNs  were  harvested  and  prepared  for  immunohistochemistry. 
Tissue sections were stained for DO11.10 TCR transgenic T cells (red) and Itch (blue). 
Photographs were taken of the tolerised (A) and primed (B) tissue. Itch expression in T 
cells was quantified with the LSC: KJ1-26
+ T cells were gated and the percentage of 
these cells expressing Itch plotted (C); the MFI of Itch in KJ1-26
+Itch
+ T cells was 
plotted in D. Data represent mean ± SEM for three mice per group. Student’s unpaired t 
test analysis for two-tail p value was used. Tolerised Primed
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Figure  3.32:  Smurf1  expression  in  DO11.10  TCR  transgenic  T  cells  within  the 
lymph node of tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with OVA323-339 (tolerised) or OVA323-339 + LPS (primed). At D5 
after  immunisation,  PLNs  were  harvested  and  prepared  for  immunohistochemistry. 
Tissue sections were stained for DO11.10 TCR transgenic T cells (red) and Smurf1 
(blue).  Photographs  were  taken  of  the  tolerised  (A)  and  primed  (B)  tissue.  Smurf1 
expression in T cells was quantified with the LSC: KJ1-26
+ T cells were gated and the 
percentage of these cells expressing Smurf1 plotted (C); the MFI of Smurf1 in KJ1-
26
+Smurf1
+ T cells was plotted in D. Data represent mean ± SEM for three mice per 
group. Student’s unpaired t test analysis for two-tail p value was used. Tolerised Primed
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Figure  3.33:  Smurf2  expression  in  DO11.10  TCR  transgenic  T  cells  within  the 
lymph node of tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with OVA323-339 (tolerised) or OVA323-339 + LPS (primed). At D5 
after  immunisation,  PLNs  were  harvested  and  prepared  for  immunohistochemistry. 
Tissue sections were stained for DO11.10 TCR transgenic T cells (red) and Smurf2 
(blue).  Photographs  were  taken  of  the  tolerised  (A)  and  primed  (B)  tissue.  Smurf2 
expression in T cells was quantified with the LSC: KJ1-26
+ T cells were gated and the 
percentage of these cells expressing Smurf2 plotted (C); the MFI of Smurf2 in KJ1-
26
+Smurf2
+ T cells was plotted in D. Data represent mean ± SEM for three mice per 
group. Student’s unpaired t test analysis for two-tail p value was used. Tolerised Primed
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Figure 3.34: Setting up antigen-specific T cells for anergy and priming analysis in 
the maintenance phase. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of immobilised anti-CD3 antibody or immobilised anti-CD3 antibody and anti-CD28 
antibody to induce anergy or priming, respectively. Excess antibody was washed off 
and the cells re-plated and rested for an additional 2 d in fresh medium. Naïve (freshly 
isolated),  anergised  and  primed  DO11.10  T  cells  were  (re-)stimulated  with  LPS-
matured DCs which had been pulsed with or without OVA323-339 for the indicated time. P
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Figure 3.35: Functional analysis of DO11.10 T cells in the maintenance phase of 
anergy and priming. 
T cells were tested for functional hallmarks such as IL-2 expression (A and B) and 
proliferation (C and D) at 20 and 48 h, respectively. DO11.10 T cells were anergised or 
primed in vitro via TCR activation by antibodies and subsequently re-stimulated with 
DCs to call the maintenance phase of either anergy or priming. A) Cells were washed 
and stained for CD4, DO11.10 TCR and IL-2; the percentage of CD4
+KJ1-26
+ T cells 
expressing  IL-2  was measured via flow cytometry in all populations of T cells and 
plotted as fold increase of the percentage of naïve CD4
+KJ1-26
+ T co-cultured with 
LPS-matured DCs (the percentage of naïve CD4
+KJ1-26
+ T expressing IL-2 was taken 
as  basal  and  assigned  the  “1”  value);  results  shown  are  representative  of  two 
independent experiments. B) Levels of IL-2 production were measured in the cultures’ 
supernatants by ELISA; the results shown are the mean ± SD of triplicate cultures and 
are representative of three independent experiments. C and D) Proliferation of DO11.10 
T  cells  was  measured  by  means  of  counts  per  minute  (cpm)  of  [
3H]thymidine 
incorporation  in  newly-synthesised  DNA;  the  results  shown  are  the  mean  ±  SD  of 
triplicate cultures and are representative of three independent experiments. 0
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Figure 3.36: Setting up DO11.10 TCR transgenic, antigen-specific T cells in the 
maintenance phases of anergy and priming for Western blotting analysis. 
Lymph  nodes  were  extracted  from  DO11.10  mice  on  a  BALB/c  background  and 
mashed up. The resulting cells were cultured in vitro with anti-CD3 antibody (2), or 
anti-CD3 and anti-CD28 antibodies (3) for 2 d. Excess antibody was washed off and the 
cells re-plated and rested for an additional 2 d in fresh medium. A set of naïve (1) 
(freshly isolated), anergic (2) and primed (3) T cells were co-cultured in fresh medium 
with LPS-matured DCs which had been pulsed with OVA323-339; the other set of T cell 
populations received only fresh medium. After 20 h, cells were harvested and lysed. 
Total  protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a 
nitrocellulose membrane. The membrane was analysed by Western blotting for proteins 
of interest. P
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Figure 3.37: Expression of E3 ubiquitin-protein ligases in the maintenance phase 
of anergic and primed T cells. 
Lymph  nodes  were  extracted  from  DO11.10  mice  on  a  BALB/c  background  and 
mashed up. The resulting cells were cultured in vitro with anti-CD3 antibody (2), or 
anti-CD3 and anti-CD28 antibodies (3) for 2 d. Excess antibody was washed off and the 
cells re-plated and rested for an additional 2 d in fresh medium. A set of naïve (1) 
(freshly isolated), anergic (2) and primed (3) T cells were co-cultured in fresh medium 
with LPS-matured DCs which had been pulsed with OVA323-339; the other set of T cell 
populations received only fresh medium. After 20 h, cells were harvested and lysed. 
Total  protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a 
nitrocellulose membrane. The membrane was analysed by Western blotting for proteins 
of interest: it was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 10 min with TBS-T, 
probed with primary antibody overnight in the cold room, washed 3 x 5 min with TBS-
T, incubated with HRP-linked secondary antibody for 1 h, washed 3 x 5 min with TBS-
T,  incubated  with  ECL  solution  for  1  m,  and  developed.  The  membrane  was  then 
stripped and subsequently re-probed again, originating the profile observed. Total Erk 
was used as loading control (LC). Grail: 75 KDa
Itch: 113 KDa
Cbl-b: 109 KDa
LC: Erk 1/ 2
PLCγ-1: 135 KDa
Smurf2: 86 KDa
Smurf1: 86 KDa
Ikaros: 56 KDa
1 2 3 1 2 3
+ LPS-matured, 
OVA323-339-loaded DCs158 
Figure 3.38: Ubiquitination of proteins in the maintenance phase of anergic and 
primed T cells. 
Lymph  nodes  were  extracted  from  DO11.10  mice  on  a  BALB/c  background  and 
mashed up. The resulting cells were cultured in vitro with anti-CD3 antibody (2), or 
anti-CD3 and anti-CD28 antibodies (3) for 2 d. Excess antibody was washed off and the 
cells re-plated and rested for an additional 2 d in fresh medium. A set of naïve (1) 
(freshly isolated), anergic (2) and primed (3) T cells were co-cultured in fresh medium 
with LPS-matured DCs which had been pulsed with OVA323-339; the other set of T cell 
populations received only fresh medium. After 20 h, cells were harvested and lysed. 
Total  protein  extracts  were  separated  by  SDS-PAGE  and  transferred  onto  a 
nitrocellulose  membrane.  The  membrane  was  analysed  by  Western  blotting  for  all 
ubiquitinated conjugates and free ubiquitin (A): it was blocked in 5% milk/ TBS-T for 1 
h, washed 3 x 10 min with TBS-T, probed with primary antibody overnight in the cold 
room, washed 3 x 5 min with TBS-T, incubated with HRP-linked secondary antibody 
for 1 h, washed 3 x 5 min with TBS-T, incubated with ECL solution for 1 m, and 
developed.  The  membrane  was  then  stripped  and  subsequently  re-probed  again  for 
mono-  and  poly-ubiquitinated  conjugates  (B)  and  K63-linked  poly-ubiquitinated 
conjugates (C). The loading control can be observed in Figure 3.39. Mono- and 
polyubiquitinylated 
conjugates
K63-linked polyubiquitinylated 
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conjugates and free 
ubiquitin
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Figure 3.39: Setting up DO11.10 TCR transgenic, antigen-specific T cells in the 
maintenance phases of anergy and priming for Western blotting analysis. 
Lymph  nodes  were  extracted  from  DO11.10  mice  on  a  BALB/c  background  and 
mashed up. The resulting cells were cultured in vitro with ionomycin (A), anti-CD3 
antibody (B), or anti-CD3 and anti-CD28 antibodies (C) for 2 d. Cells were washed, re-
plated and rested for an additional 2 d in fresh medium. Anergic (A and B) and primed 
(C) T cells were co-cultured in fresh medium with LPS-matured DCs which had been 
pulsed with OVA323-339. After 20 h, cells were harvested and DO11.10 TCR T cells 
indirectly magnetically labelled with the use of the KJ1-26 antibody. Both the positive 
fraction (KJ1-26
+ T cells) (+) and the negative fraction (non-KJ1-26
+ cells) (-) were 
collected  and  lysed.  Total  protein  extracts  were  separated  by  SDS-PAGE  and 
transferred onto a nitrocellulose membrane. The membrane was analysed by Western 
blotting for proteins of interest. P
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Figure 3.40: Expression of E3 ubiquitin-protein ligases in the maintenance phase 
of anergic and primed DO11.10 TCR transgenic, antigen-specific T cells. 
Lymph  nodes  were  extracted  from  DO11.10  mice  on  a  BALB/c  background  and 
mashed up. The resulting cells were cultured in vitro with ionomycin (A), anti-CD3 
antibody (B), or anti-CD3 and anti-CD28 antibodies (C) for 2 d. Cells were washed, re-
plated and rested for an additional 2 d in fresh medium. Anergic (A and B) and primed 
(C) T cells were co-cultured in fresh medium with LPS-matured DCs which had been 
pulsed with OVA323-339. After 20 h, cells were harvested and DO11.10 TCR T cells 
indirectly magnetically labelled with the use of the KJ1-26 antibody. Both the positive 
fraction (KJ1-26
+ T cells) (+) and the negative fraction (non-KJ1-26
+ cells) (-) were 
collected  and  lysed.  Total  protein  extracts  were  separated  by  SDS-PAGE  and 
transferred onto a nitrocellulose membrane. The membrane was analysed by Western 
blotting for proteins of interest: it was blocked in 5% milk/ TBS-T for 1 h, washed 3 x 
10 min with TBS-T, probed with primary antibody overnight in the cold room, washed 
3 x 5 min with TBS-T, incubated with HRP-linked secondary antibody for 1 h, washed 
3  x  5  min  with  TBS-T,  incubated  with  ECL  solution  for  1  m,  and  developed.  The 
membrane was then stripped and subsequently re-probed again, originating the profile 
observed. Total Erk was used as loading control (LC). Grail: 75 KDa
Itch: 113 KDa
Cbl-b: 109 KDa
LC: Erk 1/ 2
Traf6: 58 KDa
Ikaros: 56 KDa
A A B B C C
DO11.10 TCR: 44 KDa
- + - + - +161 
Figure 3.41: Quantification of Arf6 expression in KJ1-26
+ T cells after 20 h of in 
vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs which had been pulsed with or 
without OVA323-339. Cells were harvested, washed, cytocentrifuged, stained for nuclear 
DNA  (DAPI),  DO11.10  TCR  and  Arf6  and  Arf6  expression  in  KJ1-26
+  T  cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these KJ1-26
+ T cells 
were gated. A) shows the percentage of KJ1-26
+ T cells that are positive for Arf6 out of 
the whole population of KJ1-26
+ T cells, in terms of total cell expression. B) shows the 
mean fluorescence intensity (MFI) of Arf6 expression in those KJ1-26
+ T cells that are 
also positive for Arf6 in terms of total cell expression. C) shows the percentage of KJ1-
26
+ T cells that are positive for Arf6 out of the whole population of KJ1-26
+ T cells, in 
terms of peripheral cell expression. D) shows MFI of Arf6 expression in those KJ1-26
+
T cells that are also positive for Arf6 in terms of peripheral cell expression. The results 
shown are representative of two independent experiments. A
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Figure 3.42: Quantification of the ubiquitination of proteins in KJ1-26
+ T cells 
after in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs which had been pulsed with or 
without OVA323-339. Cells were harvested, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI), DO11.10 TCR and ubiquitin and the levels of protein ubiquitination in 
KJ1-26
+ T cells quantified with the LSC as described in the Materials and Methods 
chapter. Firstly, all events were sorted on their nuclear staining (“cells”) and from these 
KJ1-26
+  T  cells  were  gated.  A)  shows  the  mean  fluorescence  intensity  (MFI)  of 
ubiquitinated proteins in the whole KJ1-26
+ T cells after 1 h of co-culture with DCs. B)
shows the MFI of ubiquitinated proteins in the whole KJ1-26
+ T cells after 20 h of co-
culture with DCs. C) shows the MFI of ubiquitinated proteins in the periphery of KJ1-
26
+ T cells after 1 h of co-culture with DCs. D) shows the MFI of ubiquitinated proteins 
in the periphery of KJ1-26
+ T cells after 20 h of co-culture with DCs. The results shown 
are representative of three independent experiments. N
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Figure 3.43: Visualisation of ubiquitinated proteins in KJ1-26
+ T cells after 20 h of 
in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs which had been pulsed with or 
without OVA323-339 for 20 h. Cells were harvested, washed, cytocentrifuged, stained for 
nuclear DNA (DAPI; blue), DO11.10 TCR (red) and ubiquitin (green). Fluorescence 
was visualised using an Olympus BX50 fluorescent microscope and images captured 
and merged (x40 objectives). Cells were identified by nuclear staining with the DNA 
dye DAPI (blue). The ubiquitination of proteins was determined with an α-ubiquitin-
specific antibody coupled to tyramide amplification and the fluorochrome Alexa Fluor 
488 (AF488 - green). Staining of the DO11.10 TCR (also by means of an α-DO11.10-
specific  antibody  [KJ1-26]  coupled  to  tyramide  amplification  and  the  fluorochrome 
Alexa Fluor 647 [AF647 – red]) allowed locating the cell plasma membrane. Merging 
these three images results in the far right image – “Merge”. LPS-matured DCs
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Figure 3.44: Quantification of Cbl-b expression in KJ1-26
+ T cells after 1 h of in 
vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs pulsed with OVA323-339 for 1 h. 
Cells  were  harvested,  washed,  cytocentrifuged,  stained  for  nuclear  DNA  (DAPI), 
DO11.10 TCR and Cbl-b and Cbl-b expression in KJ1-26
+ T cells quantified with the 
LSC as described in the Materials and Methods chapter. Firstly, all events were sorted 
on their nuclear staining (“cells”) and from these KJ1-26
+ T cells were gated. A) shows 
the percentage of KJ1-26
+ T cells that are positive for Cbl-b out of the whole population 
of KJ1-26
+ T cells, in terms of total cell expression. B) shows the mean fluorescence 
intensity (MFI) of Cbl-b expression in those KJ1-26
+ T cells that are also positive for 
Cbl-b in terms of total cell expression. C) shows the percentage of KJ1-26
+ T cells that 
are  positive  for  Cbl-b  out  of  the  whole  population  of  KJ1-26
+  T  cells,  in  terms  of 
peripheral cell expression. D) shows MFI of Cbl-b expression in those KJ1-26
+ T cells 
that are also positive for Cbl-b in terms of peripheral cell expression. The results shown 
are representative of three independent experiments. Naïve Anergic Primed
0
10
20
30
40
K
J
1
-
2
6
+
C
b
l
-
b
+
 
c
e
l
l
s
 
a
s
 
%
 
o
f
 
K
J
1
-
2
6
+
 
T
 
c
e
l
l
s
(
t
o
t
a
l
 
c
e
l
l
 
e
x
p
r
e
s
s
i
o
n
)
Naïve Anergic Primed
0
1000000
2000000
3000000
4000000
C
b
l
-
b
 
t
o
t
a
l
 
i
n
t
e
g
r
a
l
 
M
F
I
 
i
n
 
K
J
1
-
2
6
+
 
T
 
c
e
l
l
s
Naïve Anergic Primed
0
10
20
30
K
J
1
-
2
6
+
C
b
l
-
b
+
 
c
e
l
l
s
 
a
s
 
%
 
o
f
 
K
J
1
-
2
6
+
 
T
 
c
e
l
l
s
(
p
e
r
i
p
h
e
r
a
l
 
c
e
l
l
 
e
x
p
r
e
s
s
i
o
n
)
Naïve Anergic Primed
0
500000
1000000
1500000
2000000
C
b
l
-
b
 
p
e
r
i
p
h
e
r
a
l
 
i
n
t
e
g
r
a
l
 
M
F
I
 
i
n
 
K
J
1
-
2
6
+
 
T
 
c
e
l
l
s
A)
C)
B)
D)165 
Figure 3.45: Quantification of Cbl-b expression in KJ1-26
+ T cells after 20 h of in 
vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs pulsed with OVA323-339 for 20 h. 
Cells  were  harvested,  washed,  cytocentrifuged,  stained  for  nuclear  DNA  (DAPI), 
DO11.10 TCR and Cbl-b and Cbl-b expression in KJ1-26
+ T cells quantified with the 
LSC as described in the Materials and Methods chapter. Firstly, all events were sorted 
on their nuclear staining (“cells”) and from these KJ1-26
+ T cells were gated. A) shows 
the percentage of KJ1-26
+ T cells that are positive for Cbl-b out of the whole population 
of KJ1-26
+ T cells, in terms of total cell expression. B) shows the mean fluorescence 
intensity (MFI) of Cbl-b expression in those KJ1-26
+ T cells that are also positive for 
Cbl-b in terms of total cell expression. C) shows the percentage of KJ1-26
+ T cells that 
are  positive  for  Cbl-b  out  of  the  whole  population  of  KJ1-26
+  T  cells,  in  terms  of 
peripheral cell expression. D) shows MFI of Cbl-b expression in those KJ1-26
+ T cells 
that are also positive for Cbl-b in terms of peripheral cell expression. The results shown 
are representative of three independent experiments. Naïve Anergic Primed
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Figure 3.46 Quantification of Itch expression in KJ1-26
+ T cells after 1 h of in vitro
re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs which had been pulsed with or 
without OVA323-339 for 1 h. Cells were harvested, washed, cytocentrifuged, stained for 
nuclear DNA (DAPI), DO11.10 TCR and Itch and Itch expression in KJ1-26
+ T cells 
quantified with the LSC as described in the Materials and Methods chapter. Firstly, all 
events were sorted on their nuclear staining (“cells”) and from these KJ1-26
+ T cells 
were gated. A) shows the percentage of KJ1-26
+ T cells that are positive for Itch out of 
the whole population of KJ1-26
+ T cells, in terms of total cell expression. B) shows the 
mean fluorescence intensity (MFI) of Itch expression in those KJ1-26
+ T cells that are 
also positive for Itch in terms of total cell expression. C) shows the percentage of KJ1-
26
+ T cells that are positive for Itch out of the whole population of KJ1-26
+ T cells, in 
terms of peripheral cell expression. D) shows MFI of Itch expression in those KJ1-26
+ T 
cells that are also positive for Itch in terms of peripheral cell expression. The results 
shown are representative of three independent experiments. A
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Figure 3.47: Visualisation of Itch expression in KJ1-26
+ T cells after 1 h of in vitro
re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 1 h. Cells 
were harvested, washed, cytocentrifuged, stained for nuclear DNA (DAPI; blue) and 
Itch  (green).  Fluorescence  was  visualised  using  an  Olympus  BX50  fluorescent 
microscope and images captured and merged (x40 objectives). Cells were identified by 
nuclear staining with the DNA dye DAPI. The expression of Itch was determined with 
an  α-Itch-specific  antibody  coupled  to  tyramide  amplification  and  the  fluorochrome 
Alexa Fluor 488 (AF488 - green). Merging these two images results in the far right 
image – “Merge”. N
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Figure 3.48: Quantification of Itch expression in KJ1-26
+ T cells after 20 h of in 
vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated with LPS-matured DCs which had been pulsed with or 
without OVA323-339 for 20 h. A, B, C and D) T cells co-cultured with LPS-matured DCs 
pulsed with OVA323-339 were harvested, washed, cytocentrifuged, stained for nuclear 
DNA (DAPI), DO11.10 TCR and Itch and Itch expression in KJ1-26
+ T cells quantified 
with the LSC as described in the Materials and Methods chapter. Firstly, all events were 
sorted on their nuclear staining (“cells”) and from these KJ1-26
+ T cells were gated. A)
shows the percentage of KJ1-26
+ T cells that are positive for Itch out of the whole 
population of KJ1-26
+ T cells, in terms of total cell expression. B) shows the mean 
fluorescence intensity (MFI) of Itch expression in those KJ1-26
+ T cells that are also 
positive for Itch in terms of total cell expression. C) shows the percentage of KJ1-26
+ T 
cells that are positive for Itch out of the whole population of KJ1-26
+ T cells, in terms of 
peripheral cell expression. D) shows MFI of Itch expression in those KJ1-26
+ T cells 
that are also positive for Itch in terms of peripheral cell expression. E) Cells were fixed 
and stained for CD4, DO11.10 TCR and Itch; the percentage of CD4
+KJ1-26
+ T cells 
expressing Itch was measured via flow cytometry. The results shown are representative 
of three independent experiments. Naïve Anergic Primed
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Figure 3.49: Visualisation of Itch expression in KJ1-26
+ T cells after 20 h of in vitro
re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 20 h. Cells 
were harvested, washed, cytocentrifuged, stained for nuclear DNA (DAPI; blue) and 
Itch  (green).  Fluorescence  was  visualised  using  an  Olympus  BX50  fluorescent 
microscope and images captured and merged (x40 objectives). Cells were identified by 
nuclear staining with the DNA dye DAPI. The expression of Itch was determined with 
an  α-Itch-specific  antibody  coupled  to  tyramide  amplification  and  the  fluorochrome 
Alexa Fluor 488 (AF488 - green). Merging these two images results in the far right 
image – “Merge”. N
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Figure 3.50: Analysis of cell cycle stage distribution in KJ1-26
+ T cells after in vitro
re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 1 h (A) or 20 
h (B), washed, cytocentrifuged, stained for the nucleus and DO11.10 TCR (plus further 
label with adequate fluorochrome). The slides were analysed in the LSC: KJ1-26
+ T 
cells were gated, their DAPI max pixel Vs integral values plotted and adequate regions 
drawn matching the different cell cycle stages. Values are presented as percentage of 
KJ1-26
+ T cells in a particular cell cycle stage out of the whole population of KJ1-26
+ T 
cells,  for  that  particular  stimulus.  Some  stimulated  populations  were  normalised  to 
100%. “Ap” stands for apoptotic cells and “NFDC” for newly-formed daughter cells. 
The results shown are the mean ± SEM of triplicate slide staining and are representative 
of three independent experiments. Naïve
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Figure 3.51: Analysis of Cbl-b expression according to cell cycle stage in KJ1-26
+ T 
cells after 1 h of in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 1 h, washed, 
cytocentrifuged, stained for the nucleus, DO11.10 TCR and Cbl-b (these were further 
labelled with adequate fluorochromes). The slides were analysed in the LSC. A) KJ1-
26
+  T  cells  were  gated,  Cbl-b
+  cells  gated  after  this  and  their  DAPI  max  pixel  Vs
integral values plotted. Values are presented as percentage of KJ1-26
+Cbl-b
+ T cells in a 
particular cell cycle stage out of the whole population of KJ1-26
+Cbl-b
+ T cells, for that 
particular stimulus. Some stimulated populations were normalised to 100%. B) KJ1-26
+
T cells were gated, their DAPI max pixel Vs integral values plotted after this and cells 
within the different cell cycle stages checked for Cbl-b expression. Values are presented 
as MFI of Cbl-b of the KJ1-26
+Cbl-b
+ cells in a particular cell cycle stage. C) KJ1-26
+
T cells were gated, their DAPI max pixel Vs integral values plotted after this and cells 
within the different cell cycle stages checked for Cbl-b expression. Values are presented 
as percentage of Cbl-b
+ cells out of the KJ1-26
+ cells in a particular cell cycle stage. Ap G0/ G1 S G2/ M NFDC
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Figure 3.52: Analysis of Cbl-b expression according to cell cycle stage in KJ1-26
+ T 
cells after 20 h of in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 20 h, washed, 
cytocentrifuged, stained for the nucleus, DO11.10 TCR and Cbl-b (these were further 
labelled with adequate fluorochromes). The slides were analysed in the LSC. A) KJ1-
26
+  T  cells  were  gated,  Cbl-b
+  cells  gated  after  this  and  their  DAPI  max  pixel  Vs
integral values plotted. Values are presented as percentage of KJ1-26
+Cbl-b
+ T cells in a 
particular cell cycle stage out of the whole population of KJ1-26
+Cbl-b
+ T cells, for that 
particular stimulus. Some stimulated populations were normalised to 100%. B) KJ1-26
+
T cells were gated, their DAPI max pixel Vs integral values plotted after this and cells 
within the different cell cycle stages checked for Cbl-b expression. Values are presented 
as MFI of Cbl-b of the KJ1-26
+Cbl-b
+ cells in a particular cell cycle stage. C) KJ1-26
+
T cells were gated, their DAPI max pixel Vs integral values plotted after this and cells 
within the different cell cycle stages checked for Cbl-b expression. Values are presented 
as percentage of Cbl-b
+ cells out of the KJ1-26
+ cells in a particular cell cycle stage. Ap G0/ G1 S G2/ M NFDC
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Figure 3.53: Analysis of Itch expression according to cell cycle stage in KJ1-26
+ T 
cells after 1 h of in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 1 h, washed, 
cytocentrifuged, stained for the nucleus, DO11.10 TCR and Itch (these were further 
labelled with adequate fluorochromes). The slides were analysed in the LSC. A) KJ1-
26
+ T cells were gated, Itch
+ cells gated after this and their DAPI max pixel Vs integral 
values plotted. Values are presented as percentage of KJ1-26
+Itch
+ T cells in a particular 
cell cycle stage out of the whole population of KJ1-26
+Itch
+ T cells, for that particular 
stimulus. Some stimulated populations were normalised to 100%. B) KJ1-26
+ T cells 
were gated, their DAPI max pixel Vs integral values plotted after this and cells within 
the different cell cycle stages checked for Itch expression. Values are presented as MFI 
of Itch of the KJ1-26
+Itch
+ cells in a particular cell cycle stage. C) KJ1-26
+ T cells were 
gated, their DAPI max pixel Vs integral values plotted after this and cells within the 
different  cell  cycle  stages  checked  for  Itch  expression.  Values  are  presented  as 
percentage of Itch
+ cells out of the KJ1-26
+ cells in a particular cell cycle stage. Ap G0/ G1 S G2/ M NFDC
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Figure 3.54: Analysis of Itch expression according to cell cycle stage in KJ1-26
+ T 
cells after 20 h of in vitro re-stimulation. 
DO11.10 T cells were extracted from lymph nodes and cultured in vitro in the  presence 
of  anti-CD3  or  anti-CD3  and  anti-CD28  antibodies  to  induce  anergy  or  priming, 
respectively. Excess antibody was washed off and the cells re-plated and rested for an 
additional 2 d in fresh medium. Naïve (freshly isolated), anergised and primed DO11.10 
T cells were (re-)stimulated LPS-matured DCs pulsed with OVA323-339 for 20 h, washed, 
cytocentrifuged, stained for the nucleus, DO11.10 TCR and Itch (these were further 
labelled with adequate fluorochromes). The slides were analysed in the LSC. A) KJ1-
26
+ T cells were gated, Itch
+ cells gated after this and their DAPI max pixel Vs integral 
values plotted. Values are presented as percentage of KJ1-26
+Itch
+ T cells in a particular 
cell cycle stage out of the whole population of KJ1-26
+Itch
+ T cells, for that particular 
stimulus. Some stimulated populations were normalised to 100%. B) KJ1-26
+ T cells 
were gated, their DAPI max pixel Vs integral values plotted after this and cells within 
the different cell cycle stages checked for Itch expression. Values are presented as MFI 
of Itch of the KJ1-26
+Itch
+ cells in a particular cell cycle stage. C) KJ1-26
+ T cells were 
gated, their DAPI max pixel Vs integral values plotted after this and cells within the 
different  cell  cycle  stages  checked  for  Itch  expression.  Values  are  presented  as 
percentage of Itch
+ cells out of the KJ1-26
+ cells in a particular cell cycle stage. Ap G0/ G1 S G2/ M NFDC
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Figure 3.55: The maintenance phase in tolerised and primed mice. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry;  tissue  sections  were  stained  for  DO11.10  TCR  transgenic  T 
cells and B cells (A). B) The number of KJ1-26
+ T cells in each section was quantified 
by LSC. C) The LSC was used to identify the location of KJ1-26
+ T cells within the 
LN: B cell rich areas (follicles) and the B cell-free area (paracortex) were identified 
allowing the generation of a tissue map depicting the follicular and paracortical areas of 
the LN; KJ1-26
+ T cells were also identified, a map of their location also generated and 
the two maps fused, which allows quantification of KJ1-26
+ T cells in the context of 
follicular and paracortical location. Of the total number of KJ1-26
+ T cells in a section, 
the percentages which correspond to follicular and paracortical location were plotted. 
Data  represent  mean  ±  SEM  of  three  mice  per  group.  Statistical  significance  was 
determined  by  one-way  ANOVA  (one  way  analysis  of  variance)  followed  by  the 
Bonferroni post-test in B) and by regular two-way ANOVA (not repeated measures) 
followed  by  the  Bonferroni  post-test  (to  test  significance  of  LN  location  for  each 
stimulus; no interaction between the two variables [LN location Vs mice stimulation] 
was found) in C). Statistical significance was assumed when p≤0.05; *≤0.05, **<0.01; 
***<0.001. Naïve Tolerised Primed
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Figure 3.56: Cbl-b expression in DO11.10 TCR transgenic T cells within the lymph 
node of tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry. Tissue sections were stained for DO11.10 TCR transgenic T 
cells (red), B cells (green) and Cbl-b (blue). Cbl-b expression in DO11.10 T cells was 
quantified with the LSC: KJ1-26
+ T cells were gated and the percentage of these cells 
expressing Cbl-b plotted (A); the MFI of Cbl-b in KJ1-26
+Cbl-b
+ T cells was plotted in 
B. Photographs were taken of the naïve (C), tolerised (D) and primed tissue (E). Data 
represent mean ± SEM of three mice per group. Statistical significance was determined 
by one-way ANOVA (one way analysis of variance) followed by the Bonferroni post-
test. Statistical significance was assumed when p≤0.05; *≤0.05, **<0.01; ***<0.001. A
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Figure  3.57:  Analysis  of  the  effect  of  Cbl-b  expression  in  DO11.10  T  cells’ 
migration into B cell follicles in tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry;  tissue  sections  were  stained  for  DO11.10  TCR  transgenic  T 
cells, B cells and Cbl-b. The LSC was used to identify the location of KJ1-26
+ T cells 
within the LN and to quantify Cbl-b expression in the KJ1-26
+ T cells. A) Of the total 
number  of  KJ1-26
+Cbl-b
+  cells  in  a  section,  the  percentages  which  correspond  to 
follicular  and  paracortical  location  were  plotted.  B)  shows  the  mean  fluorescence 
intensity (MFI) of Cbl-b expression in those KJ1-26
+ T cells that are also positive for 
Cbl-b. C) shows the the percentage of KJ1-26
+ T cells that are positive for Cbl-b out of 
the population of KJ1-26
+ T cells within that specific LN area. Data represent mean ± 
SEM of three mice per group. Statistical significance was determined by regular two-
way  ANOVA  (not  repeated  measures)  followed  by  the  Bonferroni  post-test  (to  test 
significance of the stimulus for each LN location). Statistical significance was assumed 
when p≤0.05; *≤0.05, **<0.01; ***<0.001. Naïve Tolerised Primed
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Figure 3.58: Itch expression in DO11.10 TCR transgenic T cells within the lymph 
node of tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry. Tissue sections were stained for DO11.10 TCR transgenic T 
cells (red), B cells (green) and Itch (blue). Itch expression in DO11.10 T cells was 
quantified with the LSC: KJ1-26
+ T cells were gated and the percentage of these cells 
expressing Itch plotted (A); the MFI of Itch in KJ1-26
+Itch
+ T cells was plotted in B. 
Photographs were taken of the naïve (C), tolerised (D) and primed tissue (E). Data 
represent mean ± SEM of three mice per group. Statistical significance was determined 
by one-way ANOVA (one way analysis of variance) followed by the Bonferroni post-
test. Statistical significance was assumed when p≤0.05; *≤0.05, **<0.01; ***<0.001. A
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Figure 3.59: Analysis of the effect of Itch expression in DO11.10 T cells’ migration 
into B cell follicles in tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry;  tissue  sections  were  stained  for  DO11.10  TCR  transgenic  T 
cells, B cells and Itch. The LSC was used to identify the location of KJ1-26
+ T cells 
within the LN and to quantify Itch expression in the KJ1-26
+ T cells. A) shows the 
percentage of KJ1-26
+ T cells that are positive for Itch out of the population of KJ1-26
+
T cells within that specific LN area. B) shows the mean fluorescence intensity (MFI) of 
Itch expression in those KJ1-26
+ T cells that are also positive for Itch. Data represent 
mean ± SEM of three mice per group. Statistical significance was determined by regular 
two-way ANOVA (not repeated measures) followed by the Bonferroni post-test (to test 
significance of the stimulus for each LN location). Statistical significance was assumed 
when p≤0.05; *≤0.05, **<0.01; ***<0.001. Naïve Tolerised Primed
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Figure 3.60: Grail expression in DO11.10 TCR transgenic T cells within the lymph 
node of tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry. Tissue sections were stained for DO11.10 TCR transgenic T 
cells, B cells and Grail. Grail expression in DO11.10 T cells was quantified with the 
LSC: KJ1-26
+ T cells were gated and the percentage of these cells expressing Grail 
plotted (A); the MFI of Grail in KJ1-26
+Grail
+ T cells was plotted in B. Data represent 
mean ± SEM of three mice per group. Statistical significance was determined by one-
way  ANOVA  (one  way  analysis  of  variance)  followed  by  the  Bonferroni  post-test. 
Statistical significance was assumed when p≤0.05; *≤0.05, **<0.01; ***<0.001. Naïve Tolerised Primed
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Figure  3.61:  Analysis  of  the  effect  of  Grail  expression  in  DO11.10  T  cells’ 
migration into B cell follicles in tolerised and primed mice after re-stimulation. 
DO11.10 TCR transgenic T cells were adoptively transferred into naïve recipients 24 h 
prior to i.v. injection with sterile PBS (naïve), OVA323-339 (tolerised) or OVA323-339 + 
LPS (primed); a secondary response was elicited by challenge with OVA323-339 and LPS 
seven  days  later;  PLNs  were  harvested  24  h  after  that  and  prepared  for 
immunohistochemistry;  tissue  sections  were  stained  for  DO11.10  TCR  transgenic  T 
cells, B cells and Grail. The LSC was used to identify the location of KJ1-26
+ T cells 
within the LN and to quantify Itch expression in the KJ1-26
+ T cells. A) shows the 
percentage of KJ1-26
+ T cells that are positive for Grail out of the population of KJ1-
26
+  T  cells  within that specific  LN  area.  B)  shows  the  mean  fluorescence  intensity 
(MFI) of Grail expression in those KJ1-26
+ T cells that are also positive for Grail. Data 
represent mean ± SEM of three mice per group. Statistical significance was determined 
by regular two-way ANOVA (not repeated measures) followed by the Bonferroni post-
test (to test significance of the stimulus for each LN location). Statistical significance 
was assumed when p≤0.05; *≤0.05, **<0.01; ***<0.001. Naïve Tolerised Primed
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CHAPTER 4 
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4 DISCUSSION 
4.1 Methods and results 
This study focused on the analysis of expression of E3 ubiquitin-protein ligases by 
T cells after stimulation; in studying a plastic signal such as ubiquitination, it would 
have  been  desirable  to  have  analysed  more  time  points;  furthermore,  the  elements 
involved  in  T  cell  signalling  exhibit  multiple  levels  of  regulation,  ranging  from 
transcriptional, to translational, to posttranslational, all of these important aspects to 
investigate and all of them occurring in specific time-frames. However, due to practical 
reasons related to obtaining the biological material (e.g. cells and LNs) in quantities 
needed for the experimental procedures, only a limited number of time points could be 
chosen and these were selected relative to functional readouts. Naturally, in the process 
of such selection, some information about the system might not have been gathered. In 
addition, E3 ligases are known to be regulated not only by ubiquitination but also by 
phosphorylation by multiple pathways; a closer look at the phosphorylation status of the 
E3 ligases might have contributed to a better understanding of their activation state and 
hence  clarified  the  potential  role  of  E3s  in  targeting  different  substrates  for 
ubiquitination,  under  different  conditions.  While  the  antibodies  used  throughout  the 
Western  blotting  experiments  reported  here  were  shown  to  be  specific,  occasional 
technical  glitches  occurred  such  as  air  bubbles  in  the  membrane  and  lanes  with 
incomparable levels of protein; while in most cases the presence of air bubbles does not 
affect  the  global  interpretation  of  any  one  blot,  interpreting  blots  with  lanes  with 
differential levels of protein is much more difficult, and densitometry analysis of these 
blots  would  be  of  great  help  in  validating  the  data.  LSC  allowed  the  in  situ
quantification of the expression of the E3 ligases in CD4
+ T cells; while generally the 
numbers of cells analysed were quite high, in some circumstances, such as in some of 
the stages of the cell cycle analysis, few cells were available for analysis and, as a 
result, these data are not as robust. Similarly, the in vivo experiments, both the induction 
and maintenance phases reflect one experiment, albeit with three mice per group. 184
4.2 Cbl-b 
4.2.1 Induction 
In the in vitro study of induction of priming and tolerance, Cbl-b was found to be 
upregulated in CD4
+ T cells after 20 h of TCR ligation, an effect that was potentiated 
when coupled with CD28 co-stimulation (Figure 3.6). Analysis of the expression of 
Cbl-b at the single-cell level at least partially confirmed these data as the priming CD4
+
T cell population, but not the anergising population, has a higher proportion of cells 
expressing Cbl-b than the unstimulated population (Figure 3.11). Moreover, at later 
time points Cbl-b is still more expressed in the anti-CD3+anti-CD28 priming population 
than in the anti-CD3 anergising population, as seen at 40 h via LSC (Figure 3.13) and 
at 48 h via Western blotting (Figure 3.9). Similarly, the in vivo study of the induction 
phase  of  tolerance  and  priming  (Figure  3.30)  revealed  no  significant  differences 
between  the  two  groups  after  5  d  of  tolerance  or  priming  induction  in  terms  of 
proportion of antigen-specific T cells positive for Cbl-b or in terms of intensity of Cbl-b 
total  protein  expression  per  antigen-specific  T  cell;  however  in  the  in  vivo  system, 
although not significant, both parameters did tend to show slightly higher expression of 
Cbl-b in the tolerised group. 
These findings are perhaps rather surprising as it has generally been reported that 
Cbl-b is most highly expressed in anergic cells [183] although a previous study had 
shown that, in splenic T cells stimulated in vitro with immobilised anti-CD3 antibody, 
Cbl-b  expression  decreases  after  8  h  to  a  barely  noticeable  intensity  by  24  h,  only 
recovering to the levels of the 8 h time point by 72 h [100]. Moreover, lower expression 
of Cbl-b in TCR/CD28 co-stimulated cells was expected as CD28 co-stimulation has 
been reported to induce greater proteasomal degradation than CD3 stimulation alone 
[185]. However, the proteasomal inhibitor data from our model of anti-CD3-mediated 
anergy of CD4
+ T cells suggest that increased proteasomal-mediated Cbl-b degradation 
takes place in anergic relative to that of naïve or primed cells (Figure 3.7). This effect 
requires TCR signalling as, while anergy induction by means of TCR ligation leads to 
accumulation  of  Cbl-b  in  proteasome-inhibited  cells,  anergy  induction  by  means  of 
direct  Ca
2+  mobilisation  fails  to  result  in  further  substantial  accumulation  of  Cbl-b 
(Figure 3.7), perhaps suggesting that Cbl-b expression is itself dynamically regulated 
by proteasomal degradation during antigen- but not ionomycin-mediated anergy and 
hence explaining the observed Cbl-b upregulation in ionomycin-anergised cells when 185
compared  to  unstimulated  cells  in  the  absence  of  proteasome  inhibitors  [183]. 
Interestingly, whilst Cbl-b is also more intensely expressed at 6 h in ionomycin+PMA-
stimulated cells than cells stimulated with ionomycin alone, the opposite happens at 20 
h (Figure 3.9). This latter finding is in keeping with a study which showed increased 
Cbl-b  expression  after  ionomycin  stimulation  comparing  to  ionomycin+PMA  and 
unstimulated cells after 24 h of stimulation in fetal liver chimeras of CD4
+ T cells [203]. 
A more recent study also found Cbl-b protein expression was upregulated after in 
vitro stimulation; curiously, although initially anti-CD3-stimulated cells expressed more 
Cbl-b than anti-CD3+anti-CD28-stimulated cells (4 and 8 h), in keeping with the results 
presented in this thesis, at later time-points (12, 24, 48 and 72 h) the reverse was true 
[297].  Indeed,  in  long-term  (±  120  h)  in  vitro  culture  experiments  (Figure  3.37), 
priming LN cells were still expressing more Cbl-b than those undergoing anergy or 
naïve cells. Consistent with this, and counter to what was previously thought from Cbl-b 
knockout studies [182, 190, 193-195], Cbl-b may be involved in positive regulation of T 
cell activation, as a recent study showed it can associate and polyubiquitinate SHIP for 
proteasomal degradation [298]. However, most studies still point towards Cbl-b playing 
a role in the negative regulation of T cell activation, by means of dampening and/or 
terminating TCR signalling with such possible downstream targets as Vav, Akt, Erk, 
p38 and PLCγ-1 [188, 193]. Cbl-b can also target TCR signalling directly, as loss of 
Cbl-b  increased  the  phosphorylation  of  TCRζ  without  affecting  TCR  degradation, 
leading to augmented T cell activation and spontaneous autoimmunity [221]; such direct 
regulation of TCR activity is achieved by polyubiquitinating TCRζ via a K33 linkage, 
which  reduces  its  association  with  Zap-70  [221].  Thus,  these  contradictory  and 
counteregulatory effects of Cbl-b may be explained by a model that suggests that in the 
first 24 h Cbl-b contributes to reduce IL-2 production and IL-2R and CD71 expression 
by regulating TCR signalling (both in anti-CD3- and anti-CD3+CD28-stimulated CD4
+
T cells); after 24 h upregulation of Cbl-b may result not only in de-sensitisation of TCR 
signalling but also in preventing cell cycle progression and proliferation in the absence 
of antigen [297]. 
However, despite this model, to date Cbl-b expression had not been analysed in 
the context of cell cycle stage; this has now been done in this study using LSC. Perhaps 
arguing against the above model, however, after 20 h of stimulation a higher proportion 
of CD4
+Cbl-b
+ cells could be found in the mitotic phases than in G0/G1, regardless of 
the nature of the stimulus (Figure 3.23). Interestingly, the population of cells stimulated 
with anti-CD3+anti-CD28 showed a considerable higher proportion of their CD4
+Cbl-186
b
+ cells in G0/G1 (42%) than any of the other populations, although it also seems to 
express  Cbl-b  more  intensely  in  CD4
+Cbl-b
+  cells  in  the  mitotic  stages.  Moreover, 
analysis of the expression of Cbl-b according to cell cycle stage at 40 h of in vitro
stimulation revealed similar profiles (Figure 3.24), as again the majority of CD4
+Cbl-b
+
cells are found in the mitotic stages regardless of the nature of the stimulus. Though 
others  have  reported  Cbl-b  negatively  regulating  cell  survival  and  late  cell  cycle 
progression (but not cell cycle entry) [196, 297], in these current data, high levels of 
Cbl-b expression per se do not appear to dictate cell cycle arrest. 
4.2.2 Maintenance 
As Cbl-b has been reported to be involved in modulating TCR ligation and CD28 
co-stimulation signalling in the maintenance phase of anergy and priming [193], as well 
as being upregulated in anergic T cells following ionomycin re-stimulation [193], Cbl-b 
expression was next assessed in the maintenance phase of anergic and primed cells. 
Again in this in vitro model, after 20 h of re-stimulation with LPS-matured, OVA-
loaded DCs, Cbl-b levels appear to be similar in anergic and primed LN cells (Figure 
3.37) and anergic and primed KJ1-26
+ T cells (Figure 3.40), as determined by Western 
blotting.  Indeed,  single  cell  analysis  by  LSC  shows  that,  while  Cbl-b  expression  is 
upregulated in the anergic and primed populations, it is the primed population of KJ1-
26
+ T cells that has the highest proportion of cells expressing Cbl-b and the primed KJ1-
26
+ T cells have the most intense expression of Cbl-b (Figure 3.45). Interestingly, after 
just 1 h of co-culture with LPS-matured, OVA-loaded DCs, the primed population of 
KJ1-26
+ T is already shown to be upregulating Cbl-b when compared  to naïve and 
anergic cells (Figure 3.44). Also interesting, while Cbl-b is expressed most highly at 
the periphery of anergic T cells after 1 h of re-stimulation (Figure 3.44), after 20 h it is 
the primed T cells that express Cbl-b more intensely at the periphery (Figure 3.45). 
These data may therefore point towards different kinetics in the regulation of Cbl-b 
expression and consequent differential mechanisms of action of this E3 ligase in the 
maintenance phase of priming versus tolerance; as Cbl-b appears to be concentrated in 
the periphery of anergic cells at early time points this would be consistent with its roles 
in  blocking  early  CD28-mediated  signalling  in  anergic  T  cells,  namely  by 
downregulating PKCθ and p85α [183, 190, 191] and by interfering with IS activity 
[208]. Also, later on, the primed cells express Cbl-b more intensely at the periphery 
which  is  consistent  with  Cbl-b’s  involvement  in  dampening  TCR  ligation+CD28-
costimulation signalling in order to prevent hyperreactivity; this can be achieved by 187
downregulating the TCR, PLCγ-1, Vav, Akt, Erk and/or p38 [188, 193, 221], or, at least 
in the induction phase by inhibiting cell cycle progression [297]. 
Expression of Cbl-b was analysed in the naïve, anergic and primed populations of 
T cells and correlated with cell cycle stage after 20 h of (re-)stimulation with LPS-
matured, OVA-loaded DCs (Figure 3.52). Consistent with the data from the induction 
phase experiments, which showed that KJ1-26
+Cbl-b
+ T cells undergoing priming could 
be found mainly in the G0/G1 phase at this time point, the “naïve” population - which is 
effectively  undergoing  antigen-driven  priming  -  also  shows  a  high  and  equivalent 
proportion of their KJ1-26
+Cbl-b
+ cells in G0/G1. In fact, both the naïve and the primed 
population have roughly the same proportion of their KJ1-26
+Cbl-b
+ T cells in G0/G1 
(~40%), which is a higher proportion than that of the equivalent anergic population. 
Interestingly, and like what happens during the induction phase, generally, the level of 
expression  of  Cbl-b  is  lowest  in  apoptotic  and  G0/G1-arrested  cells,  regardless  of 
stimulus  (Figure  3.52).  Although  the  three  populations  have  roughly  the  same 
proportion of their KJ1-26
+Cbl-b
+ T cells in the S phase (~40%), the anergic population 
is the one with the highest percentage of KJ1-26
+Cbl-b
+ T NFDCs (35%). As seen in the 
induction  phase  therefore,  high  levels  of  Cbl-b  expression  per  se  do  not  appear  to 
dictate  cell  cycle  arrest  (one  might  think  they  might  actually  be  associated  with 
proliferation in anergic cells). However, expression of Cbl-b in re-stimulated primed 
antigen-specific T cells is predominantly associated with the G0/G1 stage and might 
contribute to a G1/S block associated with homeostatic regulation. 
Following secondary antigenic challenge in vivo, and consistent with the in vitro
data, although not significant, if anything there appears to be higher expression of Cbl-
b, both in terms of the proportion of antigen-specific T cells and levels of expression in 
such  Cbl-b
+  cells,  in  the  primed  relative  to  tolerised  mice  (Figure  3.56).  Perhaps 
reflecting this, after challenge with antigen, there is a higher percentage of KJ1-26
+ T 
cells from the naïve population expressing Cbl-b and higher levels of Cbl-b expression 
in  such  Cbl-b
+  cells  compared  to  either  the  re-stimulated  tolerised  or  primed  mice 
(Figure  3.56).  Also,  this  primary  response  population  of  KJ1-26
+  T  cells  in  the 
paracortex has a significantly higher percentage of cells positive for Cbl-b than that of 
the equivalent tolerised population of KJ1-26
+ T cells (Figure 3.57). 
In  fact,  the  general  trend  is  that  the  naïve  population  of  KJ1-26
+  T  cells 
undergoing a primary priming response, either in the paracortex or the follicles, has a 
higher percentage of cells positive for Cbl-b and a higher intensity of expression of Cbl-
b than either the tolerised or primed populations (Figure 3.57). Moreover, analysis of 188
Cbl-b expression in vivo does not show a clear correlation between this parameter and 
differential function in terms of the maintenance phases of tolerance or priming, in vivo. 
Hence, its functions may lie more in the direction of TCR signal modulation rather than 
promotion/maintenance  of  anergy.  Similarly,  Cbl-b  expression  does  not  appear  to 
correlate with a particular LN location of antigen-specific T cells, regardless of their 
activation/functional status. Indeed, it may be that Cbl-b is more involved in holding T 
cells in check by preventing excess activation rather being involved as a selective agent 
for anergy promotion/enforcement. 
If T cells without functioning Cbl-b [123] and Cbl-b
-/- T cells are susceptible to 
anergy [196], and taking into account the above data provided by this thesis, why does 
Cbl-b deficiency predispose toward autoimmunity [194, 195]? Part of the explanation 
may relate to the increased resistance of Cbl-b
-/- T cells to dominant/extrinsic peripheral 
tolerance factors such as TGF-β and Treg cells [197, 198]. Also, Cbl-b is also expressed 
in  other  tissues  [174]  and  immune  cells  [175,  177,  179],  whose  functions  might 
contribute to tolerance induction. Another potential factor may be that Cbl-b is involved 
in regulating the transition from the DN stage in developing thymocytes [299] and thus 
Cbl-b knockout mice bear developmentally-compromised T cells. Additionally, because 
self-reactive T cells can express effector functions transiently while they are undergoing 
peripheral tolerance [109, 300], the augmented initial expansion observed in Cbl-b
-/- T 
cells immediately following self-antigen recognition could result in a greater amount of 
effector functions just because there are now more self-reactive cells even though the 
effector activities of individual T cells are not enhanced. Finally, one has to consider the 
different  nature  of  the  “anergy”  condition  in  vivo  and  in  vitro;  considering  that 
proliferation is a critical determinant in regulating anergy in vitro [49], but not in vivo
[301], and that Cbl-b regulates proliferation [194, 195], it is perhaps less surprising that 
Cbl-b may play a more critical role in regulating anergy in experimental models in vitro
than  in  vivo.  However  Cbl-b  may  act  as  a  more  general  and  less  anergy-specific 
gatekeeper  of  lymphocyte  activation,  nonetheless  targeting  different  substrates  in 
response to functionally different stimuli to ensure that immune tolerance is properly 
maintained.  Understanding  such  mechanisms  may  therefore  benefit  therapeutic 
intervention in human autoimmune diseases. 189
4.3 Itch 
4.3.1 Induction 
As with Cbl-b, the data presented in this thesis suggest that Itch is upregulated, as 
evidenced by Western blotting (Figure 3.6 and 3.9) and LSC (Figure 3.15), in CD4
+ T 
cells undergoing induction of both priming and anergy, when compared to naïve cells; 
however,  CD4
+  T  cells  undergoing  priming  appear  to  express  more  Itch  than  those 
being  anergised.  This  upregulation  occurs  in  T  cells  regardless  of  the  nature  of  the 
stimulus,  ie,  whether  it  involves  TCR  ligation  by  means  of  antibody  or  direct 
mobilisation  of  Ca
2+  by  a  pharmacological  agent;  the  pathway(s)  that  leads  to  such 
upregulation  therefore  probably  requires  Ca
2+  flux  and  calcineurin  in  both  cases,  as 
previously reported for ionomycin-mediated anergy of a T cell line [183]. However, 
distinct  signals  may  also  be  involved  as  when  CD4
+  T  cells  are  stimulated  by  the 
pharmacological agents this induces increased intensity of Itch expression in CD4
+Itch
+
cells while TCR ligation results in an increased percentage of cells which express Itch 
(Figure 3.15). The studies with the in vivo model for induction of tolerance and priming 
confirmed expression of Itch in tolerised and primed antigen-specific T cells, although 
no significant differences between the two groups after 5 d of tolerance or priming 
induction in terms of proportion of antigen-specific T cells positive for Itch or in terms 
of intensity of total Itch protein expression per antigen-specific T cell could be found 
(Figure 3.30). This further strengthens the view that Itch plays roles in T cell signalling 
other than in just the context of anergy. In fact, as described in the Introduction section, 
Itch expression and activity favours TH1 differentiation by targeting the TH2-driving 
transcription factor JunB for degradation; this occurs after TCR ligation plus CD28 co-
stimulation-mediated Jnk activation, which in turn activates Itch [226, 228]. It is also 
thought Itch-mediated degradation of JunB and c-Jun can suppress AP-1 formation and 
thus contribute to anergy [222], although the signalling inputs that would lead to Itch 
activation will have to be different since CD28 co-stimulation would not lead to anergy. 
One such differential signalling input could be CTLA-4-mediated, promoting anergy 
and  leading  to  Itch  activation  [231].  Itch  is  most  likely  therefore  to  be  involved  in 
signalling in both priming and tolerance of T cells, although the pathways which lead to 
its activity in each case will impart different functional outcomes. 
While Itch activity can be modulated by kinases [226, 228, 229], this is not the 
only  way  to  regulate  Itch.  In  fact,  Itch  proteasomal  degradation  has  been  reported 190
following a process in which Itch polyubiquitinates itself [302] and consistent with this, 
association between Itch and the ubiquitin protease FAM/USP9X was shown to prevent 
Itch degradation [302]. Moreover, another study in human cell lines, showed that auto-
polyubiquitination  of  Itch  via  K29-linked  chains,  leads  to  its  lysosomal  degradation 
[303]. In the present study, after proteasome inhibition, Itch accumulates more in CD4
+
T  cells  undergoing  anergy  (anti-CD3)  than  priming  (anti-CD3+anti-CD28)  (Figure 
3.7);  as  Itch  appears  to  be  more  expressed  in  priming  than  anergising  cells  in  the 
absence of proteasome inhibition, these data suggest that TCR ligation-mediated Itch 
upregulation is a very dynamic process reflecting a high turnover of Itch while the less 
dynamic process observed under conditions of CD28 co-stimulation ultimately results 
in stronger Itch expression at this time point. Curiously, T cells undergoing ionomycin-
induced  anergy  do  not  display  increased  accumulation  of  Itch  after  proteasomal 
inhibition (Figure 3.7), giving rise to the possibility that Itch is not being dynamically 
regulated or alternatively, any such degradation of Itch is lysosome-mediated. 
Itch has been recently implicated in cell survival [304], albeit in a non-T cell 
related context; Itch was shown to ubiquitinate Bid, a pro-apoptotic protein of the Bcl-2 
family  involved  in  death  receptor-mediated  apoptosis  [305],  targeting  it  to  the 
proteasome  and  decreasing  cellular  apoptosis  [304].  The  expression  of  Itch  in  this 
context during priming and tolerance of T cells had not been analysed before and so to 
address whether the higher expression of Itch in primed cells reflected a role for this E3 
ligase in promoting survival, we correlated Itch expression with apoptosis and cell cycle 
progression.  Interestingly, these data show that only a low percentage of CD4
+Itch
+
cells from the unstimulated population are apoptotic (16%), and the other populations 
have even a lower percentage of their CD4
+Itch
+ cells in apoptosis (less than 5%) after 
20 h of in vitro stimulation (Figure 3.25). However, by 40 h of stimulation although the 
percentage  of  non-apoptotic  CD4
+Itch
+  cells  is  still  higher  than  the  percentage  of 
apoptotic CD4
+Itch
+ cells in all populations, the proportion of CD4
+Itch
+ T cells has 
increased substantially in response to all stimuli apart from ionomycin (Figure 3.26). 
These data may indicate Itch is not working as a mediator of cell survival in TCR-
mediated signalling and may reflect the finding that at 20 h, the highest proportion of 
CD4
+Itch
+ cells from the naïve (unstimulated), anergic (anti-CD3) and primed (anti-
CD3+anti-CD28) groups could be found in the G0/G1 phase, perhaps indicating their 
growth arrest prior to commitment to apoptosis. By contrast, the highest percentage of 
CD4
+Itch
+ T cells from the ionomycin and ionomycin+PMA groups at 20 h could be 
found  in  the  mitotic  stages  (Figure  3.25)  and  by  40  h  all  stimuli  yielded  a  higher 191
proportion  of  CD4
+Itch
+  cells  in  the  mitotic  stages  (Figure  3.26);  moreover,  Itch 
intensity of expression also seemed to increase with cell cycle progression regardless of 
the functional outcome of the population, at least at 20 h (Figure 3.25). Taken together 
these data reveal that the mechanism used to prime or anergise T cells (antibodies Vs 
pharmacological agents) influences the kinetics of Itch expression in a population of T 
cells, depending on the cell cycle stage. Also, regardless of functional outcome of the 
population, Itch expression is more associated with mitosis than cell cycle arrest, and 
least associated with apoptosis. 
4.3.2 Maintenance 
The  studies  analysing  the  maintenance  phase  show  that  just  after  1  h  of  (re-) 
stimulation by antigen primed KJ1-26
+ T cells are already upregulating Itch while the 
naïve and the anergic populations exhibit comparable lower proportions of Itch-positive 
cells irrespective of whether they have been exposed to antigen or not (Figure 3.46). By 
20 h following (re-)stimulation by antigen, both anergic and primed populations were 
found  to  be  upregulating  Itch  expression,  when  compared  to  the  naïve  population 
(Figure 3.48). Therefore, it seems that in the maintenance phase, like in the induction 
phase, priming induces Itch expression more strongly than anergy. As Itch expression 
was observed to be upregulated at the periphery of anergic and primed cells, compared 
to naïve cells (Figure 3.48), part of this effect could be due to the reported relocation of 
Itch from the cytoplasm to endocytic vesicles observed in anergic cells re-stimulated 
with  antigen  [183].  Interestingly,  the  primed  cells  showed  foci  of  concentrated  Itch 
expression in the periphery, which is consistent with Itch being expressed in endocytic 
vesicles (Figure 3.49). However, naïve cells also express Itch at the periphery and the 
upregulation in anergic cells could merely reflect a higher intensity of expression in this 
area rather than relocation, as Itch is known to be strongly associated with endocytic 
vesicles [306]; the present data cannot rule out the possibility that relocation occurs, 
although it might not necessarily be a hallmark of Itch-mediated maintenance of anergy. 
Correlation  of  Itch  expression  with  cell  cycle  stage  after  re-stimulation  with 
antigen  revealed  Itch  to  be  expressed  more  intensely  in  KJ1-26
+Itch
+  cells  in  the 
advanced stages of cell cycle, regardless of the functional status of the population both 
at the 1 h (Figure 3.53) and the 20 h (Figure 3.54) time points; these results are similar 
to the ones observed for the induction phase. Also similar is the fact Itch expression is 
least associated with apoptosis. What is clearly different from the induction phase is the 
distribution  of  KJ1-26
+Itch
+  cells  according  to  cell  cycle  stage;  in  the  maintenance 192
phase naïve, anergic and primed populations exhibit differential distribution profiles of 
KJ1-26
+Itch
+  T  cells,  indicating  that  the  functional  status  of  the  cell  may  be  an 
important factor in the maintenance phase of priming and anergy; in fact, under these 
conditions,  in  the  anergic  population  Itch  expression  could  indeed  be  related  to 
apoptotic and G0/G1 T cells. 
Following secondary antigenic challenge in vivo, and unlike the in vitro data, no 
upregulation of Itch was observed in either the tolerised or primed tissues, compared to 
the  naïve  tissue  (Figure  3.58),  as  all  groups  have  equivalent  percentages  of  KJ1-
26
+Itch
+ cells and equivalent Itch intensity of expression in those KJ1-26
+Itch
+ cells. 
There  were  also  no  significant  differences  in  terms  of  intensity  of  Itch  expression 
according to LN localisation between naïve, anergic or primed KJ1-26
+ cells (Figure 
3.59). However, the percentage of antigen-stimulated naïve KJ1-26
+ T cells expressing 
Itch is higher in those cells located in the paracortex relative to the follicles and it is also 
higher than either tolerised or primed KJ1-26
+ T cells, irrespective of the LN location. 
This is an interesting result as these naïve T cells are undergoing a primary priming 
response and hence should migrate into B cell follicles. While these cells do indeed 
migrate into the follicles as much as re-challenged tolerised and primed cells (Figure 
3.55), perhaps the higher percentage of Itch-positive KJ1-26
+ T cells observed in the 
paracortex suggests that these cells are being signalled not to migrate into the follicles 
by an Itch-dependent homeostatic mechanism to control hyperreactivy of the induction 
of priming. Indeed, a role for Itch in preventing unwarranted expansion of B cells has 
already been described [224], although these were not conventional LN B cells. 
As suggested by the results in the present study, there is increasing evidence from 
the  literature  that  the  involvement  of  Itch  in  regulating  T  cell  anergy  is  not 
straightforward.  For  example,  a  recent  study  has  shown  that  siRNA-mediated 
knockdown  of  Itch  leads  to  a  downregulation  of  IFNγ  and  IL-2  mRNA  after  re-
stimulation [231] a finding that is rather counterintuitive given that an upregulation of 
the production of these two cytokines might have been expected in the absence of a 
protein which promotes anergy. However, deficiency of Itch is known to favour TH2 
differentiation [222] (in the in vivo model used in the studies reported in this thesis,
stimulation of the transgenic antigen-specific T cells gives rise to a mixed TH1/TH2 
phenotype) and as such, under these conditions other effector cytokines than IFN-γ and 
IL-2 could be favoured. Itch has also been shown to mediate K29-polyubiquitination of 
Deltex1, targeting it to the lysosome [303] and Deltex1, which is a transcription target 
of NFAT, is reported to be upregulated in T cells undergoing anergy where it is thought 193
to inhibit their activation by promoting optimum expression of Cbl-b via interaction 
with Egr2 [307]. Again, therefore, Itch-mediated degradation of Deltex1 would seem to 
be counterproductive for anergy induction. 
Thus, in the light of the high expression of Itch exhibited by primed cells in this 
study together with previously published  reports of the induction of anergy in  Itch-
defective T cells [183, 231], it is necessary to question whether Itch is a factor for T cell 
anergy. If not, how is it possible to explain the severe autoimmune phenotype of the 
itchy mice [210-212]? Certainly, part of the inflammation observed in those mice was 
caused by lymphocyte-independent dysregulation of the innate immune system [213] as 
well as the resistance of Itch
-/- T cells to undergo anergy in response to Treg-mediated 
inhibition and to TGF-β treatment [218]. Additionally, Itch has also been reported to be 
involved in dampening the signal in priming T cells [223], and as such even properly 
primed  Itch-deficient  T  cells  could  become  hyperreactive,  contributing  to  the 
autoimmune  phenotype.  Finally,  Itch  can  influence  T  cell  differentiation  and 
polarisation [222], and hence its deficiency alters the balance between the clones of 
effector TH cells further contributing to the autoimmune phenotype. Having said that, 
Itch is expressed in both the induction and maintenance phases of T cell anergy and, 
under  such  conditions,  has  been  shown  to  act  to  prevent  the  activation  of  the 
transcriptional program leading up to T cell priming [183]. Thus, Itch can drive T cell 
anergy but this is not its exclusive role; Itch acts in the context of TCR signalling, both 
in the context of T cell priming and T cell anergy. Coupled with its role in T cell 
differentiation, Itch appears to act as a fine regulator of T cell responses. 
Itch is also of importance for the modulation of the human immune system, as can 
be seen from the recent description of the first human phenotype associated with Itch 
deficiency [308]. Those patients, who have a mutation resulting in truncation of Itch, 
display morphologic and developmental abnormalities and may develop a multisystemic 
autoimmune disease characterised by cell infiltration of the lungs, liver and gut [308]. 
The fact that not all of these Itch-deficient patients have severe autoimmune disease 
suggests  the  involvement  of  other  modifiers,  either  genetic  or  environmental,  in 
promoting quiescence, although the activity of other ubiquitin-protein ligases was not 
sufficient to restore a normal phenotype [308]. As such, the study of Itch modulation of 
the  immune  system  may  yet  result  in  potential  human  beneficial  therapeutic 
intervention. 194
4.4 Grail 
4.4.1 Induction 
Grail is expressed in LN cells and, in contrast to what was expected, was found to 
be upregulated in CD4
+ T cells undergoing priming, compared to those from either the 
unstimulated or anergic groups of cells after 20 h of stimulation (Figures 3.2 and 3.6). 
However,  proteasome  inhibition  leads  to  Grail  accumulation  in  anti-CD3-induced 
anergic cells but not primed cells suggesting that Grail may have been expressed at 
higher levels transiently during the processes leading to induction of anergy (Figure 
3.7). Nevertheless, these data taken together point towards TCR ligation leading to Grail 
upregulation and CD28 co-stimulation preventing its proteasome-mediated degradation, 
thus keeping Grail expression high in primed T cells, at the 20 h time point. As Grail 
expression has been associated to anergy induction [233] and also reported to be high in 
naïve T cells [235], these results were not expected. However, a recent study showed 
that priming CD4
+ T cells with anti-CD3+anti-CD28 only leads to Grail downregulation 
after  20  h  [248].  This  downregulation  was  found  to  be  dependent  on  CD28  co-
stimulation and required for T cell proliferation and IL-2 production [248]. For full 
Grail downregulation however, IL-2R signalling via STAT5, Akt and mTOR is needed 
[248] which, at the 20 h time point of the in vitro system used in the studies reported in 
this thesis, would not yet have achieved full strength. 
Interestingly, after 48 h of stimulation, Grail was found to be expressed more in 
anti-CD3-stimulated cells than in anti-CD3+anti-CD28-stimulated cells (Figure 3.9), in 
agreement  with  the  above  study  reporting  Grail  downregulation  after  20  h  that  is 
maintained until at least the 48 h time point following anti-CD3+anti-CD28-mediated 
priming of CD4
+ T cells [248]. By contrast, ionomycin+PMA-stimulated cells express 
Grail more intensely than cells stimulated with ionomycin alone, at 3 and 6 h of in vitro
culture, though  at 20 h the opposite happens  (Figure 3.9).  Interestingly,  at 20 h in 
ionomycin-treated cells, Grail is not being downregulated by proteasome degradation 
(Figure 3.7). The expression of Grail at the single cell level after 20 h of stimulation 
was  also  quantified  by  the  LSC  (Figure  3.19),  revealing  a  lower  proportion  of 
ionomycin+PMA-stimulated CD4
+ T cells expressing Grail than any other populations, 
consistent with the Western blotting findings (Figure 3.9). Also consistent with the 
Western blotting findings, the anti-CD3+anti-CD28-stimulated population has a higher 
proportion of cells expressing Grail and a higher intensity of Grail expression per Grail-195
positive cell than anti-CD3-stimulated cells (Figure 3.19). It is clear from these data 
that anergising cells via TCR ligation or via direct Ca
2+ mobilisation has very different 
consequences on Grail regulation and on the kinetics of Grail regulation, despite similar 
functional  outcomes.  Although  the  high  expression  at  early  time  points  may  be 
surprising at first, it has been shown recently that ionomycin+PMA stimulus can indeed 
induce  strong  Grail  expression;  thus,  in  primary  murine  TH1  cells  stimulated  with 
ionomycin+PMA,  Grail  expression  was  found  to  be  activated  by  direct  binding  of 
NFAT  dimers  to  the  Grail  promoter  [309].  Also  in  this  study,  ionomycin-mediated 
anergy induction in primary murine TH1 cells, also increased NFAT dimers binding to 
the Grail promoter [309], agreeing with the findings of the present study that E3 ligases 
are similarly regulated, at least during the early stages of induction of both priming and 
tolerance. 
Interestingly,  fluorescence  imaging  of  these  populations  of  cells  revealed  the 
biggest  difference  lies  between  unstimulated  (naïve)  and  stimulated  (regardless  of 
stimulus) cells as unstimulated CD4
+ T cells have a rather diffuse Grail expression and
stimulated cells have a more intense and peripheral Grail expression (Figure 3.20). This 
is consistent with Grail being reported as an endosomal protein [233], though evidence 
for  relocation  to  the  endosomes  can  not  really  be  concluded  from  these  fluorescent 
microscopy images. 
At  the  40  h  time  point  in  our  single-cell  analysis  of  Grail  expression,  Grail 
expression was found to be higher in anti-CD3- than in anti-CD3+anti-CD28-stimulated 
CD4
+ T cells (Figure 3.21), in agreement with the Western blotting data regarding the 
kinetics  of  Grail  expression  as  well  as  with  the  study  which  reported  that  Grail 
downregulation after 20 h was maintained until at least 48 h [248]. 
Regulation  of  Grail  appears  to  be  transcriptional,  translational  and 
posttranslational  as  another  recent  study  reported  Grail  mRNA  expression  by  naïve 
CD4
+ T cells was upregulated 2 d after in vitro stimulation with anti-CD3, peaking at 
D3;  however,  although  stimulation  with  anti-CD3+anti-CD28  also  upregulated  Grail 
mRNA expression at D2, by D3 these levels were reduced [236]. What the different 
data  are  showing  is  that  Grail  upregulation  is  not  exclusive  to  anergic  cells,  as 
previously thought; in fact, the differential upregulation of Grail proposed for anergic 
versus  primed  cells  takes  considerable  time  (~2  d).  Moreover,  Grail  is  dynamically 
synthesised and degraded according to different stimuli; the timing and extent to which 
these  occur  is  of  further  assistance  to  the  final  functional  outcome  of  the  cell.  For 
example, recent work has shown that Grail can have an effect on the activation status of 196
Erk in primed T cells: after 30 min of TCR ligation and co-stimulation, Grail
-/- splenic 
naïve CD4
+ T cells showed more phosphorylated and total Erk than wt cells, while no 
differences were found at the level of calcineurin or NFAT expression [235]. Also very 
interestingly, it has been reported that anti-CD3-stimulated (anergising) Grail
-/- CD4
+ T 
cells expressed less Lck, Zap70 and PKCθ than wt cells at 24 h (there was no difference 
between wt and Grail
-/- naïve populations of cells) [236], which would place Grail as a 
positive regulator of these proteins during the first 24 h of anergy induction, an apparent 
contradiction as Lck, Zap70 and PKCθ are involved in the promotion of proliferation 
and cytokine production. Of course, the process of anergy induction does lead initially 
to  the  clonal  expansion  of  T  cells  [109],  so  these  results  are  not  completely 
irreconcilable. 
A  role  for  Grail  in  cell  cycle  arrest  or  apoptosis  induction  has  not  yet  been 
described. Similarly, Grail expression has not been analysed according to the different 
cell cycle stages. Using the LSC it was possible to achieve this, at the single-cell level. 
After 20 h of stimulation Grail was found to be expressed more intensely in mitotic cells 
than cells in any other stages while a higher proportion of CD4
+Grail
+ cells could be 
found in the G0/G1 than in the mitotic phases, regardless of the nature of the stimulus 
(Figure 3.27). This would appear to indicate Grail is not really involved in regulating T 
cell anergy or priming via cell cycle regulation. In fact, any association of Grail with 
G0/G1 observed at 20 h presumably reflected cells transiting through this stage as, at 40 
h, apart from the anti-CD3+anti-CD28-stimulated population, in all other populations 
the majority of CD4
+Grail
+ cells are in the mitotic stages (Figure 3.28). However, the 
high  proportion  of  CD4
+Grail
+  cells  from  the  anti-CD3+anti-CD28-stimulated 
population which can be found in apoptosis at 40 h, coupled with the high intensity of 
Grail expression in CD4
+Grail
+ cells in both apoptotic and G0/G1 phases at 20 h does 
contribute to the idea that Grail may act to dampen T cell activation, preventing hyper-
responsiveness under priming conditions. Though evidence for Grail promoting direct 
induction of apoptosis has not yet been demonstrated - to the contrary, TH1, TH2 and 
TH17 populations of Grail
-/- splenic CD4
+ T cells actually had less viability after 5 d of 
in vitro stimulation than Grail
+/+ cells [235] - both anti-CD3- and anti-CD3+anti-CD28-
stimulated Grail
-/- CD4
+ T cells exhibited enhanced proliferation and IL-2 and IFNγ
production  when  compared  to  similarly-stimulated  wt  cells  [235,  236].  Again, 
collectively, these data seem to suggest Grail is involved, as a negative modulator, in 
the control of T cell activation. However, Grail deficiency is not enough to completely 
suppress the requirement for CD28 co-stimulation as anergising Grail
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still exhibited less proliferation and cytokine production than wt priming cells [235, 
236]. 
In terms of how Grail could modulate T cell activation, as mentioned above, this 
could be initiated via the downregulation of total and phosphorylated Erk, which takes 
place within 30 min of TCR ligation and co-stimulation [235]. It is also interesting, in 
the context of the differential results obtained in the present study, to point out that, 
from the functional point of view it is not equivalent to study the effect of Grail in anti-
CD3+anti-CD28- and ionomycin+PMA-mediated priming cells as Grail
-/- splenic naïve 
CD4
+ T cells showed higher proliferation during anti-CD3+anti-CD28 stimulation than 
wt cells, while ionomycin+PMA-stimulated Grail-deficient cells did not [235]. As Grail 
is usually associated with hyporresponsiveness and can probably assist in preventing 
hyperresponsiveness,  it  is  interesting  to  note  that  such  ionomycin+PMA  stimulation 
does not lead to a differential functional outcome in wt and Grail
-/- T cells when the data 
here  (Figure  3.9)  and  that  of  others  [309]  did  show  upregulation  of  Grail  in 
ionomycin+PMA-stimulated  cells.  This  is  reminiscent  of  what  was  observed  during 
anergy induction, that is, that direct Ca
2+ mobilisation has different consequences for 
Grail expression regulation and function than TCR ligation-mediated Ca
2+ mobilisation 
- not only in anergy induction but also in priming.
4.4.2 Maintenance 
After prolonged in vitro culture, naïve LN cells express more Grail than anergic or 
primed  cells  (Figure  3.37),  perhaps  indicative  of  their  resting  state  and  potential 
consequent  induction  of  apoptosis  due  to  lack  of  selection  signals.  Moreover,  the 
experiments studying the maintenance phase of anergy and priming show that after re-
stimulation  with  LPS-matured,  OVA-loaded  DCs,  naïve  and  anergic  LN  cells  from 
DO11.10 mice upregulate Grail expression more than primed cells (Figure 3.37), the 
further upregulation during the maintenance phase of anergy relative to that of priming 
being  unlike  what  happens  in  the  similar  stage  of  the  induction  phases  of  these 
functional  outcomes.  Indeed,  anergised  DO11.10  TCR-transgenic  T  cells  (either  via 
ionomycin or TCR ligation in the absence of co-stimulation) express higher levels of 
Grail than primed DO11.10 T cells after re-stimulation with LPS-matured, OVA-loaded 
DCs  (Figure  3.40).  In  fact  Grail  protein  has  previously  been  shown  to  be 
downregulated in the maintenance phase of primed CD4
+ T cells, after 24 h of anti-
CD3+anti-CD28 re-stimulation, rather than with antigen as in the present study [310]; 
Grail was shown to ubiquitinate and degrade CD83 via the proteasome on CD4
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anergised with ionomycin and re-stimulated with anti-CD3+anti-CD28 antibodies [310]. 
Downregulation of CD83, which is also expressed in DCs and mediates intercellular 
interactions between DCs and T cells, led to reduced proliferation and production of IL-
2 and IL-17 [310]. 
So, Grail protein levels in each population appear to depend not only on the nature 
of the stimulus but also on whether that population of T cells is undergoing induction or 
maintaining a previously achieved functional state.
In the in vivo model of tolerance maintenance, after antigenic challenge Grail was 
expressed in a higher percentage of naïve DO11.10 TCR transgenic T cells undergoing 
a  primary  response  than  in  tolerised  or  primed  cells  maintaining  their  differential 
functional outcomes to secondary challenge (Figure 3.60). This was interesting as at 
this time point, Grail was least expressed in tolerised DO11.10 TCR transgenic T cells, 
in contrast to what was suggested by the Western blotting data convey from the in vitro
maintenance  phase  experiments,  in  which  primed  DO11.10  TCR  transgenic  T  cells 
expressed the least Grail. These differences may reflect different kinetics of the in vitro
and in vivo tolerance mediators. 
Regarding  the  functionality  of  in  vivo  primed  and  tolerised  T  cells,  it  is 
hypothesised these tolerant T cells, once in the follicles, remain incapable of providing 
B cell help, unlike the primed T cells [267, 296]. As indicated by the present study, re-
challenge of tolerised T cells induces their migration into B cell follicles as much as re-
challenge of primed T cells (Figure 3.55). However, a higher percentage of DO11.10 
TCR T cells located in the follicles express Grail than those in the paracortex (Figure 
3.61); also, the antigen-specific T cells found in the follicles express more Grail than 
those found in the paracortex; this might hint towards the preference of Grail expression 
in T cells migrating into the follicles. Indeed, recent work has suggested that Grail is 
involved in the formation of the follicles, though there, retroviral expression of Grail in 
bone  marrow  chimeric  mice  was  associated  with  diminished  lymphoid  follicle 
formation [245] while here Grail is associated with T cell presence in the follicular 
areas. The relatively downregulated expression of Grail detected in tolerised compared 
to naïve and primed DO11.10 TCR T cells localised in the follicles could, on the other 
hand, potentially implicate a role for Grail in capacitating T cells to provide B cell help, 
as there could be a threshold of Grail intensity of expression, that once reached would 
enable B cell help. 
It would not be surprising that the cells termed “naïve” in this experiment would 
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primary  stimulus  and  they  should  be  undergoing  priming  after  that.  This  would 
implicate Grail as a promoter of T cell activation, a function which, so far, has not been 
described for Grail. 
4.5 Smurfs 
Smurf1  is  expressed  in  naïve  CD4
+  T  cells  and  CD4
+  T  cells  during  primary 
stimulation (Figure 3.6). The presence of a ladder of Smurf1 bands, coupled with the 
finding of co-precipitation of Smurf1 with ubiquitin (Figure 3.4) suggests Smurf1 is 
ubiquitinated  and/or  associated  with  ubiquitin-containing  proteins.  Smurf1  can 
ubiquitinate target proteins [250] and be itself ubiquitinated [254]; in either case, the 
ubiquitinated  target  is  downmodulated.  In  anergising  T  cells,  proteasome  inhibition 
does lead to Smurf1 accumulation (Figure 3.7) and thus, it might be the case that whilst 
TCR ligation upregulates Smurf1, lack of CD28 co-stimulation does not prevent its 
proteasomal  degradation.  The  in  vivo  study  of  the  induction  phase  of  tolerance  and 
priming (Figure 3.32) revealed no significant differences between the two groups in 
terms of proportion of OVA peptide TCR-specific T cells positive for Smurf1 or in 
terms of intensity of total protein expression per OVA peptide TCR-specific T cell, 
although this last parameter did show slightly more intense expression of Smurf1 in the 
primed group, consistent with the Western blotting data. Likewise, the expression of 
Smurf1 after re-stimulation (maintenance phase) is roughly equivalent in anergic and 
primed cells (Figure 3.37). 
Smurf2  is  also  expressed  in  CD4
+  T  cells,  but  appears  to  be  upregulated  by 
priming  stimuli  (Figure  3.6).  As  proteasome  inhibition  leads  to  increased  Smurf2 
accumulation  in  anergised,  but  not  naïve  or  primed,  T  cells  (Figure  3.7),  this  may 
suggest  that,  in  vitro,  TCR  ligation  leads  to  Smurf2  upregulation  and  CD28  co-
stimulation  prevents  its  degradation  by  inhibiting  its  proteasomal  degradation,  thus 
keeping  Smurf2  expression  high  in  priming  T  cells.  Alternatively,  the  proteasome 
inhibition data may reflect a transient high anergising signal via the TCR at an earlier 
time  point.  However,  in  our  model  of  in  vivo  tolerance  and  priming  induction,  no 
significant differences between the tolerised and primed antigen-specific T cells were 
found  after  5  d  of  stimulation  (Figure  3.33).  Also,  after  in  vitro  re-stimulation  of 
DO11.10 cells, naïve, anergic and primed populations expressed the same amount of 
Smurf2 (Figure 3.37). It might be the case Smurf2 helps the establishment of signalling 
events leading to effective T cell priming; once this is accomplished Smurf2 expression 200
would  return  to  its  basal  levels,  a  proposal  perhaps  consistent  with  the  in  vitro
proteasomal inhibition data. Smurf2 could in fact assist in the signalling events leading 
to T cell priming by degrading Rap1 [249], as Rap1 accumulation in anergic T cells has 
been linked to inhibition of Erk activation [48, 131]. When T cell priming had taken 
place,  Smurf2  could  ubiquitinate  itself,  targeting  its  expression  back  to  basal  levels 
[253]; this could explain the ladder pattern observed in the long term in vitro-cultured 
naïve,  anergic  and  primed  cells.  Smurf2  has  also  been  found  to  be  involved  in 
downregulating TGF-β signalling via ubiquitination of the TGF-β receptor, leading to 
enhanced  T  cell  activity  [252,  311].  This  is  potentially  interesting  as  it  is  thought 
experimental setups used for anergy induction can partly lead to Treg differentiation and 
Treg-mediated suppression, which can depend on TGF-β signalling. In this case, Smurf2 
would act to prevent Treg-mediated suppression of activated cells. Smurf2 has also been 
reported  to  be  able  to  ubiquitinate  and  degrade  Smurf1,  adding  another  level  of 
complexity to the mechanism [254]. 
4.6 Other potential anergy markers 
Despite exhaustive characterisation of phenotype over the years, there is still no 
clear  marker  exclusive  to  anergic  T  cells.  This  is  an  issue  that  prevents  not  only 
recognition of the state of activation of T cells in vivo but which also limits the analysis 
potential  of  a  number  of  in  vitro  experimental  systems.  Moreover,  two  major 
mechanisms of peripheral tolerance, cell-intrinsic anergy and the dominant tolerance 
afforded by Tregs, can be co-ordinately induced by the exposure of T cells to antigen 
administered in a tolerogenic context, as shown by oral or intravenous administration of 
peptide, which upregulated both antigen-specific anergic T cells and CD4
+CD25
+ Treg
populations [30, 312, 313]. 
As  most  of  the  in  vitro  experimental  systems  rely  on  priming  and  anergising 
populations of cells and reading the collective output, single-cell analysis can be tricky 
since  not  all  cells  in  an  anergised  population  will  be  anergic.  However  single-cell 
analysis  can  be  used  to  search  for  an  anergy  marker  common  and  exclusive  to  all 
anergic cells. 
For  example,  human  anergic  T  cells  were  reported  to  exhibit  differential 
localisation of Arf6 according to the activation state of T cells: in the plasma membrane, 
in anergic cells; and scattered throughout endosomes and the cytoplasm, in primed cells 
[288].  However,  in  our  antigen-specific  model  of  the  maintenance  of  priming  and 201
tolerance,  Arf6  total  protein  levels  or  localisation  could  not  be  used  to  distinguish 
anergic from primed cells (Figure 3.41). 
4.6.1 Traf6 
The expression of the adaptor protein Traf6, which promotes the activation of NF-
κB  in  its  capacity  as  an  E3  ubiquitin-protein  ligase  [70,  71],  was  found  to  be 
upregulated in priming LN cells and highly reduced in ionomycin-induced anergising 
LN cells (Figure 3.2). However, in purified CD4
+ T cells only minimal differences 
were  found  although  under  conditions  of  anti-CD3-induced  anergy,  cells  tended  to 
express more Traf6 than primed cells (Figure 3.6). The idea of Traf6 as a positive 
mediator of T cell priming – derived from its role in the activation of the IKK complex, 
leading to translocation of NF-κB to the nucleus [71, 73] – could thus not be confirmed. 
Interestingly, and perhaps consistent with the present results, King et al [314], showed 
that Traf6 is actually required for anergy induction in T cells. According to their report, 
the loss of Traf6 restored the ability of CD28
-/- T cells to proliferate and produce IL-2; 
consistent  with  this,  Traf6-∆T  T  cells  showed  resistance  to  anergising  stimuli;  and, 
interestingly,  resistance  to  anti-CD3-mediated  anergy  induction  was  co-related  with 
decreased mRNA and protein expression of Cbl-b [314]. So, it appears that, while Traf6 
can promote IKK activation by means of K63 ubiquitination [315], leading to NF-κB 
activation, it can also have a role in anergy induction. Data from Figure 3.6 can support 
both these apparently contradictory roles of Traf6, as it shows Traf6 is being expressed 
in both anergising and priming CD4
+ T cells; this would imply Traf6 is carrying out 
different  functions  according  to  context,  which  would  require  additional  regulatory 
mechanisms, possibly posttranslational ones, behind this potential change of role; such 
mechanisms remain to be elucidated. 
Since Traf6-∆T T cells were resistant to the induction of anergy, the maintenance 
phase of anergy could not be assessed [314]. Data from Figure 3.40 do not help to 
elucidate this point, as the KJ1-26
+ antigen-specific T cells were shown not to express
Traf6, regardless of the functional state; perhaps this is an indication that Traf6 plays a 
secondary role in this phase. On the other hand, Traf6 is expressed in the cells from the 
non-KJ1-26
+ fraction, in which DCs will be found most abundantly. As Traf6 has been 
reported to be expressed in DCs, where it regulates the critical processes required for 
maturation, activation, and development [316], this finding does not come as a surprise. 
In  DCs,  proteasome-mediated  degradation  of  Traf6  has  been  shown  to  inhibit  pro-202
inflammatory  cytokine  production  [317]  and,  consistent  with  this  role  of  Traf6  in 
promoting  immune  responses,  Traf6  expression  in  the  non-KJ1-26
+  fraction  is 
differential as Traf6 is expressed most highly in the population co-cultured with the 
primed T cells (Figure 3.40). 
4.6.2 Ikaros 
Ikaros expression was found only to be slightly upregulated after 20 h of anti-
CD3-mediated anergy induction relative to that of priming CD4
+ T cells (Figure 3.6), a 
difference  that  was  maintained  until  120  h  of  the  induction  processes  in  LN  cells 
(Figure 3.37). At the 120 h time point however, naïve, anergic and primed LN cells all 
expressed very high levels of Ikaros and, interestingly, after re-stimulation, Ikaros was 
expressed more strongly in primed and anergic T cells than naïve T cells, though it may 
be the case that relative to the non-re-stimulated T cells, that after re-stimulation all T 
cell  populations  downregulate  Ikaros,  the  naïve  T  cells  simply  being  the  ones  that 
downregulate it the most. Nevertheless, Ikaros is clearly expressed the most by primed 
KJ1-26
+  T  cells,  at  slightly  lower  levels  in  TCR  ligation-induced  anergic  T  cells, 
although ionomycin-induced anergic T cells exhibit substantially less Ikaros expression 
(Figure 3.40). 
While  the  induction  phase  results  are  somewhat  within  the  parameters  of  the 
expected, as Thomas et al [119] had previously reported CD4
+ T cells with reduced 
Ikaros  activity  to  be  resistant  to  clonal  anergy,  the  maintenance  phase  data  are 
somewhat more intriguing. Moreover, the slight differences observed in the induction 
phase might be related to the way Ikaros function is controlled, and this does not seem 
to rely mostly on protein expression. Thus, Thomas et al [119] found that naïve, primed 
and anergic CD4
+ T cells expressed comparable amounts of Ikaros protein isoforms and 
that Ikaros binds to the Il2 promoter/enhancer in resting CD4
+ T cells, meaning Ikaros 
can mediate anergy even when present at comparable levels to those expressed in naïve 
cells, and hence it is the regulation of the transcriptional repressor activity that is likely 
to take prime stage for anergy induction. 
Thomas et al [119] did not look at what happens in the maintenance phase; in the 
present data Ikaros is more highly expressed in antigen-specific primed T cells than 
anergic  ones,  while  one  would  expect  that  in  anergic  T  cells  Ikaros  transcriptional 
repressor  activity  would  be  higher  than  in  primed  T  cells.  This  is  not  necessarily 
contradictory as the function of Ikaros has been proven to be controlled by a multitude 
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Ikaros  function  is  controlled  by  posttranslational  modification.  For  instance, 
Ikaros can be subject to SUMOylation, which does not alter its DNA-binding activity, 
but  rather  inhibits  its  association  with  co-repressor  complexes  [318].  Therefore, 
differential  SUMOylation,  a  posttranslational  modification  which  consists  in  the 
addition of the UBL SUMO to the target protein, in anergic Vs primed cells could alter 
the constituents of Ikaros complexes that bind to the Il2 promoter, and impact on the 
repressive capacity of Ikaros at this locus. 
Ikaros has also been shown to be phosphorylated by CK2 in response to mitogenic 
signals,  a  posttranslational  modification  which  inhibits  Ikaros  DNA  binding  activity 
allowing G1/S progression [319]. Moreover, Ikaros can be de-phosphorylated by PP1, 
resulting in its stabilisation and preventing its degradation [320]. The activity of Ikaros 
depends therefore on a delicate balance of two opposing signalling pathways and this 
balance  can  be  shifted  depending  on  differential  extracellular  signals  such  as  co-
stimulation  from  CD28  or  IL-2R,  translating  into  differential  signalling  events,  say 
differential  phosphorylation  occurring  under  anergic  versus  primed  conditions. 
Curiously, Ikaros can also form complexes with ubiquitin in the nucleus, and these are 
responsible for targeting Ikaros to the proteasome, for degradation [320]. 
Perhaps  more  interestingly,  Ikaros  can  also  promote  gene  activation  [321].  This  is 
accomplished  by  association  with  Brg-1,  a  catalytic  subunit  of  the  SWI/SNF 
nucleosome complex, while its role in gene repression is mediated by association with 
the  histone  deacetylase-containing  complexes  NuRD  and  Sin3  [322,  323].  The 
function(s) associated with Ikaros upregulation after re-stimulation of primed T cells 
remain therefore to be determined but as a marker for anergic cells, simple analysis of 
Ikaros expression can not be used. 
4.7 Ubiquitination 
Analysis of the ubiquitination status of total protein lysates does not reveal many 
differences between CD4
+ T cells undergoing priming and anergy (Figure 3.10). Both 
populations  of  cells  show  similar  bands  of  ubiquitinated  proteins,  with  a  similar 
intensity. However, the kinetics of ubiquitination in response to the different stimuli are 
distinct as intensity of ubiquitination changes throughout the time points. These data do 
not  conflict  with  those  of  a  previous  study  showing  upregulation  of  total  protein 
ubiquitination in a TH1 cell line undergoing ionomycin-induced anergy, when compared 
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ubiquitination is involved in TCR signalling in many ways, namely also in signalling 
pathways  leading  to  T cell  priming,  measuring  total  levels  in  such  a context  is  not 
necessarily informative. Rather it is more important to assess the status of some selected 
targets,  which  are  crucial  for  the  signalling  pathways  they  are  involved  in.  In  this 
regard,  immunoprecipitation  of  ubiquitin-containing  complexes  revealed  co-
precipitation  of  some  E3s  and  PLCγ-1  (Figure  3.4),  suggesting  ubiquitination  as  a 
possible  modulation  factor  in  the  expression  of  PLCγ-1  in  the  context  of  anergy 
induction  in  responses  to  anti-CD3,  as  has  been  described  for  ionomycin-induced 
anergy of T cells [183]. 
The  kinetics  and  differential  patterns  and  intensities  of  ubiquitinated  proteins, 
observed in primed and anergic cells resulting from TCR signalling imply a rapid and 
dynamic upregulation and downregulation of proteins. For instance, the ubiquitination 
process at the IS can be detected as soon as 5 min after T cell-APC conjugate formation 
and it is maintained for up to at least 30 min [324]. In the IS, it is thought the TCR:CD3 
complex is a prime target for regulation by ubiquitination [278] and its ubiquitination 
appears to be mediated both by Cbl-b and Itch [221], with effector proteins downstream 
from the TCR ubiquitinated later. 
Analysing  the  expression  of  K63-linked  polyubiquitinated  proteins  did  reveal 
some potentially interesting differences between naïve (unstimulated) and the primed 
(anti-CD3+anti-CD28)  and  tolerised  (anti-CD3)  groups  (Figure  3.3).  The  use  of 
antibodies that specifically recognise a particular ubiquitin linkage is very useful in 
determining the potential regulatory mechanism involving that protein. For example, the 
HWA4C4 monoclonal antibody specifically recognises K63-linked polyubiquitin chains 
but not any other isopeptide-linked polyubiquitin or monoubiquitin and can be used for 
detection  of  proteins  in  whole  lysates  via  Western  blotting  [325].  Obviously  it  will 
recognise  all  the  K63-linked  polyubiquitinated  proteins  in  the  whole  cell  lysate, 
displaying  the  pattern  of  K63-linked  polyubiquitinated  proteins.  Whilst  K48-linked 
polyubiquitination  typically  leads  to  protein  degradation  by  the  26S  proteasome, 
monoubiquitination  and  K63-linked  polyubiquitination  are  usually  associated  with 
proteasome-independent regulatory processes [326]. It is interesting to note though, that 
K63-linked  polyubiquitination  can  also  lead  to  proteasomal  degradation  [327,  328], 
although  this  is  not  the  usual  outcome;  instead  it  can  promote  downmodulation  by 
targeting  proteins  to  the  endocytic  pathway,  where  they  can  be  recycled  back  to 
function or degraded in the lysosome [159]. 205
One way of investigating which proteins are being degraded in the proteasome is 
to block it. Accumulation of polyubiquitinated proteins is a consequence of inhibition of 
proteasomal  protein  degradation  and  is  observed  as  soon  as  1  h  after  lactacystin 
treatment, reaching its peak after 16 h [329]. However this accumulation of proteins due 
to  proteasome  inhibition  affects  cell  function;  for  instance,  it  induces  apoptosis  of 
activated human CD4
+ T cells compared to unstimulated cells and those cells surviving 
proteasome  inhibition  undergo  inhibition  of  proliferation  by  induction  of  p27
kip1-
mediated G1 phase cell cycle arrest [329]; re-stimulated cells also proliferate less when 
treated with proteasome inhibitors [329]; moreover, production of IFNγ, IL-4 and IL-5 
production in human CD4
+ T cells activated by DCs was suppressed after proteasome 
inhibition [329]. The mechanism involved in this cytokine production suppression is 
actually of relevance for anergic T cells as it was found it was due to inhibition of 
activation and nuclear translocation of NFAT [329], a transcription factor reported to be 
involved in the upregulation of anergy factors [114]. Thus, while allowing studying the 
mechanism of regulation of critical components of the anergic program, proteasome 
inhibition can also influence it. Here, in the studies of the role of proteasome-mediated 
degradation in the expression of critical intermediaries in T cell anergy and priming 
(Figure 3.7), generally less protein was found in those cells treated with lactacystin than 
those which were not, an effect which could be related to induction of apoptosis/growth 
arrest. However, all the E3s sought for analysis could be found being expressed in these 
proteasome-inhibited  cells,  and  as  discussed  above,  some  exhibited  differential 
behaviour regarding the anergising or priming stimuli. 
Finally,  the  study  of  the  maintenance  phase  revealed  that  ubiquitination  may 
develop a more prominent role in maintaining the anergic phenotype rather than the 
primed one. While the levels of ubiquitinated proteins do not vary much between the 
three populations after just 1 h of re-stimulation, after 20 h of re-stimulation there is an 
increase  in  protein  ubiquitination  in  the  periphery  of  anergic  KJ1-26
+  T  cells  re-
stimulated  with  LPS-matured,  OVA-loaded  DCs,  compared  to  any  of  the  other 
populations (Figure 3.42). Also, analysis of protein ubiquitination by Western blotting 
revealed  that  after  re-stimulation  of  LN  cells,  the  anergic  population  had  the  most 
intense protein ubiquitination (Figure 3.38). 206
4.8 E3 ubiquitin-protein ligases in the context of T cell anergy 
Taken together, these results indicate that upregulation of E3 ligase expression is 
not exclusive to anergising and anergic T cells as previously thought [183], as priming 
and primed T cells also exhibit upregulation of these proteins, and, as such, inference 
about their expression can not be used as marker for anergic T cells. As the evidence for 
the  role  of  E3s  in  the  regulation  of  signal  transduction  pathways  leading  up  to  or 
maintaining anergy is increasing [116, 183, 236], so is the evidence for the role of E3s 
in the modulation of the activity of primed cells [193, 223, 241]. 
Another  interesting  point  of  discussion  relates  to  the  interactions  between 
different E3s and, more specifically, whether there is cooperation or redundancy in their 
actions in the context of TCR signalling downmodulation. In defence of the unique 
function hypothesis, several studies, which focused on the phenotype of the knockout of 
a single E3 ligase [193-195, 222, 236], reported naïve T cells as being hyperresponsive 
to stimulation. However, as studies relying on the manipulation of a particular gene tend 
to overemphasize its function in a response, these mice could have developed a generic 
lower  activation  threshold  which  could  lead  to  a  more  robust  response  after  the 
induction of anergy regardless of the function of that particular molecule. In fact, some 
E3s have been shown to target the same substrates - for instance Cbl-b, Itch and Grail 
all ubiquitinate the TCR [221, 236] - and that is an indication that some degree of 
functional redundancy exists. However, while many E3 ubiquitin-protein ligases seem 
active after TCR stimulation (Figure 3.4), differences in the turnover rate of some of 
the E3s suggest some may act later or have a more short-term action in the induction of 
anergy  than  others,  while  also  affecting  different  cellular  processes.  It  is  yet  to  be 
established which of these E3 ubiquitin-protein ligases are responsible for the long-term 
selective blocks preventing IL-2 production, though possibly some kind of cooperation 
between them takes place. Indeed, some of the processes regulated by E3s in T cell 
anergy do seem dependent on functional interactions between various anergy factors, 
such that all must work together to maintain T cells in the tolerant state. For instance, 
Grail and Cbl-b may be mechanistically linked through Cbl-b downregulation of Akt 
phosphorylation;  a  decrease  in  Akt  phosphorylation  decreases  mTOR  activation, 
abrogating otubain 1 protein expression and thus resulting in the upregulation of Grail 
and  inhibition  of  cell  proliferation.  The  nature  of  such  cooperation  is  also  up  for 
discussion; some E3s have been shown to interact directly, as seen for example in Itch-
mediated ubiquitination of Cbl-b [205], while other forms of interaction have also been 207
reported which are more indirect: for example, Itch can also inhibit upregulation of Cbl-
b in the absence of anergy-inducing conditions by ubiquitinating Deltex1 [303, 307]. 
The  modulation  of  the  activity  of  these  E3  ubiquitin-protein  ligases  is  of 
paramount importance for their timely action in the induction of anergy. Interestingly, 
this can be achieved via ubiquitination (Figure 3.7). As mentioned before, for example, 
Itch can ubiquitinate Cbl-b targeting it for proteasomal degradation, but there are also 
reports  of  self-ubiquitination  with  regulatory  value  for  Itch  [302,  303],  Grail  [247], 
Smurf1 [254] and Smurf2 [253]. 
4.9 Dissecting  the  mechanisms  underlying  differential 
signalling in anergy and priming 
PLCγ-1  is  one  of  the  key  effectors  of  TCR  signalling  [55]  promoting,  via 
intermediaries, the Ca
2+ flux and Ras-Erk pathway activation that are required for T cell 
priming [14]. TCR signalling in the absence of CD28 co-stimulation results in Ca
2+ flux 
but impaired Ras-Erk pathway activation, leading to T cell anergy [45, 114]. While 
PLCγ-1 is required for T cell priming, during the induction of anergy its expression and 
activity are downregulated [111, 183], indicating that it is one of the key targets of the 
anergy inducing program. We therefore initially used total expression of PLCγ-1 as a 
way to assess the effectiveness of the different stimuli in inducing differential functional 
outcomes  on  T  cells  via  Western  blotting.  Consistent  with  this  proposal,  PLCγ-1 
expression was found to be upregulated during priming and downregulated in T cells 
undergoing anergy when comparing to unstimulated naïve CD4
+ T cells (Figures 3.2 
and 3.6). After prolonged T cell culture (± 120 h), primed T cells still expressed more 
PLCγ-1 than unstimulated or anergic cells (Figure 3.37) and, after re-stimulation, the 
primed cells continued to express more PLCγ-1 than anergic cells (Figure 3.37). These 
(and other) data confirmed that the different stimuli were inducing the desired outcomes 
while  also  showing  PLCγ-1  protein  expression  changes  according  to  the  functional 
outcome of the cell. 
To address the mechanisms underlying this modulation of protein expression it 
was  found  that  PLCγ-1  co-precipitates  with  ubiquitin  as  early  as  within  1  h  during 
induction of anergy but not priming (Figure 3.4). By 20 h, cells undergoing both anergy 
and priming show substantial PLCγ-1 co-precipitation with ubiquitin, suggesting this
protein is being regulated by ubiquitination, as had been previously suggested [183]. 208
While  ubiquitination  of  PLCγ-1  at  early  time  points  seems  associated  with  anergy 
induction, later ubiquitination seems common to both anergising and priming cells, and 
hence  possibly  reflects  dampening  of  TCR  signalling,  thus  preventing  T  cell 
hyperreactivity. To address whether ubiquitination of PLCγ-1 could be targeting it for 
proteasomal  degradation,  experiments  were  repeated  in  the  presence  of  proteasome 
inhibitors (Figure 3.7); while previous work had shown that ubiquitination-mediated 
degradation of PLCγ-1 occurred via the lysosome as evidenced by the failure of the 
proteasome inhibitor MG132 to result in PLCγ-1 accumulation [183], the present study 
found that at least some PLCγ-1 is being degraded in the proteasome in cells undergoing 
anergy, after 20 h stimulation (Figure 3.7). 
Other  crucial  effectors  in  TCR  signalling  which  have  been  reported  to  be 
downregulated during anergy induction (compared to priming induction) are PKCθ and 
Lck [183]. While PKCθ downregulation in the context of anergy induction appears to 
be  mediated  by  monoubiquitination  and  to  be  mostly  proteasome-independent,  Lck 
downregulation has been reported as dependent on ubiquitin but, depending on context, 
as either proteasome-dependent or cysteine protease-dependent [282, 283]. As seen in 
Figure 3.7, evidence for proteasome-mediated degradation of Lck was not found in this 
study. 
Although progress has been made in identifying potential targets of differential 
signalling, the majority of work in this field has been carried out in vitro using T cell 
lines or purified T cells using biochemical analysis which takes no account of cell-cell 
interactions and physiological microenvironment. In situ examination of signalling in T 
cells primed and tolerised in vivo will therefore reflect more accurately the molecular 
mechanisms underlying tolerance induction and maintenance. Different ways to induce 
in  vivo  anergy  have  been  used  to  study  T  cell  signalling,  namely  administration  of 
peptide i.v. and feeding whole protein [111, 330]. However, in vitro studies require 
quite  different  methods  for  inducing  tolerance  than  those  more  physiological 
mechanisms used in in vivo anergy induction and this might help explain the apparently 
conflicting  data  generated  from  comparison  of  both  types  of  experiments  as  the 
different methods might be inducing different kinds of tolerance. 
In fact, the cellular response leading to anergy in the in vitro models has indeed 
been reported to be quite distinct from what occurs during the development of in vivo
anergy. In vitro anergy typically develops in less than 1 day [49, 116] and in the process 
CD4
+  T  cells  have  been  reported  not  to  enter  cell  cycle  [52],  while  in  vivo  anergy 
induced by peripheral self-antigen is preceded by a proliferative phase, which goes on 209
for a few days [118]. Moreover, the in vivo studies describe a defect in Ca
2+-mediated 
translocation  of  NFAT  into  the  nucleus  that  has  been  proposed  to  be  caused  by 
downregulation  of  PLCγ−1  activation,  whilst  normal  activation  of  Erk  is  observed 
[331],  although  in  not  all  in  vivo  studies  [131];  by  contrast,  in  vitro  anergy  is 
characterised  by  normal  Ca
2+  mobilisation  but  impaired  Ras-Erk  pathway  activation 
[123, 183]. Some have argued that the discrepancies observed in in vitro and in vivo
models of anergy show that in vitro clonal anergy (commonly induced via treatment 
with  anti-CD3  or  ionomycin)  and  in  vivo  adaptive  tolerance  (usually  induced  using 
antigen in protein or peptide form) are two distinct biochemical states [260]. Both types 
of tolerance models result in reduced transcription of IL-2 and proliferation, but the 
defects in TCR-mediated signalling occur in different signalling cascades. 
Thus, in adaptive tolerance, T cells appear to exhibit impaired phosphorylation of 
ZAP-70,  LAT  and  PLCγ−1  leading  to  decreased  Ca
2+  mobilisation  whereas  clonal 
anergy appears to be predominantly mediated by defects in the Ras-Erk pathway (which 
can also occur in adaptive tolerance [131], with little or no defects in the Ca
2+-NFAT 
pathway. Thus, this concept of distinct biochemical states leading to the same functional 
outcome (T cell anergy), can help explain why some of in vivo responses differ from 
those observed in vitro. For instance, no significant differences were found between 
tolerised and primed transgenic T cells in terms of expression of Cbl-b, Itch, Smurf1 
and Smurf2 in the in vivo tolerance induction model while the in vitro experiments 
showed otherwise. Moreover, although most of the in vitro experiments related to a 20 h 
time point whilst the in vivo studies predominantly analysed  LN tissue at 5 d after 
stimulus, the differences between anergic and primed cells were generally maintained in 
the long-term (± 120 h) in vitro culture experiments (Figure 3.37) suggesting that such 
differences did not simply reflect kinetics. Given the above in vivo data, it is therefore 
interesting  to  note  that  no  detectable  difference  in  the  development  of  adaptive 
tolerance, as measured by cell number and cytokine production, was found between 
Cbl-b-deficient CD4
+ T cells and wt cells [260]. 
As mentioned above, even within the literature of in vitro T cell anergy, different 
anergy-inducing protocols produce different signalling outcomes. The most popular in 
vitro anergy-inducing methods involve stimulation of the T cells with immobilised anti-
CD3 antibodies or stimulation with ionomycin; whilst in the first case ligation of the 
TCR  (which  leads  to  Ca
2+  mobilisation  and  subsequent  NFAT  activation)  to  mimic 
antigen-stimulation  occurs  [49],  in  the  second  case  Ca
2+  mobilisation  is  promoted 
directly  [259].  In  either  case,  there  is  no  co-stimulation  and  Ca
2+-NFAT  signalling 210
induces a limited set of anergy-associated genes, distinct from genes induced in the 
productive immune response [116]. However, as ionomycin bypasses TCR ligation, the 
initial  steps  in  T  cell  anergy  are  also  omitted,  steps  in  which  Lck,  ZAP-70,  LAT, 
PLCγ−1 and the TCR itself have been found to be downregulated. It is not difficult to 
speculate that they themselves might be involved in the regulation of expression of E3 
ubiquitin-protein ligases, thus helping explaining the conflicting data regarding the two 
in vitro tolerance induction models. Similarly, the strong, unregulated mobilisation of 
intracellular calcium and calcium influx triggered by ionomycin may initiate a distinct 
transcriptional programme to that dictated by PLCγ-1 signalling. 
While T cell anergy is commonly associated with lack of cytokine production, this 
might not simply be due to a defect in synthesis and/or secretion but rather, also reflect 
disruption of the cell-cell interactions in microenvironments observed in priming. For 
instance, in a T cell population undergoing anergy induction, although some cells will 
develop  an  apoptotic  program,  anergic  T  cells  are  also  thought  to  have  impaired 
migration,  or  at  least  impaired  B  cell  help  capability.  Many  factors  play  a  role  in 
controlling cell numbers, namely by regulating cell cycle progression: for example,  the 
G1/S checkpoint inhibitor Smad3 is a critical effector downstream of p27
kip1, which has 
been implicated in the induction of tolerance [332]. Also important is the control of 
cellular growth; for example, as glucose uptake is limiting in T cell activation [333], 
CD28  co-stimulation  is  required  to  maximally  increase  its  uptake  through  Akt-
dependent and Akt-independent pathways which lead to elevated glucose transporter 
Glut1 expression and traffic to the cell surface [333]. A key protein in the decision 
between  priming  and  anergy,  mTOR  integrates  the  inputs  of  co-stimulatory  signals, 
determining the outcome of TCR engagement [334]; antigen recognition in the setting 
of mTOR activation leads to full immune responses, whereas recognition in the setting 
of  mTOR  inhibition  results  in  quiescence  [334].  The  PI3K-Akt-mTOR  pathway  is 
necessary for IL-2 production and proliferation [334]; however, these two functional 
hallmarks of primed cells can be uncoupled one from the other, with IL-2 production 
appearing to be a more accurate determinant of priming [334]. 
As discussed above, Cbl-b, Itch and Grail are involved in many different ways in 
the regulation of the immune response, from Treg-mediated suppression [200, 238] to T 
cell  differentiation  [222],  and  their  regulatory  role  is  not  even  restricted  to  the 
modulation  of  T  cell  responses.  In  terms  of  differential  gene 
upregulation/downregulation in anergic Vs priming T cells, previous work using gene 
chip analysis has shown that very few genes are differentially transcriptionally regulated 211
between these two populations of cells [335, 336], indicating that regulation of this 
system is either dependent on a handful of genes or that posttranslational regulatory 
mechanisms play a much more prominent role. E3 ubiquitin-protein ligases have been 
postulated to be induced in anergic T cells to modulate the activity and/or expression of 
other crucial proteins by ubiquitination. However, the data presented here suggest that 
upregulation  of  Cbl-b,  Itch  and  Grail  is  not  exclusive  to  T  cells  undergoing  or 
maintaining anergy, on the contrary, it can be exacerbated by a co-stimulatory priming 
stimulus. The question regarding their role in anergy and priming therefore still remains 
and may be explained by increasing evidence that Cbl-b, Itch and Grail can modulate 
different proteins and can interact with each other. Thus, further studies regarding their 
kinetics  of  expression  and  activity  –  and,  if  they  are  to  exist,  the  identification  of 
exclusive targets in anergic and primed cells – can further assist in elucidating their 
differential roles in these two very distinct functional T cell outcomes. Furthermore, 
they will also shed light on the regulation of associated but general cellular processes, 
such as apoptosis, cell cycle progression and migration. 
Ideally, an anergic program should be able to modulate all these cellular processes 
as well as cytokine production and others such as B-T cell cooperation. How can this be 
achieved? A stable difference in the gene expression profile between naïve and primed 
or anergic T cells could be achieved through ubiquitin modification translating into an 
increase in turnover of signalling mediators involved in the T cell response, thereby 
establishing a persistent unresponsive state in anergy. One of the attractive features of 
this mechanism is that signalling mediators would only require downmodulation when 
activated. One possibility for such E3-mediated driving of anergy involves cooperation 
between Cbl-b and Itch, resulting in the ubiquitination of the TCR, PLCγ-1 and PKCθ
and  subsequent  internalisation  into  an  endocytic  vesicle  which,  following  Itch 
signalling, would be targeted to the lysosomes for degradation. Grail, which resides in 
the endosomal membrane, could also synergise with these effectors to further enhance 
protein ubiquitination. It is an interesting question whether any or all of these proteins 
remain active in anergic cells in the absence of antigenic challenge or whether they are 
rapidly upregulated only upon re-stimulation. Assessment of  the prevalence of the E3s 
over longer periods in this study (± 120 h) shows that they are still present in anergic 
and primed cells, which means they could be actively contributing to the enforcement of 
the anergy program even in the absence of re-exposure to antigen. 212
4.10Summary 
The data presented here, of which a brief summary can be found in Table 4.1, 
indicate that expression and/or upregulation of Cbl-b, Itch and Grail is not exclusive to 
T cells undergoing or maintaining anergy, as priming and primed T cells also exhibit 
not only expression but also upregulation of these proteins. By contrast, the data show 
that  downregulation  of  PLCγ-1  correlates  nicely  with  anergy  and,  similarly  that  its 
upregulation correlates with priming; in anergising T cells, PLCγ-1 downregulation was 
found to occur via the ubiquitin-proteasome pathway and, as others have implicated Itch 
and Cbl-b in the ubiquitination of PLCγ-1, this is likely mediated by these two E3 
ubiquitin-protein ligases. 
After 20 h of stimulation, both priming and anergising populations of cells have 
higher expression of Cbl-b, Itch and Grail than the naïve population, which may point 
towards a role of these proteins in the downregulation or negative feedback inhibition of 
T cell activity. As Cbl-b, Itch and Grail have all been reported to downregulate TCR, 
this is a tempting mechanism through which such regulation could be achieved. Itch and 
Cbl-b can also downregulate PLCγ-1, and in the context of CD28 co-stimulation, Itch
can  promote  the  ubiquitin-mediated  degradation  of  Bcl10  (Figure  4.1).  In  the 
maintenance phase, although perhaps immediately after antigen re-stimulation Cbl-b, 
Itch and Grail might exert anergy-specific effects, at 20 h after re-stimulation of anergic 
and  primed  cells  these  E3  ubiquitin-protein  ligases  are  again  upregulated  in  both 
populations, which suggests they might again be involved in the homeostatic control of 
T  cell  activation.  Potential  targets  for  ubiquitin-mediated  downregulation  in  the 
maintenance phase are, for Itch, the transcription factor Jun and Bcl10, for Grail, CD83, 
whilst all three can downregulate the TCR:CD3 complex. 
These data therefore open up new possibilities with respect to the mechanisms 
modulating T cell activation which could contribute to the development of work on the 
identification  of  targets  that  are  specifically  downregulated  in  order  to  prevent 
hyperreactivity. Also of interest would be to understand the mechanism and context by 
which  these  E3  ubiquitin-protein  ligases  switch  between  roles,  as  this  might  help 
identify new anergy factors. 213 
Table 4.1: Summary of the results yielded by the main experimental approaches 
regarding the expression of Cbl-b, Itch and Grail. +
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Figure  4.1:  Expression  of  Cbl-b,  Itch  and  Grail  after  20  h  of  stimulation  and 
potential targets for their action in the downmodulation of T cell activity. 
TCR ligation leads to upregulation of Cbl-b, Itch and Grail; Itch and Cbl-b can enforce 
the anergic programme by targeting PLCγ-1 (and others) to the ubiquitin-proteasome 
pathway  and  Cbl-b,  Itch  and  Grail  can  quench  excess  TCR  signalling  by 
downmodulating the TCR. TCR ligation coupled with CD28 co-stimulation leads to
upregulation  of  Cbl-b,  Itch  and  Grail;  Itch  can  promote  the  ubiquitin-mediated 
degradation of Bcl10, quenching CD28-mediated signalling, and Cbl-b, Itch and Grail 
can  quench  excess  TCR  signalling  by  downmodulating  the  TCR.  Re-stimulation  of 
anergic  cells  with  antigen  leads  to upregulation  of  Cbl-b,  Itch  and  Grail;  these  E3 
ubiquitin-protein  ligases  can  quench  excess  TCR  signalling  by  downmodulating  the 
TCR  whilst  Grail  can  target  CD83  and  Itch  can  promote  the  ubiquitin-mediated 
degradation  of  Bcl10  and  Jun.  Re-stimulation of  primed  cells  with  antigen  leads  to
upregulation of Cbl-b and Itch; these E3 ubiquitin-protein ligases can quench excess 
TCR signalling by downmodulating the TCR whilst Itch can promote the ubiquitin-
mediated degradation of Bcl10 and Jun. P
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